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Abstract
Adalimumab, etanercept and ustekinumab for treating
plaque psoriasis in children and young people: systematic
review and economic evaluation
Ana Duarte,1 Teumzghi Mebrahtu,2 Pedro Saramago Goncalves,1
Melissa Harden,2 Ruth Murphy,3 Stephen Palmer,1 Nerys Woolacott,2
Mark Rodgers2* and Claire Rothery1
1Centre for Health Economics, University of York, York, UK
2Centre for Reviews and Dissemination, University of York, York, UK
3Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
*Corresponding author mark.rodgers@york.ac.uk
Background: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab
(HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and ustekinumab
(STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments currently licensed
for psoriasis in children.
Objective: To determine the clinical effectiveness and cost-effectiveness of adalimumab, etanercept and
ustekinumab within their respective licensed indications for the treatment of plaque psoriasis in children
and young people.
Data sources: Searches of the literature and regulatory sources, contact with European psoriasis registries,
company submissions and clinical study reports from manufacturers, and previous National Institute for
Health and Care Excellence (NICE) technology appraisal documentation.
Review methods: Included studies were summarised and subjected to detailed critical appraisal. A network
meta-analysis incorporating adult data was developed to connect the effectiveness data in children and
young people and populate a de novo decision-analytic model. The model estimated the cost-effectiveness
of adalimumab, etanercept and ustekinumab compared with each other and with either methotrexate or
best supportive care (BSC), depending on the position of the intervention in the management pathway.
Results: Of the 2386 non-duplicate records identified, nine studies (one randomised controlled trial for
each drug plus six observational studies) were included in the review of clinical effectiveness and safety.
Etanercept and ustekinumab resulted in significantly greater improvements in psoriasis symptoms than
placebo at 12 weeks’ follow-up. The magnitude and persistence of the effects beyond 12 weeks is less
certain. Adalimumab resulted in significantly greater improvements in psoriasis symptoms than methotrexate
for some but not all measures at 16 weeks. Quality-of-life benefits were inconsistent across different
measures. There was limited evidence of excess short-term adverse events; however, the possibility of rare
events cannot be excluded. The majority of the incremental cost-effectiveness ratios for the use of biologics
in children and young people exceeded NICE’s usual threshold for cost-effectiveness and were reduced
significantly only when combined assumptions that align with those made in the management of psoriasis in
adults were adopted.
Limitations: The clinical evidence base for short- and long-term outcomes was limited in terms of total
participant numbers, length of follow-up and the absence of young children.
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Conclusions: The paucity of clinical and economic evidence to inform the cost-effectiveness of biological
treatments in children and young people imposed a number of strong assumptions and uncertainties.
Health-related quality-of-life (HRQoL) gains associated with treatment and the number of hospitalisations
in children and young people are areas of considerable uncertainty. The findings suggest that biological
treatments may not be cost-effective for the management of psoriasis in children and young people at a
willingness-to-pay threshold of £30,000 per quality-adjusted life-year, unless a number of strong assumptions
about HRQoL and the costs of BSC are combined. Registry data on biological treatments would help determine
safety, patterns of treatment switching, impact on comorbidities and long-term withdrawal rates. Further
research is also needed into the resource use and costs associated with BSC. Adequately powered randomised
controlled trials (including comparisons against placebo) could substantially reduce the uncertainty surrounding
the effectiveness of biological treatments in biologic-experienced populations of children and young people,
particularly in younger children. Such trials should establish the impact of biological therapies on HRQoL in this
population, ideally by collecting direct estimates of EuroQol-5 Dimensions for Youth (EQ-5D-Y) utilities.
Study registration: This study is registered as PROSPERO CRD42016039494.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adverse effect An abnormal or harmful effect, caused by and attributable to exposure to a chemical
(e.g. a drug), that is indicated by some result such as death, a physical symptom or a visible illness.
An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change
in the homeostasis of the organism or increases the susceptibility of the organism to other chemical or
biological stress.
Between-study variance A measure of statistical heterogeneity that depends on the scale of the
outcome measured. It represents the variation in reported study effects over and above the variation
expected given the within-study variation.
Biological therapy (biologic) Any pharmaceutical product derived from biological sources. In psoriasis
treatment, biological therapies are generally monoclonal antibodies that bind to and inactivate immune cell
signalling molecules (e.g. tumour necrosis factor and interleukins), thereby dampening the inflammatory
response.
Biosimilar An imitation biological medical product (such as anti-tumour necrosis factor) usually marketed
by a different manufacturer from the manufacturer of the original biological product, once a patent has
expired. The biosimilar should be similar to the original licensed product in terms of safety and efficacy.
Ciclosporin A medication originally developed to prevent the immune system from rejecting transplanted
organs but which has also proved helpful in treating psoriasis.
Confidence interval The typical (‘classical’ or ‘frequentist’) definition is the range within which the ‘true’
value (e.g. the size of effect of an intervention) would be expected to lie (e.g. 95% or 99%) if sampling
could be repeated a large number of times.
Cost-effectiveness analysis An economic analysis that expresses the effects or consequences of
interventions on a single dimension. This would normally be expressed in ‘natural’ units (e.g. cases cured,
life-years gained). The difference between interventions in terms of costs and effects is typically expressed
as an incremental cost-effectiveness ratio (e.g. the incremental cost per life-year gained).
Credible interval In Bayesian statistics, a credible interval is a posterior probability interval estimation that
incorporates problem-specific contextual information from the prior distribution. Credible intervals are used
for purposes similar to those of confidence intervals in frequentist statistics.
Crohn’s disease An inflammatory condition of the digestive tract; rheumatic diseases are often associated
with Crohn’s disease and ulcerative colitis is related to it.
Deviance information criterion A model fit statistic and used for Bayesian model comparison. The model
with the smallest deviance information criterion is estimated to be the model that would best predict a replicate
data set that has the same structure as that currently observed.
Disease-modifying antirheumatic drug A drug that is capable of modifying the progression of
rheumatic disease. The term is applied to what are now considered to be traditional (or conventional)
disease-modifying drugs, in particular sulfasalazine, methotrexate and ciclosporin, as well as azathioprine,
cyclophosphamide, antimalarials, penicillamine and gold. The newer agent leflunomide is also a disease-
modifying antirheumatic drug. Biologics are not generally referred to as disease-modifying antirheumatic
drugs, although occasionally the term ‘bDMARD’ may be used.
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EuroQol-5 Dimensions A standardised instrument for measuring generic health-related quality of life,
used in computation of quality-adjusted life-years.
Fixed-effect model A statistical model that stipulates that the units under analysis (e.g. people in a trial
or studies in a meta-analysis) are the ones of interest and thus constitute the entire population of units.
Only within-study variation is taken to influence the uncertainty of the results (as reflected in the
confidence interval) of a meta-analysis using a fixed-effect model.
Health Assessment Questionnaire A self-administered questionnaire measuring an individual’s physical
disability and pain. The ability to perform various activities is scored between 0 (without any difficulty) and
3 (unable to do). The final score is reported as an average of all activity scores.
Heterogeneity In systematic reviews, heterogeneity refers to variability or differences between studies in
the estimates of effects. A distinction is sometimes made between ‘statistical heterogeneity’ (differences in
the reported effects), ‘methodological heterogeneity’ (differences in study design) and ‘clinical heterogeneity’
(differences between studies in terms of the key characteristics of the participants, interventions or outcome
measures).
Intention to treat An intention-to-treat analysis is one in which all of the participants in a trial are
analysed according to the intervention to which they were allocated, regardless of whether they received it
or not.
Methotrexate One of the oldest chemotherapy drugs used in the treatment of cancer and autoimmune
diseases such as rheumatoid and psoriatic arthritis.
Network meta-analysis (synonyms: mixed-treatment comparison, indirect treatment
comparison) Used when there is insufficient direct evidence linking two interventions, this is a meta-analysis
comparing three or more different treatments using both direct comparison within randomised controlled
trials and indirect comparison between trials based on a common comparator (such as placebo).
Placebo An inactive substance or procedure administered to a patient, usually to compare its effects with
those of a real drug or other intervention, but sometimes for the psychological benefit to the patient
through a belief that he or she is receiving treatment.
Plaque psoriasis The most common form of psoriasis, also known as psoriasis vulgaris, recognised by red,
raised lesions covered by silvery scales. About 80% of patients with psoriasis have this type of disease.
Psoriasis A chronic skin disease characterised by inflammation and scaling. Scaling occurs when cells in
the outer layer of the skin are produced faster than normal and build up on the skin’s surface. It is thought
to be caused by a disorder of the immune system.
Psoriasis Area and Severity Index score A number representing the extent of skin coverage, redness,
scaliness and thickness of a person’s psoriasis. The Psoriasis Area and Severity Index response is presented
as PASI 50, PASI 75 or PASI 90. This represents the reduction of the individual’s Psoriasis Area and Severity
Index score from baseline as a percentage.
Psoriatic arthritis A disease characterised by stiffness, pain and swelling in the joints, especially of the
hands and feet. It affects about 30% of people with psoriasis. Early diagnosis and treatment can help
inhibit the progression of joint deterioration.
Quality-adjusted life-year An index of health gain in which survival duration is weighted or adjusted by
the patient’s quality of life during the survival period. Quality-adjusted life-years have the advantage of
incorporating changes in both quantity (mortality) and quality (morbidity) of life.
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Quality of life A concept incorporating all of the factors that might affect an individual’s life, such as the
absence of disease or infirmity, as well as other factors that might affect their physical, mental and social
well-being.
Random-effects model A statistical model sometimes used in meta-analysis in which both within-study
sampling error (variance) and between-study variation are included in the assessment of the uncertainty
(confidence interval) of the results of a meta-analysis.
Randomised controlled trial (synonym: randomised clinical trial) An experiment in which
investigators randomly allocate eligible people into intervention groups to receive or not receive one or
more of the interventions that are being compared.
Relative risk (synonym: risk ratio) The ratio of risk in the intervention group to risk in the control
group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the total
number in the group. A relative risk of 1 indicates no difference between comparison groups. For
undesirable outcomes, a relative risk of < 1 indicates that the intervention was effective in reducing the
risk of that outcome.
Residual deviance An analysis used for model comparison and goodness of fit. The residual deviance is
equal to the deviance for a given model minus the deviance for a saturated model. A saturated model is
one in which all of the predictions from the model are equal to the observed data values. Total residual
deviance should approximate the number of data points for a good fit.
Rheumatoid arthritis A chronic autoimmune disease characterised by pain, stiffness, inflammation,
swelling and, sometimes, destruction of joints.
Sensitivity analysis An analysis used to determine how sensitive the results of a study or systematic
review are to changes in how it was carried out. Sensitivity analyses are used to assess how robust the
results are to uncertain decisions or assumptions about the data and the methods that were used.
Statistical significance An estimate of the probability of an association (effect) as large as or larger than
that observed in a study occurring by chance, usually expressed as a p-value.
Tumour necrosis factor alpha A cell signalling molecule (cytokine) involved in the inflammatory
response pathway, known to be fundamental to the pathological processes causing psoriasis and psoriatic
arthritis. It plays a key role in the onset and persistence of joint and skin inflammation.
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SAE serious adverse event
S-MAPA Simple Measure for Assessing
Psoriasis Severity
sPGA Static Physician Global Assessment
STA single technology appraisal
TA technology appraisal
TNF tumour necrosis factor
TNF-α tumour necrosis factor alpha
T-QoL Teenager’s Quality of Life Index
WHO World Health Organization
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
information (or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Psoriasis is an inflammatory disease that mostly affects the skin but is also associated with joint diseaseand other illnesses. It can greatly reduce a person’s quality of life. A range of treatments are used in
psoriasis, including the more recent ‘biologic’ drugs. The National Institute for Health and Care Excellence
recommends a number of biologic drugs for treating severe psoriasis in adults. The purpose of this study
was to assess the gains and harms associated with three biologic drugs that can be used in children –
adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and
ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) – as well as their cost-effectiveness.
We took all available information from clinical trials. The results showed that adalimumab, etanercept and
ustekinumab all improve symptoms of psoriasis in the short term, but the limited evidence in children
means that the effects later in life are unclear (e.g. long-term effects on heart disease). The only way to
find which treatment was best was to include extra information about the effects of these drugs in adults.
The economic assessment found that the use of biologics in children and young people would be good
value for NHS money only if many consequences of biologic treatment in children are assumed to be the
same as those in adults.
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Scientific summary
Background
Psoriasis is a chronic inflammatory disease of the skin and joints and typically results in red, scaly and flaky
skin, also known as plaque psoriasis.
Existing psoriasis guidance for all age groups [National Institute for Health and Care Excellence (NICE) clinical
guideline CG153 in England)] recommends traditional topical therapies as first-line therapy. Second-line
therapies include phototherapy and non-biological systemic agents. Third-line therapy includes systemic
biological therapies. Although there is currently no childhood-specific treatment pathway, CG153 highlights
special considerations for children {e.g. referral to a specialist at presentation; avoidance of very potent
corticosteroids, photochemotherapy [psoralen plus UVA light (PUVA)] and acitretin}.
Adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), etanercept (Enbrel®, Pfizer, New York, NY, USA) and
ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA) are the biologics currently licensed in
children, although the exact populations included in these licences vary.
Objective
The aim of this study was to determine the clinical effectiveness and cost-effectiveness of adalimumab,
etanercept and ustekinumab within their respective licensed indications for the treatment of plaque
psoriasis in children and young people.
Methods
Clinical review and network meta-analysis
Studies were identified through searches of the literature and regulatory sources, direct requests for clinical
study reports and contact with European psoriasis registries. Searches were carried out on 24/25 May 2016
and updated during September 2016. The following databases were searched: EMBASE, MEDLINE, Cochrane
Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative
Index to Nursing and Allied Health Literature (CINAHL) Plus, Database of Abstracts of Reviews of Effects (DARE),
Health Technology Assessment (HTA) database, NHS Economic Evaluation Database (NHS EED), PubMed and
Science Citation Index.
Studies of children and/or young people with moderate to severe plaque psoriasis, in whom topical or
systemic therapies or phototherapies were inadequate, inappropriate or not tolerated, were eligible
for inclusion.
Relevant interventions were adalimumab, etanercept and ustekinumab and relevant comparators included
alternative biological therapies with relevant marketing authorisation (adalimumab, etanercept or ustekinumab)
and their biosimilars, non-biological systemic therapy, topical therapy and biological treatments used outside
their marketing authorisation.
Data on effectiveness, adverse effects, patient-centred outcome measures, health service costs and
cost-effectiveness were eligible for inclusion.
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Randomised controlled trials (RCTs) were eligible for the review of clinical efficacy. To address longer-term
measures of efficacy and drug survival, published analyses based on large and long-term data sets were
also considered.
The results of the included studies were presented in a series of structured tables, summarised narratively
and subjected to critical appraisal. A naive indirect treatment comparison of adalimumab and etanercept
was initially conducted based on the available placebo-controlled RCT data in children with psoriasis.
A network meta-analysis (NMA) framework incorporating adult data was developed to allow the
effectiveness data in children and young people to be connected and to inform the economic model.
Cost-effectiveness review
A systematic review was undertaken to identify published evidence on the cost-effectiveness of adalimumab,
etanercept and ustekinumab, and relevant comparators, for the treatment of psoriasis in children and young
people. This included the company submissions from Janssen Biotech, Inc. (ustekinumab) and AbbVie
(adalimumab); Pfizer, the manufacturer of etanercept, did not submit any evidence. Additional hand-searching
of published documents associated with previous NICE technology appraisals of psoriasis in adults was carried
out. The aim was to examine existing decision-analytic models to identify important structural assumptions,
highlight key areas of uncertainty and outline the potential issues associated with generalising evidence from
the adult population to a population of children and young people.
Economic modelling
A de novo decision-analytic model was developed to estimate the cost-effectiveness of adalimumab,
etanercept and ustekinumab compared with each other and with either methotrexate or best supportive
care (BSC), depending on the position of the intervention in the management pathway. Before systemic
therapy methotrexate was considered the relevant comparator (as the current standard of care), whereas
after systemic therapy BSC was considered the most relevant comparator. The cost-effectiveness model
took the form of a cohort Markov model and the time horizon was extended until individuals reached
18 years of age, when separate NICE recommendations for the use of the interventions in adults apply.
Outcomes were expressed using quality-adjusted life-years (QALYs) and costs use a NHS and Personal
Social Services perspective.
To reflect differences in marketing authorisation by age and the positioning of treatment in the pathway,
the cost-effectiveness analysis considered three separate populations:
1. Children and young people aged 4–17 years, with adalimumab as the only licensed intervention for the
treatment of severe plaque psoriasis in individuals inadequately controlled by, or intolerant to, topical
therapy and phototherapies, that is, as an alternative to systemic therapies.
2. Children and young people aged 6–11 years, with adalimumab and etanercept used for the treatment
of severe plaque psoriasis in individuals inadequately controlled by, or intolerant to, systemic therapies
or phototherapies.
3. Children and young people aged 12–17 years, with adalimumab, etanercept and ustekinumab used for
the treatment of severe plaque psoriasis in individuals inadequately controlled by, or intolerant to,
systemic therapies or phototherapies.
Results
Clinical effectiveness review
Of the 2386 non-duplicate records identified, nine studies (three RCTs and six observational studies) were
included in the clinical effectiveness review.
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Efficacy data from pivotal randomised controlled trials
One RCT was identified for each of the biologics of interest. The etanercept and ustekinumab trials
included 12 weeks of follow-up and used a placebo as the comparator, whereas the adalimumab trial was
of 16 weeks’ duration and included methotrexate as the comparator. The risk of bias was low for most
domains in each study.
Although only older children and adolescents (aged 12–17 years) were included in the ustekinumab trial,
the median age of children did not differ greatly across the three trials as relatively few younger children
were recruited. Across the three RCTs, only 11 children aged < 6 years received biological treatment.
All three trials used a composite measure of disease severity incorporating baseline Psoriasis Area and
Severity Index (PASI), Physician Global Assessment (PGA) and body surface area measurements. Average
PASI scores ranged from 18.3 to 21.2, with 93–100% of participants having a PGA score of > 3 (mild/
moderate disease). Although adalimumab and etanercept are licensed for ‘severe chronic plaque psoriasis’
and ustekinumab is licensed for ‘moderate to severe plaque psoriasis’, on average, measures of disease
duration and the component measures of severity did not appear to differ markedly between the trials.
In total, 29.8% and 42.7% of participants in the adalimumab and ustekinumab trials, respectively, had
received prior systemic therapy and 56.8% of participants in the etanercept trial had received either prior
systemic therapy or phototherapy.
A similar proportion of participants in the adalimumab and ustekinumab trials had received some form of
biological treatment prior to enrolment (9.6% and 10.8% respectively). No participants recruited to the
etanercept trial had previously been treated with a biologic.
Adalimumab
One multicentre RCT (M04-717) found that adalimumab at the licensed dose of 0.8 mg/kg (up to 40 mg)
led to significantly greater responses than methotrexate for the outcomes of PASI 50 and PASI 75 but
not PASI 90 at 16 weeks. PGA 0/1 response rates were non-significantly higher for adalimumab than
for methotrexate. The benefits of half-dose adalimumab were not statistically greater than those for
methotrexate. Evidence on quality of life was inconsistent across different measures, possibly because of
baseline imbalances on the Pediatric Quality of Life Inventory (PedsQL™). In children and young people,
adalimumab did not appear to be associated with an increase in adverse events relative to methotrexate
over 16 weeks, although the possibility of rare adverse events cannot be entirely excluded. The trial did not
provide any comparative evidence for children aged 4–6 years of age.
Etanercept
One multicentre RCT (20030211) found etanercept to be significantly more effective than placebo in improving
the severity of plaque psoriasis, based on PASI 50, 75 and 90 and PGA 0/1 response rates at 12 weeks.
Improvements in health-related quality of life were larger for etanercept than for placebo but reached statistical
significance only when measured using the Children’s Dermatology Life Quality Index (CDLQI).
Adverse event rates were mostly similar in the etanercept and placebo groups at 12 weeks, with no serious
adverse events observed for either treatment. However, a higher observed rate of infections among
participants receiving etanercept was of borderline statistical significance. Relatively few young children
(9% aged < 8 years; 4.3% aged < 6 years) were included in the study.
Up to 6 years of open-label follow-up (20050111) found that the proportions of PASI and PGA responders
were stable over time, although only 36% of participants were available at the latest follow-up point.
The proportion of participants withdrawing because of lack of efficacy is unknown. Through 264 weeks
of follow-up, withdrawals because of adverse events were infrequent and no deaths or malignancies
were observed.
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Ustekinumab
One multicentre trial (CADMUS) in children aged 12–17 years found that both the standard dosage and
the half dosage of ustekinumab were significantly more effective than placebo in improving the severity of
plaque psoriasis, based on PASI 50, 75 and 90 and PGA 0/1 responses at 12 weeks. Both ustekinumab
dosages also led to significantly greater improvements in health-related quality of life, measured using the
CDLQI and PedsQL.
Among participants originally allocated to ustekinumab, PASI and PGA effects observed at 12 weeks
appeared to be largely sustained at 52 weeks, with few withdrawals because of lack of efficacy.
There were no notable adverse effects associated with ustekinumab, although the number of observations
was small and the longest follow-up time was only 60 weeks. Few participants withdrew because of
adverse effects.
Efficacy data from network meta-analyses
The treatment effects for the interventions were assumed to be exchangeable across age as no statistically
significant differences were identified in PASI response outcomes by age within the trials. The wider
network including evidence from adult trials facilitated an indirect comparison of adalimumab, etanercept
and ustekinumab. The NMA results – adjusted for differences in population and placebo response rates –
demonstrated that ustekinumab is the most effective intervention, followed by adalimumab, etanercept
and methotrexate.
Cost-effectiveness evaluation
Cost-effectiveness reported in existing published studies and manufacturer submissions
No previously published cost-effectiveness studies of adalimumab, etanercept or ustekinumab for psoriasis
in children and young people were identified. One economic model was discussed as part of the All Wales
Medicines Strategy Group advice for the use of etanercept within NHS Wales.
None of the companies participating in this appraisal submitted an economic model.
Cost-effectiveness results from de novo modelling
The de novo model generated incremental cost-effectiveness ratios (ICERs) for the three populations
according to age and position of the intervention in the treatment pathway. Results were generated for a
base case and for separate scenarios:
1. In the evaluation of adalimumab as an alternative to systemic therapy, the ICER for adalimumab
compared with methotrexate was £308,329 per QALY.
2. In the evaluation of adalimumab and etanercept after failed systemic therapy in those aged 6–11 years,
adalimumab was more effective but also more costly than etanercept and BSC. Based on a fully
incremental analysis, the ICER for etanercept compared with BSC was £71,903 per QALY whereas the
ICER for adalimumab compared with etanercept was £174,519 per QALY. The individual pairwise ICER
for adalimumab compared with BSC was £115,825 per QALY.
3. In the evaluation of ustekinumab, adalimumab and etanercept after failed systemic therapy in those
aged 12–17 years, ustekinumab was the most effective and most costly treatment, followed by
adalimumab, etanercept and BSC. Based on a fully incremental analysis, etanercept was extendedly
dominated by adalimumab (i.e. etanercept produces additional gains in effectiveness at incremental
costs higher than those of the next most effective strategy of adalimumab), the ICER for adalimumab
compared with BSC was £110,430 per QALY and the ICER for ustekinumab compared with
adalimumab was £201,507 per QALY. The individual pairwise ICERs for etanercept, adalimumab and
ustekinumab compared with BSC were £137,059, £110,430 and £116,568 per QALY respectively.
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Using utility values from an adult population brought the ICER for etanercept compared with BSC under a
threshold of £30,000 per QALY in children and young people aged 6–11 years. The ICERs for ustekinumab
and adalimumab were reduced significantly but remained above the £30,000 per QALY threshold.
Under the assumption of no health benefits for BSC, the ICERs were reduced substantially but remained
quite high, with the lowest ICER being £56,430 per QALY for etanercept compared with BSC.
If the average number of days hospitalised per annum was increased from 0 days to 6.49 days based on a
study in adults, the ICERs for the interventions reduced significantly; however, the only ICER that fell below
the £30,000 threshold was for the use of etanercept compared with BSC in children and young people
aged 6–11 years. If the average length of hospitalisation per annum was increased significantly to 26.6 days
per annum based on a very high-need adult population, the biological treatments were all considered
cost-effective compared with BSC in individuals who have failed systemic therapy.
Discussion
Although the number of included participants and trial follow-up periods were limited, this systematic review
included the best available evidence on the efficacy and short- to medium-term safety of adalimumab,
etanercept and ustekinumab that was directly relevant to the decision problem.
Very little evidence on efficacy or safety was available for young children. The ustekinumab trial restricted
inclusion to participants aged > 12 years and the adalimumab and etanercept studies included few
children aged < 8 years. Only 11 children aged 4–5 years were included across all of the RCTs of biologics
for psoriasis.
The review of cost-effectiveness evidence in this population, and the absence of economic models
submitted by the manufacturers involved in this appraisal, highlight the challenges involved in evaluating
the cost-effectiveness of biological interventions in children and young people with plaque psoriasis.
The fundamental challenge is the limited clinical evidence base for short- and long-term outcomes. A key
strength of this evaluation was that it went beyond the scope of the appraisal by bringing together
evidence from the adult population to support an economic evaluation in children and young people.
However, inevitably the results are subject to a number of uncertainties.
Conclusions
The paucity of clinical and economic evidence to inform the cost-effectiveness of biological treatments in
children and young people has imposed a number of strong assumptions and uncertainties. Health-related
quality-of-life gains associated with treatment and the number of hospitalisations in children and young
people are areas of considerable uncertainty.
Based on the economic assessment, the majority of ICERs for the use of biologics in children and young
people were above NICE’s usual cost-effectiveness threshold and were reduced significantly only by
adopting combined assumptions that align with those made in the management of psoriasis in adults.
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Suggested research priorities
l The continued collection of data through registries of biological therapies for individuals aged
< 18 years is warranted to enable safety, patterns of treatment switching, the impact on comorbidities
and long-term withdrawal rates to be investigated.
l Adequately powered RCTs could substantially reduce the uncertainty surrounding the effectiveness of
biological treatments in biologic-experienced populations of children and young people. In particular,
evidence for the comparative clinical effectiveness and safety of adalimumab and etanercept in younger
children is currently lacking.
l Further research is needed on the resource use and costs associated with BSC.
Study registration
This study is registered as PROSPERO CRD42016039494.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Epidemiology
Psoriasis is a chronic but non-contagious inflammatory disease of the skin and joints.1 The disease
predominantly affects body parts such as the scalp, elbows, knees and lower back and results in typical
red, scaly and flaky skin, also known as plaque psoriasis.2 Plaque psoriasis is the most common type of
psoriasis, although there are also other types of psoriasis such as guttate psoriasis (mostly in the trunk
area), flexural psoriasis (affecting the flexures), palmoplantar pustulosis psoriasis (affecting the palms) and
psoriatic nail diseases.2 In children, plaque lesions appear most frequently on the scalp, followed by the
extensor surfaces of the extremities and the trunk.3
Psoriasis can appear at any age although it predominantly starts during adulthood.1,2,4 The prevalence of
psoriasis varies across the world, ranging from 0% to 2.1% in children and from 0.91% to 8.5% in the
adult population.5 The prevalence of psoriasis in the UK is estimated to be around 0.4% in children
(including adolescents) and 2.2% in adults, with both sexes affected equally.6
Aetiology, pathology and prognosis
The aetiology of psoriasis remains largely unknown; however, a genetic predisposition and environmental
factors are believed to be the key players.7,8 It is estimated that the heritability of psoriasis is 60–90%;
however, a worldwide positive family history of psoriasis ranges between 4.5% and 88%.9 Among
environmental factors, alcohol consumption, infection, emotional stress, medications, obesity and smoking
may be risk factors for psoriasis.1,9
The natural history of psoriasis varies by clinical subtype, that is, it may present as chronic, stable plaques
with intermittent remissions and exacerbations or acutely with a rapid progression and widespread
involvement.1 Plaque psoriasis usually manifests as a chronic disease, with intermittent remissions and, in
some cases, the joints and eyes can be involved.1 In contrast to adults, plaque psoriasis in children is less scaly
and the lesions are often smaller and thinner. This can result in delayed diagnosis of the disease.3 In addition,
in children, plaques appear most frequently on the scalp and may lead to hair loss (psoriatic alopecia) if severe.3
Significance in terms of ill health
The impact of psoriasis encompasses functional, psychological and social dimensions.10 Factors that
contribute to this include symptoms specifically related to the skin (e.g. chronic itch, bleeding, scaling and
nail involvement), problems related to treatments (mess, odour, inconvenience and time), psoriatic arthritis
and the effect of living with a highly visible, disfiguring skin disease (difficulties with relationships, difficulties
with securing employment and poor self-esteem). Even people with minimal involvement (less than the
equivalent of three palm areas) state that psoriasis has a major effect on their life. The combined long-term
therapy costs and social costs of the disease have a major impact on health-care systems and on society
in general.11
Mortality primarily as a result of psoriasis is not common; however, the chronic and incurable nature of
psoriasis means that associated morbidity is significant.11 Studies show that a significant proportion of
children with psoriasis (12–37%) do not grow out of it,12 which implies that childhood psoriasis has a
substantial long-term social and economic impact on individuals and the community.13
Some reports also suggest that adult psoriasis patients who were diagnosed during childhood have worse
lifetime quality of life than those diagnosed during adulthood,14,15 although this claim is not supported by
other studies.16
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Assessment and management of psoriasis in children
Currently, there is no treatment pathway specific to psoriasis for children in the UK. Treatment depends
to some extent on the extent and severity of an individual’s disease and local customs and practice.
Existing psoriasis guidance for all age groups [National Institute for Health and Care Excellence (NICE)
clinical guideline CG153 in England11) states that traditional topical therapies (such as corticosteroids,
vitamin D and analogues, dithranol and tar preparations) can be prescribed as first-line therapy. Second-line
therapies can include phototherapy, broad- or narrow-band ultraviolet B (NBUVB) light, with or without the
supervised application of complex topical therapies such as dithranol in Lassar’s paste or crude coal tar and
photochemotherapy, psoralen plus UVA light (PUVA) and non-biological systemic agents such as ciclosporin,
methotrexate and acitretin. Third-line therapies include systemic biological therapies that use molecules
designed to block specific molecular steps important in the development of psoriasis, such as the tumour
necrosis factor (TNF) antagonists, and anti-interleukin (IL)-12/IL-23 monoclonal antibodies. However, this
guideline highlights special considerations for children (e.g. avoidance of very potent corticosteroids, PUVA
and acitretin) and recommends that children and young people with any type of psoriasis should be referred
to a specialist at presentation.
Assessment of treatment response and quality of life
In children, a variety of clinical scales are used to assess treatment response in psoriasis, including the
Physician Global Assessment (PGA), the Psoriasis Area and Severity Index (PASI),17 the Children’s
Dermatology Life Quality Index (CDLQI),18 the Pediatric Quality of Life Inventory (PedsQL™)19 and the
Teenager’s Quality of Life Index (T-QoL).20
Physician Global Assessment
The PGA is an instrument that provides a subjective overall evaluation of plaque psoriasis severity using a
scale of seven categories (‘clear’, ‘almost clear’, ‘mild’, ‘mild to moderate’, ‘moderate’, ‘moderate to severe’,
‘severe’).21 There are two primary forms: a static form [Static Physician Global Assessment (sPGA)], which
measures the physician’s impression of the disease at a single point, and a dynamic form [Dynamic Physician
Global Assessment (dPGA)], in which the physician assesses the global improvement from baseline.17
The sPGA uses seven scaled scores to describe the severity of disease: 0 = ‘clear’, 1 = ‘almost clear’,
2 = ‘mild’, 3 = ‘mild to moderate’, 4 = ‘moderate’, 5 = ‘moderate to severe’ and 6 = ‘severe’.17,22 The dPGA,
on the other hand, uses six scaled scores to describe either improvement or deterioration of disease. For
disease improvement the scores are +1 = ‘mild’, +2 = ‘moderate’, +3 = ‘moderate to large’, +4 = ‘large’
and +5 = ‘very large’. For disease deterioration the scores are –1 = ‘mild’, –2 = ‘moderate’, –3 = ‘moderate
to large’, –4 = ‘large’ and –5 = ‘very large’. A score of zero indicates no or minimal change.
As the sPGA scoring system is simpler to use than the dPGA scoring system, because, with the dPGA,
physicians have to record the severity of psoriasis at baseline to evaluate the change in disease status after
a follow-up period, the sPGA has become a widely used treatment response assessment tool in practice.17
However, the sPGA does not discriminate small changes and the score ranges are not robust.17
Psoriasis Area and Severity Index
In clinical trials of patients with psoriasis, assessment of the response to treatment is usually based on the
PASI.17 Although it is widely used, the PASI also has a number of deficiencies: its constituent parameters
have never been properly defined; it is insensitive to change in mild-to-moderate psoriasis; estimation of
disease extent is notoriously inaccurate; and the complexity of the formula required to calculate the final
score further increases the risk of errors. It combines an extent and a severity score for each of the four
body areas (head, trunk, upper extremities and lower extremities). The extent score of 0–6 is allocated
according to the percentage of skin involvement (e.g. 0 and 6 represent no psoriasis and 90–100%
involvement respectively). The severity score of 0–12 is derived by adding scores of 0–4 for each of the
qualities of erythema (redness), induration and desquamation, representative of the psoriasis within
the affected area. It is probable, but usually not specified in trial reports, that most investigators take
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induration to mean plaque thickness without adherent scale and desquamation to mean thickness of scale
rather than severity of scale shedding. The severity score for each area is multiplied by the extent score and
the resultant body area scores, weighted according to the percentage of total body surface area (BSA) that
the body area represents (10% for head, 30% for trunk, 20% for upper extremities and 40% for lower
extremities), are added together to give the PASI score. Although the PASI score can theoretically reach 72,
scores in the upper half of the range (> 36) are not common, even in severe psoriasis. Furthermore, the
PASI score fails to capture the disability that commonly arises from involvement of functionally or
psychosocially important areas (hands, feet, face, scalp and genitalia), which together represent only a
small proportion of total BSA.23 However, PASI-based measures have discriminatory capability and are
generally accepted for the assessment of treatment effects. However, clinical expert opinion is that the
PASI is not widely used in clinical practice.
Despite the fact that it has not been validated in children and young people as a measure of disease
severity, the PASI was chosen as the primary outcome variable for psoriasis in the economic evaluation
because it is used in the majority of randomised controlled trials (RCTs). Typically, the PASI is reported as a
dichotomous measure indicating a 50%, 75% or 90% reduction in PASI score from baseline (PASI 50,
PASI 75 and PASI 90 respectively).
Children’s Dermatology Life Quality Index
The CDLQI is a 10-item questionnaire that aims to measure the quality of life of children (aged 4–16 years)
based on how much they have been affected by a skin problem over the week preceding the date of
questioning.18 The 10 items cover six areas of daily activities: symptoms and feelings, leisure, school or
holidays, personal relationships, sleep and treatment.24,25 Usually, children, either alone or with the help of
their parents, choose one of the four possible replies (scored from 0 to 3), with a maximum overall score of
30 and with a high score corresponding to low quality of life and vice versa.25
Children’s Dermatology Life Quality Index scores can be divided into scoring bands – band 0 (score of 0–1),
band 1 (score of 2–6), band 2 (score of 7–12), band 3 (score of 13–18) and band 4 (score of 19–30) – that
respectively correspond to no, small, moderate, very large or extremely large effects on the child’s quality
of life.25 However, the CDLQI is not considered appropriate for use as a health-related quality-of-life
(HRQoL) assessment tool beyond the age of 16 years.
Pediatric Quality of Life Inventory
The PedsQL is a modular instrument for measuring HRQoL in children and adolescents (age 2–18 years).
It consists of 23 items in four domains: physical functioning (8 items), emotional functioning (5 items),
social functioning (5 items) and school functioning (5 items). Each item receives a score of 0–4 (0 = ‘never
a problem’, 1 = ‘almost never a problem’, 2 = ‘sometimes a problem’, 3 = ‘often a problem’, 4 = ‘almost
always a problem’) and are reverse scored and linearly transformed to a 0–100 scale (0 = 100, 1 = 75,
2 = 50, 3 = 25, 4 = 0), so that higher scores indicate better HRQoL.26 Paediatric self-report is measured in
children and adolescents aged 5–18 years and parent proxy report of child HRQoL is measured for children
and adolescents aged 2–18 years.
Teenager’s Quality of Life Index
Built on qualitative data from patients, the Teenager’s Quality of Life Index (T-QoL) is a validated tool to
quantify the impact of skin disease on adolescents’ quality of life.20 The index consists of 18 items
categorised into three domains: self-image, physical well-being and the future, and psychological impact
and relationships. The authors have proposed the T-QoL as an outcome measure in both clinical practice
and clinical research.20
General issues with quality-of-life measurement in childhood psoriasis
Quality-of-life measurements may not be particularly meaningful in younger children with psoriasis, who
are less good at articulating how much the disease is bothering them. In the case of younger children,
proxy measurements may more accurately reflect parental perception or concern. There is only moderate
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correlation between PASI/PGA response measures and the CDLQI;27 some children with relatively mild
disease can have very poor HRQoL scores, whereas others with more severe disease can have acceptable
HRQoL. As well as disease symptoms and consequences, the frequency of injections can be an important
quality-of-life consideration in children.
Description of the technology under assessment
Biological therapies, or biologics, are agents that are extracted or semi-synthesised from biological sources and
which are used for treating specific medical conditions, including autoimmune diseases. They are frequently
produced using recombinant deoxyribonucleic acid (DNA) technology and are designed to act on specific parts
of the human immune system. For example, biologics such as certolizumab, etanercept (Enbrel®, Pfizer,
New York, NY, USA), adalimumab (HUMIRA®, AbbVie, Maidenhead, UK), infliximab (Remicade®, Janssen
Biotech, Inc., Horsham, PA, USA) and golimumab (Simponi®, Janssen Biotech, Inc., Horsham, PA, USA) block
tumour necrosis factor alpha (TNF-α), and ustekinumab (STELARA®, Janssen Biotech, Inc., Titusville, NJ, USA)
and secukinumab (Cosentyx®, Novartis, Basel, Switzerland) inhibit IL-12/IL-23 and IL-17-A respectively. Such
biologics are indicated for a range of conditions, including psoriasis, psoriatic arthritis, rheumatoid arthritis,
ankylosing spondylitis and inflammatory bowel disease.
Three biologics (adalimumab, etanercept and ustekinumab) have regulatory approval for the treatment of
plaque psoriasis in children and young people (Table 1).
Adalimumab is a fully human immunoglobulin G1 monoclonal antibody that inhibits the activity of TNF-α.
It has a marketing authorisation in the UK for treating severe chronic plaque psoriasis in children and
adolescents from 4 years of age who have an inadequate response to, or who are inappropriate candidates
for, topical therapy and phototherapies.
Etanercept is a recombinant human TNF-α receptor fusion protein that inhibits the activity of TNF-α. It has
a marketing authorisation in the UK for treating chronic severe plaque psoriasis in children and adolescents
from the age of 6 years who are inadequately controlled by, or who are intolerant to, other systemic
therapies or phototherapies.
TABLE 1 Summary of drug properties and marketing authorisations
Treatment
Age
range Disease status
Mechanism
of action Dose/frequency Treatment pathway
Adalimumab ≥ 4 years Severe chronic
plaque psoriasis
TNF-α
inhibitor
0.8 mg/kg up to a maximum
of 40mg at weeks 0 and 1,
then every 2 weeks thereafter
When topical therapy
and phototherapies
are inadequate or
inappropriate
Etanercept ≥ 6 years Severe chronic
plaque psoriasis
TNF-α
inhibitor
0.8 mg/kg up to a maximum
of 50mg weekly for up to
24 weeks
When systemic therapies
or phototherapies are
inadequate or not
tolerated
Ustekinumab ≥ 12 years Moderate to
severe plaque
psoriasis
IL-12/IL-23
inhibitor
0.75 mg/kg for body weight
of < 60 kg, 45 mg for body
weight of 60–100 kg and
90mg for body weight of
> 100 kg at weeks 0 and 4,
then every 12 weeks
thereafter
When systemic therapies
or phototherapies are
inadequate or not
tolerated
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Ustekinumab is a fully human monoclonal antibody that acts as a cytokine inhibitor by targeting IL-12
and IL-23. It has a marketing authorisation for treating moderate to severe plaque psoriasis in adolescent
patients from the age of 12 years who are inadequately controlled by, or who are intolerant to, other
systemic therapies or phototherapies.
More recently, versions of biological drugs have become available that have been manufactured after the
expiry of an original innovator agent’s patent. These ‘biosimilars’ are developed to be highly similar to the
existing biological agents in physicochemical and biological terms and are typically cheaper than the original
agents. Biosimilar medicines are usually licensed for all indications specified in the licence of the originator
biological medicine, but this requires appropriate scientific justification on the basis of demonstrated or
extrapolated equivalence. Benepali® (Biogen Idec Ltd, Maidenhead, UK), a biosimilar of etanercept, has been
approved in Europe for use in adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, severe
ankylosing spondylitis, severe non-radiographic axial spondyloarthritis and moderate to severe plaque
psoriasis. Currently, three biosimilars of infliximab (Inflectra®, Pfizer; Remsima, Pfizer; and Flixabi®, Biogen,
Cambridge, MA, USA) are approved for use in ankylosing spondylitis, Crohn’s disease, psoriatic arthritis,
psoriasis, rheumatoid arthritis and ulcerative colitis.
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Chapter 2 Definition of the decision problem
According to NICE guideline CG153 in England,
11 psoriasis patients are treated in three stages.
First-line therapy includes traditional topical therapies (such as corticosteroids, vitamin D and
vitamin D analogues, dithranol and tar preparations). Second-line therapies include the phototherapies
NBUVB light and PUVA and systemic non-biological agents such as ciclosporin, methotrexate and acitretin.
Systemic biological therapies such as the TNF antagonists adalimumab, etanercept and infliximab and the
monoclonal antibody ustekinumab, which targets IL-12 and IL-23, can be provided as third-line therapy.
The three biologics that have regulatory approval for the treatment of plaque psoriasis in children and
young people (adalimumab, etanercept and ustekinumab) have not yet been appraised by NICE and no
NICE technology appraisal (TA) guidance is available for treating children and adolescents in the UK with
these treatments for this indication.
Objective
The aim of this study was to determine the clinical effectiveness and cost-effectiveness of adalimumab,
etanercept and ustekinumab within their respective licensed indications for the treatment of plaque
psoriasis in children and young people.
Note
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
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Chapter 3 Assessment of clinical effectiveness
Methods for the synthesis of evidence of clinical effectiveness
A systematic review of the clinical effectiveness of adalimumab, etanercept and ustekinumab within their
respective licensed indications for the treatment of plaque psoriasis in children and young people was
performed following the general principles recommended in the Centre for Reviews and Dissemination
(CRD)’s guidance28 and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement.29 A protocol was registered with PROSPERO.
Literature searching: adalimumab, etanercept and ustekinumab
The literature search for the clinical effectiveness review aimed to systematically identify relevant RCTs of
adalimumab, etanercept and ustekinumab used to treat children and young people with plaque psoriasis.
The search strategy was developed in MEDLINE (via Ovid) and included search terms for:
l psoriasis
l adalimumab, etanercept, ustekinumab or biosimilars
l children or young people.
The three sets of terms were combined using the Boolean operator AND. Search terms were developed
through discussion with the review team and use of database thesauri and online drug information
resources. No language, date, geographical or study design limits were applied. The MEDLINE strategy was
adapted for use in the other resources searched.
The searches were carried out on 24/25 May 2016 and updated during September 2016. The following
databases were searched: MEDLINE (including MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other
Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE), Cochrane Central Register of Controlled
Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), Cumulative Index to Nursing and
Allied Health Literature (CINAHL) Plus, Database of Abstracts of Reviews of Effects (DARE), EMBASE,
Health Technology Assessment (HTA) database, NHS Economic Evaluation Database (NHS EED), PubMed
and Science Citation Index.
In addition, the following resources were searched for ongoing, unpublished or grey literature:
ClinicalTrials.gov, Conference Proceedings Citation Index – Science, EU Clinical Trials Register, PROSPERO
and World Health Organization (WHO) International Clinical Trials Registry Platform portal.
A search for guidelines on psoriasis in children or young people was carried out through the following
guideline websites: National Guideline Clearinghouse (www.guideline.gov; accessed 14 June 2017),
NICE Clinical Knowledge Summaries (https://cks.nice.org.uk/; accessed 14 June 2017), NHS Evidence
(www.evidence.nhs.uk; accessed 14 June 2017), NICE evidence summaries: new medicines (www.
evidence.nhs.uk/Search?q=Evidence+summary+new+medicine; accessed 14 June 2017) and the NICE
website (www.nice.org.uk/; accessed 14 June 2017).
In addition to utilising these published and unpublished data resources, requests for clinical study reports (CSRs)
relating to adalimumab, etanercept and ustekinumab were made to AbbVie, Pfizer and Janssen respectively.
The search results were imported into EndNote X7 (Thomson Reuters, CA, USA) and deduplicated.
Full search strategies can be found in Appendix 1.
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Literature searching: network meta-analysis
Alternative treatments in children and young people
To inform the network meta-analysis (NMA), searches were undertaken to identify relevant RCTs of
systemic non-biological (acitretin, methotrexate and ciclosporin) and other biological (infliximab,
secukinumab) therapies used in children and young people with plaque psoriasis. No language, date,
geographical or study design limits were applied to the searches.
The searches were carried out on 31 May 2016 in the following databases: MEDLINE (including MEDLINE
Epub Ahead of Print, MEDLIINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid
MEDLINE), CENTRAL, CDSR, CINAHL Plus, DARE, EMBASE, HTA database, PubMed and Science
Citation Index.
In addition, the following resources were searched for ongoing, unpublished or grey literature:
ClinicalTrials.gov, Conference Proceedings Citation Index – Science, EU Clinical Trials Register, PROSPERO
and WHO International Clinical Trials Registry Platform portal.
The search results were imported into EndNote X7 and deduplicated. The search was updated in
September 2016 to capture more recent studies. Full search strategies can be found in Appendix 1.
Registry data
To identify longer-term follow-up evidence, a literature search was conducted within the MEDLINE database
for the search terms ‘psoriasis AND regist*’. The results of this search were screened for publications from
psoriasis registries, secondary analyses of registry data and systematic reviews of broader dermatological
and psoriasis registry data. The list of registries generated through these searches was compared against
those in three relevant systematic reviews30–32 to verify the studies included and to identify any that had
been overlooked. Twenty patient registries for psoriasis treatment were identified in this way; 14 were
located in European countries, three were international in scope, two were based in the USA and one was
based in Malaysia. Each registry name was then separately used as a search term in MEDLINE and any
publications referencing these that had not been found in the initial searches were retrieved.
In addition, representatives of the 14 psoriasis registries from European countries (Austria, Australia, Czech
Republic, Denmark, France, Germany, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland
and the UK) were contacted and asked to provide any relevant information on the use of the biologics
adalimumab, etanercept and ustekinumab for the treatment of psoriasis in children and young people.
Inclusion and exclusion criteria
Two reviewers independently screened all titles and abstracts. Full manuscripts for any potentially relevant
titles/abstracts were obtained when possible and the relevance of each study was assessed by two
reviewers according to the following criteria. Any discrepancies were resolved by consensus and, if
necessary, a third reviewer was consulted. Studies available only as abstracts were included and attempts
were made to contact the authors for further details.
Study design
Randomised controlled trials (including any open-label extensions of RCTs) were eligible for the review of
clinical efficacy.
Information on adverse events (AEs) was also sought from regulatory sources when appropriate. Registries
and observational studies were included when relevant outcome data were available.
To address longer-term measures of efficacy and drug survival, published analyses based on large and
long-term data sets (including studies of registry data) were also considered.
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Participants
Studies of children and/or young people with moderate to severe plaque psoriasis were included. Severity
could be defined using the PASI, PGA, BSA or other measures, alone or in combination, although there
is no universal definition of severity for this population. Studies of guttate, erythrodermic and pustular
psoriasis were excluded, as were studies of psoriatic arthritis.
Studies in children or young people with psoriasis in whom topical therapies, systemic therapies or
phototherapies were inadequate, inappropriate or not tolerated were eligible for inclusion. Participants
aged < 12 years were considered to be children whereas those aged 12–17 years were considered to be
young people.
Interventions
The relevant interventions were adalimumab, etanercept and ustekinumab.
Comparators
The relevant comparators were:
l alternative biological therapies with relevant marketing authorisation (adalimumab, etanercept
or ustekinumab)
l non-biological systemic therapy (including, but not limited to, ciclosporin and methotrexate)
l topical therapy (for people in whom non-biological systemic therapy is not suitable), that is, best
supportive care (BSC)
l biological treatments used outside their marketing authorisation (such as infliximab, adalimumab,
etanercept or ustekinumab if used outside the constraints of the relevant marketing authorisation in
children and young people)
l biosimilars of etanercept, adalimumab or ustekinumab
l placebo.
Outcomes
Data on effectiveness, adverse effects, patient-centred outcome measures, costs to the health service and
cost-effectiveness were eligible for inclusion, including the following outcomes:
l severity of psoriasis (e.g. BSA, PGA score)
l response and remission rates (e.g. PASI 50/75/90 response)
l relapse rate
l rates of treatment discontinuation and withdrawal
l short- and long-term adverse effects of treatment (e.g. injection site and allergic reactions, serious
infections, reactivation of infections including tuberculosis, malignancy)
l HRQoL [e.g. CDLQI, PedsQL and EuroQol-5 Dimensions (EQ-5D)33 scores].
Data extraction
Data relating to both study design and study quality were extracted by one reviewer using a standardised
data extraction form and independently checked for accuracy by a second reviewer. Disagreements were
resolved through consensus and, if necessary, a third reviewer was consulted. Data from studies with
multiple publications were extracted and reported as a single study.
Quality assessment
The quality of RCTs was assessed using the Cochrane risk-of-bias tool,34 with additional assessments made
for baseline imbalance of important prognostic indicators.35 Relevant prognostic and treatment response
indicators were identified from both published research and clinical advice. The risk-of-bias assessment was
performed by one reviewer and independently checked by a second. Disagreements were resolved through
consensus and, if necessary, a third reviewer was consulted.
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The quality of non-randomised studies was assessed using a checklist based on CRD guidance28 and used
in previous technology assessments for NICE.36 This assesses study eligibility criteria and recruitment
methods, the baseline similarity of comparison groups, the blinding of allocation, the completeness of
follow-up and outcome reporting.
Methods of data synthesis
The analysis and synthesis of clinical data in this review was conducted in distinct sections. In the absence
of sufficient trials to conduct pairwise meta-analysis, the results of included studies are presented in a
series of structured tables and summarised narratively and subjected to detailed critical appraisal.
To assess the relative clinical effectiveness of the three biologics (i.e. adalimumab, etanercept and
ustekinumab), syntheses of both pairwise (head-to-head) and indirect comparative data were planned.
When possible, treatment response (PASI) outcomes were to be synthesised using Bayesian NMA methods.
Bayesian statistical methods provide information on the benefits of the active treatments relative to the
appropriate comparators and each other.37 Meta-analysis using mixed-treatment comparisons enables the
estimation of different parameters from several studies with similar comparisons to be combined when
direct evidence on comparisons of interest is absent or sparse.38 For example, should active treatments
being evaluated have a common comparator of placebo, this would allow a network to be established
between them, providing information on the benefits of these treatments relative to placebo and to
each other.
However, the available trials conducted in children precluded the construction of the necessary network.
To inform the economic evaluation, trials conducted in adults were included in a NMA. Full details of the
methods and results are presented in Chapter 4 (see Framework of analysis for informing the relative
efficacy of the interventions).
Results
Quantity of identified evidence
A total of 2386 non-duplicate records were identified from the clinical effectiveness database searches.
Of these, 2284 records were excluded after title or abstract screening. In addition, eight relevant regulatory
documents were retrieved. Thus, a total of 111 records were read in full, resulting in 63 records being
excluded and a total of 48 records being included in the review,39–86 relating to nine studies (three RCTs
and six open-label or observational follow-up studies) (Figure 1). The included records are summarised in
Appendix 2. Appendix 3 lists the excluded studies and reasons for exclusion.
Searches for relevant registry data identified 685 publications. Three publications from two registries were
found to include children with psoriasis who were treated with biologics. Of the 14 national psoriasis
registry representatives contacted, seven responded but no relevant additional data were available.
Characteristics of the included studies
Three RCTs were retrieved, one for each of the biologics of interest (i.e. adalimumab,39–47,79,80,87 etanercept48–69
and ustekinumab72–75,81,82,88). The RCTs investigated short-term clinical efficacy and AEs. The etanercept and
ustekinumab trials included 12 weeks of follow-up and used placebo as a comparator whereas the adalimumab
trial was of 16 weeks’ duration and included oral methotrexate, a non-biological systemic treatment, as the
comparator. Participant selection criteria for these trials are reported in Table 2. Each RCT also incorporated an
open-label phase (Table 3). These open-label or observational periods investigated longer-term efficacy and AEs,
incorporating withdrawal and/or retreatment phases. The adalimumab, etanercept and ustekinumab trials had
52, 312 and 60 weeks of follow-up data available respectively.
ASSESSMENT OF CLINICAL EFFECTIVENESS
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Baseline characteristics of participants
The baseline characteristics of the participants in the included RCTs are presented in Table 4. Although
only older children and adolescents (aged 12–17 years) were included in the ustekinumab trial, the median
age of children across the three trials did not differ greatly, as it appears that relatively few younger
children were included in the adalimumab and etanercept trials.
All three trials used a composite measure of disease severity incorporating baseline PASI, PGA and BSA
measurements. When used in isolation, a PASI score between 10 and 20 is considered to indicate
moderate to severe psoriasis, whereas severe psoriasis has a score of > 20. Across the included studies,
the average PASI score ranged from 18.3 to 21.2, with 93–100% of participants having a PGA score of
> 3 (mild/moderate disease). Although adalimumab and etanercept are licensed for severe chronic plaque
psoriasis and ustekinumab is licensed for moderate to severe plaque psoriasis, on average, measures of
disease duration and the component measures of severity did not appear to differ markedly between the
three trials. The degree of psoriasis affecting high-impact and difficult-to-treat sites (e.g. face, scalp, palms,
soles, flexures and genitals) across the three studies was less clear.
A key difference between the licences for the three agents is the availability of adalimumab for patients for
whom topical therapy and phototherapy are inadequate or inappropriate. Unlike the licences for etanercept
and ustekinumab, there is no mention in the licence for adalimumab of previous non-biological systemic
treatment. However, a substantial minority of participants in the adalimumab trial (29.8%) had received
Number of non-duplicated records identified
through database searching
Number of records identified
through other sources (regulatory
documents and company
submissions)
(n = 9)
Number of records screened (title and
abstract reading)
(n = 2386)
Number of records excluded
(n = 2284)
Number of full-text articles assessed for eligibility
(n = 102)
Number of full-text articles excluded
with reasons
(n = 62)
Number of records included in systematic review
(n = 48, relating to 9 studies)
Number of records included in NMA
(n = 3)
• RCTs, n = 3
• Observational studies, n = 6
• Initial search, n = 2294
• Update search, n = 92
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of studies
in children and young people.
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TABLE 2 Inclusion and exclusion criteria for included RCTs
Criteria
Study
Adalimumab (M04-717) Etanercept (20030211) Ustekinumab (CADMUS)
Inclusion criteria l Aged ≥ 4 years and < 18 years
l Weight of ≥ 13 kg
l Failed to respond to topical therapy
l Needs systemic treatment to control his or her
disease and meets one of the following:
¢ sPGA score of ≥ 4
¢ BSA involvement of > 20%
¢ very thick lesions with BSA involvement
of > 10%
¢ PASI score of > 20
¢ PASI score of > 10 and at least one of the
following: active psoriatic arthritis unresponsive
to non-steroidal anti-inflammatory drugs,
clinically relevant facial involvement, clinically
relevant genital involvement, clinically relevant
hand and/or foot involvement, CDLQI score
of > 10
l If < 12 years of age and resides in a geographical
region where heliotherapy is practical, must have
failed to respond, be intolerant or have a
contraindication to heliotherapy or is not a suitable
candidate for heliotherapy
l If ≥ 12 years of age, must have failed to respond,
be intolerant or have a contraindication to
phototherapy or is not a suitable candidate
for phototherapy
l Must have a clinical diagnosis of psoriasis for at
least 6 months as determined by the medical history
and confirmation of diagnosis through physical
examination by the investigator
l Must have had stable plaque psoriasis for at least
2 months prior to baseline
l Aged 4–17 years
l Stable, moderate to severe plaque psoriasis at
screening, defined as a PASI score of ≥ 12
l A static PGA score of at least 3 (in which 0
indicates clear and 5 indicates severe psoriasis)
and BSA involvement of ≥ 10%
l A history of psoriasis for at least 6 months
l Previous or current treatment with
phototherapy or systemic psoriasis therapy
(e.g. methotrexate, ciclosporin or retinoids) or
psoriasis considered by the investigator as
being poorly controlled with topical therapy
l Aged 12–17 years (inclusive)
l Diagnosis of moderate to severe plaque
psoriasis (i.e. baseline PASI score of ≥ 12, PGA
score of ≥ 3 and ≥ 10% BSA involved with
psoriasis) for ≥ 6 months
l Candidate for phototherapy or systemic
treatment or had psoriasis that was poorly
controlled with topical therapy
l Diagnosis of plaque-type psoriasis with or
without psoriatic arthritis for at least 6 months
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Criteria
Study
Adalimumab (M04-717) Etanercept (20030211) Ustekinumab (CADMUS)
Exclusion criteria l Previous biological therapy use other than previous
treatment with etanercept
l Treatment with etanercept therapy within 4 weeks
of the baseline visit
l Methotrexate use within the past year or previous
methotrexate use at any time in which the
participant did not respond or did not
tolerate methotrexate
l Contraindication for treatment with methotrexate
during the study
l Erythrodermic psoriasis, generalised or localised
pustular psoriasis, medication-induced or medication-
exacerbated psoriasis or new-onset guttate psoriasis
l Infection(s) requiring treatment with intravenous
anti-infectives within 30 days of the baseline visit or
oral anti-infectives within 14 days of the baseline visit
l Treatment of psoriasis with topical therapies such as
corticosteroids, vitamin D analogues or retinoids
within 7 days of the baseline visit
l Treatment of psoriasis with UVB phototherapy,
excessive sun exposure or the use of tanning beds
within 7 days of the baseline visit
l Treatment of psoriasis with PUVA phototherapy,
non-biological systemic therapies for the treatment
of psoriasis or systemic therapies known to improve
psoriasis within 14 days of the baseline visit
l Pregnancy or lactation (sexually active patients
were required to use contraception)
l Guttate, erythrodermic or pustular psoriasis
l Skin conditions that would interfere with
study evaluations
l Previous treatment with anti-TNF agents
l Major concurrent medical conditions
l Treatment with PUVA, UVA, UVB, systemic
psoriasis medications, oral or parenteral
corticosteroids, topical corticosteroids, topical
vitamin A or D analogue preparations,
anthralin or calcineurin inhibitors within a
14-day washout period before the study
l Treatment with biological agents within a
30-day washout period before the study.
Patients could use low-to-moderate-potency
topical steroids on the scalp, axillae or groin
l Currently has non-plaque forms of psoriasis
(e.g. erythrodermic, guttate or pustular) or drug-
induced psoriasis (e.g. a new onset of psoriasis
or an exacerbation of psoriasis from beta-
blockers, calcium channel blockers or lithium)
l Has used any therapeutic agent targeted at
reducing IL-12 or IL-23, including but not
limited to ustekinumab and briakinumab
(Abbott Laboratories, Lake Bluff, IL, USA)
l Received conventional systemic therapies or
phototherapy within the last 4 weeks
l Received biological therapies within the last
3 months
UVA, ultraviolet A; UVB, ultraviolet B.
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TABLE 3 Trial durations (including open-label extensions) and dosing regimens
Study Relevant dosing and regimens used
Duration of
randomised
and blinded
phase Post-randomised period design details
Latest time
point with
available
results
Anticipated time to response:
information from Summary of
Product Characteristics
Adalimumab
(M04-717)
Adalimumab: standard dose (initial 0.8 mg/kg
up to a maximum of 40mg, followed by
0.8 mg/kg every other week) or half-dose.
Methotrexate: initial dose 0.1 mg/kg, up to a
maximum of 7.5 mg per week, followed by
a dose of up to 0.4 mg/kg from week 1
onwards, up to a maximum dose of 25 mg
per week
16 weeks After the primary treatment phase (period A –
blinded period), responders from period A
were withdrawn from active treatment for up
to 36 weeks and monitored for loss of
disease control (withdrawal phase or period
B). Participants from period B who had
experienced loss of disease control were
treated with adalimumab for up to 16 weeks
(retreatment phase or period C). Participants
from periods A, B and C who met entry
criteria to the long-term follow-up phase or
period D received adalimumab or were
observed off treatment (if disease remained
under control during period B)
52 weeks Continued therapy beyond 16 weeks
should be carefully considered in a
patient not responding within this time
period
Etanercept
(20030211)
Etanercept: dose of 0.8 mg/kg of body
weight up to a maximum intended dose
of 50 mg
12 weeks A 24-week, open-label treatment period
(weeks 13–36) to assess the efficacy of
etanercept therapy in all patients and a
12-week, randomised, double-blind,
withdrawal–retreatment period (weeks 37–48)
to examine the effects of withdrawal of the
study drug and subsequent retreatment
312 weeks The recommended dose is 0.8 mg/kg
(up to a maximum of 50mg per dose)
once weekly for up to 24 weeks.
Treatment should be discontinued in
patients who show no response after
12 weeks. If retreatment with
etanercept is indicated, the above
guidance on treatment duration should
be followed
Ustekinumab
(CADMUS)
Ustekinumab: standard dose (0.75 mg/kg
for those weighing up to 60 kg, fixed 45mg
for those weighing 60–100 kg, fixed 90mg
for those weighing > 100 kg) or half-dose
at 0 and 4 weeks and every 12 weeks
subsequently
12 weeks After the double-blinded period (12 weeks),
those in the placebo group were allowed
to cross over to receive either standard or
half-dose ustekinumab at weeks 12 and
16 and then every 12 weeks. Participants
were followed for efficacy and safety
through weeks 52 and 60 respectively
60 weeks Consideration should be given to
discontinuing treatment in patients
who have shown no response up to
28 weeks of treatment
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TABLE 4 Baseline characteristics of participants in the included RCTs
Characteristic
Study
Adalimumab (M04-717) Etanercept (20030211) Ustekinumab (CADMUS)
Adalimumab
0.8 mg/kg
Adalimumab
0.4mg/kg Methotrexate
Etanercept
0.8mg/kg Placebo
Ustekinumab
0.75mg/kg
Ustekinumab
0.375mg/kg Placebo
Study duration (weeks) 16 16 16 12 12 12 12 12
Number of participants 38 39 37 106 105 36 37 37
Age (years), median (range) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
14 (4–17) 13 (4–17) 15.0 (12–17) 15.0 (12–17) 16 (12–17)
Age (years), mean (SD) 13.0 (3.3) 12.6 (4.4) 13.4 (3.5) – – 14.8 (1.7) 15.1 (1.7) 15.6 (1.5)
Male (%) 44.7 53.8 29.7 52 50 44.4 48.6 54.1
Duration of psoriasis (years),
mean (SD)
5.0 (3.8) 4.8 (3.3) 5.1 (3.8) – – 5.6 (3.8) 5.9 (4.0) 6.2 (5.0)
Duration of psoriasis (years),
median (range)
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
6.8 (0.3–17.9) 5.8 (0.3–15.8) 5.5 (0.6–13.6) 5.7 (0.5–15.0) 5.1 (0.4–17.8)
Weight (kg), mean (SD) – – – – – 62 (17.1) 68.2 (24.5) 64.7 (14.7)
Weight (kg), median (range) 48.5 (17–95) 53 (15–108) 52 (20–87) 59.6
(17.7–168.3)
59.8
(17.2–131.5)
61.7
(33.8–109.5)
62.0
(32.0–173.5)
60.3
(43.8–107.0)
Height (cm), mean (SD) – – – – – 163.9 (9.2) 168 (11.0) 169.7 (11.3)
Height (cm), median (range) 156.5
(104–185)
157 (121–182) 157 (121–182) 159 (104–188) 158 (104–191) 163.0
(145.0–181.0)
168.0
(142.0–188.0)
171.3
(147.0–188.0)
BSA % affected, mean (SD) 27.7 (20.4) 26.0 (16.2) 30.3 (21.2) – – 31.9 (23.2) 33.6 (21.4) 27.4 (16.4)
BSA % affected, median
(range)
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
21 (10–90) 20 (10–95) – – –
continued
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TABLE 4 Baseline characteristics of participants in the included RCTs (continued )
Characteristic
Study
Adalimumab (M04-717) Etanercept (20030211) Ustekinumab (CADMUS)
Adalimumab
0.8 mg/kg
Adalimumab
0.4mg/kg Methotrexate
Etanercept
0.8mg/kg Placebo
Ustekinumab
0.75mg/kg
Ustekinumab
0.375mg/kg Placebo
PASI score, median (range) 15.3
(10.2–50.4)
15.6 (6.1–29.4) 17.5 (5.0–51.4) 16.7
(12.0–51.6)
16.4
(12.0–56.7)
16.8 19.5 19.6
PASI score, mean (SD) 18.9 (10) 16.9 (5.8) 19.2 (10) 18.5 (6.7) 18.6 (6.8) 21.7 (10.4) 21.0 (8.5) 20.8 (8.0)
PGA score of ≥ 3 (%) 92 90 97 99 99 100 100 100
Psoriatic arthritis (%) 0 2.6 0 5 13 5.6 5.4 5.4
Previous use of topical
therapy (%)
100 100 100 – – 91.7 83.8 91.9
Previous use of
phototherapy (%)
44.7 59 51.4 – – 38.9 48.6 29.7
Previous use of systemic
therapy (%)
36.8 28.2 24.3 55a 59a 47.2 37.8 43.2
Previous use of biological
therapy (%)
10.5 10.3 8.1 0 0 8.3 10.8 13.5
CDLQI score, mean (SD) 10.9 (6.6) 11.6 (7.9) 11.4 (5.6) 8.7 (6.0) 10 (6.4) 10.3 (6.6) 9.4 (6.5) 9.1 (6.4)
CDLQI score, median (range) 10 (1–23) 10.5 (0–27) 12 (1–23) 7.0 (0–26) 9.5 (0–29) 9.0 (1.0–26.0) 10.5 (0.0–24.0) 10.0 (1.0–26.0)
PedsQL score, mean (SD) 70.4 (14.2) 70.4 (21.3) 78.8 (14.9) 74.8 (17.8) 76.1 (16.9) 76.4 (15.3) 75.2 (16.2) 73.3 (17.5)
PedsQL score, median
(range)
72.3
(41.3–93.5)
75 (5.4–100) 84.8 (38.98.9) 77.2 (5.4–100) 79.9 (79.9–100) 79.4
(42.4–100.0)
77.7
(34.8–97.8)
77.2
(26.1–98.9)
SD, standard deviation.
a Phototherapy or systemic therapy.
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prior systemic therapy, compared with 42.7% of participants in the ustekinumab trial; 56.8% of participants
in the etanercept trial had received either prior systemic therapy or prior phototherapy (separate data were
not reported).
A similar proportion of participants in the adalimumab and ustekinumab trials had received some form of
biological treatment prior to enrolment (9.6% and 10.8% respectively). As etanercept was the first TNF-α
inhibitor to be approved for psoriasis, none of the participants recruited to the etanercept trial had
previously been treated with biological therapy.
Although there were noticeable differences in participant characteristics between the trials, these were not as
clear as the respective licences for the three treatments might suggest. Notwithstanding methodological
differences, there appears to be sufficient overlap in the trial populations to discuss these three trials together.
Length of follow-up and early escape
The initial randomised treatment period was 12 weeks in the etanercept and ustekinumab trials and
16 weeks in the adalimumab trial. Twelve-week outcome data were not available for the adalimumab trial,
although clinical advice (Dr Ruth Murphy, Consultant Dermatologist, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, 25 October 2016, personal communication) suggested that the difference in
length of follow-up between treatments was acceptable.
All three trials allowed participants to ‘escape’ from the randomised treatment period before the
12-/16-week follow-up. The criteria for early escape and statistical handling of early escape data are
discussed separately for each trial in the relevant sections.
Post-randomised treatment periods are briefly summarised in Table 3.
Outcomes
The adalimumab and etanercept trials considered the PASI 75 response to be the primary outcome
measure, whereas the ustekinumab trial used a primary outcome measure of a PGA score of 0 or 1
(‘clear’ or ‘almost clear’). However, all three trials reported PASI and PGA scores and some measure of
HRQoL (CDLQI and/or PedsQL), which are presented in the following sections.
Efficacy and safety of adalimumab
One multicentre RCT (M04-717) comparing two doses of adalimumab against methotrexate met the
selection criteria for the review. Although this trial has not been published in a peer-reviewed journal, data
were available from regulatory documentation,46,47 conference proceedings39–44,87 and a CSR provided by
the manufacturer.45
The M04-717 trial was separated into four periods:
1. period A – double-blind RCT of initial treatment (16 weeks)
2. period B – observational study of treatment withdrawal (up to 36 weeks)
3. period C – double-blind retreatment study based on original randomisation in period A (16 weeks)
4. period D – long-term follow-up (up to 52 weeks).
The double-blind RCT (period A) recruited paediatric patients (aged 4–17 years, weighing ≥ 13 kg) with
severe chronic psoriasis from 42 centres across 13 countries. Severe chronic psoriasis was defined as failure
to respond to topical therapy, requiring systemic treatment to control disease, and one of the following:
(1) sPGA of ≥ 4, (2) BSA involvement of > 20%, (3) very thick lesions with BSA involvement of > 10%,
(4) PASI score of > 20, or (5) PASI score of > 10 plus one of the following: (i) active psoriatic arthritis
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unresponsive to non-steroidal anti-inflammatory drugs, (ii) clinically relevant facial involvement, (iii) clinically
relevant genital involvement, (iv) clinically relevant hand and/or foot involvement, or (v) CDLQI score
of > 10.
In total, 114 participants were randomised: 38 to standard-dose adalimumab (subcutaneous; initial dose of
0.8 mg/kg up to a maximum of 40mg, followed by 0.8 mg/kg every other week); 39 to low-dose adalimumab
(subcutaneous; initial dose of 0.4 mg/kg up to a maximum of 20 mg, followed by 0.4 mg/kg every other
week); and 37 to methotrexate (orally; initial dose of 0.1 mg/kg up to a maximum of 7.5 mg, followed by a
weekly dose of up to 0.4 mg/kg, up to a maximum dose of 25 mg/week). To maintain blinding, participants
allocated to adalimumab received placebo tablets and participants allocated to methotrexate received a
placebo injection according to the adalimumab schedule. As methotrexate is a folic acid antagonist, all
participants received folic acid (0.8–1.0 mg/day) as a dietary supplement (to maintain study blinding).
Previous therapy received by trial participants included topical therapy (100%), phototherapy (52%),
non-biological systemic therapy (30%) and biological therapy (10%; all etanercept).
Risk-of-bias assessment
The risk of bias for the trial was low for most domains, with appropriate methods used for the allocation
of participants, blinding, handling of missing data and reporting of outcomes (on the basis of information
reported in the CSR;45 Table 5). Baseline characteristics were mostly balanced across treatment groups,
with the exception of percentage of males, which appeared to be lower in the methotrexate arm. It should
be noted that only six of the 114 children randomised were aged < 7 years at recruitment, all of whom
TABLE 5 Risk-of-bias assessment using the Cochrane risk-of-bias tool34 for the adalimumab trial (M04-717)
(period A)
Assessment criterion
Risk-of-bias
judgement Support for judgement
Sequence generation Low ‘Participants were randomised by interactive voice/web response system to
receive adalimumab 0.8 mg/kg, adalimumab 0.4 mg/kg, or MTX in a 1 : 1 : 1
ratio, respectively. Randomisation was stratified by prior treatment with
etanercept’ (p. 15)45
Allocation concealment Low Participants were randomised using an interactive voice/web response
(IVR/IWR) system
Baseline comparability Moderate There was a higher proportion of female participants in the methotrexate
group than in the adalimumab groups. Only six children aged < 7 years were
included in the trial, all of whom were in the 0.4 mg/kg adalimumab group.
There was a higher baseline PedsQL score in the methotrexate group
Blinding of participants,
personnel and outcome
assessors
Low ‘All AbbVie personnel with direct oversight of the conduct and management
of the trial, (with the exception of the AbbVie Drug Supply Management
Team), the PI, study site personnel, and the participant were to remain
blinded to each participant’s treatment throughout the blinded period of the
study. The IVR/IWR system was to provide access to blinded participant
treatment information in the case of medical emergency’ (p. 15).45 There was
one participant for whom the blind was broken because of a serious adverse
event (proctocolitis) that occurred on day 195 of period B and who was thus
non-treatment emergent
Incomplete outcome data Low Eight participants ‘early escaped’ by week 8 of period A: five initially
randomised to methotrexate, two randomised to low-dose adalimumab and
one randomised to standard-dose adalimumab
(Confidential information has been removed)
Selective reporting Low All outcomes from the trial protocol were reported in the CSR45
IVR, interactive voice response; IWR, interactive web response; PI, principal investigator.
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were randomised to the low-dose adalimumab group. This means that, despite adalimumab having a
marketing authorisation in children aged ≥ 4 years, this particular trial does not provide any comparative
efficacy data on the licensed standard dose of adalimumab in children aged 4–6 years.
In total, 16 of the 114 participants received the wrong medication. Regulatory documents indicate that the
incidence of the error ‘wrong medication’ occurred at single time points and was unlikely to have affected
the results of the study.45 A small number of patients (n < 5) across the three treatment arms received
topical therapies during the randomised period, despite it being prohibited under the trial protocol,
although this is unlikely to have had a substantial impact on the efficacy estimates.
Primary efficacy end points for the randomised controlled period were a ≥ PASI 75 response at week 16
and a sPGA rating of ‘cleared’ or ‘minimal’ (0 or 1) at week 16. Secondary outcomes included PASI 50,
90 and 100 responses, a PGA score of 0 and CDLQI and PedsQL scores.
Participants were evaluated at all visits for worsening of psoriasis. Up to and including the week 8 visit,
participants were eligible for ‘early escape’ if they met one of the following criteria: (1) PASI scores
increased by 50% at week 4 relative to baseline or (2) PASI scores increased by 25% relative to baseline
and by ≥ 4 points at each of two consecutive study visits (prior to or at week 8). After week 8, participants
were to continue in the trial until the week 16 visit.
Participants entering ‘early escape’ were permitted to enter a longer-term observational study period
(period D; see Period D: long-term follow-up) in which they received open-label adalimumab at a dose of
0.8 mg/kg every other week (up to a maximum of 40 mg).
Primary efficacy analyses were conducted in the intention-to-treat (ITT) population (i.e. all randomised
participants). Participants with missing or incomplete data at week 16 (including those entering ‘early
escape’) were imputed to be non-responders for categorical variables (non-responder imputation method)
and had their last observation carried forward for continuous variables. Analyses using per-protocol and ‘as
observed’ data were also reported in the CSR.45 The safety analysis was conducted in the safety population
(i.e. all participants who received at least one dose of the study medication).
Efficacy of adalimumab at 16 weeks
The absolute and relative results for PASI, sPGA, CDLQI and PedsQL outcomes at week 16 are shown in
Tables 6 and 7.
TABLE 6 Results of key outcomes in the adalimumab trial (M04-717) at 16 weeks
Treatment
Participants who achieved the outcome, n/N (%)
Mean (SD) change from
baseline
PASI 50 PASI 75 PASI 90
sPGA
0 or 1 CDLQI PedsQL
ADA 0.8 mg/kg Confidential information
has been removed
22/38
(57.9)
11/38
(28.9)
23/38
(60.5)
6.6 (6.2)
n = 38
10.8 (15.4)
n= 38
ADA 0.4 mg/kg Confidential information
has been removed
17/39
(43.6)
12/39
(30.7)
16/39
(41.0)
4.9 (6.2)
n = 38
9.5 (12.3)
n= 38
MTX 0.1 mg/kg Confidential information
has been removed
12/37
(32.4)
8/37
(21.6)
15/37
(40.5)
5 (7.1)
n = 36
1.9 (10.4)
n= 36
ADA, adalimumab; MTX, methotrexate; SD, standard deviation.
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Psoriasis Area and Severity Index response
(Confidential information has been removed) and PASI 75 response rates at 16 weeks were significantly
greater for standard-dose adalimumab (0.8 mg/kg) than for methotrexate [(confidential information has
been removed) 58% vs. 32% respectively)]. Low-dose adalimumab (0.4 mg/kg) did not show a statistically
significant improvement over methotrexate for these outcomes [(confidential information has been
removed) and 44% vs. 32% respectively]. PASI 90 response rates did not differ significantly between the
three treatment arms (Table 8).
(Confidential information has been removed.)
Physician Global Assessment
The proportion of participants achieving a sPGA score of 0 or 1 (‘clear’ or ‘minimal’) at 16 weeks was
greater for standard-dose adalimumab than for low-dose adalimumab or methotrexate (61% vs. 41% vs.
41% respectively), although this difference was not statistically significant.
(Confidential information has been removed.)
Quality of life
Two HRQoL measures, CDLQI and PedsQL, were reported at 16 weeks. All three treatment groups showed
improvements from baseline in the dermatology-specific quality-of-life measure (CDLQI), exceeding the
published minimal clinically important difference (MCID) of a 2.5-point change from baseline.48 However,
these improvements were similar across the three treatment groups, with no significant difference between
either dose of adalimumab or methotrexate (6.6 for adalimumab 0.8 mg/kg vs. 4.9 for adalimumab 0.4 mg/kg
vs. 5.0 for methotrexate respectively).
Unlike the CDLQI, improvements on the generic HRQoL measure (PedsQL) significantly favoured both
doses of adalimumab over methotrexate (mean changes of 10.8 and 9.5 for standard- and low-dose
adalimumab, respectively, vs. 1.9 for methotrexate). The mean changes in the adalimumab groups both
exceeded the published MCID of 4.4 for the PedsQL.26
It is unclear why PedsQL scores would increase in the absence of dermatology-related quality-of-life benefits
as measured by the CDLQI. However, both mean and median PedsQL scores at baseline were noticeably
higher in the methotrexate arm than in the adalimumab treatment arms (see Table 4) and so the observed
PedsQL change scores in the adalimumab arms may be overestimates because of regression to the mean.89
TABLE 7 Relative risks of key outcomes in the adalimumab trial (M04-717) at 16 weeks
Treatment
Relative risk (95% CI) Mean difference (95% CI)
PASI 50 PASI 75 PASI 90 sPGA 0 or 1 CLDQI PedsQL
ADA 0.8 mg/kg Confidential
information has
been removed
1.79
(1.04 to 3.06)
1.34
(0.61 to 2.95)
1.49
(0.94 to 2.38)
1.6
(–1.44 to 4.64)
8.9
(2.94 to 14.86)
ADA 0.4 mg/kg Confidential
information has
been removed
1.34
(0.75 to 2.42
1.42
(0.65 to 3.08)
0.81
(0.46 to 1.41)
–0.1
(–3.14 to 2.94)
7.6
(2.42 to 12.78)
MTX 0.1 mg/kg
(reference)
Confidential
information has
been removed
1.00 1.00 1.00 0.00 0.00
ADA, adalimumab; CI, confidence interval; MTX, methotrexate.
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TABLE 8 Psoriasis Area and Severity Index and sPGA responses by age subgroups at 16 weeks
Subgroup
(years) Treatment
Participants who achieved the outcome, n/N (%)
PASI 50 PASI 75 PASI 90 sPGA 0 or 1
4–6 ADA 0.8 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA 0.4 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
MTX Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
> 6 to 9 ADA 0.8 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA 0.4 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
MTX Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
> 9 to 12 ADA 0.8 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA 0.4 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
MTX Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
> 12 to 15 ADA 0.8 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA 0.4 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
MTX Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
> 15 ADA 0.8 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA 0.4 mg/kg Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
MTX Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
ADA, adalimumab; MTX, methotrexate.
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Longer-term efficacy of adalimumab
Period B: withdrawal
(Confidential information has been removed.)
Period C: retreatment
(Confidential information has been removed.)
(Confidential information has been removed.)
Period D: long-term follow-up
(Confidential information has been removed.)
Safety of adalimumab
Adverse events at 16 weeks
Adverse event rates were comparable among the three treatment groups (Table 11). Three serious adverse
events (SAEs) considered unrelated to treatment (hand fracture, gastrointestinal infection from food
poisoning and agitation as a result of alcohol consumption) were reported, all of which occurred in
TABLE 10 Reported PASI responses during the long-term follow-up phase (week 52 of period D)
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TABLE 9 Reported PASI responses during the retreatment phase (week 16 of period C)
Disease status at the end of period B
and retreatment patterns in period C
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Confidential
information
has been
removed
Participants from period B who experienced
loss of disease control, retreated with the
originally randomised dose of adalimumab
of 0.8 mg/kg
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Participants from period B who experienced
loss of disease control, retreated with the
originally randomised dose of adalimumab
of 0.4 mg/kg
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Participants from period B who experienced
loss of disease control who were initially
randomised to methotrexate, retreated with
adalimumab at a dose of 0.8 mg/kg
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
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participants receiving 0.4 mg/kg of adalimumab. One participant in the same treatment arm withdrew
because of an AE (moderate psoriasis flare).
Longer-term safety of adalimumab
Table 12 shows that the overall numbers of AEs during patient follow-up across all four study periods were
similar across treatment arms. A total of nine SAEs were reported in six participants. In terms of episodes
per 100 patient-years, the total rate of SAEs was 5.9 for all participants ever treated with 0.8 mg/kg of
adalimumab from the first dose of 0.8 mg/kg adalimumab and 7.4 for all participants treated with
adalimumab (0.4 mg/kg and 0.8 mg/kg) from the first dose of 0.8 mg/kg adalimumab.
One SAE (haemorrhagic ovarian cyst) occurred in period B in a participant who had been initially
randomised to 0.8 mg/kg of adalimumab.
Five SAEs occurred during period D, including one death from an accidental fall, one tendon injury in a
participant receiving 0.4 mg/kg of adalimumab, one maculopapular rash in a participant receiving 0.8
mg/kg of adalimumab, one case of chest pain in a participant randomised to methotrexate but receiving
0.8 mg/kg of adalimumab and one case of eye naevus in a participant receiving 0.8 mg/kg of adalimumab.
All SAEs were considered by investigators to be unrelated or probably unrelated to the study drug with the
exception of the case of eye naevus, which was assessed as being possibly related.
In addition to the participant who discontinued treatment because of a moderate psoriasis flare in period A,
one participant initially randomised to methotrexate but receiving 0.8 mg/kg of adalimumab during period
D discontinued treatment because of severe urticaria.
The rate of all infections reported by participants receiving 0.8 mg/kg of adalimumab was 170.4 episodes
per 100 patient-years. Only two events of tuberculosis occurred, both during period D.
Summary of the efficacy and safety of adalimumab
l There was evidence from one 16-week RCT comparing adalimumab with methotrexate in children and
young people with severe chronic psoriasis.
l This trial did not provide comparative evidence for children aged 4–6 years.
l Adalimumab at the licensed dose of 0.8 mg/kg (up to 40 mg) leads to significantly greater responses
than methotrexate for the outcomes of PASI 50 and PASI 75, but not for the outcome of PASI 90.
l PGA 0/1 response rates were higher for 0.8 mg/kg of adalimumab than for methotrexate, although the
difference was not statistically significant.
l The benefits of half-dose adalimumab were not statistically greater than those observed for methotrexate.
TABLE 11 Reported safety outcomes in the adalimumab trial (M04-717) at week 16
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection
site
reactions Malignancies
Withdrawals
because of
AEs
ADA 0.8mg/kg 26/38 (68.4) 0/38 (0.0) 18/38 (47.4) 0/38 (0.0) 4/38 (10.5) 0/38 (0.0) 0/36 (0.0)
ADA 0.4mg/kg 30/39 (76.9) 3/39 (7.7)a 22/39 (56.4) 1/39 (2.6) 3/39 (7.7) 0/39 (0.0) 1/39 (2.6)b
MTX 28/37 (75.7) 0/37 (0.0) 20/37 (54.1) 0/37 (0.0) 3/37 (8.1) 0/37 (0.0) 0/37 (0.0)
ADA, adalimumab; MTX, methotrexate.
a One hand fracture, one gastrointestinal infection and one case of agitation.
b Because of moderate psoriasis flare.
DOI: 10.3310/hta21640 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 64
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
TABLE 12 Reported safety outcomes in the adalimumab trial (M04–717) in the different follow-up periods
Follow-up period
Participants with safety reports, n
AEs SAEs Infections Serious infections
Injection site
reactions Malignancies Tuberculosis
Withdrawals
because of AEs
Period B
ADA 0.8 mg/kg (n = 23) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 0 0 0
ADA 0.4 mg/kg (n = 18) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 0 0 0
MTX (n= 13) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 0 0 0
Period C
ADA 0.8 mg/kg (n = 19) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 2 0 0
ADA 0.4 mg/kg (n = 11) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 0 0 0
MTX (n= 8) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0 0 0 0 1
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l Evidence on quality of life was inconsistent across different measures, possibly because of baseline
imbalances on the PedsQL.
l (Confidential information has been removed.)
l In children and young people, adalimumab does not appear to be associated with an increase in
adverse effects relative to methotrexate over 16 weeks, (confidential information has been removed).
l However, because of the small numbers of observed participants, the possibility of rare AEs cannot be
entirely excluded.
Efficacy and safety of etanercept
One multicentre RCT (20030211) comparing etanercept with placebo met the selection criteria for
the review. Data on short-term safety and efficacy (blinded period) were available from published
peer-reviewed journal papers,48–53 conference proceedings54–60 and regulatory documents.61–71
This double-blind RCT recruited children aged between 4 and 17 years from 42 sites in the USA and
Canada who had stable, moderate-to-severe plaque psoriasis at screening. Moderate to severe plaque
psoriasis was defined as a PASI score of ≥ 12 (PASI scores range from 0 to 72, with higher scores
indicating a worse condition); a sPGA of ≥ 3 (in which 0 indicates clear and 5 indicates severe psoriasis)
and psoriasis involvement of ≥ 10% of the BSA; a history of psoriasis for ≥ 6 months; and previous or
current treatment with phototherapy or systemic psoriasis therapy (e.g. methotrexate, ciclosporin or
retinoids) or psoriasis considered by the investigator as poorly controlled with topical therapy.
Within each age stratum, participants were randomised in a 1 : 1 ratio to either 0.8 mg/kg of etanercept
once weekly up to a maximum dose of 50 mg or placebo.
The primary outcome measure used in the RCT was the PASI 75 response at week 12. The secondary
outcome measures were PASI 50 response, PASI 90 response, clear or almost clear status on the sPGA and
percentage improvement from baseline in the CDLQI at week 12.
A total of 264 participants were screened and 211 children were randomised to etanercept (n = 106) or
placebo (n = 105). At baseline, both groups were similar in terms of age and sex, BSA and PASI and PGA
scores, although the placebo group had a slightly higher proportion of patients with psoriatic arthritis
(13% vs. 5%). There was no previous use of biological therapy in either group (see Table 4). It should be
noted that only 19 children included in the study (9.0%) were aged < 8 years and only nine (4.3%) were
aged < 6 years.
At or after week 4, participants with a > 50% increase or an absolute increase of ≥ 4 points in the
PASI score from baseline were allowed to enter an ‘escape’ arm to receive open-label etanercept every
week up to week 12. During this initial 12-week comparative period, a higher number of participants from
the placebo group (n = 27/105) than the etanercept group (n = 5/106) entered the early escape arm.
Participants who entered the escape arm were recorded as non-responders at the time that they entered
the escape arm. Data for those participants from before they entered the escape arm were not changed.
For participants who had missing data, their missing data were imputed as non-responses but their existing
data were included as observed.
Risk-of-bias assessment
The trial had a low overall risk of bias for most domains, with appropriate methods used for randomisation,
handling of missing data and reporting of outcomes (Table 13). The study was described as ‘double-blinded’,
although the methods used to achieve blinding were not described.
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Efficacy of etanercept at week 12
Data on the treatment response outcomes were available from publications and regulatory
documents.49–70,87,89 PASI and PGA scores are reported in Tables 14 and 15.
Psoriasis Area and Severity Index response
Psoriasis Area and Severity Index 50, 75 and 90 responses in the etanercept group were 74.5%, 56.6%
and 27.4% respectively. Response rates for the placebo group were 22.9%, 11.4% and 6.7%. When
translated into relative risk (RR) values, the etanercept group had a significantly higher probability of
achieving PASI 50, 75 and 90 responses, with RRs of 3.26 [95% confidence interval (CI) 2.26 to 4.71],
4.95 (95% CI 2.84 to 8.65) and 4.10 (95% CI 1.88 to 8.95) respectively.
TABLE 13 Risk-of-bias assessment using the Cochrane risk-of-bias tool34 for the etanercept trial (20030211)
Assessment criterion
Risk-of-bias
judgement Support for judgement
Sequence generation Low Interactive voice or web response system was used
Allocation concealment Low Interactive voice or web response system was used during randomisation
Baseline comparability Low No obvious baseline imbalances although slightly higher psoriatic arthritis rate
(13% vs. 5%) in the placebo group
Blinding of participants
and personnel
Unclear Although double blinded initially, patients could enter an escape arm and
receive open-label etanercept. In total, 27/105 placebo-allocated patients
entered the escape arm vs. 5/106 etanercept-allocated patients. For binary
end points, efficacy measures taken after entering the escape group were
imputed as non-responses. Blinding methods not described
Blinding of outcome
assessment
Unclear Participants, caregivers, investigators and outcomes assessors were blinded,
although the method of blinding was not described
Incomplete outcome
data
Low For binary measures, missing post-baseline data were imputed as non-responses.
Continuous measures were imputed to have baseline values
Selective reporting Low The reported treatment response and HRQoL outcomes match those
described in the study protocol
TABLE 14 Reported treatment response and HRQoL outcomes in the etanercept trial (20030211) at week 12
Treatment
Participants who achieved the outcome, n/N (%) Mean (SD) change from baseline
PASI 50 PASI 75 PASI 90 sPGA 0 or 1 CDLQI PedsQL
ETA 79/106 (74.5) 60/106 (56.6) 29/106 (27.4) 56/106 (52.8) 5.4 (5.6) 6.8 (17.6)
PLB 24/105 (22.9) 12/105 (11.4) 7/105 (6.7) 14/105 (13.3) 3.1 (5.1) 3.8 (10.1)
ETA, etanercept; PLB, placebo; SD, standard deviation.
TABLE 15 Relative risks of key outcomes in the etanercept trial (20030211) at week 12
Treatment
Relative risk (95% CI) Mean difference (95% CI)
PASI 50 PASI 75 PASI 90 sPGA 0 or 1 CDLQI PedsQL
ETA 3.26
(2.26 to 4.71)
4.95
(2.84 to 8.65)
4.10
(1.88 to 8.95)
3.96
(2.36 to 6.66)
2.3
(0.85 to 3.74)
3.0
(–0.87 to 6.87)
PLB 1.00 1.00 1.00 1.00 0.00 0.00
CI, confidence interval; ETA, etanercept; PLB, placebo.
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Physician Global Assessment
The proportion of participants achieving a PGA score of 0 or 1 (‘clear’ or ‘minimal’) at 12 weeks was
significantly greater in the etanercept group than in the placebo group (52.8% vs. 13.3%), equating to a
RR of 3.96 (95% CI 2.36 to 6.66).
Quality of life
Data for two HRQoL measures, CDLQI and PedsQL, were available at 12 weeks (see Table 14). Both the
etanercept group and the placebo group showed improvements from baseline in CDLQI scores, exceeding
the published MCID of a 2.5-point change from baseline,48 although the improvement in the etanercept
group was statistically significantly greater than that in the placebo group (mean difference 2.3, 95% CI
0.85 to 3.74).
Both treatment groups also showed improvements on the PedsQL, although for the placebo group this fell
below the published MCID of 4.4. The mean change in PedsQL score from baseline, although favouring
etanercept, was not statistically significantly different between the treatment groups (mean difference 3.0,
95% CI –0.87 to 6.87).
Subgroup outcomes
Age-based subgroup analysis results of PASI responses for the etanercept trial (20030211) were available
(Table 16). A higher proportion of the etanercept treatment group than the placebo group achieved PASI
50, 75 and 90 responses in all age categories. Imputation of treatment failure for participants entering the
early escape arm reduced the magnitude of the difference between treatments, although these differences
remained formally statistically significant for all comparisons, with the exception of PASI 90, which was of
borderline statistical significance (p = 0.054).
Longer-term efficacy of etanercept
Weeks 12–36: open-label etanercept treatment
At the end of the 12-week double-blind period a total of 208 participants (105 and 103 of the original
etanercept and placebo groups respectively) entered an open-label treatment phase (i.e. all were treated
with etanercept) and were followed up until week 36.
Patients who did not achieve a PASI 50 response at week 24 were given the option to discontinue the
study or enter the incomplete responder arm. Participants in the incomplete responder arm had the option
to receive topical psoriasis therapy according to the standard of care in addition to receiving open-label
etanercept (Figure 2).
TABLE 16 Subgroup PASI responses at week 12 (published results)50
Age (years) Treatment
Participants who achieved the outcome, n/N (%)
PASI 50 PASI 75 PASI 90
≥ 8 ETA 70/95a (73.7) 52/95a (54.7) 26/95a (27.4)
PLB 23/97a (23.7) 11/97a (11.3) 6/97a (6.2)
4–11 ETA 29/38 (76.3), 30/38 (78.9)b 22/38 (57.9), 22/38 (57.9)b NA, 12/38 (31.6)b
PLB 8/38 (21.1), 16/38 (42.1)b 4/38 (10.5), 10/38 (26.3)b NA, 5/38 (13.2)b
12–17 ETA 50/68 (73.5), 51/68 (75.0)b 38/68 (55.9), 38/68 (55.9)b NA, 17/68 (25.0)b
PLB 16/67 (23.9), 21/67 (31.3)b 8/67 (11.9), 11/67 (16.4)b NA, 4/67 (5.6)b
ETA, etanercept; NA, not available; PLB, placebo.
a Back-calculated from reported percentages so integers may not be entirely accurate.
b ITT, with treatment failure imputation extracted from European Medicines Agency document.63
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Participants screened
(n = 264)
Participants randomised for
12-week double-blind period
(n = 211)
Received placebo
(n = 105)
Received etanercept
(n = 106)
Entered
escape group
(n = 27)
Completed
blinded period
(n = 78)
Entered 24-week open-label period, all received etanercept
(n = 208)
Withdrew
(n = 6)
Withdrawal of
consent
(n = 1)
Completed
blinded period
(n = 100)
Entered
escape group
(n = 5)
Withdrew owing to
administrative
decision
(n = 1)
Withdrawal of
consent
(n = 1)
From the original placebo 
group
(n = 103)
From the original etanercept 
group
(n = 105)
Withdrew
(n = 5)
Withdrew
(n = 1)
Eligible to
receive topical
therapy
(n = 34)
Completed
open-label
period
(n = 63)
Completed
open-label
period
(n = 75)
Eligible to
receive topical
therapy
(n = 25)
Lost to
follow-up
(n = 1)
Remained in this
group until the end
of the study
(n = 33)
Underwent randomisation for 12-week withdrawal–
retreatment period
(n = 138)
Remained in this
group until the end
of the study
(n = 24)
Assigned to receive placebo
(n = 69)
Assigned to receive etanercept
(n = 69)
Lost to
follow-up
(n = 1)
Entered
retreatment and
completed the
study
(n = 29)
Continued to receive
blinded drug and
completed the study
withdrawal phase
(n = 40)
Continued to receive blinded
drug and completed the study
withdrawal phase
(n = 55, 8 did not enter
retreatment after
disease relapse)
Entered retreatment
and completed the
study
(n = 13, 1 without having
disease relapse)
At week 48, 10/28 (36%,
1 patient had missing
data) achieved PASI 
response of 75
At week 48, 34/40
(85%) maintained
PASI response of 75
At week 48, 52/65 (80%, 3 patients had missing data)
maintained PASI response of 75
FIGURE 2 Short-term and long-term participant follow-up flow chart for the etanercept trial.
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By weeks 24 and 36 (i.e. after 12 and 24 weeks of open-label etanercept respectively), participants who
were originally randomised to placebo during the double-blind period achieved similar PASI and PGA
responses as participants receiving etanercept throughout (Table 17).
Weeks 36–48: re-randomised ‘withdrawal–retreatment’ period
At week 36, 138 patients who had achieved a PASI 50 response at week 24 or a PASI 75 response at
week 36 were randomised in a 1 : 1 ratio to receive either etanercept or placebo in a double-blinded
fashion. Patients were followed up for a further 12 weeks until week 48.
During the follow-up, 42 participants from the ITT population (29/69 and 13/69 from the placebo and
etanercept arms respectively) lost their PASI 75 response and so were allocated to receive etanercept in an
open-label fashion until week 48.
Overall, 52 out of 65 participants (80%) who received etanercept throughout the withdrawal–retreatment
period maintained a PASI 75 response and 85% of those re-randomised to placebo and who did not lose
a PASI 75 response during follow-up retained their response at week 48. Only 36% of those who were
retreated with open-label etanercept after losing a PASI 75 response on placebo had regained a response
by week 48 (Table 18). The use of PASI 75 response as both a retreatment rule and as an outcome
makes these results difficult to interpret; however, a relatively high rate of late crossover from placebo to
etanercept could partly explain a lack of response on PASI and PGA measures among these participants.
Weeks 48–312 (20050111)
In total, 194 participants completed 48 weeks of follow-up in the etanercept trial (20030211) (57 participants
who received etanercept and topical therapy starting from the open-label treatment phase, 95 participants
TABLE 17 Results of key outcomes in the etanercept trial (20030211) at 12 and 36 weeks
Follow-up
Participants who achieved the outcome, n/N (%)
PASI 50 PASI 75 PASI 90
Week 24
ETA/ETA 92/105 (88) 72/105 (69) 39/105 (37)
PLB/ETA 80/103 (78) 64/103 (62) 37/103 (36)
Week 36
ETA/ETA 91/105 (87) 71/105 (68) 43/105 (41)
PLB/ETA 89/103 (86) 67/103 (65) 39/103 (38)
ETA/ETA, participants randomised to etanercept and who received etanercept after the double-blind period (12 weeks);
PLB/ETA, participants randomised to placebo but who received etanercept after the double-blind period.
TABLE 18 Results of key outcomes in the etanercept trial (20030211) at week 48 (observed data)
Re-randomisation status at week 36 and treatment course until week 48
Participants who achieved
the outcome, n/N (%)
PASI 75 sPGA 0 or 1
Re-randomised to etanercept and received blinded etanercept (no loss of PASI
75 response) or open-label etanercept (after loss of PASI 75 response)
52/65 (80) 38/65 (58)
Re-randomised to placebo and stayed on blinded placebo until week 48
(no loss of PASI 75 response)
34/40 (85) 27/40 (68)
Re-randomised to placebo but received open-label etanercept after loss of PASI
75 response
10/28 (36) 8/28 (29)
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who were randomised to the etanercept and placebo arms and who continued to receive the blinded drug
and 42 participants who were randomised to either etanercept or placebo but who did not achieve a PASI 75
response and who were retreated with etanercept until the end of the study).
Of the 194 participants who completed the etanercept trial (20030211), 182 were enrolled in an open-
label extension study (20050111)66 to establish the long-term safety of etanercept. Participants received
0.8 mg/kg of etanercept (up to a maximum dose of 50 mg) subcutaneously once weekly for a further
264 weeks. In total, 63 participants (34.6%) completed 264 weeks of follow-up.
During the 264 weeks of further follow-up, the probability of achieving a PASI 50, 75 and 90 response
was similar across all of the outcome recording points (Table 19). However, it should be noted that, by
week 264, 63.6% of the participants (115/181) had withdrawn from the study and the reasons for
withdrawal were unavailable.
Safety of etanercept
Adverse events at 12 weeks
The number of AEs reported during the 12-week randomised phase was similar for etanercept and
placebo (68 vs. 62). There were 50 infections and seven injection site reactions in the etanercept group,
compared with 33 infections and five injection site reactions in the placebo group. Although the difference
in rate of infections fell short of formal statistical significance, there were noticeably more infections in the
etanercept group (47.2% vs. 31.4%; p = 0.0683). One participant in the etanercept group withdrew
because of an adverse effect (no further details available). No SAEs were observed during the 12-week
randomised phase (Table 20).
TABLE 20 Reported safety outcomes in the etanercept trial (20030211) at week 12
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection site
reactions Malignancies
Withdrawals
because of AEs
ETA 68/106 (64.2) NR 50/106 (47.2) 0/106 (0.0) 7/106 (6.6) NR 1/106 (0.9)
PLB 62/105 (59.0) NR 33/105 (31.4) 0/105 (0.0) 5/105 (4.8) NR 0/105 (0.0)
ETA, etanercept; NR, not reported; PLB, placebo.
TABLE 19 Reported efficacy outcomes during the long-term follow-up period (20050111)
Week
Participants who achieved the outcome, n/N (%)
≥ PASI 50 ≥ PASI 75 ≥ PASI 90 sPGA 0 sPGA 0 or 1
12 162/181 (89.5) 122/181 (67.4) 64/181 (35.4) 24/181 (13.3) 97/181 (53.6)
48 150/168 (89.3) 113/168 (67.3) 55/168 (32.7) 18/168 (10.7) 82/168 (48.8)
96 123/138 (89.1) 84/138 (60.9) 41/138 (29.7) 16/139 (11.5) 66/139 (47.5)
144 101/114 (88.6) 71/114 (62.3) 32/114 (28.1) 9/114 (7.9) 52/114 (45.6)
192 80/92 (87.0) 64/92 (69.6) 33/92 (35.9) 19/92 (20.7) 44/92 (47.8)
240 68/74 (91.9) 48/74 (64.9) 27/74 (36.5) 13/74 (17.6) 37/74 (50.0)
264 58/66 (87.9) 42/66 (63.6) 19/66 (28.8) 8/66 (12.1) 25/66 (37.9)
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Adverse events at weeks 12–36
Up to week 36, 282 infections were reported during treatment with etanercept (238.18 events per
100 person-years). The most common infections were upper respiratory tract infection, nasopharyngitis,
influenza, pharyngitis, streptococcal pharyngitis and viral upper respiratory tract infection (59.97, 33.79,
16.05, 15.20, 8.45 and 8.45 events per 100 participant-years respectively). During the same period,
a single serious non-infectious AE (benign ovarian mass) and one serious case of gastroenteritis with
dehydration were observed (Table 21).
Over the same time period, 2.4% of participants (5/208) withdrew because of AEs: three participants
withdrew because of non-infectious AEs (psoriasis, atopic dermatitis and muscle cramps) and two
participants withdrew because of infections (pneumonia and skin infection).
Adverse events at weeks 48–312
A total of 161 participants (89.0%) reported at least one AE up to week 264 of the follow-up study
(20050111). Seven participants (3.9%) reported a SAE, with each participant reporting a single event:
anxiety, cellulitis, infectious mononucleosis, postoperative intestinal obstruction, osteonecrosis and a
thyroid cyst, with the seventh participant undergoing an elective abortion (Table 22). Of the seven SAEs,
only the cellulitis infection was considered by the investigator to be related to etanercept treatment.
Six participants (3.3%) withdrew from the study because of either an infectious or a non-infectious AE.
Two participants withdrew because of Crohn’s disease and one participant each withdrew because
of glomerulonephritis (secondary to infection), psoriasis, sinusitis and nerve paralysis. The case of
glomerulonephritis and one of the cases of Crohn’s disease were considered to be related to treatment.
No SAE led to study withdrawal. No opportunistic infections or deaths occurred during the study and no
malignancies were reported.
TABLE 21 Reported safety outcomes in the etanercept trial (20030211) up to week 36
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection
site
reactions Malignancies
Withdrawals
because of
AEs Deaths
ETA 584.48
events per
100 person-
years
1/208
(0.5)
238.18
events per
100 person-
years
1/208 (0.5) 26/208
(12.5)
0 5/208 (2.4)a 0/208
(0.0)
ETA, etanercept.
a Psoriasis, atopic dermatitis, muscle cramps, pneumonia and skin infection.
TABLE 22 Reported safety outcomes in the etanercept trial (20050111) up to week 264
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection
site
reactions Malignancies
Withdrawals
because of
AEs
ETA 161/181
(89.0)
7/181
(3.9)
140/181
(77.3)
2/181 (1.1) 16/181 (8.8) NR 6/181 (3.3)a
ETA, etanercept; NR, not reported.
a Two cases of Crohn’s disease, one case of glomerulonephritis, one case of psoriasis, one case of sinusitis and one case
of nerve paralysis.
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Summary of the efficacy and safety of etanercept
l One multicentre RCT (20030211) compared etanercept with placebo in children aged 4–17 years with
moderate to severe plaque psoriasis.
l Relatively few young children (9% aged < 8 years; 4.3% aged < 6 years) were included in the study.
l At 12 weeks etanercept was significantly more effective than placebo in improving the severity of
plaque psoriasis based on PASI 50, 75 and 90 and PGA cleared or minimal scores.
l Improvements in HRQoL were larger for etanercept than for placebo, but reached statistical significance
only for the CDLQI.
l Adverse events rates were similar between the etanercept group and the placebo group at 12 weeks,
with no SAEs observed for either treatment. However, the observed higher rate of infections among
participants receiving etanercept was of borderline statistical significance.
l A subsequent open-label extension study followed up participants for up to 6 years from entry into the
original RCT. The proportions of PASI and PGA responders were stable over time, although only 36%
of participants were available at the last follow-up point. The proportion of participants withdrawing
because of lack of efficacy is unknown. These longer-term uncontrolled observational response data
may therefore overestimate the efficacy of etanercept.
l Withdrawals because of AEs were infrequent and no deaths or malignancies were observed up to
264 weeks of additional follow-up.
Efficacy and safety of ustekinumab
One multicentre RCT (1275PSO3006; CADMUS) comparing standard and half-standard dosages of
ustekinumab with placebo met the selection criteria for the review. Data on safety and efficacy (blinded
period) were available from one peer-reviewed journal paper,72 a conference abstract,73 regulatory
documentation74 and a CSR provided by the manufacturer.88
The CADMUS RCT was a double-blind, placebo-controlled study in adolescent participants (aged 12–17 years)
who had had a diagnosis of moderate to severe plaque psoriasis for ≥ 6 months, which was conducted at
multiple sites in Europe (Belgium, France, Germany, Hungary, Portugal, Russian Federation, Sweden, Ukraine
and the UK) and Canada. Moderate-to-severe disease was defined as a PASI score of ≥ 12, a PGA score of
≥ 3 and BSA involvement of ≥ 10%.
A total of 157 participants were screened, of whom 110 were eligible and randomised (37 participants to
placebo, 37 participants to the half-standard dosage of ustekinumab and 36 participants to the standard
dosage of ustekinumab). The standard dosage of ustekinumab was 0.75 mg/kg for participants weighing
≤ 60 kg, 45 mg for participants weighing 60–100 kg and 90 mg for participants weighing > 100 kg. The
half-standard dosage of ustekinumab was 0.375 mg/kg for participants weighing 60–100 kg and 45 mg
for participants weighing > 100 kg. Randomisation was stratified by investigational site and baseline
weight (≤ 60 kg or > 60 kg).
The study had three periods:
1. Controlled period (0–12 weeks): participants received either ustekinumab (full dose or half dose) or
placebo. In the ustekinumab groups, participants were allowed to escape early at week 8 and receive
moderate- to high-potency topical steroid preparations up to week 12 if their PASI scores increased by
≥ 50% from baseline. However no participants entered the escape route during this period.
2. Placebo crossover and active treatment period (12–52 weeks): participants randomised to placebo
during the controlled period were allowed to cross over to the full or half-standard dose of
ustekinumab at week 12.
3. Follow-up period (52–60 weeks): participants continued to be followed for safety analysis.
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To preserve blinding, participants in the half-standard-dosage and standard-dosage groups received ustekinumab
at week 0 and week 4 followed by doses every 12 weeks until week 40. Participants in the placebo group also
received placebo at week 0 and week 4 and crossed over to receive either the half-standard dosage or standard
dosage of ustekinumab at week 12 or week 16, followed by 12 weekly doses of either a half-standard dosage
or standard dosage of ustekinumab, with the last dose at week 40. All participants were followed up for efficacy
up to week 52 and for safety up to week 60.
The primary outcome measure was the proportion of participants who achieved a sPGA score of ‘cleared’
or ‘minimal’ at week 12. Data from all randomised participants were analysed according to their assigned
treatment group. Participants who met treatment failure criteria prior to week 12 or who entered the early
escape arm were considered non-responders at week 12. In addition, participants who had a missing PGA
score at week 12 were considered as not achieving the primary end point at week 12.
The secondary outcome measures were PASI 50, 75 and 90 response at week 12 based on all randomised
participants and changes from baseline in CDLQI score at week 12 based on efficacy-evaluable participants.
Risk-of-bias assessment
Based on the Cochrane risk-of-bias assessment tool,34 the CADMUS trial double-blind period had a low risk
of bias: appropriate randomisation and blinding techniques were implemented, no obvious difference in
baseline characteristics between treatment arms was apparent, missing data were handled appropriately
and all protocol-stated outcome measures were reported (Table 23).
Efficacy of ustekinumab
Efficacy at week 12
Data on treatment response (PASI and sPGA) and HRQoL (CDLQI and PedsQL) outcomes for the CADMUS
RCT are presented in Tables 24 and 25.
Physician Global Assessment
Significantly greater proportions of participants in the standard-dosage and the half-standard-dosage
groups (69.4% and 67.6% respectively) than in the placebo group (5.4%) achieved a PGA score of cleared
(0) or minimal (1) at week 12. The proportions of participants who achieved a PGA score of cleared (0)
were also higher in the standard-dosage and half-standard-dosage groups (47.2% and 32.4% respectively)
than in the placebo group (2.7%). The RRs for these outcomes are shown in Table 25.
Psoriasis Area and Severity Index response
Higher proportions of participants in the standard-dosage and the half-standard-dosage groups than in the
placebo group achieved PASI 50, 75 and 90 responses. For example, 80.6% and 78.4% of the standard-
dosage and half-standard-dosage groups, respectively, achieved a PASI 75 response at week 12 whereas
only 10.8% of the placebo group achieved the same PASI 75 response (see Table 24). The RR values also
show that both ustekinumab dosage groups had significantly higher probabilities of achieving the PASI 50,
75 and 90 responses than the placebo group (see Table 25).
Health-related quality of life
Changes from baseline in CDLQI score were significantly greater in both the standard-dosage and half-
standard-dosage groups (mean of –6.7 and –5.6 respectively) than in the placebo group (–1.5). Although
both ustekinumab treatment groups showed improvements from baseline in the CDLQI that exceed the
published MCID of a 2.5-point change from baseline, this was not the case for the placebo group.
The mean difference values indicate that CDLQI changes were significantly greater for both ustekinumab
dosage groups than for the placebo group (mean difference: standard dosage 5.2, 95% CI 2.96 to 7.44;
half-standard dosage 4.1, 95% CI 1.7 to 6.5; see Table 25).
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Participants in both the standard-dosage group and the half-standard-dosage group showed significantly
larger improvements in the PedsQL total scale scores from baseline (mean 8.03 and 10.81 respectively)
than participants in the placebo group (mean 3.35). The mean changes for the half-standard dosage and
standard dosage were above the published MCID of 4.4 whereas the mean change in the placebo group
TABLE 24 Results of key outcomes in the ustekinumab trial (CADMUS) at week 12
Treatment
Participants who achieved the outcome, n/N (%)
Mean (SD) change from
baseline
PASI 50 PASI 75 PASI 90 sPGA 0 or 1 sPGA 0 CDLQI PedsQL
UST 0.75 mg/kg 32/36 (88.9) 29/36 (80.6) 22/36 (61.1) 25/36 (69.4) 17/36 (47.2) –6.7 (5.6)
n= 32
8.03 (10.4)
n= 32
UST 0.375mg/kg 30/37 (81.2) 29/37 (78.4) 20/37 (54.1) 25/37 (67.6) 12/37 (32.4) –5.6 (6.4)
n= 35
10.81 (12.9)
n= 35
PLB 11/37 (29.7) 4/37 (10.8) 2/37 (5.4) 2/37 (5.4) 1/37 (2.7) –1.5 (3.2)
n= 32
3.35 (10.0)
n= 32
PLB, placebo; SD, standard deviation; UST, ustekinumab.
TABLE 23 Risk-of-bias assessment using the Cochrane risk-of-bias tool34 for the ustekinumab trial (CADMUS)
Assessment criterion
Risk-of-bias
judgement Support for judgement
Sequence generation Low Dynamic central randomization was implemented in conducting this
study. Participants were randomly assigned to 1 of 4 treatment groups
based on an algorithm implemented in the Interactive Voice/Web
Response System (IVRS or IWRS) before the study
pp. 26–774
Allocation concealment Low Based on the algorithm, the IVRS/IWRS assigned a unique treatment code,
which dictated the treatment assignment
Baseline comparability Low No obvious differences in baseline characteristics
Blinding of participants,
personnel and outcome
assessors
Low The Sponsor, investigative study sites, and participants remained blinded
to treatment assignment until the last participant enrolled completed the
Week 60 evaluations and the database was locked
pp. 26–774
Incomplete outcome data Low Participants who discontinued study treatment due to lack of efficacy,
an adverse event (AE) of worsening of psoriasis, or who started a
protocol-prohibited medication/therapy during the study that could
affect their psoriasis were considered as treatment failures. A participant
who met 1 or more treatment failure criteria was considered as a
treatment failure from that point onward. The baseline values were used
for all directly measured endpoints regardless of the actual measurements.
Zeros were assigned to improvements and percent improvements, and
nonresponder status was assigned to binary response variables
p. 2774
Participants who used a moderate to high potency topical steroid as a
result of being eligible to early escape were considered as nonresponders
at Week 12 for binary endpoints and their continuous outcomes at
Week 12 were imputed by the last value at or prior to week 8. The
analysis at Week 16 was the observed data without imputation. After
Week 16, if participants continued to use a moderate to high potency
topical steroid, treatment failure rules were applied to those participants
p. 2774
Selective reporting Low Primary and secondary outcomes reported match the study protocol
IVRS, interactive voice response system; IWRS, interactive web response system.
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was below the MCID. Mean differences at 12 weeks indicate that the standard-dosage and half-standard-
dosage groups had a significantly higher improvement in PedsQL score than the placebo group (mean
difference: standard dosage 8.9, 95% CI 2.46 to 15.34; half-standard dosage 7.6, 95% CI 2.16 to 13.04).
Subgroup efficacy outcomes
Subgroup efficacy results for the PASI 75 and PGA 0 or 1 outcomes were available from the CSR88 (Table 26).
(Confidential information has been removed.)
Longer-term efficacy of ustekinumab
Psoriasis Area and Severity Index response
Among participants continuing ustekinumab treatment, PASI responses observed in week 12 appeared
to be sustained at week 52, with few participants lost to follow-up (one participant was lost from the
standard-dose arm and two from the half-standard-dose arm) (Table 27).
Participants who were randomised to placebo and who crossed over to the standard ustekinumab dosage
(0.75 mg/kg) achieved better PASI responses than those who were randomised to placebo and crossed
over to the half-standard dosage of ustekinumab (0.375 mg/kg) (see Table 27).
Physician Global Assessment
A similar pattern of responses was seen for the sPGA, with similar response rates at week 52 as at week 12
among participants continuing ustekinumab treatment and a large improvement between weeks 12 and 52
for participants crossing over to active treatment from placebo (see Table 27).
Safety of ustekinumab
Adverse events at week 12
The percentage of participants reporting AEs did not differ significantly between the ustekinumab groups
(44.4% standard-dosage group and 51.4% half-standard-dosage group) and the placebo group (56.8%)
(Table 28). No SAEs were reported in the standard-dosage group or the placebo group, whereas one
participant in the half-standard-dosage group was hospitalised for worsening of psoriasis (see Table 28).
One participant in the standard dosage group had a mild injection site reaction. There were no incidences
of serious infection, tuberculosis, malignancy or withdrawals because of AEs during the initial 12-week
treatment period (see Table 28).
TABLE 25 Relative risks of key outcomes in the ustekinumab trial (CADMUS) at week 12
Treatment
Outcome, RR (95% CI) Mean difference (95% CI)
PASI 50 PASI 75 PASI 90 sPGA 0/1 sPGA 0 CDLQI PedsQL
UST
0.75 mg/kg
2.99
(1.79 to 4.97)
7.5
(2.9 to 19.1)
11.0
(2.8 to 43.5)
12.9
(3.3 to 50.3)
17.5
(2.5 to 124.5)
5.2
(2.96 to 7.44)
8.9
(2.46 to 15.34)
UST
0.375mg/kg
2.72
(1.62 to 4.48)
7.3
(2.8 to 18.6)
10.0
(2.5 to 39.8)
12.5
(3.2 to 49)
12.0
(1.6 to 87.7)
4.1
(1.7 to 6.5)
7.6
(2.16 to 13.04)
PLB 1.00 1.00 1.00 1.00 1.00 0.00 0.00
PLB, placebo; UST, ustekinumab.
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Discontinuation up to week 40
Up to week 40, 8.2% of the participants (9/110) discontinued the trial. The most common reasons for
discontinuation were a lack of efficacy and AEs (Table 29). Five participants (13.5%) who were originally
randomised to the half-standard-dosage group discontinued the trial compared with two participants
(5.6%) in the standard-dosage group. Two patients who crossed over from placebo to the half-standard
dosage of ustekinumab withdrew because of AEs.
TABLE 26 Subgroup efficacy outcomes in the ustekinumab trial (CADMUS) at week 12
Subgroup
Participants who achieved the outcome, n/N
PASI 75a sPGA 0 or 1a
Age
≤ 15 years
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
> 15 years
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
Sex
Male
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
Female
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
Weight
≤ 60 kg
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
> 60–≤ 100 kg
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
> 100 kg
UST 0.75 mg/kg Confidential information has been removed Confidential information has been removed
UST 0.375mg/kg Confidential information has been removed Confidential information has been removed
PLB Confidential information has been removed Confidential information has been removed
PLB, placebo; UST, ustekinumab.
a Back-calculated from reported percentages, so values may not be entirely accurate.
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Adverse events up to week 60
Up to week 60, 81.8% of participants (90/110) in the ustekinumab combined group reported one or more
AEs (Table 30). Of the 74 participant-recorded infections, 18 (24%) were considered reasonably related to
ustekinumab treatment.
In total, 5.5% of participants (6/110) in the ustekinumab combined group (five participants in the
half-standard-dosage group and one participant in the standard-dosage group) reported SAEs (see Table 30).
Four (one because of worsening of psoriasis) of the 110 participants in the ustekinumab combined group
discontinued the trial because of an AE by week 60.
TABLE 27 Results of key outcomes in the ustekinumab trial (CADMUS) at week 52
Treatment
Participants who achieved the outcome, n/N (%)
PASI 50 PASI 75 PASI 90 sPGA 0 sPGA 0 or 1
UST 0.75 mg/kg Confidential information
has been removed
28/35 (80.0) 23/35 (65.7) 18/36 (50) 26/36 (72)
UST 0.375mg/kg Confidential information
has been removed
23/34 (67.6) 17/34 (50.0) 13/37 (35) 23/37 (62)
PLB→ UST 0.75 mg/kg Confidential information
has been removed
17/17 (100.0) 16/17 (94.1) 11/17 (65) 16/17 (94)
PLB→ UST 0.375mg/kg Confidential information
has been removed
12/17 (70.6) 9/17 (52.9) 9/19 (47) 13/19 (68)
PLB, placebo; UST, ustekinumab.
TABLE 28 Reported safety outcomes in the ustekinumab trial (CADMUS) at week 12
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection
site
reactions Malignancies
Withdrawals
because of
AEs
UST 0.75 mg/kg 16/36 (44.4) 0/36 (0.0) 8/36 (22.2) 0/36 (0.0) 1/36 (2.8) 0/36 (0.0) 0/36 (0.0)
UST 0.375mg/kg 19/37 (51.4) 1/37 (2.7)a 12/37 (32.4) 0/37 (0.0) 0/37 (0.0) 0/37 (0.0) 0/37 (0.0)
PLB 21/37 (56.8) 0/37 (0.0) 14/37 (37.8) 0/37 (0.0) 0/37 (0.0) 0/37 (0.0) 0/37 (0.0)
PLB, placebo; UST, ustekinumab.
a One participant in the half-standard-dosage group was hospitalised for worsening of psoriasis.
TABLE 29 Reported number of participants discontinuing ustekinumab treatment (CADMUS) up to week 40
Treatment
Participants with safety reports, n/N (%)
Total discontinued Because of AEs Because of death Because of lack of efficacy
UST 0.75 mg/kg 2/36 (5.6) 0/36 (0.0) 0/36 (0.0) 2/36 (5.6)
UST 0.375mg/kg 5/37 (13.5) 1/37 (2.7) 1/37 (2.7) 3/37 (8.1)
PLB→ UST 0.75 mg/kg 0/18 (0.0) 0/18 (0.0) 0/18 (0.0) 0/18 (0.0)
PLB→ UST 0.375mg/kg 2/19 (10.5) 2/19 (10.5) 0/19 (0.0) 0/19 (0.0)
PLB, placebo; UST, ustekinumab.
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Summary of the efficacy and safety of ustekinumab
l Both the standard dosage and the half-standard dosage of ustekinumab were significantly more
effective than placebo in improving the severity of plaque psoriasis based on PASI 50, 75 and 90
responses, sPGA cleared or minimal response and sPGA cleared response at 12 weeks.
l Both ustekinumab dosages also led to significantly greater improvements in HRQoL (CDLQI and
PedsQL) at 12 weeks than placebo.
l Among participants originally allocated to ustekinumab, PASI and PGA effects observed at 12 weeks
appeared to be largely sustained at 52 weeks, with few withdrawals because of lack of efficacy.
l Participants originally allocated to placebo showed substantial improvements in PASI and PGA
responses at 52 weeks after crossing over to ustekinumab treatment at week 12. There was some
indication that the gains were greater among those who received the standard dosage of ustekinumab
than among those who received the half-standard dosage.
l There were no notable differences between the ustekinumab group and the placebo group in terms of
short-term and longer-term AEs, although the number of observations was small and the longest
follow-up time was only 60 weeks. Few participants withdrew because of adverse effects.
Additional observational evidence
Retrospective case series
Two retrospective case series reported the use of adalimumab, etanercept and ustekinumab from 4 to
165 weeks in children with moderate to severe psoriasis.76,77 The key characteristics and results from these
studies are reported in Table 31.
Garber et al.76 reported a retrospective chart review of 27 participants (19 males, 8 females) attending a
single US general dermatology clinic from 2008 to 2014. Insufficient details were reported to establish
how many patients received more than one biologic over this period. Clearance rates [defined as
99% reduction on the Simple Measure for Assessing Psoriasis Severity or (S-MAPA)] were reported
(see Table 31). No SAEs were reported. Although the authors concluded that the use of adalimumab,
etanercept and ustekinumab is safe in paediatric psoriasis and that these treatments are efficacious,
this study provides insufficient data on the efficacy or safety profiles of these agents in practice.
TABLE 30 Reported safety outcomes in the ustekinumab trial (CADMUS) up to week 60a
Treatment
Participants with safety reports, n/N (%)
AEs SAEs Infections
Serious
infections
Injection
site
reactions Malignancies
Withdrawals
because of
AEs
UST 0.75 mg/kg 29/36 (80.6) 1/36 (2.8)b 24/36 (66.7) 1/36 (2.8)b 1/36 (2.8) 0/36 (0.0) 0/36 (0.0)
UST 0.375mg/kg 33/37 (89.2) 5/37c,d (13.5) 26/37 (70.3) 1/37d (2.7) 0/37 (0.0) 0/37 (0.0) 2/37 (5.4)
PLB→ UST
0.75 mg/kg
13/18 (72.2) 0/18 (0.0) 11/18 (61.1) 0/18 (0.0) 0/18 (0.0) 0/18 (0.0) 0/18 (0.0)
PLB→ UST
0.375mg/kg
15/19 (79.0) 0/19 (0.0) 13/19 (68.4) 0/19 (0.0) 0/19 (0.0) 0/19 (0.0) 2/19 (10.5)
PLB, placebo; UST, ustekinumab.
a Incorporates week 12 and week 40 data.
b Ear infection.
c In addition to events recorded before week 60, one death in an automobile accident, one case of allergic contact
dermatitis and one participant with laboratory values for absolute leucocyte count, absolute neutrophil count and white
blood cell count of 0.53, 0.87 and 1.62 × 103 µl, respectively, while undergoing treatment with aciclovir for concurrent
herpes simplex.
d Pyelonephritis.
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TABLE 31 Retrospective case series of adalimumab, etanercept or ustekinumab in children and young people
with psoriasis
Study,
country Treatment (dose)
Number of
patients
Treatment
duration
(weeks)
Age
(years),
median
(range)
Mean
PGA
score at
baseline
Reported
outcomes/key AEs
Garber et al.,
2015,76 USA
Adalimumab (40 mg every
other week)
7 146 – – Achieved clearance,
n= 4/6; secondary
failure, n = 3;
injection site
reaction, n= 1;
minor infection,
n= 3a
Etanercept (50 mg weekly) 13 87 – – Achieved clearance,
n= 6/9; injection site
reaction, n= 1;
secondary failure,
n= 6; lack of
response, n= 3;
minor infection,
n= 4b
Ustekinumab (45 mg at
weeks 0 and 4, then every
12 weeks)
3 165 – – Achieved clearance,
n= 1/3
Adalimumab +methotrexate 2 11 – – Achieved clearance,
n= 1/2
Etanercept +methotrexate 2 121 – – Achieved clearance,
n= 2/2
Etanercept + ciclosporin 1 20 – – –
Klufas et al.,
2016,77 USA
Adalimumab (40 mg every
other week)
11 3–134 16.5
(7.0–18.0)
2.4 Mean PGA scorec 0.7
Injection site
reaction, n= 1
Etanercept (25 or 50 mg
once or twice weekly)
23 8–135 14.0
(8.0–18.0)
3.0 Mean PGA scorec 1.5
Injection site
reaction, n= 2
Ustekinumab (45 or 90 mg
at weeks 0 and 4, then
every 12 weeks)
6 4–72 16.5
(7.0–18.0)
2.6 Mean PGA scorec 1.5
Adalimumab (40 mg
eow)+methotrexate
(7.5–15mg weekly)
9 8–118 15.0
(11.0–17.0)
2.4 Mean PGA scorec 1.0
Injection site
reaction, n= 1
Etanercept (50 mg once or
twice weekly+methotrexate
(7.5–15mg weekly)
5 4–30 15.0
(13.0–17.0)
3.1 Mean PGA scorec 1.8
Ustekinumab (45 mg at
weeks 0 and 4, then every
12 weeks) +methotrexate
(12.5 mg weekly)
2 NR 16.5
(16.0–17.0)
3.8 Mean PGA scorec 1.3
NR, not reported.
a Across all participants who received adalimumab (n= 9).
b Across all participants who received etanercept (n= 16).
c At 5–7 months.
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Klufas et al.77 similarly reported a retrospective case series evaluating 51 children with moderate to severe
psoriasis treated with systemic therapies for AE occurrence and PGA-measured disease response. For all
biologics (alone or in combination with methotrexate), mean PGA values fell at 5–7 months’ follow-up. In
total, 29 AEs were reported in relation to 80 treatment data points (some patients received more than one
biologic); most were minor subjective side effects, with no infections or SAEs reported. Again, limitations in
the sample size and study design preclude strong inferences being drawn from these data.
Registry data
Published findings or papers detailing study design were identified for 16 registries. Information on biological
drug safety in their psoriasis cohorts was published by nine registries, with 11 articles on biological efficacy
and nine articles including drug survival data. This does not necessarily mean that the other registries did not
record these outcomes, but they were not covered in the identified literature output.
Registry data for children
Further screening was carried out to find registry publications making explicit reference to children with
psoriasis and specifically providing information on the survival of biological treatment. Two registries
(Child-CAPTURE and DERMBIO) were found to include children with psoriasis who were treated with
biologics. Child-CAPTURE (the Netherlands) contained seven children treated with etanercept,90 but did
not differentiate between biological and non-biological therapies in drug survival analyses. We identified
from the 2014 annual report91 by the DERMBIO (Denmark) registry that there are 37 children enrolled who
are undergoing treatment with adalimumab, etanercept or ustekinumab, although data for this group
were not reported separately. Cox regression modelling of covariates in two studies found no significant
predictive relationship between patient age and drug survival, suggesting that treatment withdrawal rates
among children were similar to those in adults.92,93
Wider registry data
In one 2015 DERMBIO study following 1277 (predominantly adult) psoriasis patients for up to 10 years,92
median drug survival for etanercept was 30 months (95% CI 25.1 to 34.9 months), which was significantly
lower than for adalimumab (59 months, 95% CI 45.6 to 72.4 months) and ustekinumab (median not reached).
Year-on-year drug survival for etanercept (estimated from the Kaplan–Meier curve) was 0.70 at 1 year, 0.53
at year 2 and 0.30 at year 5, whereas year-on-year drug survival for ustekinumab was 0.85 after 1 year, 0.78 at
year 2 and 0.65 at year 5 (Table 32). Loss of efficacy was the most likely reason for drug discontinuation, but
this was of greater significance proportionally for etanercept than for the other biologics analysed.
Findings from the British Association of Dermatologists Biologic Interventions Register (BADBIR) were broadly
similar to those seen in the Danish cohort. A study by Warren et al.94 on drug survival over 3 years in 3523
biologic-naive patients found that 77% of patients remained on biologic treatment over the first year,
falling to 53% by the third year. Again, there were significant differences in the treatment withdrawal rates
between biologics. Ustekinumab exhibited the highest first-course survival rate at 0.89 at year 1 and 0.75
at year 3. Adalimumab showed the highest survival of the anti-TNF-α drugs, at 0.79 at year 1 and 0.59 at
year 3. Disregarding the very small population of patients on infliximab, etanercept was consistently the
TABLE 32 Survival of first biologic in the DERMBIO registry92
Biologic
Drug survival
1 year 2 years 5 years
Adalimumab (n= 567) 0.77 0.67 0.48
Etanercept (n= 364) 0.70 0.53 0.30
Infliximab (n = 176) 0.75 0.62 0.43
Ustekinumab (n= 170) 0.85 0.78 0.65
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worst-performing drug in terms of treatment withdrawal, with a 1-year survival rate of 0.70, dropping to
0.40 at 3 years (Table 33). Etanercept was also found to be a significant predictor of discontinuation of
therapy because of loss of efficacy. Other significant predictors of treatment withdrawal were female sex,
smoking status and a higher baseline Dermatology Life Quality Index (DLQI) score.
Overview of the randomised controlled trial results
Despite differences in inclusion criteria, the relative lack of younger children in the adalimumab and etanercept
trials meant that the median age of children across the three trials did not differ greatly. Similarly, measures of
disease duration and the component measures of severity did not appear to differ markedly between the three
trials. Few participants in any trial had previous experience of biological treatment.
The biologics and their respective comparators in the relevant RCTs in children and young people are
summarised in Table 34.
There were no head-to-head comparative data available for the three biologics. In addition, although the
etanercept and ustekinumab trials had a placebo as a common comparator, the adalimumab trial used
methotrexate as a comparator.
Table 35 shows the relative effects for all three biologics from the three RCTs. However, an implicit
comparison is not useful for the purposes of the decision-analytic modelling required for the economic
evaluation. Chapter 4 therefore describes a formal evidence synthesis to inform the relative efficacy of
these interventions.
TABLE 33 Survival of first biologic in the BADBIR
Biologic
Drug survival
1 year 2 years 3 years
Adalimumab (n= 1879) 0.79 0.67 0.59
Etanercept (n= 1098) 0.70 0.51 0.40
Infliximab (n = 96) 0.65 0.50 0.35
Ustekinumab (n= 450) 0.89 0.82 0.75
TABLE 34 Summary of the biologics and their comparators based on RCTs
Treatment Class of therapy Dosage Comparator
Adalimumab Anti-TNF-α Standard (0.8 mg/kg) Methotrexate
Half-standard (0.4 mg/kg)
Etanercept Anti-TNF-α Standard (0.8 mg/kg) Placebo
Ustekinumab Anti-IL-12/-IL-23 Standard (0.75 mg/kg) Placebo
Half-standard (0.375 mg/kg)
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TABLE 35 Relative risks of PASI outcomes for biological therapy trials in children and young people
Trial
PASI outcome, RR (95% CI)
PASI 50 PASI 75 PASI 90
Adalimumab vs. methotrexate (M04-717) (16 weeks)
Standard dosage (0.8 mg/kg) Confidential information
has been removed
1.79 (1.04 to 3.06)a 1.34 (0.61 to 2.95)
Half-standard dosage (0.4 mg/kg) Confidential information
has been removed
1.34 (0.75 to 2.42)a 1.42 (0.65 to 3.08)
Etanercept vs. placebo (20030211) (12 weeks)
Standard dosage (0.8 mg/kg) 3.26 (2.26 to 4.71) 4.95 (2.84 to 8.65)a 4.10 (1.88 to 8.95)
Ustekinumab vs. placebo (CADMUS) (12 weeks)
Standard dosage (0.75 mg/kg) 2.99 (1.79 to 4.97) 7.5 (2.9 to 19.1) 11.0 (2.8 to 43.5)
Half-standard dosage (0.375 mg/kg) 2.72 (1.62 to 4.48) 7.3 (2.8 to 18.6) 10.0 (2.5 to 39.8)
a Stated as primary outcome.
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Chapter 4 Evidence synthesis to inform the
relative efficacy of the interventions
Overview
Randomised controlled trials of the effectiveness of adalimumab, etanercept and ustekinumab for the
treatment of plaque psoriasis in children and young people have been discussed and summarised in Chapter 3.
The efficacy end point consistently reported across the trials was PASI response rates, which is the key efficacy
parameter used in the economic analysis. To determine the relative efficacy of the interventions, it would be
ideal to have results from good-quality adequately powered RCTs comparing the active treatments with one
another in the population of children and young people. However, the evidence base presents a number of
challenges for informing the relative efficacy of the interventions in this population. First, the interventions of
interest have not been directly compared in head-to-head RCTs. Second, no common comparator (e.g. placebo)
exists across all of the RCTs. Third, the age of the populations included in the trials differs across the RCTs and
the interventions of interest have marketing authorisation for different age groups. Fourth, the severity of
plaque psoriasis is defined differently in the populations included in the RCTs and the interventions are licensed
for different levels of psoriasis severity in children and young people. These challenges mean that a number of
assumptions are required to inform the benefits of the active treatments relative to the appropriate comparators
and each other.
Meta-analysis using mixed-treatment comparisons enables the estimation of different parameters from several
studies with similar comparisons to be combined when direct evidence on comparisons of interest is absent
or sparse. The statistical synthesis method of NMA enables the comparison of multiple treatment options
using both direct comparisons of interventions from RCTs and indirect comparisons across trials based on a
common comparator.95,96 As suggested by the term, NMA needs a ‘network of evidence’ to be established
between all of the interventions of interest. However, with neither direct comparisons nor a common
comparator in the evidence base for children and young people from which to derive indirect comparisons of
comparator treatments, the evidence base is structured as a ‘disconnected network’ (Figure 3).
MTX
PLB
ETA
ADA
UST 45CADMUS72
2003021149
M04-71742
FIGURE 3 Network of evidence for children and young people. ADA, adalimumab 0.8mg/kg, maximum 40mg/week;
ETA, etanercept 0.8mg/kg, maximum 50mg/week; MTX, methotrexate 0.1–0.4mg/kg/week; PLB, placebo; UST 45,
ustekinumab 0.75mg/kg or 45mg/week. Trial names are stated when trial evidence informs the network
treatment link.
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In the following sections we build on the challenges listed above by exploring treatment efficacy by age
subgroup and by performing a naive indirect treatment comparison of adalimumab and etanercept,
highlighting the limitations of such analysis. Furthermore, a framework of analysis is described that uses
different levels of evidence from the adult population to specifically address the issue of having a
disconnected network structure.
Efficacy differences by age subgroup
Adalimumab, etanercept and ustekinumab have marketing authorisation for different age groups in the
population of children and young people (≥ 4 years for adalimumab, ≥ 6 years for etanercept and ≥ 12 years
for ustekinumab). This is the result of variation in the ages of the patient populations included in the RCTs for
these interventions. Furthermore, the trial population for etanercept also included patients who were younger
than the licensed age group (i.e. the inclusion criteria for the etanercept trial was children and adolescents
aged 4–17 years and nine children were included in the trial who were younger than the subsequent licensed
age group of ≥ 6 years). To establish the relative efficacy of the interventions it was necessary to either
(1) assume that the PASI response rates for the treatments are independent of age within the full population
of children and young people or (2) consider outcomes in a population subgroup by age.
Chapter 3 presents the PASI response rates for each study by age subgroup. On inspection of the PASI
response rates, there does not appear to be a pattern across the efficacy outcomes for the different age
subgroups within the same study, which could explain any differences in efficacy as a result of age.
This would seem to suggest that the PASI response rates for the study as a whole are reflective of the
outcomes expected in a particular subpopulation by age. This was examined further by using standard
parametric statistical tests to assess the equality of proportions (i.e. the probability of PASI 50/75/90
response rates) across different age subgroups within each study. Within each study there were no
statistically significant differences identified across the age subgroups for each of the PASI response rates
of 50, 75 or 90 (Table 36). Therefore, to compare the relative efficacy of the interventions, it was assumed
that the PASI response rates for the treatments are independent of age within the full population of
children and young people and that the studies are comparable for this population.
Indirect treatment comparison
Figure 3 shows that there is no common comparator arm between the adalimumab trial (M04-717) and
the trials of etanercept (20030211) and ustekinumab (CADMUS), with the adalimumab trial having a
comparator of methotrexate and the other two trials having a comparator of placebo. Therefore, it is not
possible to establish an indirect comparison between adalimumab and etanercept or ustekinumab without
drawing on evidence from other sources (e.g. evidence on the relative efficacy of the interventions in
adults) or by creating a common comparator (e.g. assuming that the methotrexate and placebo response
rates are exchangeable between the trials). In this section, attention is focused on the indirect comparison
that can be established between etanercept and ustekinumab.
An indirect treatment comparison of PASI response rates at 12 weeks was performed between the licensed
doses of etanercept (0.8 mg/kg up to a maximum dose of 50 mg) and ustekinumab (standard dose) using
placebo as a common comparator. A Bayesian indirect treatment comparison was undertaken using a
probit model for ordered multinomial outcomes of PASI response rates (using a fixed-effect model with
multinomial likelihood and a probit link (see Appendix 4). Table 37 presents the absolute probabilities of
PASI 50, 75 and 90 responses for etanercept and ustekinumab and Table 38 presents the relative
treatment effects expressed as RRs with 95% Bayesian credible intervals (CrIs).
EVIDENCE SYNTHESIS TO INFORM THE RELATIVE EFFICACY OF THE INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
TABLE 36 Hypothesis testing of age subgroup PASI responses by study and treatment arm
Study/treatment arma All
Age subgroup (years)
Hypothesis test of equality
of proportions, p-value4–6 > 6–9 > 9–12 > 12–15 > 15
M04-717
Adalimumab n= 38 n= 0 n= 7 n= 8 n= 13 n= 10
PASI 50 (%) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.72
PASI 75 (%) 57.9 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.84
PASI 90 (%) 28.9 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.47
Methotrexate n= 37 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
PASI 50 (%) Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.91
PASI 75 (%) 32.4 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.44
PASI 90 (%) 21.6 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
0.77
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TABLE 36 Hypothesis testing of age subgroup PASI responses by study and treatment arm (continued )
Study/treatment arma All
Age subgroup (years)
Hypothesis test of equality
of proportions, p-value≤ 15 > 15
CADMUS
Placebo n= 37 n= 15 n= 22
PASI 50 (%) 29.7 NA NA NA
PASI 75 (%) 10.8 Confidential information
has been removed
Confidential information
has been removed
0.90
PASI 90 (%) 5.4 NA NA NA
Ustekinumab n= 36 n= 20 n= 16
PASI 50 (%) 88.9 NA NA NA
PASI 75 (%) 80.6 Confidential information
has been removed
Confidential information
has been removed
0.60
PASI 90 (%) 61.1 NA NA NA
Study/treatment arma All
Age subgroup (years)
Hypothesis test of equality
of proportions, p-value4–11 > 12–17
20030211
Placebo n= 105 n= 38 n= 67
PASI 50 (%) 22.9 21.1 23.9 0.93
PASI 75 (%) 11.4 10.5 11.9 1.00
PASI 90 (%) 6.7 NA NA NA
Etanercept n= 106 n= 38 n= 68
PASI 50 (%) 74.5 76.3 73.5 0.93
PASI 75 (%) 56.6 57.9 55.9 1.00
PASI 90 (%) 27.4 NA NA NA
NA, not available.
a Adalimumab 0.8 mg/kg, maximum 40mg/week; methotrexate 0.1–0.4 mg/kg/week; etanercept 0.8 mg/kg, maximum 50mg/week; ustekinumab 0.75 mg/kg or 45 mg/week.
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The results demonstrate that ustekinumab appears to be more effective than etanercept in this population.
The PASI 75 absolute probability of response for ustekinumab at 12 weeks was estimated to be 78%
(95% CrI 63% to 90%) whereas that for etanercept was estimated to be 57% (95% CrI 44% to 69%).
The 95% CrIs were wide and overlap, which reflects the small sample size and limited number of data
points used in this analysis. The pooled RR presented in Table 38 for ustekinumab compared with
etanercept is 1.41, but this is not statistically significant as the 95% CrI includes 1. The indirect comparison
results are in line with the direct evidence from the clinical trials.
The company submission for ustekinumab presented a similar indirect treatment comparison for
ustekinumab compared with etanercept [Janssen. Adalimumab, Etanercept and Ustekinumab for Treating
Plaque Psoriasisin Children and Young People – Company Evidence Submission. ID854. 2016 (unpubished)].
The company’s analysis produced results for the full population and for a subgroup aged 12–17 years. The
results of the company’s full population NMA are broadly similar to the results from the Assessment Group’s
(AG) analysis, for example the ustekinumab PASI 75 response was estimated to be 79.8%, compared with
78.1% in Table 37.
It is important to note that these analyses are limited for a number of reasons.
l It draws conclusions only regarding the short-term use of ustekinumab and etanercept in the
population of children and young people from the corresponding trials.
l The placebo arms in the etanercept trial (20030211) and the ustekinumab trial (CADMUS) are assumed
to be exchangeable between the trials.
l Inclusion criteria for age were different between the trials.
l There is uncertainty in both the within-trial and between-trial treatment effect estimates because of the
small sample sizes in the trials.
TABLE 37 Absolute probabilities of PASI 50, 75 and 90 response rates in the indirect treatment comparison of
etanercept and ustekinumab
Treatment PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI)
Placebo 0.265 (0.190 to 0.346) 0.131 (0.082 to 0.191) 0.042 (0.021 to 0.073)
Etanercepta 0.744 (0.631 to 0.841) 0.565 (0.437 to 0.688) 0.330 (0.218 to 0.454)
Ustekinumabb 0.896 (0.797 to 0.962) 0.781 (0.632 to 0.898) 0.571 (0.395 to 0.742)
a 0.8 mg/kg, maximum 50mg/week.
b 0.75 mg/kg or 45 mg/week.
TABLE 38 Relative effect estimates (as RRs, means and 95% CrIs) for each treatment combination for PASI 75 in the
direct trial comparisons (upper diagonal) and the indirect treatment comparison for etanercept and ustekinumab
(lower diagonal)
PLB 4.95 (2.84 to 8.65) 7.50 (2.90 to 19.10)
4.48 (2.99 to 6.64) ETAa –
6.27 (3.80 to 10.00) 1.41 (0.99 to 1.93) USTb
ETA, etanercept; PLB, placebo; UST, ustekinumab.
a 0.8 mg/kg, maximum 50mg/week.
b 0.75 mg/kg or 45 mg/week.
Notes
Lower diagonal: pooled RRs from the NMA model; RRs > 1 favour the row agent. Upper diagonal: RRs from the direct
comparisons; RRs > 1 favour the column agent. Significant differences in the relative effects between a pair of agents are
given in bold.
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l There are differences between the trials in terms of baseline characteristics and trial design: these
differences have been explored separately in Chapter 3.
l The indirect treatment comparison does not provide sufficient information to inform the economic
analysis as the use of adalimumab has been excluded from the analysis because of a lack of a
common comparator.
As a consequence of the above limitations, in particular the exclusion of the adalimumab trial (M04-717)
evidence, the results in Table 37 could not be used to assess the relative cost-effectiveness of adalimumab,
etanercept and ustekinumab for the treatment of plaque psoriasis in children and young people.
Framework of analysis for informing the relative efficacy of the
interventions
Because of the lack of a common comparator arm between the adalimumab trial (M04–717) and the
ustekinumab (CADMUS) and etanercept (20030211) trials, an analysis plan was developed that entailed
exploring the possibility of using PASI response data from adults with moderate to severe plaque psoriasis
to fill the evidence gap in the population of children and young people. The use of data from the adult
population was supported by our clinical advisor (Dr Ruth Murphy, personal communication), who did not
see any reason why the relative effectiveness of the interventions in adults could not be used to infer relative
effectiveness in children and young people, especially in the absence of evidence in the latter population.
A framework of analysis was thus developed for the NMA approach that allowed all available and relevant
evidence to be included. The framework explored two separate networks, which differed according to the
extent of evidence utilised from the adult trials.
1. The network of trials in children and young people was connected by bringing the minimum amount of
evidence required from the adult population to link the adalimumab trial with the other trials in the
disconnected network in Figure 3.
2. The network of trials in children and young people was connected by bringing together all relevant
evidence on the efficacy of all of the interventions in adults.
This approach allows treatment-specific estimates to be modelled in each population by drawing strength
from the network of evidence available. The use of a NMA in preference to pairwise meta-analyses enables
the inclusion of all relevant evidence, allowing for precise estimates of treatment effects to be calculated.
In addition, the results from the NMA feed directly into the economic model to provide the relevant
cost-effectiveness of adalimumab, etanercept and ustekinumab compared with relevant comparators and
each other. This approach has been used in previous NICE TAs for the treatment of plaque psoriasis in
adults (TA103,97 TA134,98 TA146,99 TA180,100 TA350,101 and TA368102).
In each of the NICE TAs in adults the evidence network was updated with new studies reported since the
previous appraisal. Therefore, we took the most recent single TAs in adults (TA368102 and TA350101) as
the starting point for developing a network of studies that could potentially connect the adalimumab trial
in children and young people to the other interventions. The Evidence Review Groups (ERGs) for these
appraisals generally rated the systematic reviews underpinning the identification of trials for inclusion in the
NMA as appropriate and the evidence networks were subsequently used to inform NICE recommendations
in these appraisals. Therefore, it was assumed that the vast majority of relevant evidence for the interventions
in adults had been captured in the most recent appraisals in 2015.101,102 Relevant adult trials were identified
based on the indirect comparison and/or multiple treatment comparisons reported within these appraisals.
Lists of excluded trials and reasons for exclusion were also reviewed and relevant trials identified. To
supplement this review, the results of a recently published systematic review and NMA,103 which adjusted for
cross-trial differences in the comparative efficacy of biological treatments for moderate to severe psoriasis in
adults, were also examined to cross-check that the majority of relevant studies had been identified in the
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previous appraisals. Furthermore, we also considered studies reported in the original multiple TA in adults
(TA10397), which included interventions such as methotrexate and ciclosporin. The key inclusion and
exclusion criteria used to identify relevant trials for the NMA are shown in Table 39. A list of excluded trials
(n = 18) and reasons for exclusion can be found in Appendix 5. Table 40 presents a summary of the trials in
adults, including the comparator agents used in each trial, which was used to inform the NMA.
Thirty-four trials in adults with moderate to severe plaque psoriasis were found to be relevant for the
NMA; 29 of these considered a placebo arm and six were three-arm trials. As described in the ERG reports
for the previous TAs, selected studies were mostly comparable in terms of their inclusion criteria regarding
previous and concomitant medication use. The majority of studies included patients who had failed or who
had had an insufficient response to previous topical therapy and conventional systemic agents such as
ciclosporin or methotrexate. Some studies included only biologic-naive individuals, whereas others allowed
previous biological therapy use. Almost all of the studies did not allow concomitant treatment with
systemic agents or phototherapy. A few studies did not mention their criteria regarding concomitant
medication use.
The full set of interventions and comparators included adalimumab, etanercept, 45 mg of ustekinumab,
90 mg of ustekinumab, apremilast, methotrexate, ciclosporin, fumaric acid, infliximab and placebo.
Response rates for PASI 50, 75 and 90 from the selected trials were identified and extracted, together with
sample size and key baseline patient characteristics by treatment arm. Table 41 presents a summary of the
data extracted together with the corresponding data from the three trials in children and young people.
Network meta-analysis using minimum evidence from the adult population
The disconnected network of evidence in children and young people was connected in the first instance by
bringing together the minimum amount of evidence required from the adult population to link the adalimumab
trial with the other trials (Figure 4). Among the studies presented in Table 40, there was only one trial in adults
that could directly connect methotrexate with placebo and adalimumab with placebo (CHAMPION106). A
number of trials compared adalimumab with placebo alone but inclusion of these trials would mean that
methotrexate was connected only indirectly through adalimumab and placebo, potentially undermining the
evidence from M04-717 on this agent. Therefore, the CHAMPION study represented the best way to
connect adalimumab and methotrexate to etanercept and ustekinumab using the least amount of evidence
drawn from the adult population.
In the CHAMPION trial,106 the primary efficacy end point was the proportion of individuals achieving a PASI
75 response at 16 weeks. Adalimumab was found to have significantly greater efficacy (79.6% achieving
a PASI 75 response) than either methotrexate (35.5%) or placebo (18.9%). PASI outcome data and key
baseline characteristics for the CHAMPION trial are provided in Table 41. The average age of patients
recruited into the CHAMPION trial was approximately 42 years. The CHAMPION trial was a larger trial than
the trials carried out in children and young people (n = 271 vs. n = 75 in the M04-717 trial), with an
approximately 10–20% higher proportion of males.
TABLE 39 Key inclusion and exclusion criteria for adult studies
Inclusion criteria Exclusion criteria
l RCTs in adults that considered one or more of the three treatments of interest in
recommended dosages: adalimumab, etanercept or ustekinumab
l RCTs in adults that considered the systemic treatment methotrexate, a key
comparator in the adalimumab trial (M04-717)
l RCTs in adults that directly or indirectly informed comparisons between agents
or the comparator of interest (adalimumab, etanercept, ustekinumab and
methotrexate) or between the agents of interest and placebo/BSC
l RCTs in adults and/or arms
that considered irrelevant
doses or comparators
l RCTs in adults that reported
PASI outcome data at
irrelevant time points
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TABLE 40 Summary of trials in adults selected to inform the NMA
Study
Treatment
Adalimumab
(dose, mg/week)
Etanercept
(dose, mg/week)
Ustekinumab
(dose, mg/week) Methotrexate Apremilasta Ciclosporin Fumaric acid Infliximab Placebo
Adalimumab (n = 5)
Gordon et al., 2006104 ✓ (40) ✓
Menter et al., 2008105 (REVEAL) ✓ (40) ✓
Saurat et al., 2008106 (CHAMPION) ✓ (40) ✓ ✓
Asahina et al., 2010107 ✓ (40) ✓
Bissonnette et al., 2013108 ✓ (40) ✓
Etanercept (n= 6)
Gottlieb et al., 2003109 ✓ (50) ✓
Leonardi et al., 2003110 ✓ (50) ✓
Elewski et al., 2004111 ✓ (50) ✓
Papp et al., 2005112 ✓ (50) ✓
van de Kerkhof et al., 2008113 ✓ (50) ✓
Reich et al., 2016114 (LIBERATE) ✓ (50) ✓ ✓
Ustekinumab (n = 7)
Tsai et al., 2011115 (PEARL) ✓ (45) ✓
Zhu et al., 2013116 (LOTUS) ✓ (45) ✓
Krueger et al., 2007117 ✓ (45, 90) ✓
Leonardi et al., 2008118 (PHOENIX I) ✓ (45, 90) ✓
Papp et al., 2008119 (PHOENIX II) ✓ (45, 90) ✓
Griffiths et al., 2010120 (ACCEPT) ✓ (45, 90) ✓
Igarashi et al., 2012121 ✓ (45, 90) ✓
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TABLE 41 Summary of PASI response data used in the NMA and key baseline patient characteristics by treatment arm
Study
Treatment/weekly
dose Population
Time point
(weeks) n
Age (years),
mean
Male
(%)
PASI 50
(n)
PASI 50
(%)
PASI 75
(n)
PASI 75
(%)
PASI 90
(n)
PASI 90
(%)
2003021148–71 Placebo Children and
young people
12 105 – 50 24 22.9 12 11.4 7 6.7
Etanercept 0.8 mg/kg
(maximum 50mg)
12 106 – 52 79 74.5 60 56.6 29 27.4
CADMUS 201572–75 Placebo Children and
young people
12 37 16 54 11 29.7 4 10.8 2 5.4
Ustekinumab SD
(maximum 45mg)
12 36 15 44 32 88.9 29 80.6 22 61.1
M04-71739–47,87 Adalimumab 0.8 mg/kg
(maximum 40mg)
Children and
young people
16 37 13 45 30 78.9 22 57.9 11 28.9
Methotrexate 16 38 13 30 20 54.1 12 32.4 8 21.6
Guenther et al.,
1991129
Placebo Adults 10 11 – – 1 9.0 – – – –
Ciclosporin 10 12 – – 12 100.0 – – – –
Altmeyer et al.,
1994131
Placebo Adults 16 51 – – – – 1 2.0 – –
Fumaric acid 16 49 – – – – 12 24.5 – –
Meffert et al.,
1997130
Placebo Adults 10 43 – – – – 2 4.7 – –
Ciclosporin 10 41 – – – – 4 9.8 – –
Chaudhari et al.,
2001132
Placebo Adults 10 11 45 73 – – 2 18.2 – –
Infliximab 5mg/kg 10 11 51 64 – – 9 81.8 – –
Gottlieb et al.,
2003109
Placebo Adults 12 55 47 67 6 10.9 1 1.8 0 0.0
Etanercept 50 mg 12 57 48 58 40 70.2 17 29.8 6 10.5
Heydendael et al.,
2003122
Methotrexate Adults 16 43 42 65 – – 26 60.5 – –
Ciclosporin 16 42 38 69 – – 30 71.4 – –
Leonardi et al.,
2003110
Placebo Adults 12 166 46 63 24 14.5 6 3.6 1 0.6
Etanercept 50 mg 12 162 45 67 94 58.0 55 34.0 19 11.7
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Study
Treatment/weekly
dose Population
Time point
(weeks) n
Age (years),
mean
Male
(%)
PASI 50
(n)
PASI 50
(%)
PASI 75
(n)
PASI 75
(%)
PASI 90
(n)
PASI 90
(%)
Elewski et al.,
2004111
Placebo Adults 12 193 45 64 18 9.3 6 3.1 1 0.5
Etanercept 50 mg 12 196 45 65 126 64.3 67 34.2 2 1.0
Gottlieb et al.,
2004133 (SPIRIT)
Placebo Adults 10 51 45 61 11 21.6 3 5.9 1 2.0
Infliximab 5mg/kg 10 99 44 74 96 97.0 87 87.9 57 57.6
Papp et al., 2005112 Placebo Adults 12 193 44 64 18 9.3 6 3.1 1 0.5
Etanercept 50 mg 12 196 46 65 126 64.3 67 34.2 21 10.7
Reich et al., 2005134
(EXPRESS I)
Placebo Adults 10 77 44 79 6 7.8 2 2.6 1 1.3
Infliximab 5mg/kg 10 301 43 69 274 91.0 242 80.4 172 57.1
Gordon et al.,
2006104
Placebo Adults 12 52 43 65 7 13.5 2 3.8 0 0.0
Adalimumab 40mg 12 45 46 71 34 75.6 24 53.3 11 24.4
Krueger et al.,
2007117
Placebo Adults 12 64 44 72 7 10.9 1 1.6 1 1.6
Ustekinumab 45mg 12 64 45 61 59 92.2 43 67.2 28 43.8
Ustekinumab 90mg 12 64 44 81 59 92.2 52 81.3 33 51.6
Menter et al.,
2007135 (EXPRESS II)
Placebo Adults 10 208 44 69 – – 4 1.9 1 0.5
Infliximab 5mg/kg 10 314 45 65 – – 237 75.5 142 45.2
Flytström et al.,
2008123
Methotrexate Adults 12 37 48 76 24 64.9 9 24.3 4 10.8
Ciclosporin 12 31 45 87 27 87.1 18 48.6 9 24.3
Leonardi et al.,
2008118 (PHOENIX I)
Placebo Adults 12 255 45 72 26 10.2 8 3.1 5 2.0
Ustekinumab 45mg 12 255 46 69 213 83.5 171 67.1 106 41.6
Ustekinumab 90mg 12 256 45 68 220 85.9 170 66.4 94 36.7
Menter et al.,
2008105 (REVEAL)
Placebo Adults 16 398 45 65 60 15.1 28 7.0 8 2.0
Adalimumab 40mg 16 614 44 67 667 81.9 578 71.0 366 45.0
continued
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TABLE 41 Summary of PASI response data used in the NMA and key baseline patient characteristics by treatment arm (continued )
Study
Treatment/weekly
dose Population
Time point
(weeks) n
Age (years),
mean
Male
(%)
PASI 50
(n)
PASI 50
(%)
PASI 75
(n)
PASI 75
(%)
PASI 90
(n)
PASI 90
(%)
Papp et al., 2008119
(PHOENIX II)
Placebo Adults 12 410 47 69 41 10.0 15 3.7 3 0.7
Ustekinumab 45mg 12 409 45 69 342 83.6 273 66.7 173 42.3
Ustekinumab 90mg 12 411 47 67 367 89.3 311 75.7 209 50.9
Saurat et al., 2008106
(CHAMPION)
Placebo Adults 16 53 41 66 16 30.2 10 18.9 6 11.3
Adalimumab 40mg 16 108 43 65 95 88.0 86 79.6 55 50.9
Methotrexate 16 110 42 66 68 61.8 39 35.5 15 13.6
van de Kerkhof
et al., 2008113
Placebo Adults 12 46 44 54 4 8.7 1 2.2 1 2.2
Etanercept 50 mg 12 96 46 62 66 68.8 36 37.5 13 13.5
Asahina et al.,
2010107
Placebo Adults 16 46 44 89 9 19.6 2 4.3 0 0.0
Adalimumab 40mg 16 43 44 83 35 81.4 27 62.8 17 39.5
Griffiths et al.,
2010120 (ACCEPT)
Ustekinumab 45mg Adults 12 209 45 64 182 87.1 141 77.5 76 53.9
Ustekinumab 90mg 12 347 45 67 319 91.9 256 80.3 155 60.5
Torii et al., 2010136 Placebo Adults 10 19 43 74 2 10.5 0 0.0 0 0.0
Infliximab 5mg/kg 10 35 47 63 29 82.9 26 68.6 19 54.3
Barker et al., 2011124
(RESTORE I)
Methotrexate Adults 16 215 42 69 130 60.5 90 41.9 41 19.1
Infliximab 5mg/kg 16 653 44 67 567 86.8 508 77.8 356 54.5
Fallah et al., 2011125 Methotrexate Adults 12 27 41 59 15 55.6 6 22.2 2 7.4
Fumaric acid 12 27 43 74 11 40.7 5 18.5 1 3.7
Tsai et al., 2011115
(PEARL)
Placebo Adults 12 60 40 88 8 13.3 3 5.0 1 1.7
Ustekinumab 45mg 12 61 41 82 51 83.6 41 67.2 30 49.2
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Study
Treatment/weekly
dose Population
Time point
(weeks) n
Age (years),
mean
Male
(%)
PASI 50
(n)
PASI 50
(%)
PASI 75
(n)
PASI 75
(%)
PASI 90
(n)
PASI 90
(%)
Igarashi et al.,
2012121
Placebo Adults 12 31 49 84 4 12.9 2 6.5 1 3.2
Ustekinumab 45mg 12 64 45 83 53 82.8 38 59.4 21 32.8
Ustekinumab 90mg 12 62 44 76 52 83.9 42 67.7 27 43.5
Papp et al., 2012126 Placebo Adults 16 88 44 60 22 25.0 5 5.7 1 1.1
Apremilast 16 88 44 57 53 60.2 36 40.9 10 11.4
Yang et al., 2012137 Placebo Adults 10 45 40 78 6 13.2 1 2.2 0 0.0
Infliximab 5mg/kg 10 84 39 71 79 94.0 68 81.0 48 57.1
Bissonnette et al.,
2013108
Placebo Adults 16 10 57 60 – – 2 20.0 – –
Adalimumab 40mg 16 20 56 85 – – 14 70.0 – –
Zhu et al., 2013116
(LOTUS)
Placebo Adults 12 162 40 78 32 19.8 18 11.1 5 3.1
Ustekinumab 45mg 12 160 49 84 146 91.3 132 82.5 107 66.9
Papp et al., 2015127
(ESTEEM I)
Placebo Adults 16 282 47 69 48 17.0 15 5.3 1 0.4
Apremilast 16 562 46 67 330 58.7 186 33.1 55 9.8
Paul et al., 2015128
(ESTEEM II)
Placebo Adults 16 137 46 73 27 19.7 8 5.8 1 0.7
Apremilast 16 274 45 64 152 55.5 79 28.8 24 8.8
Reich et al., 2016114
(LIBERATE)
Placebo Adults 16 84 – – 28 33.3 10 11.9 – –
Etanercept 50 mg 16 83 – – 69 83.1 40 48.2 – –
Apremilast 16 83 – – – – 33 39.8 – –
SD, standard dose.
Note
Outcome data measured at weeks 10–16 were generally used, with a preference for data at 12 weeks if outcomes were reported at multiple time points.
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The PASI 75 response rates for adalimumab and methotrexate in the CHAMPION trial were similar to those
reported in the M04-717 trial in children and young people. An important difference between the CHAMPION
trial and the trials in children and young people was the observed placebo effect on the primary end point of
PASI 75. Whereas in the etanercept trial (20030211) and the ustekinumab trial (CADMUS) the proportion of
individuals achieving a PASI 75 response in the placebo arm was approximately 11%, the proportion achieving
a PASI 75 response in the placebo arm in the CHAMPION trial106 was approximately 19%. The authors of the
CHAMPION trial identified two reasons for this anomalous placebo response: (1) placebo response rates are
generally greater in European studies and (2) the observed placebo response may partly have resulted from the
correction of an underlying folate deficiency following folate supplementation, which was mandatory for all
study patients.
Given that the CHAMPION trial connects the adalimumab trial in children and young people (M04-717) to
etanercept and ustekinumab through placebo, it is important to ensure that the differences in placebo
response rates do not ‘artificially’ inflate or deflate the PASI response outcomes for the interventions of
interest. Therefore, as well as using a baseline unconstrained prediction model, whereby baseline risk
(placebo response rates) is predicted using evidence from all studies included in the network (analysis 1a),
a baseline constrained prediction model was also considered, whereby placebo response rates are predicted
based on the placebo arm trials in children and young people only [i.e. the etanercept (20030211) and
ustekinumab (CADMUS) trials] (analysis 1b). As the number of trials to inform each treatment effect is small,
a fixed-effect model was used. The results of this analysis are presented in Results.
Network meta-analysis using full evidence from the adult population
The second approach to the NMA involved connecting the evidence from the adalimumab trial in children
and young people to the evidence from the other trials (20030211 and CADMUS) by drawing strength
from the full network of evidence available in adults. The relative efficacy of adalimumab, etanercept and
ustekinumab has been evaluated extensively in adults with moderate to severe plaque psoriasis. Given the
limited evidence base in children and young people, and the expectation that the difference in response
rates between the interventions is predominantly the result of the relative efficacy of the biologics rather
than age or other patient characteristics, it would seem appropriate to combine the weight of evidence
MTX
PLB
ETA
ADA
UST 45CADMUS
72
2003021149
M04-71742
CHAMPION106
CHAMPION106
CHAMPION106
FIGURE 4 Network of evidence using minimum evidence from the adult population. ADA, adalimumab 0.8 mg/kg,
maximum 40mg/week; ETA, etanercept 0.8mg/kg, maximum 50mg/week; MTX, methotrexate 0.1–0.4mg/kg/week;
PLB, placebo; UST 45, ustekinumab 0.75mg/kg or 45mg/week. Trial names are stated when trial evidence informs
the network treatment link.
EVIDENCE SYNTHESIS TO INFORM THE RELATIVE EFFICACY OF THE INTERVENTIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
60
from all relevant trials and comparators, including those in adults. This wider network of evidence can be
used to facilitate an indirect comparison of adalimumab with etanercept and ustekinumab by examining
the relationships that exist between the different treatments and study populations and drawing strength
from the full network of evidence.
Figure 5 presents the full network of evidence in both populations. This wider network considers nine
active treatments and placebo, encompassing 37 RCTs in total (three in children and young people and
34 in adults), with six of these being three-arm trials. The majority of network links (‘head-to-head trial
comparisons’) are populated by more than one study.
A Bayesian evidence synthesis approach was employed that draws on the relationships that exist between
treatments and populations while also preserving differences that exist across populations by adjusting
for age and placebo response rates. NMA meta-regression models on baseline risk (i.e. placebo response)
were explored.103 These models impose a common interaction effect between baseline risk and relative
effectiveness that accounts for variation in reference arm response across trials. NMA meta-regression
models that explore variability caused by age effects were also implemented. These models impose an
age group interaction effect at the study level (binary variable: 1 if study is from a child or young adult
population, 0 otherwise) that attempts to explain the heterogeneity between treatment effects when
considering both adult treatment response data and data from children and young people. The age-adjusted
meta-regression models provided pooled PASI response rates by treatment for both children and young
people, and adults. A common treatment × age interaction effect was imposed. The common interaction
assumption is the least data demanding (i.e. only one extra parameter needs to be estimated), but it also
imposes the strongest assumption as it implies that the same age group effect exists regardless of treatment
MTX
PLB
UST 90
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ADA UST 45
APRE
INF
CIC
CADMUS72
PEARL115
LOTUS116
Krueger 2007117
PHOENIX I118
PHOENIX II119
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PHOENIX II119
Igarashi 2012121
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SPIRIT133
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FIGURE 5 Wider network of evidence in children and young people and adult populations. ADA, adalimumab
0.8 mg/kg, maximum 40mg/week; APRE, apremilast; CIC, ciclosporin; ETA, etanercept 0.8 mg/kg, maximum
50mg/week; FUM-A, fumaric acid; INF, infliximab 5mg/kg; MTX, methotrexate 0.1–0.4 mg/kg/week; PLB, placebo;
UST 45, ustekinumab 0.75mg/kg or 45mg/week; UST 90, ustekinumab 90mg/week. Trial names are stated when
trial evidence informs the network treatment link. Discontinued lines indicate where three-arm trials inform the
evidence network, with the number of three-arm trials indicated in boxes.
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(excluding placebo).138 For example, if the age interaction effect (of children and young people vs. adults) is
estimated to be positive and of average magnitude 25% on the absolute PASI scale, PASI response rates in
children and young people will be approximately 25% higher, on average, than those in adults, irrespective
of treatment. Further details on the implemented synthesis models and their assumptions, including the
WinBUGS code (version 1.4.3; MRC Biostatistics Unit, Cambridge, UK), are provided in Appendix 5.
Fixed- and random-effects analyses were explored for two separate scenarios: (1) a meta-regression model
with adjustment for baseline risk (i.e. placebo response rates) and (2) a meta-regression model with
adjustment for baseline risk and age. Irrespective of scenario and according to deviance information
criterion (DIC) and total residual deviance statistics, the random-effects approach provided a better fit to
the data than the fixed-effect counterpart. Therefore, only results from the random-effects model are
presented and discussed here. The results from the fixed-effect model are provided in Appendix 6.
Table 42 provides a summary of the models implemented together with the key modelling assumptions.
As no evidence was found to support the existence of a class effect, all models considered treatments to
be independent of each other. In models in analyses 2a and 2b it was assumed that treatments were
independent of each other, but treatment effects were adjusted with the trial-specific baseline effects,
assuming a common interaction term. In addition, models in analysis 2b were adjusted for trial-specific
age effects, also assuming a common interaction term. This age adjustment enabled the estimation of
treatment effects separately by age (adults and children and young people). All implemented synthesis
models assumed fixed effects on PASI response cut-off points.
Results
Analysis 1: results using minimum evidence from the adult population
Table 43 summarises the results of the NMA in terms of absolute PASI response rates for the unconstrained
(no explicit adjustment for differences in placebo response rates across the trials) and constrained (placebo
response rates predicted based on the placebo arm trials in children and young people only) models. The
results of both sets of analyses show that all active treatments are more effective than placebo. In terms of
mean response rates (analysis 1b results), ustekinumab is estimated to have the highest probability of
achieving a PASI 50 (90%, 95% CrI 81% to 96%), PASI 75 (79%, 95% CrI 64% to 90%) and PASI 90
(57%, 95% CrI 39% to 74%) response compared with any of the other treatments, suggesting that it is the
most effective intervention. This is followed by adalimumab, etanercept and methotrexate in both sets of
analyses, that is, the ranking of treatments based on mean response rates is unchanged in the different
models.
The unconstrained baseline model (analysis 1a), however, predicts a placebo effect for PASI 75 of 20.3%
(95% CrI 14% to 27%) whereas the constrained baseline model (analysis 1b) predicts a placebo effect
of 13.1% (95% CrI 8% to 19%). This difference is driven by the CHAMPION trial,106 which had a
TABLE 42 Summary of models implemented and key modelling assumptions
Analysis Study Meta-regression Baseline prediction
1a Fixed effects No adjustment Unconstrained
1b Fixed effects No adjustment Constrained to studies of
children and young people
2 Random effects No adjustment Unconstrained
2a Random effects Common interaction term for baseline effect Unconstrained; baseline adjusted
2b Random effects Common interaction term for baseline effect
and for age effect
Unconstrained; baseline adjusted
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substantially higher placebo response rate of approximately 19% for PASI 75 compared with the placebo
response rates observed in the trials of children and young people (approximately 11% in 20030211 and
CADMUS). The constrained baseline model (analysis 1b) adjusts the baseline predictions to consider only
placebo effect evidence from trials in the younger population. In this analysis, the mean PASI 75 response
rate for placebo is reduced and closer to the observed response in the children and young people trials.
As shown by the CrIs around the mean response rates, which are wide and overlap, there is uncertainty
around these response rates. This is also shown in terms of the RRs of each treatment compared with
placebo and their CrIs for the best-fitting model 1b (Table 44).
TABLE 43 Network meta-analysis results for analyses 1a and 1b: probability of achieving PASI 50, 75 and 90
response rates
Treatment
Analysis
1a 1b
PASI 50,
mean
(95% CrI)
PASI 75,
mean
(95% CrI)
PASI 90,
mean
(95% CrI) r
PASI 50,
mean
(95% CrI)
PASI 75,
mean
(95% CrI)
PASI 90,
mean
(95% CrI) r
Placebo 0.371
(0.29 to 0.46)
0.203
(0.14 to 0.27)
0.071
(0.04 to 0.11)
5 0.267
(0.19 to 0.35)
0.131
(0.08 to 0.19)
0.039
(0.02 to 0.07)
5
Etanercept 0.830
(0.73 to 0.91)
0.676
(0.54 to 0.79)
0.431
(0.30 to 0.57)
3 0.747
(0.63 to 0.84)
0.566
(0.43 to 0.69)
0.321
(0.21 to 0.44)
3
Ustekinumab
45mg
0.941
(0.87 to 0.99)
0.859
(0.73 to 0.95)
0.677
(0.49 to 0.85)
1 0.901
(0.81 to 0.96)
0.787
(0.64 to 0.90)
0.569
(0.39 to 0.74)
1
Adalimumab 0.832
(0.74 to 0.91)
0.678
(0.56 to 0.79)
0.433
(0.31 to 0.56)
2 0.746
(0.60 to 0.87)
0.567
(0.40 to 0.73)
0.324
(0.19 to 0.49)
2
Methotrexate 0.432
(0.33 to 0.54)
0.251
(0.17 to 0.34)
0.096
(0.06 to 0.15)
4 0.323
(0.20 to 0.47)
0.170
(0.09 to 0.28)
0.057
(0.02 to 0.11)
4
Residual
deviance, mean
(95% CI)
46.6a
(39.7 to 57.6)
46.6a
(39.7 to 57.6)
DIC 158.60 158.60
r, ranking of treatments according to point estimates.
a Compared with 27 data points.
Note
DIC and total residual deviance are marginally lower in analysis 1b than in analysis 1a, implying a better-fitting model.
TABLE 44 Relative effect estimates (as RRs, means and 95% CrIs) for each treatment combination for PASI 75 in the
direct trial comparisons (upper diagonal) and from the NMA results for analysis 1b (lower diagonal)
PLB 4.95 (2.84 to 8.65) 7.50 (2.90 to 19.10) – –
4.37 (3.02 to 6.56) ETA – – –
6.10 (3.84 to 10.01) 1.39 (1.00 to 1.97) UST 45 – –
4.36 (3.10 to 6.31) 1.00 (0.71 to 1.39) 0.72 (0.48 to 1.01) ADA 0.49 (0.38 to 0.59)
1.28 (0.78 to 1.98) 0.29 (0.16 to 0.50) 0.21 (0.11 to 0.38) 0.29 (0.19 to 0.43) MTX
ADA, adalimumab 0.8mg/kg, maximum 40mg/week; ETA, etanercept 0.8 mg/kg, maximum 50mg/week; MTX, methotrexate
0.1–0.4mg/kg/week; PLB, placebo; UST 45, ustekinumab 0.75 mg/kg or 45mg/week.
Notes
Lower diagonal: pooled RRs from the NMA model; RRs > 1 favour the row agent. Upper diagonal: RRs from the direct
comparisons (pooled using fixed-effects when multiple studies exist); RRs > 1 favour the column agent. Significant
differences in the relative effects between a pair of agents are given in bold.
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Analysis 2: results using all relevant evidence from the adult population
Table 45 summarises the absolute PASI response rates from the NMA that uses the full network of evidence
in both populations for the unadjusted random-effects model (analysis 2). Relative treatment effects for
analysis 2 for PASI 75 response are presented in Table 46. The random-effects approach outperformed the
fixed-effect approach in terms of model fit, suggesting that accounting for between-study heterogeneity is
an important factor (τ2 = 0.02).
The results of this analysis suggest that ustekinumab is the most effective intervention, with the highest
mean probability of PASI response (PASI 75: 73%, 95% CrI 67% to 79%), followed by adalimumab
(PASI 75: 63%, 95% CrI 55% to 70%), etanercept (PASI 75: 40%, 95% CrI 34% to 47%) and methotrexate
(PASI 75: 34%, 95% CrI 25% to 42%). Ustekinumab was statistically significantly more effective than any
other agent based on relative effect estimates for PASI 75 (vs. etanercept: RR 1.78, 95% CrI 1.50 to 2.12; vs.
adalimumab: RR 1.15, 95% CrI 1.01 to 1.35) and adalimumab was statistically significantly more effective
than etanercept (RR 1.54, 95% CrI 1.25 to 1.88). The estimated pooled placebo absolute effect is in line with
that observed, on average, across all studies in all populations.
TABLE 45 Network meta-analysis results for analysis 2: probability of achieving PASI 50, 75 and 90 response rates
Treatment
Analysis 2
PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI) r
Placebo 0.141 (0.12 to 0.16) 0.049 (0.04 to 0.06) 0.010 (0.01 to 0.01) 5
Etanercept 0.633 (0.57 to 0.70) 0.404 (0.34 to 0.47) 0.172 (0.13 to 0.22) 3
Ustekinumab 45mg 0.885 (0.85 to 0.92) 0.732 (0.67 to 0.79) 0.466 (0.40 to 0.53) 1
Adalimumab 0.818 (0.76 to 0.87) 0.629 (0.55 to 0.70) 0.354 (0.28 to 0.43) 2
Methotrexate 0.562 (0.47 to 0.65) 0.336 (0.25 to 0.42) 0.130 (0.08 to 0.18) 4
Residual deviance,
mean (95% CI)
378.1a (355.6 to 404.0)
DIC 1241.07
r, ranking of treatments according to point estimates.
a Compared with 209 data points.
TABLE 46 Relative effect estimates (as RRs, means and 95% CrIs) for each treatment combination for PASI 75 in the
direct trial comparisons (upper diagonal) and from the NMA results for analysis 2 (lower diagonal)
PLB 9.52 (7.46 to 12.35) 14.49 (11.43 to 18.28) 8.08 (6.18 to 10.53) 1.88 (1.02 to 3.47)
8.03 (6.61 to 9.64) ETA – – –
14.24 (12.17 to 16.58) 1.78 (1.50 to 2.12) UST 45 – –
12.34 (10.10 to 14.82) 1.54 (1.25 to 1.88) 0.87 (0.74 to 0.99) ADA 0.49 (0.38 to 0.59)
6.72 (4.83 to 8.90) 0.84 (0.60 to 1.11) 0.47 (0.35 to 0.60) 0.55 (0.42 to 0.68) MTX
ADA, adalimumab 0.8mg/kg, maximum 40mg/week; ETA, etanercept 0.8 mg/kg, maximum 50mg/week; MTX, methotrexate
0.1–0.4mg/kg/week; PLB, placebo; UST 45, ustekinumab 0.75 mg/kg or 45mg/week.
Notes
Lower diagonal: pooled RRs from the NMA model; RRs > 1 favour the row agent. Upper diagonal: RRs from the direct
comparisons (pooled using fixed-effects when multiple studies exist); RRs > 1 favour the column agent. Significant
differences in the relative effects between a pair of agents are given in bold.
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These unadjusted results, however, do not consider an explicit adjustment for differences in placebo
response rates across trials or differences across the populations (i.e. children and young people compared
with adults). In the following sections, the results from the adjusted analyses are presented.
Adjustment for differences in placebo response rates across the trials
The NMA in the full population compares treatment outcomes across a large number of separate clinical
trials. The reliability of these comparisons depends on the cross-trial similarity of the patient populations
included in the network. An important difference between the included trials is the observed PASI
response rates in the placebo arms of the trials, which is a common reference treatment across the
majority of the trials. Table 41 showed that the PASI response rates in the placebo arms of the trials
ranged from 0%136 to 20%.108 All of the trials varied by design, eligibility criteria, previous medication use,
average age and other characteristics. All of these variations could contribute to differences in placebo
response rates and, therefore, to differences in the relative efficacy of the intervention compared with
placebo. However, there is no systematic way to identify the reasons for these differences. A ‘placebo
creep’ phenomenon has been discussed in the literature, which identifies a relationship between placebo
response rates and time since publication of the trial results. However, such a phenomenon has not been
identified in the trials considered in the NMA (Figure 6). The average PASI 75 response rate in the placebo
arm across all trials is 6.2%, whereas the average rate in studies of adult populations is 5.9% and in studies
of children and young people is 11.1%. Three adult studies106,108,132 have substantially higher placebo
response rates (approximately 18–20%) than the other studies. Four studies, including the two trials in
children and young people72 and two in adults,114,116 have approximately double the average placebo rate.
It is not clear exactly how these varying placebo rates affect treatment effects; however, it is clear that any
differences will affect the relative efficacy of the interventions compared with placebo. Therefore, a
potential relationship between baseline risk and relative treatment effect was explored103 in analysis 2a.
Tables 47 and 48 present the results of the model that adjusts for differences in placebo response rates.
As for the unadjusted analysis (i.e. analysis 2), the baseline adjusted random-effects model was found to fit
the data considerably better than the fixed-effect counterpart (DIC: 1303.7 fixed effects vs. 1177.6 random
effects; total residual deviance: 473.5 fixed effects vs. 380.9 random effects). Furthermore, the 95% CRIs
for the estimated mean baseline effect derived in the baseline-adjusted model do not include zero (–0.93,
95% CrI –0.97 to –0.88). This suggests that adjusting for baseline risk heterogeneity is important to
explain existing between-study variation.
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FIGURE 6 Probability of a PASI 75 response in the placebo arms of trials in the NMA by publication year.
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The results of analysis 2a suggest that ustekinumab is the most effective intervention, with the highest mean
probability of PASI response (PASI 75: 73%, 95% CrI 66% to 79%), followed by adalimumab (PASI 75:
66%, 95% CrI 58% to 74%), and etanercept (PASI 75: 41%, 95% CrI 35% to 49%) and methotrexate
(PASI 75: 34%, 95% CrI 25% to 44%). Ustekinumab is statistically significantly more effective than
etanercept based on relative effect estimates for PASI 75 (RR 1.77, 95% CrI 1.48 to 2.11), but not
statistically significantly more effective than adalimumab (RR 1.10, 95% CrI 0.96 to 1.28). Adalimumab is
also statistically significantly more effective than etanercept (RR 1.60, 95% CrI 1.31 to 1.95).
Adjusting for differences in population and placebo response rates
Although evidence from trials in both children and young people and adults contributed to the full network
of evidence (effectively assuming independence between age and treatment effectiveness), it is important
to recognise that the age of the population could contribute to differences in treatment efficacy. Therefore,
in analysis 2b we adjusted for differences in the population and differences in placebo response rates (as
the placebo response rates were considerably different in the trials of children and young people and the
trials of adults). Table 49 summarises the results of this analysis in terms of PASI response outcomes for both
populations. Table 50 presents the corresponding RRs for PASI 75 for children and young people.
TABLE 47 Network meta-analysis results for analysis 2a: probability of achieving PASI 50, 75 and 90 response rates
Treatment
Analysis 2a
PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI) r
Placebo 0.151 (0.13 to 0.17) 0.053 (0.04 to 0.06) 0.010 (0.01 to 0.01) 5
Etanercept 0.642 (0.57 to 0.71) 0.414 (0.35 to 0.49) 0.180 (0.12 to 0.25) 3
Ustekinumab 45mg 0.882 (0.84 to 0.92) 0.727 (0.66 to 0.79) 0.461 (0.37 to 0.56) 1
Adalimumab 0.839 (0.78 to 0.89) 0.660 (0.58 to 0.74) 0.349 (0.25 to 0.45) 2
Methotrexate 0.570 (0.46 to 0.67) 0.344 (0.25 to 0.44) 0.178 (0.10 to 0.28) 4
Residual deviance,
mean (95% CI)
381.7a (357.5 to 409.4)
DIC 904.5
r, ranking of treatments according to point estimates.
a Compared with 209 data points.
TABLE 48 Relative effect estimates (as RRs, means and 95% CrIs) for each treatment combination for PASI 75 in the
direct trial comparisons (upper diagonal) and from the NMA results for analysis 2a (lower diagonal)
PLB 9.52 (7.46 to 12.35) 14.49 (11.43 to 18.28) 8.08 (6.18 to 10.53) 1.88 (1.02 to 3.47)
7.86 (6.46 to 9.44) ETA – – –
13.82 (11.70 to 16.32) 1.77 (1.48 to 2.11) UST 45 – –
12.53 (10.34 to 15.01) 1.60 (1.31 to 1.95) 0.91 (0.78 to 1.04) ADA 0.49 (0.38 to 0.59)
6.52 (4.68 to 8.55) 0.84 (0.58 to 1.12) 0.47 (0.34 to 0.61) 0.52 (0.38 to 0.67) MTX
ADA, adalimumab 0.8mg/kg, maximum 40mg/week; ETA, etanercept 0.8 mg/kg, maximum 50mg/week; MTX, methotrexate
0.1–0.4mg/kg/week; PLB, placebo; UST 45, ustekinumab 0.75 mg/kg or 45mg/week.
Notes
Lower diagonal: pooled RRs from the NMA model; RRs > 1 favour the row agent. Upper diagonal: RRs from the direct
comparisons (pooled using fixed-effects when multiple studies exist); RRs > 1 favour the column agent. Significant
differences in the relative effects between a pair of agents are given in bold.
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The model from analysis 2b fits the data as well as model 2a, as both present similar average total residual
deviance [380.8 (2b) vs. 381.7 (2a)]. However, the DIC is substantially higher for model 2b. This suggests
that this model is being penalised because of issues of parsimony. The children and young people
subgroup effect is estimated not to be statistically significantly different from the adult subgroup effect,
implying that the PASI absolute effect distributions of these populations overlap. This is not unexpected
because of the limited number of existing studies in the population of children and young people.
TABLE 49 Network meta-analysis results for analysis 2b: probability of achieving PASI 50, 75 and 90 response rates
in children and young people and adults
Treatment
Analysis 2b population
Children and young people Adults
PASI 50,
mean
(95% CrI)
PASI 75,
mean
(95% CrI)
PASI 90,
mean
(95% CrI) r
PASI 50,
mean
(95% CrI)
PASI 75,
mean
(95% CrI)
PASI 90,
mean
(95% CrI) r
Placebo 0.265
(0.15 to 0.40)
0.115
(0.05 to 0.20)
0.029
(0.01 to 0.06)
5 0.151
(0.13 to 0.17)
0.053
(0.04 to 0.06)
0.010
(0.01 to 0.01)
5
Etanercept 0.752
(0.62 to 0.86)
0.544
(0.39 to 0.69)
0.279
(0.16 to 0.42)
3 0.619
(0.54 to 0.69)
0.390
(0.32 to 0.47)
0.162
(0.12 to 0.22)
3
Ustekinumab
45mg
0.934
(0.87 to 0.97)
0.824
(0.71 to 0.91)
0.594
(0.43 to 0.74)
1 0.872
(0.83 to 0.91)
0.711
(0.64 to 0.78)
0.441
(0.36 to 0.52)
1
Adalimumab 0.915
(0.83 to 0.97)
0.790
(0.64 to 0.90)
0.546
(0.37 to 0.72)
2 0.844
(0.78 to 0.90)
0.667
(0.58 to 0.75)
0.393
(0.30 to 0.48)
2
Methotrexate 0.708
(0.53 to 0.85)
0.492
(0.31 to 0.68)
0.240
(0.11 to 0.40)
4 0.567
(0.45 to 0.68)
0.342
(0.24 to 0.45)
0.134
(0.08 to 0.20)
4
Residual
deviance, mean
(95% CI)
380.8a
(356.2 to 408.6)
380.8a
(356.2 to 408.6)
DIC 1229.5 1229.5
r, ranking of treatments according to point estimates.
a Compared with 209 data points.
TABLE 50 Relative effect estimates (as RRs, means and 95% CrIs) for each treatment combination for PASI 75 in the
direct trial comparisons (upper diagonal) and from the NMA results for analysis 2b in the children and young
people subgroup of the population (lower diagonal)
PLB 4.95 (2.84 to 8.65) 7.50 (2.90 to 19.10) – –
5.09 (3.30 to 8.05) ETA – – –
7.91 (4.46 to 14.14) 1.54 (1.28 to 1.92) UST 45 – –
7.53 (4.37 to 12.98) 1.47 (1.23 to 1.79) 0.96 (0.85 to 1.05) ADA 0.49 (0.38 to 0.59)
4.55 (3.01 to 6.94) 0.91 (0.66 to 1.15) 0.59 (0.41 to 0.77) 0.62 (0.44 to 0.78) MTX
ADA, adalimumab 0.8mg/kg, maximum 40mg/week; ETA, etanercept 0.8 mg/kg, maximum 50mg/week; MTX, methotrexate
0.1–0.4mg/kg/week; PLB, placebo; UST 45, ustekinumab 0.75 mg/kg or 45mg/week.
Notes
Lower diagonal: pooled RRs from the NMA model; RRs > 1 favour the row agent. Upper diagonal: RRs from the direct
comparisons (pooled using fixed-effects when multiple studies exist); RRs > 1 favour the column agent. Significant
differences in the relative effects between a pair of agents are given in bold.
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The adjustment for population resulted in similar treatment rankings for children and young people when
compared with the whole population results (see Table 47). The pooled placebo response rate for children
and young people was estimated to be higher than that for adults (PASI 75: 12%, 95% CrI 5% to 20% in
children and young people vs. 5%, 95% CrI 4% to 6% in adults), reflecting the higher placebo response
rates observed in the trials in children and young people. This affects the efficacy of treatments by
substantially increasing the estimated absolute PASI response rates across all treatments, but affecting the
relative effects to a smaller extent. On average, PASI 75 response rates were estimated to be 10–15%
higher in children and young people than in adults. The treatment rankings, however, remained
unchanged. This is consistent with clinical opinion, with efficacy rates expected to be generally higher in
children and young people than in adults as the biological interventions tend to work better in individuals
with a lower body weight. Also, children and young people tend to have fewer comorbidities and
generally have a greater exposure to ultraviolet (UV) light from participating in outside activities. The CrIs
for PASI 75 response for children and young people and adults overlap, as shown in Figure 7.
The results of analysis 2b in children and young people suggest that ustekinumab is the most effective
intervention with the highest mean probability of PASI response (PASI 75: 82%, 95% CrI 71% to 90%),
followed by adalimumab (PASI 75: 79%, 95% CrI 64% to 90%), etanercept (PASI 75: 54%, 95% CrI
39% to 69%) and methotrexate (PASI 75: 49%, 95% CrI 31% to 68%). The relative efficacy of
ustekinumab and adalimumab is similar based on relative effectiveness estimates for PASI 75 response
(ADA vs. UST 45: RR 0.96, 95% CrI 0.85 to 1.05). In children and young people, ustekinumab (RR 1.54,
95% CrI 1.28 to 1.92) and adalimumab (RR 1.47, 95% CrI 1.23 to 1.79) are statistically significantly more
effective than etanercept.
A consistency assessment was undertaken that involved excluding the trials of children and young people
from the evidence network. This assessment indicated that the results were consistent across populations
(see Appendix 7 for further details).
Absolute PASI 75 probability of response
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
MTX
ADA
UST 45
ETA
PLAB
Children and young people
Adults
Posterior median, 95% CrI
FIGURE 7 Absolute PASI 75 probability of response for children and young people and adults from NMA model 2b.
ADA, adalimumab 0.8 mg/kg, maximum 40mg/week; ETA, etanercept 0.8 mg/kg, maximum 50mg/week;
MTX, methotrexate 0.1–0.4 mg/kg/week; PLB, placebo; UST 45, ustekinumab 0.75mg/kg or 45mg/week.
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Summary of the findings on relative efficacy from the network meta-analysis
There was no direct trial evidence that could be used to establish the relative effectiveness of adalimumab,
etanercept and ustekinumab for the treatment of plaque psoriasis in children and young people.
Furthermore, there was no common comparator across the three included trials, which precluded
establishing an indirect comparison between all of the interventions without drawing on evidence from
other sources, namely from a different age population (i.e. adults).
Several NMA analyses were conducted to overcome the challenges involved in formally assessing the
relative efficacy of adalimumab, etanercept and ustekinumab for the treatment of plaque psoriasis in
children and young people.
First, statistical testing was performed on age subgroup efficacy data from the clinical trials in children
and young people to establish whether or not it is reasonable to assume that the PASI response rates for
the treatments are independent of age within the full population of children and young people, as the
trials included participants of different age ranges. An indirect treatment comparison based solely on
children and young people trial data for etanercept and ustekinumab was then performed and the results
presented. However, this analysis was of limited use for the economic analysis as the network did not
incorporate the full set of relevant interventions. Finally, a framework of analysis using different levels of
evidence from the adult population was developed to address the issue of having a disconnected network
structure. Previously appraised adult trial evidence was reviewed and extracted, and was assumed exchangeable
with evidence from children and young adults, for inclusion in the evidence base. Two main approaches were
considered, one in which the network of trials in children and young people was connected by bringing the
minimum amount of evidence required from the adult population to link the three existing trials and the
other in which all relevant efficacy evidence identified in adults was incorporated in the network. For each
NMA model fixed- and random-effects model approaches were investigated. The latter approach was
shown to be preferable, highlighting that it was important to account for variability across trials. The rate of
placebo response was identified as a source of heterogeneity. Also, population-adjusted models allowed
subpopulation-specific estimates to be obtained for (1) children and young people and (2) adults. The
different model adjustments were explored and the age- and placebo-adjusted model was identified as the
best-fitting model. For comparison and comprehensiveness, unadjusted and adjusted model results
were presented.
The PASI response results were generally consistent across the different models, both adjusted and
unadjusted. Overall, PASI responses were estimated to be higher for ustekinumab, followed by
adalimumab and etanercept. However, there was no statistically significant difference (at the 5%
significance level) between adalimumab and ustekinumab across the majority of models for PASI 75
response. Methotrexate was the least efficacious active agent, followed by placebo. The economic model
in Chapter 6 uses the results for the children and young people subgroup of the placebo and population
random-effects adjusted NMA (2b; see Table 49) to inform the effectiveness estimates. This NMA model
was considered to provide the most appropriate set of efficacy estimates to inform the economic analysis
because (1) it considers all relevant evidence, (2) it adjusts for placebo heterogeneity, (3) it adjusts for age
effects and (4) it enables the estimation of age subgroup-specific effects. Scenario analyses were also
conducted in which the results from the unadjusted baseline constrained model with minimum adult
evidence (1b; see Table 43) are applied in the model. Partial comparisons with direct trial data and the
indirect comparison reported in Indirect treatment comparison were also incorporated in a scenario analysis
for completeness.
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Chapter 5 Assessment of existing
cost-effectiveness evidence
Introduction
This chapter aims to provide an overview of the existing evidence on the cost-effectiveness of adalimumab,
etanercept, ustekinumab and relevant comparators for the treatment of plaque psoriasis in children and
young people. The overview includes the company submissions from Janssen (ustekinumab) and AbbVie
(adalimumab) [Pfizer (etanercept) did not provide a company submission]. An overview of the cost-effectiveness
evidence from related NICE TAs of the treatment of plaque psoriasis in adults (TA103,97 TA134,98 TA146,99
TA180,100 TA350101 and TA368102) is also presented. The differences in the model structures and assumptions
used across the studies are examined to identify any important differences in approaches and areas of
uncertainty. The findings from the review provide the basis for the development of a new decision-analytic
model in children and young people reported in Chapter 6.
Methods
The searches described in Chapter 3 (see Appendix 1 for details) were used to identify potentially relevant
studies for inclusion in the assessment of the cost-effectiveness of the interventions compared with any
comparator in children and young people. A broad range of studies was considered for inclusion in the
assessment of cost-effectiveness, including economic evaluations conducted alongside clinical trials and
modelling studies. Only full economic evaluations that compared two or more options and considered both
costs and consequences in children and/or young people were considered. The inclusion criteria allowed
for studies in adults to be included as long as data were reported separately for a subpopulation of
children and/or young people. Only studies with ‘cost’ in the title or abstract were included. The searches
were not restricted to level of disease severity, as a dearth of evidence was anticipated in the population of
children and young people.
Titles and abstracts were assessed independently by two reviewers for inclusion and any discrepancies
were resolved by consensus. Additional hand-searching of related TAs in adults was undertaken.
Results
Identified published studies
A total of 293 unique records were identified from the systematic literature review of existing cost-
effectiveness evidence in children and young people, of which only one study subsequently met the
inclusion criteria.139 This study, on the use of etanercept for the treatment of chronic severe plaque
psoriasis in children and adolescents from the age of 8 years in NHS Wales who are inadequately
controlled by, or who are intolerant to, other systemic therapies or phototherapies, was by the All Wales
Medicines Strategy Group (AWMSG).
One previous NICE multiple technology appraisal (MTA) (TA10397,140) and five single technology appraisals
(STAs) (TA134,98 TA146,99 TA180,100 TA350,101 and TA368102) were identified in adults with chronic
plaque psoriasis.
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Review of existing published cost-effectiveness studies
This review starts with an overview of the AWMSG cost-effectiveness model for the assessment of
etanercept in children and adolescents from the age of 8 years and then considers the cost-effectiveness
evidence submitted by the companies for ustekinumab and adalimumab in children and young people.
The final section provides an overview of the cost-effectiveness modelling used in the previous TAs in adults.
Etanercept All Wales Medicines Strategy Group cost-effectiveness model in children and
young people
The only published economic model identified was that reported as part of AWMSG advice no. 138 for the
use of etanercept within NHS Wales for the treatment of chronic severe plaque psoriasis in children and
adolescents from the age of 8 years.139 The cost-effectiveness evidence presented was deemed insufficient
for AWMSG to recommend the use of etanercept in NHS Wales. The cost-effectiveness modelling was not
reported in sufficient detail to be very informative. AWMSG considered that it was not possible to judge
whether or not the analysis presented by the company (Pfizer) in its submission represented the most
plausible estimate of the cost-effectiveness of etanercept compared with placebo in this population. This
was because of a number of limitations in the economic evidence and decision-analytic model submitted
by the company.
The economic model was a Markov model with a 28-day cycle length to represent intermittent treatment
with etanercept compared with placebo/non-systemic therapy over a 10-year time horizon. The perspective
of the evaluation was NHS Wales. For treatment with 0.8 mg/kg of etanercept weekly (up to a maximum
of 50 mg), individuals were modelled to receive initial therapy for a ‘trial period’ of 12 weeks, after which
their PASI 50 response was used to determine whether or not they were considered responders or
non-responders to treatment. Those who achieved a PASI 50 response were considered responders and
continued treatment with continuous etanercept until week 24. At week 24, those who did not achieve
a PASI 50 response discontinued treatment whereas those with a PASI response between 50 and 75
remained on continuous etanercept. Of those with a PASI 75 response, 25% were assumed to remain on
continuous etanercept and the remainder received intermittent etanercept (consisting of a treatment-free
period, with treatment reinitiated in those who experienced a relapse). Non-responders at 12 and 24 weeks
were assumed to discontinue treatment.
The effectiveness evidence was sourced from a placebo-controlled RCT of the use of etanercept in children
and adolescents aged 4–17 years with moderate to severe psoriasis and with previous or current treatment
with phototherapy or systemic therapies or psoriasis considered by the investigator to be poorly controlled
with topical treatments.57 The AWMSG estimated that only 57% of the trial population met the licensed
indication for etanercept at the time of the submission.
The HRQoL estimates applied in the model were derived from adult studies of etanercept through the
mapping of adult DLQI scores to EQ-5D utility values. The utility gains from baseline were assumed to be
independent of treatment and varied according to the severity of disease based on PASI response rates.
The AWMSG noted that there was no discussion of the uncertainty surrounding the use of utility values
from adults to inform the population of children and adolescents.
The drug costs of etanercept were based on the doses used in the RCT in children and adolescents,57 at
0.8 mg/kg up to a maximum dose of 50 mg, delivered in prefilled syringes. However, the AWMSG noted
discrepancies between what was reported and the doses used in the model, with a lower dose of 25 mg
weekly used in the model for all patients instead of 44% of patients receiving the maximum dose of
50 mg per week and 56% of patients receiving a weekly dose of 0.8 mg/kg in the trial. The median
weight in the trial was approximately 60 kg, which equates to a median dose closer to 50 mg per week
than 25 mg per week. The AWMSG noted that the model was very sensitive to the assumed weekly cost
of etanercept.
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The number of clinic visits was informed by the British Association of Dermatologists (BAD) guidelines and
length of hospital stay for patients who failed treatment was sourced from TA10397 in adults. A number of
other model parameters were not discussed in the company’s submission but appeared to have been
sourced from the original NICE MTA (TA10397) in adults. The use of adult data to populate the model and
the implications of assuming transferability of adult data to inform the decision problem in children and
adolescents did not appear to have been discussed by the company during the AWMSG appraisal.
The results of the company’s model showed that etanercept was both less expensive and more effective
(i.e. etanercept was the dominant treatment strategy) than placebo in children and adolescents aged ≥ 8
years. Sensitivity analysis was poorly reported and it was uncertain whether or not probabilistic sensitivity
analysis had been performed. The AWMSG considered it impossible to establish whether or not the
base-case analysis represented the most plausible estimate of the cost-effectiveness of etanercept in this
population based on the limited information provided in the submission. As a result, the AWMSG was
unable to recommend etanercept for children and young people because of the uncertainties inherent in
the economic model.
Janssen submission on the use of ustekinumab in children and young people
Within its submission supporting this appraisal, Janssen explored the possibility of constructing an
economic model to assess the cost-effectiveness of ustekinumab for the treatment of moderate to
severe psoriasis in children and young people. However, given the limited clinical evidence identified in
its systematic review of effectiveness, Janssen decided not to pursue the development of an economic
model. Janssen noted that the only previous economic evaluation in this population (i.e. for etanercept139)
resulted in an adaptation of an adult model in psoriasis and relied on simplifying assumptions in the
cost-effectiveness analysis. Therefore, because of the limitations of the evidence base, it concluded that
any estimation of the cost-effectiveness of biologics in children and young people with psoriasis will be
subject to a number of insuperable uncertainties and will largely be based on a number of assumptions
taken from the adult population. Janssen’s submission did, however, provide an overview of the available
evidence in children and adults to aid the development of an economic model by the AG. However,
no cost-effectiveness results were presented in Janssen’s submission on children and young people.
AbbVie submission on the use of adalimumab in children and young people
AbbVie undertook a targeted review to identify publications and major health technology assessment
bodies reporting cost-effectiveness analyses of the use of adalimumab in children and young people with
plaque psoriasis. Its submission indicates that only one relevant study was identified.141 This study estimated
the number needed to treat to achieve a PASI 75 response based on a Bayesian NMA of efficacy outcomes
for adalimumab, etanercept, infliximab and ustekinumab and evaluated the incremental cost per PASI 75
responder for the biological treatments during the first 10–16 weeks of treatment. Based on the results of
this study, AbbVie indicated that adalimumab was found to be the most cost-effective treatment option in
terms of incremental cost per PASI 75 responder compared with the other biologics. However, the AG notes
that the study by Langley et al.141 was not based on a population of children and young people and did not
present the cost-effectiveness of the biologics in terms of costs and quality-adjusted life-years (QALYs) over
a time horizon that was sufficiently long to capture differences between the interventions. Furthermore, the
study has been published only in abstract form rather than as a full publication and therefore limited details
are available to adequately critique the study. AbbVie’s submission did not include an economic model for
the assessment of the use of adalimumab in children and young people.
Cost-effectiveness models in adults
Overview
Given that the literature review identified only one unpublished model assessing the cost-effectiveness of
etanercept in children and young people and that this model was adapted from TA10397 in adults and
largely populated with adult data, additional hand-searching of published documents associated with
the previous NICE TAs of plaque psoriasis in adults was carried out. The aim was to examine existing
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decision-analytic models to identify important structural assumptions, highlight key areas of uncertainty
and outline the potential issues associated with generalising evidence from the adult population to a
population of children and young people.
The first NICE TA on biological therapies for the treatment of psoriasis was a MTA examining the cost-
effectiveness of etanercept and efalizumab (Raptiva®, Serono Europe Ltd, London, UK) within their licensed
indications in adults (TA103,97 published in July 2006). As part of this appraisal, the York Assessment
Group developed a de novo cost-effectiveness model, which was subsequently referred to as ‘the York
model’. Five subsequent STAs followed TA103:
1. TA134 – Infliximab for the Treatment of Adults with Psoriasis (published in January 2008)98
2. TA146 – Adalimumab for the Treatment of Adults with Psoriasis (published in June 2008)99
3. TA180 – Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis (published in
September 2009)100
4. TA350 – Secukinumab for Treating Moderate to Severe Plaque Psoriasis (published in July 2015)101
5. TA368 – Apremilast for Treating Moderate to Severe Plaque Psoriasis (published in November 2015).102
All of these STAs employed a similar modelling approach to that used in the original York model in
TA103.97 The only study identified that deviated from the original model was the most recent STA of
apremilast (TA368102), which included the modelling of sequences of treatment. Therefore, the main
differences between the TAs lie in the evidence base, intervention and comparators rather than there
being any major structural differences in the modelling approach used. A summary of the York model and
the key differences between the assumptions and evidence base used in subsequent adaptations of the
model are described in the following section. Table 51 provides an overview of the NICE TAs in adults.
Summary of the York model (TA103) and subsequent adaptations (TA134, TA146, TA180,
TA350 and TA368)
The York model was a cohort Markov model that was developed to estimate the costs and QALYs of
etanercept and efalizumab compared with BSC over a time horizon of 10 years (primary analysis).97
A secondary analysis was also conducted to compare the interventions with additional systemic therapies
of ciclosporin, Fumaderm® (combination of fumaric acid esters), methotrexate and infliximab. The model
adopted the perspective of the UK NHS. The price year for costs was 2004–5 and an annual discount rate of
6% for costs and 1.5% for outcomes was applied (in line with NICE guidance142 at the time of the appraisal).
The model consisted of a two-part structure: a ‘trial’ period for initial response and a ‘treatment’ period for
long-term response to treatment (Figure 8). The initial response period was used to determine initial
response rates and the decision to continue treatment. The duration of the trial period was based on the
period over which response was assessed in the efficacy trials for each treatment – this was 12 weeks for
etanercept and efalizumab and between 10 and 16 weeks for the other systemic therapies. Individuals
with a PASI 75 response were considered ‘responders’ and continued treatment after the trial period
(i.e. they entered the treatment period), whereas individuals who were ‘non-responders’ discontinued
treatment and received BSC. The treatment duration for responding individuals was based on an annual
withdrawal rate of 20%. On withdrawal, individuals were assumed to receive BSC.
The base-case analysis considered a single line of therapy consisting of a biological treatment (etanercept
or efalizumab) followed by BSC. Although specific sequences of treatments were not considered in the
York model, an analysis showing the expected costs and QALYs associated with each treatment option
compared with BSC was used to determine the most ‘cost-effective order’ in which to give the treatments,
which varied according to the cost-effectiveness threshold.
The same model structure based on a single line of treatment was used in the subsequent TAs – TA134,98
TA146,99 TA180100 and TA350101 – and to a lesser extent in TA368,102 in which it was used only for the
subpopulation of patients with a DLQI score of ≤ 10. The only difference in the modelling approach across
the appraisals was a variation in the cycle length of the Markov model (12 months in TA134,98 TA14699
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TABLE 51 Overview of the NICE TAs of psoriasis in adults
Characteristic
NICE TA
ETA and EFA (TA10397) INF (TA13498) ADA (TA14699) UST (TA180100) SEC (TA350101) APR (TA368102)
Modelling
approach
Markov model, which
became known as the
‘York model’
Based on the York
model
Based on the York
model
Based on the York model Based on the York
model but explicitly
incorporates a decision
tree for the trial period
followed by a Markov
model
Based on the York model
but with treatment
sequences
Intervention EFA; ETA 25mg b.i.w.
continuous; ETA 50mg
b.i.w. intermittent
INF ADA UST 45mg; UST 90mg SEC Primary analysis:
APR→ADA→ ETA→ BSC;
subgroup analysis:
APR→ BSC; scenario
analysis APR→ADA→
ETA/UST→ BSC
Comparators Primary analysis: BSC;
secondary analysis:
CS, Fumaderm®
(combination of fumaric
acid esters), MTX, INF
EFA; ETA 25mg b.i.w.
continuous; ETA 25mg
b.i.w. intermittent;
ETA 50mg b.i.w.
intermittent; BSC
INF; EFA; ETA 25mg
b.i.w. continuous;
ETA 25mg b.i.w.
intermittent; ETA 50mg
b.i.w. intermittent; BSC
ADA; INF; EFA; ETA 25mg
b.i.w. continuous; ETA
25mg b.i.w. intermittent;
ETA 50mg b.i.w.
intermittent; BSC
ADA; UST; INF; ETA;
BSC
Primary analysis:
ADA→ ETA→ BSC;
subgroup analysis: BSC;
scenario analysis
ADA→ ETA/UST→ BSC
Time horizon
and justification
10 years; justification NR 10 years; sufficient time
for all future costs and
outcomes to be included
10 years; based on the
York model
10 years; based on the
York model
10 years; time horizon
reflective of the
treatment duration of
moderate to severe
plaque psoriasis
10 years; to maintain
consistency with previous
analyses and in the base
case the majority of
patients are on BSC by the
end of 10 years
Cycle length 12 months (not explicit) 12 months 12 months 3 months 12 months 28 days
Discount rates 6.0% costs, 1.5%
QALYs
3.5% 3.5% 3.5% 3.5% 3.5%
Mortality Not considered Not considered Not considered Not considered Not considered All-cause mortality
incorporated
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TABLE 51 Overview of the NICE TAs of psoriasis in adults (continued )
Characteristic
NICE TA
ETA and EFA (TA10397) INF (TA13498) ADA (TA14699) UST (TA180100) SEC (TA350101) APR (TA368102)
HRQoL
instrument
DLQI scores mapped to
EQ-5D utility values
Utilities from the York
model
EQ-5D DLQI scores mapped to
EQ-5D utility values;
SF-6D used in sensitivity
analysis
EQ-5D Utilities from the York
model and EQ-5D; DLQI
scores mapped to EQ-5D
utility values
Link between
utility and
clinical efficacy
EQ-5D mapped from
ΔDLQI by ΔPASI
(coefficients not
reported)
In the base case
estimates from the York
model were used, but
only for those in the
fourth quartile of the
DLQI score (worst
HRQoL). Additional
analyses used utility
values estimated by
mapping SF-36 data
collected in two trials to
EQ-5D utility values
using an unpublished
mapping algorithm
EQ-5D association with
DLQI and changes in
PASI response rates
estimated from trial data
EQ-5D mapped from
ΔDLQI by ΔPASI (used
a mapping algorithm
based on the published
scatterplot in the York
model): EQ-5D= –0.0162 ×
DLQI+ 0.8554
Changes in EQ-5D from
baseline at a given time
point as a function of
(1) PASI response at that
time point, (2) baseline
DLQI score difference
from the pooled mean
baseline DLQI score,
(3) interaction between
these terms
Changes in utility
associated with changes
from baseline PASI were
taken from the York
model for the DLQI score
of > 10 population. For the
DLQI score of ≤ 10
population, EQ-5D data
collected in trials were
used; direct link between
%ΔPASI and ΔEQ-5D in
patients with a DLQI score
of ≤ 10. The same baseline
utility score (0.7) from a
published study was used
for both populations
Total costs Incremental vs. BSC:
BSC £0; ETA 25mg
£7743; EFA £9382; ETA
25mg continuous
£9665; ETA 50mg
£14,860
Incremental vs. BSC:
ETA 25mg continuous
£1531; INF £4562
Incremental vs. BSC:
MTX –£3844; ciclosporin
–£1987; BSC £0; ETA
intermittent £4114; ETA
high intermittent £4699;
EFA £4942; ADA £4993;
ETA £5058; INF £7736
Incremental vs. BSC: BSC
£0; EFA £5264; ETA 25mg
intermittent £3989; ETA
25mg continuous £4829;
ETA 50mg continuous
£5333; ADA £4660; UST
£4615; INF £6327
BSC £73,610;
ETA 25mg £75,788;
SEC 300mg £76,361;
ADA 40mg £76,981;
UST 45mg £79,544;
UST 90mg £79,732;
INF 5 mg/kg £93,539
DLQI > 10: apremilast
sequence £89,374;
comparator sequence
£92,589
Total QALYs BSC: 0; ETA 25mg
0.116; EFA 0.112; ETA
25mg continuous
0.116; ETA 50mg
continuous 0.123
ETA 25mg continuous
0.089; INF 0.205
Incremental vs. BSC:
MTX 0.129; ciclosporin
0.079; ETA intermittent
0.11; ETA high
intermittent 0.123;
EFA 0.124; ADA 0.164;
ETA 0.134; INF 0.182
Incremental vs. BSC: EFA
0.1308; ETA 25mg
intermittent 0.1325; ETA
25mg continuous 0.1409;
ETA 50mg continuous
0.1483; ADA 0.1502;
UST 0.156; INF 0.1616
BSC 0.97; ETA 25mg
1.13; SEC 300mg 1.36;
ADA 40mg 1.22; UST
45 mg 1.30; UST 90mg
1.33; INF 5 mg/kg 1.36
DLQI > 10: apremilast
sequence 6.83; comparator
sequence 6.69
ADA, adalimumab; APR, apremilast; b.i.w., twice weekly; CS, ciclosporin; EFA, efalizumab; ETA, etanercept; INF, infliximab; MTX, methotrexate; NR, not reported; SEC, secukinumab;
SF-6D, Short Form questionnaire-6 Dimensions; UST, ustekinumab.
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and TA350;101 3 months in TA180;100 and 28 days in TA368102), which was adapted to reflect the different
length of the trial periods when treatment response was assessed. All appraisals used a time horizon of
10 years in their base-case analysis and used additional scenarios to show the implications of a change in
the time horizon.
In TA368,102 the company adapted the model structure to allow a comparison of treatment sequences,
with up to five sequential lines of treatment. The model structure followed the same approach as in the
York model but, if the treatment response was considered inadequate at the end of the trial period,
individuals moved into the trial period of the next line of treatment (or to BSC if the end of the treatment
sequence had been reached). The company’s original economic model considered only apremilast as the
first treatment in the sequence and compared different treatment sequences with apremilast as an
additional line of therapy, rather than replacing an existing biological therapy in the sequence. However,
following the ERG critique additional analyses were presented that compared the use of apremilast at
different positions within a sequence.
No response
Response
‘Trial’ period ‘Treatment’ period
I – PPatient fails treatment
PPatient fails treatment
Patient on treatment
Patient on supportive care
FIGURE 8 Structure of the York model. Source: TA103.97 © NICE 2016 Etanercept and Efalizumab for the Treatment
of Adults with Psoriasis. Available from www.nice.org.uk/guidance/ta103. All rights reserved. Subject to Notice
of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to
regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this
product/publication.
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Clinical effectiveness evidence in the York model and subsequent appraisals
The response rates used in the York model were based on a Bayesian NMA comparing the interventions
with a broad range of comparators, including systemic therapies. An ordered probit model was used to
predict PASI 50, PASI 75 and PASI 90 response rates, with PASI 75 used as the primary measure of
response at the end of the trial period. If a trial reported only PGA 0/1 response (clear or almost clear) as
the end point, it was assumed to be equivalent to the PASI 75 response. A similar Bayesian NMA was used
in subsequent appraisals but was updated with additional evidence as more interventions and comparators
became available. There were some differences across the appraisals in terms of how heterogeneity was
accounted for in the meta-analysis and whether or not any adjustment had been made for differences in
placebo response rates across the trials.
The effectiveness data were considered to be an area of uncertainty in the previous appraisals,97–102 mainly
because of the lack of direct head-to-head comparisons between the biological treatments and the paucity
of longer-term data. Although the evidence base expanded over time with many more RCTs included in
the NMA, other concerns were raised relating to differences between the trial populations in the network
(e.g. exposure to previous therapies and severity of disease). The definition of placebo or BSC across the
different trials included in the NMA was also a contentious issue.
Health-related quality of life in the York model and subsequent appraisals
The utility values associated with treatment in the York model were based on the proportion of patients in
the different PASI response categories (< 50, 50–74, 75–89, ≥ 90) and the change in utility from baseline
associated with the PASI response category. Utility values were estimated based on a two-stage process:
1. Mean change in DLQI score between baseline and week 12 in the etanercept trials was estimated for
patients with different levels of PASI response and different baseline DLQI scores. This analysis was
facilitated by access to patient-level data from the trials and the placebo and treatment groups were pooled.
2. The DLQI data collected in the etanercept trials were then mapped onto EQ-5D values. This was
achieved through access to data from the Health Outcomes Data Repository (HODaR), which included
patients who had completed both the DLQI and EQ-5D. These data were used to map the change in
DLQI score associated with PASI responses to changes in EQ-5D utility values.
The two-stage process was used to estimate average EQ-5D gains in utility from baseline for the different
PASI response categories: 0.05 for PASI < 50, 0.17 for PASI 50–74, 0.19 for PASI 75–89 and 0.21 for PASI
≥ 90. Estimated gains in utility were also presented for individuals in the fourth quartile of the baseline DLQI
score, that is, for patients with the worst baseline quality of life. The utility values from the York model were
applied directly in TA368102 for the population with a DLQI score of > 10 and in TA13498 (values for the fourth
quartile of the baseline DLQI score). For TA146,99 TA350101 and TA368102 (scenario analysis), the company had
access to EQ-5D data collected in the trials, which were pooled across treatment groups and reported by PASI
response category. For TA180,100 a similar modelling approach was used but the mapping algorithm used in
the York model was applied to ustekinumab trial data to generate utility gains by PASI response category
based on DLQI scores in the trial. The utility values applied in the TAs are summarised in Table 52.
None of the TAs included a disutility associated with AEs from treatment. Only one TA considered a
disutility from flare-ups associated with time off treatment (intermittent etanercept) (TA14699); however,
the disutility value applied was not reported in the published documentation.
The modelling approach used in the previous TAs assumed that:
l The PASI response is a perfect proxy for the change in utility arising from treatment. In other words,
by conditioning on PASI response, utility is independent of treatment.
l Similarly, if utility is conditioned on DLQI score change, then utility is independent of PASI response.
l The relationship between DLQI score and utility is linear.
l The impact of AEs on HRQoL is unimportant.
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TABLE 52 Summary of the utility values applied in previous TAs
Key
characteristics
Previous TA
TA10397 aTA13498 TA14699 TA180100 bTA350101 TA368102
Populationc All Fourth-
quartile
DLQI
score
Fourth-
quartile
DLQI
score
All DLQI > 10 DLQI ≤ 10 DLQI ≥ 10 DLQI ≥ 10 All DLQI > 10 DLQI ≤ 10
Analysis BC SA BC SA BC SA BC SA BC BC SA BC SA
BL PASI – – – – – – – – 0.642 0.7 0.7 0.7 0.7
Source NR NR NR NR NR NR NR NR RCT Revicki et al.143
Incremental gain in utility from baseline
PASI < 50 0.050 0.120 0.120 0.054 0.063 0.045 0.04 0.0016 0.109 0.05 0.0134 0 –0.0024
PASI 50–74 0.170 0.290 0.290 0.140 0.178 0.102 0.17 0.0424 0.193 0.17 0.0537 0.02 0.0275
PASI 75–89 0.190 0.380 0.380 0.22 0.0970 0.226 0.19 0.1150 0.03 0.0256
PASI ≥ 90 0.210 0.410 0.410 0.219 0.308 0.130 0.25 0.1276 0.264 0.21 0.1333 0.07 0.0704
Source Trial DLQI data
by PASI category,
mapped to EQ-5D
utility values
TA10397 Pooled trial EQ-5D data.
Relationship with PASI
established by mixed model
Trial DLQI data
by PASI category,
mapped to
EQ-5D utility
values using
mapping
algorithm from
TA10397
RCT
sourced
SF-6D data
by PASI
response
category
Pooled trial
EQ-5D data
and a statistical
model used to
predict the
change in
HRQoL from BL
by categories of
PASI response
TA10397 Pooled trial
EQ-5D data
by PASI
response
category
Pooled trial
EQ-5D data
by PASI
response
category
Pooled trial
EQ-5D data by
PASI response
category.
Included all
available
apremilast trial
data available
BC; base case; BL, baseline; NR, not reported; SA, scenario analysis; SF-6D, Short Form questionnaire-6 Dimensions.
a A scenario analysis with utility estimates from the whole population in TA10397 was also conducted.
b A scenario analysis with utility estimates from the all population in TA14699 was also conducted.
c Populations are defined based on baseline DLQI HRQoL.
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The main critique of the approach used in the York model relates to the uncertainty introduced by
mapping from the DLQI to the EQ-5D, based on a small sample of 86 patients. The NICE Appraisal
Committees favoured the use of EQ-5D data collected directly from the trials when available. Scenario
analysis in TA10397 showed that the cost-effectiveness results were very sensitive to the selection of utility
values, with greater QALY gains from treatment in the fourth quartile of the baseline DLQI score (subgroup
with the worst baseline HRQoL) than in the overall trial population. Furthermore, as the utility values were
conditioned on the PASI response at the end of the trial period, these values were extrapolated over the
time horizon of the model, which is a key driver of differences between the treatments.
Resource use and costs in the York model and subsequent appraisals
Resource use and costs included in the York model and subsequent appraisals related to drug acquisition,
administration and monitoring, outpatient visits and inpatient hospitalisation stays. The cost of tests to
assess eligibility for biological treatment was excluded. With the exception of infliximab, all treatments
were assumed to be self-administered. Drug costs were sourced from the most recent information in the
British National Formulary (BNF). A range of monitoring and laboratory costs were considered, including for
a full blood count, liver function tests and regular physician visits. No AE costs associated with treatment
were included in the York model. TA350101 was the only appraisal in which the costs of AEs were
considered. The rates of AEs applied were sourced from the secukinumab trials and published literature
and included non-melanoma skin cancer (NMSC), other malignancies and severe infections.
Resource use and costs included in the earliest TAs (TA134,98 TA14699 and TA180100) mostly followed the
assumptions of the York model and sourced their resource use and unit costs from TA103.97 There were
small differences in resource use for drug monitoring and administration between the TAs but these
differences had only a minor impact on the cost-effectiveness results. Later TAs (TA350,101 TA368102) based
their resource use and cost estimates on the NICE clinical guideline on psoriasis (CG15311) for the
cost-effectiveness of second-line biologics and on the accompanying costing report. CG153 included the
same categories of costs as the York model but expanded on them to better characterise the costs of BSC.
The costs associated with BSC were identified as a key driver of the cost-effectiveness results in TA10397
and were considered to be an area of substantial uncertainty in subsequent TAs.
In all of the appraisals, non-responders to treatment were assumed to receive BSC (with the exception of
TA368,102 in which the sequential use of treatments was considered and non-responders moved to BSC
only when all other treatment options were exhausted). The costs associated with BSC differ across the
appraisals as there was no clear guidance on what BSC consists of. Table 53 provides a summary of the
resource use and costs relating to BSC included in each of the TAs, as well as those reported in CG153.
The cost of BSC for non-responders in the York model was limited to two annual outpatient visits in the
base-case analysis, but included one annual hospitalisation with a 21-day length of stay (LOS) in a scenario
analysis. The rate of hospitalisations for patients on BSC was based on expert opinion, with LOS sourced
from Hospital Episode Statistics (HES) data and two local surveys. Subsequent TAs (TA134,98 TA14699 and
TA18098) used the 21-day inpatient stay for BSC in their base-case analysis. In each of these appraisals it
was assumed that no treatments were given as part of BSC.
National Institute for Health and Care Excellence CG15311 departed from this definition of BSC (see
Appendix P of the guideline) because it was believed that it does not reflect what currently happens in clinical
practice for patients who require a second-line biologic. In CG153 it was assumed that 45% of patients
would receive treatment with methotrexate, 45% would receive continuous ciclosporin for a maximum of
2 years and 16% would undergo 24 sessions of NBUVB therapy per year while on BSC. Furthermore, it was
reported in CG153 that patients meeting the eligibility criteria for biological therapy are generally high-need
patients who use a sizeable number of health-care resources through inpatient admissions, lengthy hospital
stays and frequent visits to day clinics for specialist-applied topical treatments and ultraviolet B (UVB) and who
require monitoring for toxicity because of the use of systemic treatments. The NICE Guideline Development
Group (GDG) sourced the resource use estimates for BSC from two published cohort studies of patients with
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a high level of need (i.e. those with severe psoriasis), which were conducted in tertiary dermatology units in
the UK (n = 76)143 and the Netherlands (n = 67).144 Both of these studies estimated the mean number of
inpatient days in the year preceding initial treatment with biological therapy. In addition, estimates of LOS
from a multicentre prospective service review based on four specialist dermatology centres in the UK145
were used in a scenario analysis. The GDG for CG153 emphasised that there is substantial variability in the
long-term costs reported for patients with psoriasis. As a result, CG153 included extensive sensitivity analyses
for the elements of cost associated with BSC. These included variations in the number of hospitalisations per
year and the average LOS by level of need. The cost-effectiveness of second-line biological therapy compared
with BSC in CG153 was highly sensitive to the assumptions about BSC.
The more recent TAs (TA368102 and TA350101) largely followed the resource use reported in CG153 for
BSC (Table 54). The NICE Appraisal Committees for TA350 and TA368 noted that in both cases the costs
of BSC were likely to have been overestimated. The committees considered that the patient population in
CG153 and Fonia et al.144 did not match that in the appraisals and reflected a sicker group of patients.
In particular, Fonia et al.144 described care in a tertiary care centre, which is known to be associated with
treating the most severely affected cases of psoriasis. Furthermore, during the consultation process for
TA368,102 the company provided NHS HES data that showed that the average LOS associated with BSC
was 3.5 days. However, this was argued by the company to be an underestimate as it included patients
with different disease severities and patients receiving concomitant medication. The duration of hospital
stay for BSC in adults with moderate to severe psoriasis remains highly uncertain.
TABLE 53 Summary of the resource use and costs relating to BSC included in the previous TAs and NICE guidance
Study
Treatments included as
part of BSC
Outpatient
visits
(annual)
Day centre
care
(annual) Hospitalisations (annual)
Reported total
annual cost of
BSC (£)
TA368102 45% of patients on MTX,
45% of patients on
continuous CS, 16% of
patients undergo 24 sessions
of NBUVB per year
10% of
patients
undergo
five visits
All patients
undergo
five visits
82% of high-need patients
have one hospitalisation,
with a mean LOS of 20.8
days; 18% of very high
need patients have 2.55
hospitalisations, with a mean
LOS of 53.04 days. The
resulting weighted average
yielded 26.6 days
11,542.73
TA350101 45% of patients on MTX
(15 mg/week), 45% of
patients on continuous CS
(300 mg/day) for a
maximum of 2 years, 3.84
sessions of NBUVB per year
4 5 10.7 9015.00
CG15311 45% of patients on MTX,
45% of patients on
continuous CS for a
maximum of 2 years,
16% of patients undergo
24 sessions of NBUVB
per year
10% of
patients
undergo
five visits
All patients
undergo
five visits
82% of high-need patients
have one hospitalisation,
with a mean LOS of 20.8
days; 18% of very high
need patients have 2.55
hospitalisations, with a mean
LOS of 53.04 days (average
of 26.6 days)
10,730.00
TA180100 No treatments 2 0 21 6209.54
TA14699 No treatments 2 0 21 5493.00
TA13498 No treatments 18a 0 21 7365.00
TA10397 No treatments 2 0 0/21b 113.20/5327.71
CS, ciclosporin; LOS, length of stay; MTX, methotrexate.
a Non-responders who switch to BSC; responders undergo two outpatient visits.
b Zero in the base-case analysis and 21 days in scenario analysis.
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TABLE 54 Summary of CG153 assumptions for scenario analyses
Severity of
psoriasis
Proportion
of patients
(%)
Number of
admissions
(annual)
Assumed
average
LOS (days)
Patient
days in
hospital
Number of
bed-days
per annum
in the model
Base-case assumptions and
variations in scenario analysis
High need 82 1 20.8 20.8 26.6 Base case: proportion of patients
by level of need sourced from
the study by Driessen et al.146
Average LOS taken from the
study by Woods et al.145 for
patients with a baseline PASI
score of 10–20 (20.8 days).
Number of hospitalisations
calculated to match that in the
study by Driessen et al.146
(average LOS for very high-need
patients in the year prior to
biological therapy 53 days)
Very high
need
18 2.55 20.8 53.0
High need 82 1 23.7 23.7 30.3 Scenario 1: average LOS taken
from Woods et al.145 for patients
with a baseline PASI score of
> 20 (23.7 days)
Very high
need
18 2.55 23.7 60.4
High need 70 1 20.8 20.8 30.5 Scenario 2: 30% very high need
Very high
need
30 2.55 20.8 53.0
High need 95 1 20.8 20.8 22.4 Scenario 3: 5% very high need
Very high
need
5 2.55 20.8 53.0
High need 82 0.25 20.8 5.2 13.8 Scenario 4: aimed to match the
estimates of average LOS in
the study by Driessen et al.146
(53 days for patients with a LOS of
≥ 30 days and 14.9 days for the
full study population) by changing
the number of hospitalisations per
year. However, the number of
hospitalisations per year for the
high-need patients would have to
be 0.75 to yield an average LOS of
14.9 days, as reported in the study
Very high
need
18 2.55 20.8 53.0
High need 82 0.5 20.8 10.4 16.0 Scenario 5: 0.5 hospitalisations
for high-need patients and
2 hospitalisations for very-high-
need patients
Very high
need
18 2 20.8 41.6
High need 82 1 20.8 20.8 20.8 Scenario 6: 1 hospitalisation for
all
Very high
need
18 1 20.8 20.8
High need 82 0.312 20.8 6.49 6.5 Scenario 7: aimed to match
the estimate of average LOS
(6.49 days) in the study by Fonia
et al.144 by changing the number
of hospitalisations per year
Very high
need
18 0.312 20.8 6.49
Elements varied in sensitivity analysis are shown in bold; all of the variations resulted in a different estimate of the number
of bed-days per annum being applied in the model.
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Cost-effectiveness results from the York model and subsequent appraisals
The cost-effectiveness results for the base-case analyses in the previous NICE TAs in adults are summarised
in Table 55, alongside the drivers of cost-effectiveness stated in the TA documentation. The results reported
for TA134,98 TA146,99 TA180,100 TA350101 and TA368102 correspond to those in the company submissions.
In the base-case full incremental analysis for TA103,97 which compared etanercept in three dosing regimens
(25 mg intermittent, 25 mg continuous and 50 mg intermittent), efalizumab and BSC, and assuming no
hospitalisations for non-responders to biological treatment, BSC was the most cost-effective strategy at
cost-effectiveness thresholds of < £66,703 per QALY gained. At a threshold of ≥ £66,703 per QALY gained,
intermittent etanercept at 25 mg would be the cost-effective intervention, dominating (i.e. being less costly
and more effective than) continuous etanercept at 25 mg and efalizumab. Intermittent etanercept at 50 mg
had an incremental cost-effectiveness ratio (ICER) exceeding £1M per QALY gained compared with
etanercept at a lower dose (25 mg intermittent).
Inclusion of 21 days of hospitalisation for non-responders to the biological drugs reduced the ICER for
intermittent etanercept at 25 mg compared with BSC to £29,420 per additional QALY. When, in addition
to the 21 days of hospitalisation, the estimates of utility gains per PASI response were sourced from the
subgroup of patients in the highest (worst HRQoL) quartile of the baseline DLQI score (the group with the
highest gain in utility from improvement in PASI score), the ICER for intermittent etanercept at 25 mg
compared with BSC further reduced to £15,297 per QALY. In both of these scenario analyses, continuous
etanercept at 25 mg and efalizumab remained dominated by intermittent etanercept at 25 mg, whereas
the ICER for intermittent etanercept at 50 mg compared with intermittent etanercept at 25 mg decreased
but not enough to make it cost-effective at commonly accepted cost-effectiveness threshold ranges. In the
secondary analysis that compared the full range of systemic therapies (namely infliximab, methotrexate,
ciclosporin and Fumaderm) and assumed 21 days of hospitalisation for non-responders, methotrexate
dominated all interventions with the exception of infliximab, including BSC. Infliximab was more costly and
more effective than methotrexate but the resulting ICER for this comparison exceeded £1M per QALY
gained, with methotrexate emerging as the cost-effective intervention for this analysis.
The appraisals subsequent to TA103 (TA134,98 TA146,99 TA180,100 TA350101 and TA368102) all included a
cost associated with hospitalisation for non-responders (LOS ranging from 10.7 to 26.6 days per annum).
This generally resulted in more favourable cost-effectiveness estimates when biological therapies were
compared with BSC. Consistent with the findings of the York model, the duration of hospitalisation for
non-responders was identified as a key driver of cost-effectiveness for biological therapies across the
appraisals. The base-case analysis in the majority of the appraisals98–100 used estimates of utility gains by
PASI response in a subgroup with lower baseline HRQoL (TA134, TA146 and TA180), leading to higher
QALY gains for the most effective drugs in terms of PASI response. This parameter can be considered the
second driver of cost-effectiveness in the adult models.
The base-case cost-effectiveness results in the company submissions for infliximab, adalimumab and
ustekinumab (TA134,98 TA14699 and TA180100 respectively) place the ICERs for these drugs at the upper
end of the currently accepted NICE cost-effectiveness threshold range, as long as the assumptions about
HRQoL and the costs of hospitalisation for non-responders referred to above hold. The estimates of
cost-effectiveness for secukinumab and apremilast presented by the manufacturers in TA350101 and TA368102
were considered overly optimistic by the NICE Appraisal Committees and were largely driven by the costs of
BSC in non-responders to biological therapy. These costs were considerably higher than in previous appraisals
because of the assumption of a higher consumption of health-care resources by non-responders, in line with
CG15311 (see Table 54).
The National Institute for Health and Care Excellence recommended the following biological treatments
in adults with psoriasis: efalizumab,97 etanercept,97 infliximab,98 adalimumab,99 ustekinumab100 and
secukinumab.101 With the exception of infliximab the biological treatments were recommended for severe
psoriasis, defined as a baseline PASI score of ≥ 10 and a DLQI score of > 10 in patients who had previously
DOI: 10.3310/hta21640 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 64
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
83
TABLE 55 Summary of cost-effectiveness results and key drivers of cost-effectiveness for previous adult TAs
Appraisal
Previous adult TA
ETA and EFA (TA10397) INF (TA13498) ADA (TA14699) UST (TA180100) SEC (TA350101) APR (TA368102)
Base-case analysis
results [ICERs
(per QALY)]
Incremental analysis:
l ETA 25mg vs.
BSC: £66,703
l EFA: dominated
l ETA 25mg
continuous:
dominated
l ETA 50mg vs. ETA
25mg: £1035,121
ICER vs. BSC:
l ETA 25mg: £66,703
l EFA: £84,018
l ETA 25mg
continuous:
£83,258
l ETA 50mg
£120,855
Incremental analysis:
l ETA 25mg vs. BSC:
£8044
l EFA: dominated
l ETA 25mg
continuous vs. ETA
25mg: £17,208
l ETA 50mg:
extendedly
dominated
l INF vs. ETA 25 mg
continuous:
£26,095
ICER vs. BSC:
l INF: £22,240
Incremental analysis
(biologics only):
l ETA intermittent:
extendedly
dominated
l ETA high intermittent:
extendedly
dominated
l EFA: extendedly
dominated
l ADA vs. BSC:
£30,538
l ETA: dominated
l Infliximab: £147,906
ICER vs. BSC:
l MTX: –£29,759
l CS: –£25,135
l ETA intermittent:
£37,284
l ETA high intermittent:
£38,358
l EFA: £39,948
l ADA: £30,538
l ETA: £37,676
l INF: £42,492
ICERs vs. BSC:
l EFA: £40,250
l ETA 25mg
intermittent: £30,111
l ETA 25mg
continuous: £34,281
l ETA 50mg
continuous: £35,964
l ADA: £31,022
l UST: £29,587
l INF: £39,153
ICER UST vs. other
treatments:
l BSC: £29,587
l EFA: UST dominant
l ETA 25mg
intermittent: £26,637
l ETA 25mg
continuous:
UST dominant
l ETA 50mg
continuous:
UST dominant
l ADA: UST dominant
l INF vs. UST: £304,566
Incremental analysis:
l ETA 25mg b.i.w. vs.
BSC: £13,948a
l SEC vs. BSC: £2464
l ADA 40mg:
dominated by SEC
l UST 45mg:
dominated by SEC
l UST 90mg:
dominated by SEC
l INF: dominated
by SEC
APR sequence
dominated the
comparator sequence
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Appraisal
Previous adult TA
ETA and EFA (TA10397) INF (TA13498) ADA (TA14699) UST (TA180100) SEC (TA350101) APR (TA368102)
Stated drivers of
cost-effectiveness
Identified by scenario
analysis in the AG
report:
l source of utility gain
by PASI response:
use of estimates
from subgroup with
lower baseline
HRQoL (higher DLQI
score) improves the
cost-effectiveness of
biological drugs
l inclusion of 21 days
of hospitalisation
in the costs of
non-responders
favours the
cost-effectiveness of
the more effective
drugs
Identified by one-way
sensitivity analysis in the
MS:
l non-responders’
inpatient LOS
l mean patient
weight in the model
l response rates to
treatment for INF
l utility gain for
responders
Identified by scenario
analysis in the MS:
l source of utility gain
by PASI response: use
of estimates from
subgroup with lower
baseline HRQoL
(higher DLQI score)
improves the
cost-effectiveness of
biological drugs
l annual inpatient LOS
for non-responders
Identified by one-way
sensitivity analysis in the
MS:
l number of hospital
days for BSC
l estimated cost of
dosing for
intermittent ETA
25mg
l SF-6D utility scores
instead of EQ-5D
utility scores (mapped
from the DLQI)
Identified by scenario
analysis in the MS:
l costs assumed for
BSC including
hospitalisation
costs, day-care costs
and, to a lesser
extent, costs of
phototherapy
l small changes in
incremental health
benefits between
different biological
treatments, thus
ICERs could vary
considerably with
small QALY changes
Differences in costs
(mostly because of
hospitalisation LOS for
those on BSC) and
outcomes for APR
compared with BSC
were the main drivers
given the high
assumed costs of BSC
and the assumption of
no PASI response for
BSC
ADA, adalimumab; APR, apremilast; b.i.w., twice weekly; CS, ciclosporin; EFA, efalizumab; ETA, etanercept; INF, infliximab; MS, manufacturer’s submission; MTX, methotrexate;
SEC, secukinumab; SF-6D, Short Form questionnaire-6 Dimensions; UST, ustekinumab.
a ETA extendedly dominated by SEC.
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failed or who had a contraindication/intolerance to non-biological systemic therapy. The recommendation
for efalizumab further required that patients had failed on etanercept or had a contraindication/intolerance
to the drug. Efalizumab is no longer marketed in the UK.
Infliximab was recommended only for very severe psoriasis, defined as a baseline PASI score of ≥ 20 and a
DLQI score of > 18 in patients who had previously failed or who had a contraindication/intolerance to
non-biological systemic therapy. The recommendation for ustekinumab and secukinumab was conditional
on the availability of Patient Access Schemes. The Patient Access Scheme for ustekinumab guarantees a
flat price for 45 mg and 90 mg of ustekinumab so that the 90-mg dose is provided at the same price as
the 45-mg dose for patients weighing > 100 kg, whereas the Patient Access Scheme for secukinumab
consists of a confidential discount over the drug list price.
The NICE recommendations for all of these biological treatments require treatment termination if a
response is not produced at the end of the ‘trial’ period (12 weeks for etanercept and secukinumab,
10 weeks for infliximab and 16 weeks for adalimumab and ustekinumab). Treatment response is defined as
achieving a PASI 75 or PASI 50 response accompanied by a 5-point reduction in DLQI score from baseline.
Summary of the key areas of uncertainty in adult models and motivation
for a de novo model in children and young people
There are no studies comparing the cost-effectiveness of biological therapies for plaque psoriasis in children
and young people. Furthermore, none of the companies participating in this appraisal have submitted an
economic evaluation in this population. Our review of previous NICE TAs of plaque psoriasis in adults was
conducted to examine existing decision-analytic models and identify important structural assumptions and
highlight key areas of uncertainty and the potential issues associated with generalising evidence from the
adult population to a population of children and young people. In this section we summarise the key areas
of uncertainty identified in adults in light of potential implications for the de novo model in children and
young people.
Model structure
Although in clinical practice, treatment with biological therapy is expected to be sequential, that is,
patients are switched to further lines of biological therapy on failure of the first-line biological therapy,
the majority of the TAs did not consider treatment sequencing. Lack of evidence to inform treatment
sequencing, especially on the efficacy of the treatments depending on the previous therapies received,
appeared to be the main reason for not formally modelling treatment sequences in all but one appraisal
(TA368102). Given that there is very limited evidence to support the cost-effectiveness of the sequential
use of treatments in adults and that no evidence exists in children and young people (see Chapter 3),
any attempt to model treatment sequences in the population of children and young people will be
highly uncertain.
Clinical effectiveness evidence
Because of a lack of head-to-head trials comparing the biological treatments with each other, NMA was
used to compare the treatments with each other indirectly. There was concern that not all trial populations
matched those of the decision problem because of variation in the inclusion criteria, with some trials not
explicitly excluding individuals who had not failed non-biological systemic therapy. Placebo or BSC was not
defined consistently across the trials, which introduced heterogeneity in placebo response rates. Similar
issues were identified in the clinical effectiveness evidence for children and young people (see Chapter 3),
with the evidence base even more sparse, with only three RCTs and no common comparator across the
trials. Chapter 4 describes how NMA was used to expand the evidence base in children and young people
by drawing strength from the full network of evidence available for adults, while attempting to account
for heterogeneity between trial populations (i.e. children and young people vs. adults) and placebo
response rates.
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Long-term response and withdrawal rates
To extrapolate data beyond the clinical trials, previous appraisals in adults have assumed that responders to
treatment maintain their PASI response rate over time until treatment withdrawal. The same all-cause
withdrawal probability of 20% per annum has been assumed for all biological therapies in the absence
of any long-term withdrawal data. Given the paucity of long-term data in children and young people,
this parameter will also be uncertain in this population.
Health-related quality of life
Most of the previous TAs in adults used utility values based on an estimate of the relationship between
PASI response rates and changes in DLQI scores mapped onto EQ-5D utility values. Although some TAs
applied EQ-5D data collected directly in RCTs, this was limited to data collected in the trials sponsored by
the companies and no evidence synthesis methods were used to synthesise the utility estimates. The
estimates of utility gains from treatment were variable across subgroups of patients defined by baseline
DLQI score, with greater gains achieved for individuals with worse baseline HRQoL. The size of the utility
gains in previous appraisals was considered to be largely uncertain and it represented a key driver of the
cost-effectiveness results. It is expected that utility gains associated with treatment will also be highly
uncertain in the population of children and young people because of an absence of EQ-5D data in this
population. In Chapter 6, a review of HRQoL data in children and young people is reported. Scenario
analyses are used to explore the impact of uncertainty on the cost-effectiveness results.
Resource use and costs
The resource use and costs associated with BSC has been one of the key drivers of cost-effectiveness in
adult appraisals. In particular, the duration of and costs associated with inpatient hospitalisation stays for
individuals who do not respond adequately to treatment have been highly uncertain. Until the publication
of CG153,11 the resource use and costs associated with BSC in adult TAs were largely informed by
assumptions and expert opinion. The two TAs that followed the guideline (TA350101 and TA368102)
supplemented it with resource use data from cohort studies of patients treated for psoriasis with biological
treatments. However, the patient population from whom the data were collected was likely to reflect a
sicker population than that defined by the NICE scope for these appraisals and the uncertainty associated
with the estimates was not sufficiently explored. The search described in Chapter 5 (see Methods) did not
identify any evidence on the resource use and costs involved in BSC in children and young people. The use
of evidence in adults supplemented by clinical expert opinion to inform the costs of BSC in children and
young people is discussed in depth in Chapter 6. Scenario analyses are used to explore the implications for
the cost-effectiveness results of uncertainty in the assumptions made about BSC, particularly in relation to
hospitalisation LOS.
Each of these areas of uncertainty is considered in more detail in the following chapter as part of the
decision-analytic model developed to evaluate the cost-effectiveness of adalimumab, etanercept and
ustekinumab in children and young people.
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Chapter 6 Independent economic assessment
Introduction
The review of cost-effectiveness evidence in the population of children and young people and the absence
of company models highlights the challenges of developing an economic model in this population. The
fundamental challenge is the limited clinical evidence base for both short- and long-term outcomes to
inform a model. Therefore, any estimation of the cost-effectiveness of biological therapies in children and
young people will be subject to a number of uncertainties. These uncertainties cannot be avoided but a
clear and transparent approach, that highlights the assumptions entering the economic model, can be
pursued to help the decision-maker assess the cost-effectiveness of biological therapies in this population.
Plaque psoriasis is a chronic non-progressive disease that manifests itself in children and young people in a
similar manner to that in adults. The main difference between the younger population and adults is the
presence of comorbidities in adults (such as high blood pressure, liver impairment and renal impairment),
which tend to make adults less well with psoriasis than a younger population. Currently, there is no
treatment pathway specific to psoriasis in children and young people in the UK. The management of
treatment and approach to care seems to mirror that used in adults. Our clinical advisor, Dr Ruth Murphy,
indicated that when there is an absence of evidence it would be reasonable to extrapolate data from the
adult population to children and young people. The company submission for ustekinumab also supports
this approach for the development of an economic model given that there are few significant differences
in the posology or management of chronic plaque psoriasis in children, young people and adults.
The management and treatment of plaque psoriasis depends on the extent and severity of an individual’s
disease, local custom and practice. If an individual patient does not respond to or tolerate a particular
treatment option, an alternative one is usually tried. This means that treatments are usually ‘trialled’ on an
individual basis until an effective option is found. If an effective treatment is not found, then a patient will
receive some form of BSC. This approach to treatment appears to be the same for children and young
people and adults, but usually more caution is exercised in the younger population because of the limited
availability of licensed treatment options.
The trialling of treatments on treatment failure or intolerance suggests that sequences of treatments could
be considered in an cost-effectiveness model, whereby after failure of a first treatment option patients are
trialled on a second option and so on, until all options are exhausted. However, this would require additional
clinical evidence on the efficacy of the treatments conditional on the previous therapies received. There is
very limited evidence to support the cost-effectiveness of the sequential use of treatments in adults and no
evidence exists in children and young people (see Chapter 3). Therefore, although the model should ideally
explore the sequential use of treatments, any attempt to do so in the population of children and young
people would be highly uncertain. Furthermore, the optimum treatment sequence may not be suitable for an
individual patient with specific characteristics and when treatment in this population is usually tailored to the
child or adolescent because of needle phobia or the presence of psoriatic arthritis. Therefore, an alternative
approach may be better whereby the optimum ordering of treatments, in terms of their cost-effectiveness, is
established. This can be achieved by comparing each of the alternative treatment options with BSC and then
indicating the most cost-effective order in which to give the therapies based on total expected costs and
QALYs associated with each treatment option.
The previous York model appears to be the most widely accepted model of chronic plaque psoriasis.97
The five NICE TAs that followed TA103 for the treatment of moderate to severe psoriasis in adults98–102
followed the framework of the York model and these have been accepted by NICE as being relevant to
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plaque psoriasis. The main changes that have followed since the advent of the York model have been the
availability of new evidence, the methodology for linking efficacy estimates to HRQoL utility values, the
parameters used in the model to inform BSC, updated unit costs, time on treatment and the modelling of
treatment sequences in the most recent appraisal of apremilast.102 It would therefore seem appropriate
that the same modelling framework is used for children and young people but with an evidence base
informed by outcomes in the younger population. Hence, the structure of our model is very similar to that
used in previous TAs in adults and, when evidence is lacking or limited in the population of children and
young people, data have been extrapolated from the adult population and supplemented by expert opinion.
Decision problem and patient population
The decision problem addresses the cost-effectiveness of adalimumab, etanercept and ustekinumab for
the treatment of plaque psoriasis in children and young people. The population in the model reflects the
marketing authorisations of the three interventions. However, the marketing authorisations differ in terms
of the age of the population and the severity of psoriasis at baseline and also in terms of the positioning of
the biologic in the pathway of care.
A stepwise approach to treatment for the management of plaque psoriasis is usually pursued in which
topical therapies are offered as first-line treatment followed by phototherapies and/or systemic non-biological
therapies such as methotrexate as second-line treatment and then biological treatments as third-line treatment
when previous therapies have been found to be ineffective. However, adalimumab is licensed in a paediatric
population for individuals who have an inadequate response to, or who are inappropriate candidates for,
topical therapy and phototherapies, whereas etanercept and ustekinumab are licensed for individuals who are
inadequately controlled by, or who are intolerant to, other systemic therapies or phototherapies. Therefore,
adalimumab is the only biological treatment indicated in the population of children and young people who
have not failed previous systemic therapies.
The biological interventions also differ in their marketing authorisations by age and severity of psoriasis
(Figure 9). Both adalimumab (age ≥ 4 years) and etanercept (age ≥ 6 years) are indicated for younger ages
and severe psoriasis, whereas ustekinumab is indicated for an adolescent population (age ≥ 12 years) and
moderate to severe psoriasis. The definition of severity differs in the corresponding trials of the biologics in
children and young people (Table 56). In adults, severe psoriasis is defined by a total PASI score of ≥ 10
and a DLQI score of > 10. However, there is not a clear consensus on the definition of moderate or severe
psoriasis in children and young people. This is partly because the PASI has not been validated as a disease
severity assessment tool for use in this population and no other tool is available. Mean PASI scores at
baseline in the trials were 18.6 for etanercept, 18.3 for adalimumab and 21.1 for ustekinumab. Therefore,
although the licence for ustekinumab includes those with moderate to severe psoriasis, patients in the
ustekinumab trial (CADMUS) had a disease severity that was more comparable to that in patients with
severe disease in the etanercept trial (20030211) and adalimumab trial (M04-717). Hence, the population
in the model was chosen to reflect severe psoriasis as defined by the baseline characteristics of the
populations in the trials of children and young people.
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FIGURE 9 Marketing authorisations of biological therapies in children and young people by age and severity.
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To reflect the differences in marketing authorisation by age and positioning of treatment in the pathway,
three separate populations were considered in the base-case cost-effectiveness analysis:
1. Before systemic therapy – children and young people aged 4–17 years with adalimumab as the only
licensed intervention for the treatment of severe plaque psoriasis in individuals who are inadequately
controlled by, or who are intolerant to, topical therapy and phototherapies, that is, as an alternative to
systemic therapies.
2. After systemic therapy (1) – children and young people aged 6–11 years with adalimumab and
etanercept for the treatment of severe plaque psoriasis in individuals who are inadequately controlled
by, or who are intolerant to, systemic therapies or phototherapies.
3. After systemic therapy (2) – children and young people aged 12–17 years with adalimumab, etanercept
and ustekinumab for the treatment of severe plaque psoriasis in individuals who are inadequately
controlled by, or who are intolerant to, systemic therapies or phototherapies.
The population aged 4–5 years with adalimumab as the only licensed intervention for the treatment of
severe plaque psoriasis after systemic therapy was not considered as a separate population because no
children aged < 6 years were included in the adalimumab trial (M04-717); therefore, efficacy estimates for
this age group were assumed to be the same as those for children aged 6–11 years, which results in
similar cost-effectiveness estimates for adalimumab compared with BSC for ages 6–11 years.
The starting age used in the model was 4 years, 6 years and 12 years for the three populations described
above respectively. The time horizon of the model extended until individuals reached 18 years of age.
At this point, the population reaches adulthood and separate NICE recommendations for the use of the
interventions in adults apply. The differences in the marketing authorisations of the interventions by age
inevitably mean that the time horizon of the model differs according to the population. To explore the
impact of the time horizon, a separate scenario analysis is presented that considers a common time
horizon of 14 years for all populations. The time horizon of 14 years (which is greater than the time
horizon of 10 years used in previous TAs in adults) is sufficient to capture differences in costs and effects
between the interventions under comparison.
TABLE 56 Definition of disease severity in the trial populations in trials of children and young people
Marketing
authorisation Etanercept Ustekinumab Adalimumab
Licence Severe chronic plaque psoriasis Moderate to severe plaque
psoriasis
Severe chronic plaque psoriasis
Trial population Moderate to severe plaque
psoriasis with baseline PASI score
of ≥ 12, PGA score of ≥ 3 and
involvement of ≥ 10% of BSA
Moderate to severe plaque
psoriasis with baseline PASI
score of ≥ 12, PGA score of
≥ 3 and involvement of
≥ 10% of BSA for ≥ 6 months
Severe plaque psoriasis with
baseline PASI score of ≥ 20, PGA
score of ≥ 4 and involvement of
≥ 20% of BSA or very thick
lesions and involvement of
≥ 10% of BSA or baseline PASI
score of ≥ 10 and one of the
following: (1) active psoriatic
arthritis non-responsive to
non-steroidal anti-inflammatory
drugs, (2) clinically relevant facial
involvement, (3) clinically relevant
genital involvement, (4) clinically
relevant hand or foot involvement
or (5) CDLQI score of > 10
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Intervention and comparators
The interventions considered in the cost-effectiveness analysis were adalimumab, etanercept and
ustekinumab within their marketing authorisations. The following comparators were considered in the
NICE scope:147
l Non-biological systemic therapy (including, but not limited to, ciclosporin and methotrexate).
l Topical therapy (for people in whom non-biological systemic therapy is not suitable), that is, BSC.
l Biological treatments used outside their marketing authorisation (such as infliximab, adalimumab,
etanercept or ustekinumab if used outside the constraints of the relevant marketing authorisation in
children and young people).
l When appropriate, adalimumab, etanercept and ustekinumab will be compared with each other.
Because of the positioning of adalimumab in the stepwise management of psoriasis, non-biological systemic
therapy is only a relevant comparator for adalimumab as it is the only licensed intervention representing an
alternative to systemic therapy; etanercept and ustekinumab are licensed for individuals who are inadequately
controlled by, or who are intolerant to, previous systemic therapies. Standard systemic therapies such as
methotrexate, ciclosporin and acitretin are not licensed for psoriasis in children and young people. However,
it is evident from the UK audit of the assessment and management of psoriasis in children that 19% of
children have received systemic drugs (9% methotrexate, 5% acitretin, 4% ciclosporin and 1% dapsone)
outside their licensed indications.12,148 The non-biological systemic therapy considered as a comparator in the
cost-effectiveness analysis for adalimumab is methotrexate as it is the most widely used systemic therapy in
the population of children and young people and was used as a comparator in the M04-717 trial.
If biological treatments are found not to be effective, individuals are usually offered some form of BSC
rather than no treatment. Therefore, BSC is considered a relevant comparator for individuals who have
exhausted all treatment options including conventional systemic therapy and phototherapy. BSC tends to
include a mix of active non-biological systemic therapies such as methotrexate and ciclosporin and
palliative care, including phototherapy, even though these treatments may have been proven to be
largely ineffective.
The interventions of etanercept, adalimumab and ustekinumab were compared with each other as
appropriate to the licensed population. The use of these interventions outside the age constraints of their
licence (e.g. the use of etanercept in children aged < 6 years and ustekinumab in children aged < 12 years)
was considered relevant in a scenario analysis. The use of other off-label biological treatments such as
infliximab outside its licensed indication in adults was not considered. Advice from our clinical expert
(Dr Ruth Murphy, personal communication) suggested that it is very unlikely that an unlicensed TNF inhibitor
would be used as an alternative to a biological treatment that is licensed and available in this population.
Furthermore, there are no RCTs comparing the use of infliximab with the use of any comparator (or placebo)
in the population of children and young people. Infliximab also requires intravenous infusion in hospital and
our clinical expert suggested that this is not a favourable option in this young population.
The biosimilar of etanercept, namely Benepali (50 mg), is not licensed for use in children and young
people. Therefore, the biosimilar was not considered a relevant comparator in the base-case analysis.
However, a scenario analysis was considered in which the drug cost of etanercept was reduced by
approximately 10% to match the cost of Benepali in adults (£164.00 per prefilled syringe).149
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The drug doses for the interventions and comparators considered in the cost-effectiveness analysis are
shown in Table 57. These are based on licensed doses for etanercept, adalimumab and ustekinumab and
expected doses for methotrexate and BSC. Continuation of treatment was conditioned on response to
treatment at the end of the trial period, corresponding to the time point specified in the Summary of
Product Characteristics for children and young people. For etanercept and adalimumab, this was 12 and
16 weeks respectively. For ustekinumab, the Summary of Product Characteristics specifies that consideration
should be given to discontinuation if there is no response up to 28 weeks. In the analysis, the time point for
response to ustekinumab was taken to be 16 weeks, corresponding to its administration at 12 weeks after
the dose given at 4 weeks. This is the same time point that was used to assess response to ustekinumab in
adults (TA180100). It was assumed that all treatments are used continuously in responders to treatment until
treatment withdrawal. Ciclosporin (used as part of BSC) was assumed to have a maximum treatment
duration of 2 years.
Methods
Overview
A de novo decision-analytic model was developed to estimate the cost-effectiveness of adalimumab,
etanercept and ustekinumab for the treatment of plaque psoriasis in children and young people. The
cost-effectiveness model consists of a Markov cohort transition model developed in Microsoft Excel® (2013;
Microsoft Corporation, Redmond, WA, USA). The structure of the model is very similar to that used in
previous TAs of moderate to severe plaque psoriasis in adults. The model was developed in accordance
with the NICE reference case.150 The time horizon of the model extends until individuals reach 18 years of
age, when they then become adults and current NICE recommendations for the use of the interventions in
adults apply. The length of the time horizon varies by the starting age of individuals in the model. As
indicated previously, three starting ages were considered in the model to reflect the restrictions of the
marketing authorisation of the interventions.
The outcomes of the model are expressed using QALYs. The QALY provides a summary measure
combining estimates of the remaining length of life (life-years) with the associated quality of life. QALYs
are derived by multiplying a utility value (quality of life) by the time spent with this utility (length of life).
The utility values used in the model were generated from PedsQL trial data using a mapping algorithm to
convert them to EQ-5D utility values. The utilities associated with treatment were based on the proportion
of individuals in the different PASI response categories (see Health-related quality of life). All costs were
considered from the perspective of the NHS and Personal Social Services (PSS). Health-care resource use
and cost categories include the cost of treatment (acquisition, administration, monitoring and AE costs)
and changes in health service resource use because of loss of response to treatment (see Best supportive
care costs).
TABLE 57 Licensed or guideline doses of interventions and comparators used in the economic analysis
Treatment Dose
Response assessment
(weeks)
Etanercept 0.8 mg/kg up to a maximum of 50mg weekly for up to 24 weeks 12
Adalimumab 0.8 mg/kg up to a maximum of 40mg at weeks 0 and 1, then
every 2 weeks thereafter
16
Ustekinumab 0.75 mg/kg for those weighing < 60 kg, 45 mg for those
weighing 60–100 kg and 90mg for those weighing > 100 kg at
weeks 0 and 4, then every 12 weeks thereafter
16
Methotrexate 0.1–0.4 mg/kg weekly 16
Ciclosporin (as part of BSC) 2–5 mg/kg daily for up to 2 years Not applicable
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The parameters for the model were sourced from published literature, information reported in the
company submissions and the results of the evidence synthesis described in Chapter 4. Both costs and
QALYs were discounted at 3.5% per annum, in line with current NICE guidance.150
Model structure and assumptions
The model consists of four health states: ‘trial period’, ‘continued use’, BSC and death (Figure 10).
Individuals enter the model in the trial period and receive one of the three biological interventions or a
relevant comparator. The length of the trial period is dependent on the intervention and can last from
12 weeks for etanercept to 16 weeks for adalimumab and ustekinumab, corresponding to the time point at
which response to treatment is assessed. The cycle length in the model corresponds to 28 days (4 weeks),
which takes account of the different lengths of time spent in the trial period.
At the end of the trial period, individuals are assessed as responders or non-responders to treatment
based on PASI response rates. PASI response in the base-case analysis is taken to be PASI 75, that is,
response is assessed based on whether or not an individual achieves a 75% reduction in baseline PASI
score. Individuals who do not have an adequate response to treatment at the end of the trial period move
to BSC. Individuals who are considered responders to treatment transition to the health state of continued
use, remaining in this state until they withdraw from treatment and move to BSC. During the period of
continued use, individuals continue to receive the active therapy and are assumed to maintain their level of
PASI response until treatment discontinuation from any cause, such as lack of efficacy, the presence of AEs
or non-compliance to treatment (modelled together as an overall risk of all-cause withdrawal).
On treatment discontinuation (in either the trial period or the continued use state), individuals transition to
BSC. BSC consists of non-biological supportive therapies. The only transition out of the BSC state is to the
‘death’ state. Death is an all-cause mortality state to which transition is possible from any health state.
Mortality is not conditioned on treatment or treatment response. Mortality rates by age were sourced from
life tables in England and Wales for the years 2013–15151 and averaged across sexes.
Effectiveness data
The measure of treatment effectiveness used in the model was the proportion of individuals achieving a
specific threshold of PASI response relative to baseline. Relative change in PASI response is the most widely
reported outcome in clinical trials and has been used as the main outcome in previous models in adults.
The PASI response rates used in the model were taken directly from the children and young people
efficacy estimates from the NMA that incorporated all relevant adult evidence (see Chapter 4, Framework
of analysis for informing the relative efficacy of the interventions). Scenario analyses were also conducted
in which the results from the unadjusted baseline constrained model with minimum adult evidence (see
Chapter 4, Framework of analysis for informing the relative efficacy of the interventions) were applied in
the model; partial comparisons with direct trial data and the indirect comparison (see Chapter 4, Indirect
treatment comparison) were also incorporated in scenario analyses for completeness. None of the three
trials of biological therapies in children and young people with psoriasis required previous failure on
non-biological systemic therapy as an inclusion criterion. Therefore, it was assumed in the model that treatment
effectiveness is independent of failure on non-biological systemic therapy prior to starting biological therapy.
Response
No response
Trial period Continued use
BSC Death
FIGURE 10 Schematic of the model structure.
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It is unknown how the position on the care pathway is likely to affect treatment effectiveness. In the
base-case analysis, PASI 75 response rates were taken as the measure of effectiveness for treatment
continuation. Individuals who meet the threshold of PASI 75 are classified as responders at the end of
the trial period and are assumed to maintain their response for as long as they are in the health state
of continued use. In a separate scenario analysis, the threshold of PASI 50 was taken as the measure of
effectiveness for treatment continuation.
The PASI response rates from the NMA were also used in the model to inform the HRQoL utility values.
Gains in utility associated with treatment were conditioned on PASI response rates (see Chapter 5,
Health-related quality of life in the York model and subsequent appraisals), an approach that has been
taken in previous models for the treatment of psoriasis in adults. PASI response rates for BSC were assumed
to be equivalent to those for placebo in the NMA.
In the absence of data to model time-varying transition probabilities, response rates were assumed to be
constant per cycle in the model. The response rates used to inform the model are presented later in this
chapter (see Table 70). The uncertainty in the predicted response rates from the NMA was reflected in the
model by directly exporting the simulated posterior distributions from the Markov chain Monte Carlo
analysis in WinBUGS to the cost-effectiveness analysis, preserving any correlations in the data.
Treatment withdrawal rates
Responders to treatment were assumed to maintain their response until treatment discontinuation.
Discontinuation was modelled as an overall risk of withdrawal from any cause, such as lack of efficacy,
the presence of AEs or non-compliance to treatment. Previous TAs in adults assumed a constant withdrawal
rate of 20% per annum for all treatments.
A literature search, described in Chapter 3, was conducted with the aim of identifying registry data on
long-term treatment response to biologics in children and young people with psoriasis. Two registries were
identified: Child-CAPTURE90 (Netherlands) and DERMBIO92 (Denmark). However, none of the published
studies from these registries allowed the estimation of long-term withdrawal rates in individuals who are
responders to treatment; in addition, the DERMBIO registry included only a small number of children.
The data indicated that there was no significant predictive relationship between age and treatment
continuation, which may suggest that treatment withdrawal rates used in the adult population can be
extrapolated to children and young people in the absence of any alternative source of data. Data from the
DERMBIO registry suggest that the withdrawal rate on biological therapies is constant over the treatment
period (with no obvious plateau),92 which supports the use of a constant withdrawal rate over time.
A recent study on the long-term drug survival rates of four biologics (adalimumab, etanercept, infliximab
and ustekinumab) based on data from the UK BADBIR audit of 3523 biologic-naive adult patients indicated
that loss of efficacy is a major reason for treatment discontinuation, with efficacy decreasing from 77% in
the first year of use to 53% in the third year of use.94 This is consistent with a withdrawal rate of 20% per
annum, which has been used in previous TAs in adults. This study also suggested that there may be
differences in the withdrawal rate by treatment, with ustekinumab having a significantly higher survival
rate than adalimumab and etanercept. However, the study did not distinguish between discontinuation
because of a lack of treatment response in the short term, that is, during the initial trial period, and
discontinuation because of a lack of treatment response in the long-term for patients who are responders
to treatment. Therefore, the differences in withdrawal rates by treatment may reflect the higher efficacy of
ustekinumab than adalimumab and etanercept, rather than reflecting differences between the treatments
conditional on response at the initial assessment point.
In the absence of sufficient evidence on the long-term withdrawal rates in children and young people,
and given that observational data generally suggest that a constant 20% annual withdrawal rate is a
reasonable assumption in adults, the same withdrawal rate was assumed in the model (this rate equates to
a 28-day discontinuation rate of 1.70% per cycle).
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All-cause mortality
All-cause mortality was incorporated in the model by applying a risk of death during each cycle. The
mortality risk was assumed to be independent of response status or treatment received. A common
mortality risk was thus assumed for all patients based on the general population mortality risk. The general
population mortality risk was obtained from sex-specific life tables for England and Wales for the period
between 2013 and 2015, with the risk averaged across males and females, assuming equal proportions.151
Health-related quality of life
Review of utility data in children and young people with psoriasis
A systematic literature review was conducted to identify utility values for plaque psoriasis in children and
young people. The aim of the search was to identify any studies that reported utility values or other
measures of HRQoL that could be converted into utility values specifically for the population of children
and young people.
The search strategy was developed in MEDLINE (via Ovid) by an information specialist with input from the
project team. The strategy included terms for psoriasis combined, using the Boolean operator AND, with
terms for quality of life/utilities or named instruments. No language, geographical or date limits were
applied. A search filter to limit retrieval to quality-of-life studies was used when available. The search
strategy was adapted for use in the other resources searched. Full search strategies can be found in
Appendix 1.
The following databases were searched on 12 July 2016: MEDLINE [including MEDLINE Epub Ahead of
Print, MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)],
the Cost-effectiveness Analysis (CEA) Registry [see https://research.tufts-nemc.org/cear4/ (accessed
10 August 2017)] EMBASE, PubMed and the School of Health and Related Research Health Utilities
Database (ScHARRHUD) [see www.scharrhud.org/ (accessed 10 August 2017)].
The Health Economics Research Centre (HERC) database of mapping studies from the University of Oxford152
was also searched to identify any suitable mapping algorithms that would allow conversion of clinical
measures routinely collected in studies of psoriasis in children and young people into utility values.
The results from the searches were imported into an EndNote X7 library and deduplicated. After deduplication,
286 records in total were identified. The titles and abstracts were assessed independently by two reviewers for
inclusion and any discrepancies were resolved by consensus. None of the titles identified reported utility values
collected in children and young people with psoriasis. The search of the HERC mapping algorithm database
identified one study on the development of a mapping algorithm to estimate EQ-5D-Y (EuroQol-5 Dimensions
for Youth) utility values from PedsQL general core scales.153 The PedsQL is a generic instrument for measuring
HRQoL in children and adolescents with acute and chronic health conditions. The PedsQL measures core
dimensions of health as delineated by the WHO, as well as role (school) functioning. The four multidimensional
scales are physical functioning (eight items), emotional functioning (five items), social functioning (five items) and
school functioning (five items).19 The EQ-5D-Y is the youth version of the EQ-5D, which has been specifically
adapted in terms of language for children aged 8–11 years and adolescents aged 12–18 years. In the absence
of a tariff set specifically for the EQ-5D-Y, the authors153 applied the UK national tariff for the valuation of the
EQ-5D-3L (EuroQol-5 Dimensions three-level version) to generate utility values from the EQ-5D-Y instrument.154
Khan et al.153 assessed different mapping methods for estimating EQ-5D-Y health utilities from PedsQL
response scores. The study used data collected in a cross-sectional survey conducted in four secondary
schools in England among children aged 11–15 years. The sample on which the mapping models were
estimated included 559 children and the validation sample included 337 children. Children in the full study
sample (n = 896) were on average aged 13.3 years (standard deviation 1.3 years), 54% were male and
approximately 40% were of non-white ethnicity. The authors explored both direct and response mapping
approaches to predict EQ-5D-Y utility values, as well as a number of functional forms, including ordinary
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least squares (OLS) regression, generalised linear models, two-part logit–OLS regression, censored least
absolute deviation and Tobit regression. Model performance was assessed on the validation sample and
models were re-estimated on the full study sample. Table 58 presents the two best-fitting models for the
mapping algorithm. These correspond to the models estimated using OLS regression with (1) age and sex
terms included as regressors and (2) excluding age and sex terms as regressors.
The two models were considered to have similar prediction accuracy for mean EQ-5D-Y values. Model 1,
which included age and sex as regressors, had a better fit across a wider range of EQ-5D-Y values than
model 2. Model 2 reported a better fit for the EQ-5D-Y utility score range of 0.8–1.0 category. There are a
number of potential limitations to the use of this algorithm to predict EQ-5D-Y utilities. The sample on
which the models were estimated consisted of healthy children aged 11–15 years, which may limit the
predictive accuracy in sicker populations or populations outside this age range. The authors recognise that
there is a need for further validation and testing of the algorithm but, in the absence of an alternative
source, it remains a useful tool for estimating EQ-5D-Y utility values in situations in which only the PedsQL
has been administered.
TABLE 58 Best-fitting mapping algorithms from the PedsQL to EQ-5D-Y based on the study by Khan et al.153
Variables
Mapping algorithm
OLS regression with age and
sex terms (1)
OLS regression without age and
sex terms (2)
Coefficient SE Coefficient SE
Age (years) –0.006136 0.004741 – –
Sex –0.009385 0.012292
PedsQL domain scores
Physical functioning (PF) 0.009067 0.002571 0.009127 0.002568
Emotional functioning (EF) 0.006807 0.002533 0.006611 0.002530
Social functioning (SF) 0.00563 0.002831 0.005705 0.002829
School functioning (SchF) 0.005802 0.002371 0.006011 0.002367
Quadratic terms
PF squared 0.00002 0.000025 0.00002 0.000025
EF squared –0.000049 0.000018 –0.000048 0.000018
SF squared 0.000011 0.000016 0.000011 0.000016
SchF squared –0.000017 0.000015 –0.000017 0.000015
Interaction terms
PF*EF –0.000005 0.000027 –0.000004 0.000027
PF*SF –0.000053 0.000029 –0.000055 0.000029
PF*SchF –0.000066 0.000030 –0.000066 0.000030
EF*SF –0.000011 0.000023 –0.000009 0.000023
EF*SchF 0.000061 0.000021 0.000059 0.000021
SF*SchF –0.000026 0.000022 –0.000027 0.000022
Constant –0.335861 0.118035 –0.428496 0.094210
SE, standard error.
DOI: 10.3310/hta21640 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 64
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97
Utility data reported in company submissions
Health-related quality-of-life assessments were carried out in the etanercept trial (2003021149), the
ustekinumab trial (CADMUS72) and the adalimumab trial (M04-71742) using the CDLQI and the PedsQL at
selected time points. EQ-5D or EQ-5D-Y values were not collected in any of the trials. Therefore, the only way
to include EQ-5D utility values in the model was by mapping from either CDLQI scores or PedsQL scores. The
literature review described earlier did not identify any studies that estimated the relationship between CDLQI
scores and EQ-5D values, whereas the study by Khan et al.153 was the only study that estimated the relationship
between PedsQL scores and EQ-5D values. The AG requested from the companies access to individual patient
data (IPD) for PedsQL domain scores at baseline and follow-up by category of PASI response and PedsQL
summary scores at the domain level by response category. The AG did not receive access to IPD; however,
Janssen (ustekinumab) submitted aggregated summary data (mean and standard deviation) from the CADMUS
trial for the PedsQL subscale and total scale scores by treatment arm (placebo and ustekinumab standard dose)
and PASI response category at 12 weeks (< 50, 50–74, 75–89, ≥ 90) for baseline and 12, 28 and 52 weeks.
Utility estimates used in the model
The utility values associated with treatment in previous models in adults were based on the proportion of
individuals in the different PASI response categories (< 50, 50–74, 75–89, ≥ 90) and the change in utility
from baseline associated with the PASI response categories. Therefore, PASI response rates from the NMA
were assumed to be a perfect proxy for change in utility arising from treatment.
The relationship between utility and PASI response was estimated in previous TAs in adults using either
DLQI data mapped onto EQ-5D utility values or directly from EQ-5D data collected in the trials. In the
population of children and young people, the only possibility of obtaining EQ-5D values was by mapping
from PedsQL scores to EQ-5D-Y values, as described earlier. Without access to the IPD, which would allow
full uncertainty to be reflected in the values, the mapping algorithm was applied to the summary scores at
the domain level from the CADMUS trial.
Validation of the algorithm was performed by examining data reported in a study by Varni et al.,155 which
compared self-reported HRQoL (based on PedsQL scores) between paediatric patients with moderate to
severe plaque psoriasis and a healthy population sample. The sample used to represent the psoriasis
population corresponded to individuals in the main efficacy trial for etanercept (n = 208, age 4–17 years)
and measurements of PedsQL scores at baseline were pooled across the two treatment arms (etanercept
and placebo). The healthy population sample was taken from a US children’s health insurance programme
evaluation (n = 5079) open to children and young people aged 2–16 years. Table 59 summarises the
TABLE 59 Application of the mapping algorithm to estimate EQ-5D-Y utilities in paediatric populations
Covariates
Population
Psoriasis (n= 208) Healthy (n= 5079)
Mean
EQ-5D-Y utility
in model 1
EQ-5D-Y utility
in model 2 Mean
EQ-5D-Y utility
in model 1
EQ-5D-Y utility
in model 2
Age (years) 12.71 0.869 0.864 9.72 0.936 0.913
Sexa 0.519 0.517
Physical functioning score 82.5 87.8
Emotional functioning score 67.1 79.2
Social functioning score 80.7 85
School functioning score 70.2 70.2
PedsQL total score 75.5 83.9
a Assumes that the reference category is female.
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PedsQL subscale scores reported in Varni et al.155 for the psoriasis and healthy populations, alongside the
estimates obtained by applying the two best-fitting mapping algorithms to obtain EQ-5D-Y utility values
(model 1 includes age and sex terms whereas model 2 excludes these variables).
The EQ-5D utility estimates were higher in the healthy population than in the population with psoriasis,
irrespective of the model used to map PedsQL scores to EQ-5D-Y values. The distinction between the
models was minimal, especially in the psoriasis population: model 1 provided slightly higher utility values
than model 2 (0.6% and 2.5% higher in the psoriasis and healthy populations respectively). Model 2 was
subsequently used in the base-case analysis as the reference category for the variable sex was unclear in
the study by Khan et al.153
The mapping algorithm (model 2 in Table 58) was used to estimate change in EQ-5D-Y utility values from
baseline based on PedsQL data from the ustekinumab trial (CADMUS) at baseline and 12 weeks’ follow-up
(the time point at which response to treatment was assessed in the trial and blinding of randomised subjects
in the trial was terminated; after this point crossover between treatment arms was possible). The mean
change in EQ-5D-Y values between baseline and week 12 was estimated for individuals with different levels
of PASI response. Table 60 reports the EQ-5D-Y utility values estimated for the base-case-analysis, with the
placebo and treatment arms pooled.
The baseline utility estimate is similar to that derived from the etanercept trial (20030211) (0.864 in Table 59)
and is lower than the general healthy population estimate of 0.913 based on the study by Varni et al.155
The mean changes in EQ-5D utility from baseline by PASI response category are much smaller than the
corresponding changes in EQ-5D utility observed in previous TAs in adults. For example, the EQ-5D changes
in utility by PASI response category in the York model of adults were 0.05 for PASI < 50, 0.17 for PASI
50–74, 0.19 for PASI 75–89 and 0.21 for PASI ≥ 90.
To examine whether or not the changes in EQ-5D-Y utility values were accompanied by similar changes in
other measures of HRQoL in the population of children and young people, the changes in EQ-5D-Y values
were compared with reported CDLQI values by PASI response (Table 61). A comparison of EQ-5D and DLQI
values by PASI response in adults is also shown in Table 61 (taken from TA180100 for ustekinumab, which
was the only TA in adults that reported both outcomes). The mean changes in CDLQI score by PASI
response in the CADMUS trial are much smaller than the mean changes in DLQI score in TA180,100 which
is consistent with the smaller mean changes estimated for the EQ-5D-Y in the paediatric population than
for the EQ-5D in adults. These differences, however, should be interpreted with caution as CDLQI and
DLQI scores are not directly comparable and the number of observations was much smaller in the
population of children and young people than in the adult population in TA180.100
The EQ-5D-Y/EQ-5D utility estimates suggest that improvements in HRQoL associated with reductions in
PASI response rates are of a much smaller magnitude in children and young people than in adults;
however, the evidence is highly uncertain because of the small sample size and the limited data available
to validate the findings. In the absence of an alternative source to estimate EQ-5D values for the model,
TABLE 60 Baseline utility and mean change in utility by PASI response, estimated from CADMUS trial PedsQL data
mapped onto the EQ-5D-Y
Baseline utilitya
(n= 73)
Utility increment at the end of the trial period by PASI response category
< 50 (n= 30) 50–74 (n= 10) 75–89 (n= 9) ≥ 90 (n= 24)
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
a Estimated by pooling the EQ-5D-Y utility values at baseline for patients in the ustekinumab 0.75 mg/kg and placebo
arms of the CADMUS trial.
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these values were used in the base-case analysis. It is important to highlight a number of limitations of this
approach. First, the use of a mapping algorithm to estimate utilities introduces uncertainty compared with
direct EQ-5D measurement. Second, the Khan et al.153 mapping algorithm has not been validated in
children aged < 11 years or in a population with psoriasis. Third, the CADMUS trial, from which the PedsQL
data that were mapped to EQ-5D utilities were sourced, excluded children aged < 12 years; therefore, it
remains uncertain whether or not the mapped utilities are reflective of this population. Fourth, in populations
aged < 12 years, there may be issues with lack of agreement or consistency between self-reported and proxy
(parent)-reported measurements.156 Therefore, even if PedsQL data were available for younger children, the
mapping algorithm might not consistently perform for self-reported and parent-reported measurements of
the instrument. Finally, Khan et al.153 used the EQ-5D-3L value set as a proxy for EQ-5D-Y in the absence
of an alternative tariff set, but this approach is currently not recommended.157 These limitations reduce the
robustness of the utility estimates used in the model.
There might be other potential benefits of treatment that fall outside the QALY estimation. First, children
and young people may miss schooldays to attend health-care appointments and may be absent for longer
periods from school while experiencing symptoms. This can have a negative impact on their education/
academic achievements and, in future, their ability to gain employment. It may also affect their social and
psychological health through the reduced ability to participate in social and leisure activities and sport.
Second, early treatment of children and young people with biological agents may prevent long-term
multisystem morbidity (e.g. hypertension, cardiovascular disease, depression), which has a higher
prevalence in adults with psoriasis than in the general population.158 Finally, there may also be other
aspects of HRQoL that are outside the perspective defined by NICE’s reference case,150 namely the
potential impact on the HRQoL of carers of children and young people with psoriasis if treatment with
biologics reduces the spillover disutility of illness by improving patients’ outcomes. The impact on carers
may also extend to a reduced ability to participate in normal activities, both work- and non-work related.
Because of an absence of quantitative estimates of the impact on the HRQoL of children and young people
with psoriasis receiving any of the interventions and the potential benefits to their carers, it was not
possible to incorporate them into the economic analysis. Any attempt to add arbitrary values to the utility
estimates, which are already highly uncertain, would introduce further uncertainty.
Given the uncertainty surrounding the utility estimates for children and young people, scenario analyses
were conducted using utility estimates from previous TAs in adults for etanercept, adalimumab and
ustekinumab. Table 62 summarises the utility estimates considered in the scenario analyses.
TABLE 61 Mean change from baseline in CDLQI/DLQI scores and EQ-5D/EQ-5D-Y utilities by PASI response
PASI response
category
CADMUS trial TA180101
Sample
size, n
Mean change
in CDLQI score
Mean change in
EQ-5D-Y utility
Sample
size, n
Mean change
in DLQI score
Mean change in
EQ-5D utilitya
< 50 30 –1.2 Confidential
information has
been removed
430 –2.5 0.04
50–74 10 2.0 Confidential
information has
been removed
160 –10.3 0.17
75–89 9 –5.6 Confidential
information has
been removed
207 –13.4 0.22
≥ 90 24 –8.1 Confidential
information has
been removed
318 –15.3 0.25
a Pooled EQ-5D trial data.
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Utility estimates by health state
The HRQoL utility values were applied in the model based on PASI response to treatment. The utility values
in the trial period and period of continued use for each treatment were based on the proportions of
individuals in the different PASI response categories (< 50, 50–74, 75–89, ≥ 90) and the change in utility
from baseline associated with a PASI response. During the trial period, individuals are assigned utility
values based on treatment response at the end of the trial period:
uTPtrt = ½u00 × (1−p
PASI50
trt ) + u50 × (p
PASI50
trt −p
PASI75
trt ) + u75 × (p
PASI75
trt −p
PASI90
trt ) + u90 × (p
PASI90
trt ), (1)
where u00 is the utility gain for individuals not achieving a PASI 50 response; u50 is the utility gain for
individuals achieving a PASI 50 response but not a PASI 75 response; u75 is the utility gain for individuals
achieving a PASI 75 response but not a PASI 90 response; u90 is the utility gain for individuals achieving a
≥ PASI 90 response; and pPASIxxtrt is the probability of a PASI XX response with treatment.
During the period of continued use, individuals are assigned utility values based on maintaining a
treatment response at the end of the trial period, which is based on meeting the minimum of a PASI
75 response:
uCUtrt = ½u75 × (p
PASI75
trt −p
PASI90
trt ) + u90 × (p
PASI90
trt )/p
PASI75
trt . (2)
Individuals who discontinue treatment progress to BSC. The utility associated with BSC was based on the
proportion of individuals in the different PASI response categories (< 50, 50–74, 75–89, ≥ 90) for BSC
(assumed to be equal to the placebo response from the NMA):
uBSC = ½u00 × (1−p
PASI50
BSC ) + u50 × (p
PASI50
BSC −p
PASI75
BSC ) + u75 × (p
PASI75
BSC −p
PASI90
BSC ) + u90 × (p
PASI90
BSC ). (3)
A scenario analysis was considered in which the utility of individuals receiving BSC was set to be equal to
baseline utility, that is, there are no health benefits from BSC.
On entering the death state, individuals are assigned a utility value of zero. Table 63 summarises the utility
estimates applied in the base-case analysis by treatment and health state.
Given the paucity of evidence on AEs in children and young people receiving biological treatment for
psoriasis, and similarly to the majority of previous TAs in adults, no disutility from treatment was applied in
the model.
TABLE 62 Baseline utility and mean changes in utility by PASI response used in the base-case and scenario analyses
Analysis Baseline utility
Utility gain by PASI response category
< 50 50–74 75–89 ≥ 90
Base-case analysis Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
TA10397 utility values 0.7a 0.050 0.170 0.190 0.210
TA14699 utility valuesb 0.692c 0.063 0.178 0.178 0.308
TA180100 utility valuesb 0.7a 0.04 0.17 0.22 0.25
a Based on Revicki et al. 143 as it was not reported in the TAs.
b DLQI > 10.
c Constrained to this value so that the absolute utility value would not go above 1 for patients undergoing the maximum
utility increment.
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Resource utilisation and costs
Resource use and costs included in the model correspond to direct NHS costs and include treatment
acquisition costs, administration costs, monitoring costs, costs associated with AEs and the costs of BSC.
Costs were sourced from NHS reference costs 2014–15,159 the Monthly Index of Medical Specialities
(MIMS),160 the BNF,161 Curtis and Burns and published literature. When costs were not available for
2015–16, they were inflated to 2014–15 prices based on the Hospital & Community Health Services Index
published in Curtis and Burns. The systematic literature review described in Chapter 3 (see Methods for the
synthesis of evidence of clinical effectiveness) considered broad search terms to capture resource utilisation
and costs associated with the treatment of psoriasis in the population of children and young people. The
search identified five studies162–166 that estimated resource use and the costs of biological therapies in
psoriasis from insurance claim databases, but on further examination of the populations included in the
studies it became clear that only adults were considered in the databases. In addition, the studies used data
from US insurance databases, which are unlikely to reflect health-care resource use in the UK.
Given the lack of data on resource use and the costs of treatment for psoriasis in children and young
people, previous NICE TAs for adults were hand-searched to identify relevant resource use categories and
potential sources of resource use estimates and unit costs. These were tabulated and sent to our clinical
advisor (see Chapter 5, Resource use and costs in the York model and subsequent appraisals), who then
worked with us to help establish the transferability of the adult data and resource use assumptions to the
population of children and young people.
According to our clinical advisor, the management of psoriasis in children and young people is very similar
to that in adults. Therefore, it seems reasonable to assume that the resource use associated with the
administration of the treatments and monitoring costs in children and young people would be similar to
those used in previous TAs in adults. The assumptions used for resource use and costs for each of the cost
categories are described in the following sections.
Drug acquisition costs
Table 64 details the dose and frequency of administration for each treatment and comparator, including
ciclosporin, which forms part of BSC, and the unit costs associated with each treatment.
The dosages of the biological therapies were taken from the Summaries of Product Characteristics.167–169
For methotrexate and ciclosporin, which are currently not licensed for paediatric use, the dosages were
sourced from published literature78,170,171 and confirmed with our clinical advisor to ensure that they reflected
UK clinical practice in this population. Methotrexate can be administered orally or injected subcutaneously
or intramuscularly. In the model it was assumed that 72% of individuals are given methotrexate in oral
solution and 28% in injectable solution, which reflects the distribution of administration identified in the UK
psoriasis audit of the use of systemic treatments in children and young people.148 Therefore, the unit cost
per mg for methotrexate is a weighted average of the unit cost per mg of the oral and injectable solutions
(i.e. £0.71/mg). Unit costs were sourced from MIMS160 and supplemented with data from the BNF.161
TABLE 63 Utility values by treatment and health state used in the base-case analysis
Treatment
Health state in the model
Trial period Continued use BSC
Adalimumab 0.9156 0.9261 0.8713
Etanercept 0.8974 0.9177 0.8713
Ustekinumab 0.9186 0.9274 0.8713
Methotrexate 0.8994 0.9164 0.8713
BSC – – 0.8713
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Figure 11 illustrates the number of doses administered in the first five cycles of the model for each
treatment based on the licensed dose. Adalimumab is administered at weeks 0 (baseline) and 1 and then
every 2 weeks thereafter until response assessment at the end of week 16. If individuals are responders to
treatment they continue to receive adalimumab every 2 weeks until treatment withdrawal (highlighted in
grey). Ustekinumab is administered at weeks 0 and 4 and then every 12 weeks thereafter, with response
assessment at week 16. Etanercept and methotrexate are administered weekly, with response assessment
at weeks 12 and 16 respectively.
The dosages of the biological treatments are dependent on patient weight. The median weight by age and
sex in the population of children and young people was extracted from the Royal College of Paediatrics
and Child Health’s school-age growth charts.172 Table 65 shows the weights used in the model by age.
These were based on an average of the weight of boys and girls (and when the weight estimate in the
growth chart did not correspond to an integer, the next-highest integer was used).
TABLE 64 Drug acquisition costs in children and young people
Treatment
Administration
route Dose and frequency
Presentation and
unit cost Source
Adalimumab SC 0.8 mg/kg up to a maximum of
40mg at weeks 0 and 1, then
every 2 weeks thereafter
Prefilled syringe,
40 mg – £352.14
MIMS160
Etanercept SC 0.8 mg/kg up to a maximum of
50mg weekly for up to 24 weeks
Prefilled syringe,
25-mg/vial – £89.38;
prefilled syringe,
50 mg – £178.75
MIMS160
Ustekinumab SC 0.75 mg/kg for those weighing
< 60 kg, 45 mg for those
weighing 60–100 kg and 90mg
for those weighing > 100 kg
at weeks 0 and 4, then every
12 weeks thereafter
Injectable solution,
45-mg vial – £2147.00
MIMS160
Methotrexate Oral (72%), SC
(24%), IM (4%)
0.1–0.4 mg/kg weekly Oral solution (2 mg/ml),
65 ml – £125.00;
injectable solution,
50-mg vial – £2.62
MIMS,160 BNF161
Ciclosporin Oral 2–5mg/kg daily for up to 2 years Oral solution
(100 mg/ml),
50 ml – £102.30
BNF161
IM, intramuscular; SC, subcutaneous.
Weeks 0 – 1 1 – 2 2 – 3 3 – 4 4 – 5 5 – 6 6 – 7 7 – 8 8 – 9 9 – 10 10 – 11
11 –
12
12 –
13
13 –
14
14 –
15
15 –
16
16 –
17
17 –
18
18 –
19
19 –
20
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5
ADA
ETA
UST
MTX
FIGURE 11 Drug dose distribution during the first five cycles in the model. ADA, adalimumab; ETA, etanercept;
MTX, methotrexate; UST, ustekinumab; •, ADA administration; ♦, ETA administration; ▪, UST administration;
Δ, MTX administration.
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The weight by age was used to estimate the correct dosage of each treatment and the corresponding cost.
Table 66 summarises the dosages used in the model for each treatment by age and the corresponding
costs per dose. Following clinical advice it was assumed that the vial with the lowest dose available would be
used to allow administration of a single dose in the paediatric population. This inevitably results in wastage of
the remainder of the vial. For example, for individuals who weigh < 60 kg the full cost of the 45-mg vial of
ustekinumab is assumed as the remaining product in the vial cannot be stored. Vial splitting across individuals
was considered unlikely because in most cases the majority of the vial is used for a single patient and treating
patients together is less likely to occur in this population because of low patient numbers. Therefore, the
cost per dose was fixed for adalimumab and ustekinumab (£352.14 and £2147.00 respectively). For etanercept,
the 25-mg vial (£89.38) is used for children aged < 10 years whereas the 50-mg vial (£178.75) is used for those
aged ≥ 10 years.
Drug administration costs
Adalimumab, etanercept and ustekinumab were assumed to be self-administered. In the case of younger
children it was assumed that a parent or carer would administer the subcutaneous injection. Subcutaneous
injections were assumed to incur administration costs only for nurse training for self-administration (or
parent/carer administration) in the induction phase. In line with previous TAs in adults, this was assumed to
require 3 hours of nurse time, which was costed based on the cost per working hour of a band 5 hospital
nurse with qualifications (£43 per hour). A cost of £129 was applied in the first cycle of the model for the
administration of the biologics.
Monitoring costs
Table 67 summarises the resource use assumptions made in relation to monitoring and the corresponding unit
costs applied in the model. In the absence of evidence specifically relating to the population of children and
young people, resource use estimates associated with monitoring and routine laboratory tests for biological
and non-biological systemic treatments were taken from NICE CG153,173 which used similar assumptions to
those in the original York model (TA10397) and subsequent NICE appraisals of biological treatments.98–102
TABLE 65 Median weight by age used in the model
Age (years)
Median weight (kg)
Girls Boys Used in the model
4 17 18 17.5
5 19 19 19
6 21 21 21
7 23 23 23
8 26 26 26
9 29 29 29
10 33 32 32.5
11 36 35 35.5
12 41 39 40
13 46 44 45
14 50 50 50
15 54 56 55
16 56 61 58.5
17 57 66 61.5
18 58 67 62.5
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TABLE 66 Drug dosages and cost per dose by age in the model
Age Weight (kg)
Drug
Adalimumab (0.8 mg/kg,
maximum 40mg)
Etanercept (0.8 mg/kg,
maximum 50mg)
Ustekinumab (0.75mg/kg
for weight < 60 kg; 45mg
for weight 60–100 kg)
Methotrexate
(0.4 mg/kg) Ciclosporin (5 mg/kg)
Dosage
(mg)
Cost per
dose (£)
Dosage
(mg)
Cost per
dose (£)
Dosage
(mg)
Cost per
dose (£)
Dosage
(mg)
Cost per
dose (£)
Dosage
(mg)
Cost per
dose (£)
4 17.5 14 352.14 – – – – 7 6.73 87.5 1.79
5 19 15.2 352.14 – – – – 7.6 7.31 95 1.94
6 21 16.8 352.14 16.8 89.38 – – 8.4 8.08 105 2.15
7 23 18.4 352.14 18.4 89.38 – – 9.2 8.85 115 2.35
8 26 20.8 352.14 20.8 89.38 – – 10.4 10.00 130 2.66
9 29 23.2 352.14 23.2 89.38 – – 11.6 11.15 145 2.97
10 32.5 26 352.14 26 178.75 – – 13 12.50 162.5 3.32
11 35.5 28.4 352.14 28.4 178.75 – – 14.2 13.65 177.5 3.63
12 40 32 352.14 32 178.75 30.0 2147.00 16 15.38 200 4.09
13 45 36 352.14 36 178.75 33.8 2147.00 18 17.31 225 4.60
14 50 40 352.14 40 178.75 37.5 2147.00 20 19.23 250 5.12
15 55 40 352.14 44 178.75 41.3 2147.00 22 21.15 275 5.63
16 58.5 40 352.14 46.8 178.75 43.9 2147.00 23.4 22.50 292.5 5.98
17 61.5 40 352.14 49.2 178.75 45.0 2147.00 24.6 23.65 307.5 6.29
18 62.5 40 352.14 50 178.75 45.0 2147.00 25 24.04 312.5 6.39
The absence of values in the green shaded areas reflect the fact that the interventions are not licensed for these ages.
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Individuals on biological therapy were assumed to undertake a series of tests during the initial trial period,
namely a full blood count, liver function test and urea and electrolytes test. During the trial period the tests
were assumed to be carried out during two routine outpatient visits that occur at treatment initiation and
at the end of the trial period (treatment response assessment visit). As methotrexate was not included as a
comparator in CG153173 (only as part of BSC), it was assumed that the resource use for the monitoring of
methotrexate in the trial period is the same as that for biological treatment. In the maintenance period
(corresponding to the health state of ‘continued use’), individuals on systemic therapies were assumed to
be monitored once every 3 months.173 The unit costs for glomerular filtration rate and outpatient visits
were taken from NHS reference costs 2014–15,159 whereas the costs of the remaining monitoring items
were inflated to 2014–15 prices based on estimates presented in TA103.97
The costs of tests undertaken solely to screen individuals for eligibility for treatment were excluded from
the analysis, namely chest radiography, tests for tuberculosis or biopsies of lesions atypical of psoriasis.
These costs were also excluded in previous appraisals in adults. The cost of folic acid used in conjunction
with methotrexate to prevent side effects was also excluded from previous appraisals as the annual cost of
this drug is very low (< £1). Our clinical advisor indicated that children and young people would be tested
for herpes zoster before treatment initiation; however, as this test would be performed on every patient
not immune to the virus regardless of treatment, it was excluded from the analysis. The costs of liver
biopsy and type III procollagen peptide (PIIINP) monitoring for the purpose of assessing liver function in
individuals treated with methotrexate were also excluded from the analysis based on clinical advice; liver
biopsy is seldom conducted in children and young people given its invasiveness, whereas PIIINP is a marker
of growth in this population rather than of hepatic toxicity.
Best supportive care costs
Best supportive care corresponds to the management of individuals after failure of conventional systemic
therapies. BSC is also considered a relevant comparator to biological treatments. If biological treatments
are found not to be effective, individuals are usually offered some form of BSC rather than no treatment.
BSC tends to include a mix of active non-biological systemic therapies such as methotrexate and ciclosporin
and palliative care, including phototherapy, as well as outpatient visits and hospitalisations to manage
disease flare-ups.
TABLE 67 Monitoring resource use and unit costs
Item
Frequency of testing
Unit costBiological therapy Methotrexate Ciclosporin
Trial
period
Continued
use (annual)
Trial
period
Continued
use/BSC
(annual)
BSC
(annual)
Per
item (£) Source
Liver function test 2 4 2 4 4 0.77a TA10397,140
Full blood count 2 4 2 4 4 3.05a TA10397,140
Glomerular
filtration
0 0 0 0 1 195.07b NHS reference
costs, 2014–15159
Urea and
electrolytes
2 4 2 4 4 1.41a TA10397,140
Outpatient/
physician visits
2 4 2 4 4 119.99c NHS reference
costs, 2014–15159
a Costs inflated to 2014–15 prices based on the Hospital & Community Health Services Index published in Curtis
and Burns.
b Activity-weighted average of glomerular filtration rate monitoring as an outpatient procedure (currency codes RN27C
and RN27B for ages < 5 years and 6–18 years respectively).
c Activity-weighted average of non-admitted face-to-face attendance, follow-up, consultant- and non-consultant-led visits
(service code 257 Paediatric Dermatology; currency code: WF01A).
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The resource use and costs associated with BSC have represented a significant area of uncertainty in
the analysis of the cost-effectiveness of biological treatments for moderate to severe psoriasis in adults.
In TAs prior to CG153,97–100 the definition of BSC in terms of resource use and costs was restricted to
outpatient visits and hospitalisations to manage the symptoms of psoriasis, with these largely informed
by assumptions and clinical opinion. In CG153,173 the definition of BSC was expanded to also include
non-biological systemic treatments, phototherapy and attendance at tertiary day centres. As discussed
previously (see Chapter 5, Resource use and costs in the York model and subsequent appraisals), this
guideline used estimates of resource use from observational studies in the UK143 and the Netherlands144
but also relied heavily on clinical opinion and assumptions. In the absence of evidence for children and
young people, the definition of BSC from CG153173 was used in the model, with input from our clinical
advisor on the appropriateness of the assumptions for a younger population.
Table 68 summarises the resource use assumptions for BSC by category of cost in CG153173 and those
applied in the model, alongside the associated unit costs. Unit costs were sourced from the BNF,161
MIMS160 and NHS reference costs 2014–15.159 The relative proportions of individuals on active treatment
with methotrexate and ciclosporin were modified from those used in CG153173 based on clinical opinion
that children and young people are less likely to be managed with ciclosporin than adults because of
the renal toxicity of the drug. Data from a UK psoriasis audit on the use of systemic treatments in
children and young people were used to inform the relative proportion of individuals on methotrexate
and ciclosporin.148 In CG153, it was assumed that 90% of individuals receiving BSC would be on active
treatment with systemic drugs. However, in the audit, 53 patients were treated with non-biological
systemic treatments, of whom 25 patients were treated with methotrexate and 12 with ciclosporin.
Therefore, instead of assuming that individuals are equally distributed between methotrexate and
ciclosporin, a ratio (25/37 and 12/37 for those on methotrexate and ciclosporin respectively) for each
treatment was applied to the overall proportion of 90% to reflect the distribution of children and young
people receiving these treatments in the audit. The corresponding proportions of individuals assumed to
receive methotrexate and ciclosporin as part of BSC were 61% and 29%, respectively. As in CG153,173
treatment with ciclosporin was assumed to be discontinued after a maximum duration of 2 years (because
of the increased risk of renal toxicity). Monitoring costs associated with the use of these non-biological
systemic therapies were applied in the model as presented in Monitoring costs.
In line with CG153,173 16% of the population were assumed to undergo 24 sessions of phototherapy per
year (NBUVB) and five outpatient visits per annum were assumed for the 10% of individuals not managed
with systemic therapies. All individuals were assumed to incur the costs of five visits per annum to a
specialist dermatology day centre, in line with CG153.173
The resource use associated with hospitalisations for individuals on BSC was identified as an area of high
uncertainty and a key driver of cost-effectiveness in the previous TAs in adults. The number of bed-days
assumed in CG153173 (26.6 days per year) was based on the average LOS for psoriasis patients with a
baseline PASI of 10–20 points taken from a UK observational study145 combined with the average number
of hospitalisations for individuals at high need (one hospitalisation per year) and very high need (2.55
hospitalisations per year) from a Dutch observational study.144 The total of 26.6 days of hospitalisation per
annum was considered by the NICE Appraisal Committees for TA350101 (secukinumab) and TA368102
(apremilast) in adults to be too high. Our clinical advisor suggested that hospitalisations in children and
young people are very rare. This is largely because children and young people have not yet developed the
comorbidities that often lead to hospitalisations in adults with psoriasis. Therefore, in the base-case
analysis it was assumed that children and young people do not incur any inpatient stays. In separate
scenario analyses, estimates of 26.6 days of hospitalisation per annum173 and 6.49 days of hospitalisation
per annum144 were considered.
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TABLE 68 Resource use assumptions and unit costs for BSC in CG153173 and the current analysis
Cost element
CG153173 Current analysis
Resource use Unit cost Resource use Unit cost Source
Drug acquisition costs
Methotrexate 45% of patients on methotrexate
once weekly
£0.05 per mg 61% of patients on methotrexate once
weekly
£0.71 per mg MIMS,160 BNF161
Ciclosporin 45% of patients on ciclosporin
daily for a maximum of 2 years
£0.02 per mg 29% of patients on ciclosporin daily for a
maximum of 2 years
£0.02 per mg BNF161
Health-care utilisation costs
NBUVB 16% of patients have 24 sessions
of NBUVB per year
£85.16 16% of patients have 24 sessions of
NBUVB per year (same as CG153173)
£95.53a NHS reference costs
2014–15159
Monitoring Four monitoring visits per year for
all patients on systemic treatment
(including at each one outpatient
visit, one FBC, one LFT and one
U&E test) plus 0.04 liver biopsies
and four PIIINP tests per year for
patients on methotrexate and one
GFR test per year for patients on
ciclosporin
£86.85 per monitoring
visit, £553 per liver
biopsy, £25.29 per
PIIINP test, £233.00 per
GFR test
Four monitoring visits per year for all
patients on systemic treatment (including
at each one outpatient visit, one FBC, one
LFT and one U&E test) plus one GFR test
per year for patients on ciclosporin (same
as CG153173 but without liver biopsies and
PIIINP for patients on methotrexate)
£125.22 per
monitoring visit for
all patients on
systemic treatment,
£195.07 per GFR
testb
Calculated (see Monitoring
costs). For GFR, NHS
reference costs 2014–15159
Day centre care Five visits per year £362.60 per visit Five visits per year (same as CG153173) £472.55 per visitc NHS reference costs
2014–15159
Outpatient visits Five visits per year for the 10% of
patients who are not on systemic
treatment
£82 Five visits per year for the 10% of patients
who are not on systemic treatment (same
as CG153173)
£119.99d NHS reference costs
2014–15159
Hospitalisations 26.6 bed-days £271.17 0 (base case). Alternative values explored
in scenario analysis
£295.80e NHS reference costs
2014–15159
FBC, full blood count; GFR, glomerular filtration rate; LFT, liver function test; PIIINP, type III procollagen peptide; U&E, urea and electrolytes.
a Activity-weighted average of phototherapy (currency codes JC47B and JC47A for ages ≤ 12 years old and ≥ 13 years respectively) across total HRGs.
b Activity-weighted average of GFR test (currency codes RN27C and RN27B for ages < 5 years old and 6–18 years respectively) across total HRGs.
c Activity-weighted average of skin disorders without interventions (currency codes JD07F–K) for day cases.
d Activity-weighted average of non-admitted face-to-face attendance, follow-up, consultant- and non-consultant-led outpatient visits (service code 257 Paediatric Dermatology; currency
code WF01A).
e Non-elective excess bed-days across all HRGs.
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Adverse event costs
As discussed in Chapter 5 (see Resource use and costs in the York model and subsequent appraisals), only
one previous TA in adults101 considered the costs of hospitalisations resulting from AEs in the cost-effectiveness
analysis. The AEs that were assumed to lead to relevant resource use consumption (i.e. those leading to
hospitalisations) in this evaluation were (1) NMSC, (2) malignancies other than NMSC and (3) severe
infections. The rates of AEs as reported in the literature (for adalimumab, etanercept, ustekinumab and
infliximab) and from trial data (for secukinumab) were applied to each treatment arm as per the rates of
these events occurring.
The safety data from the clinical trials of biological drugs for the treatment of severe-to-moderate psoriasis
(see Chapter 3, Safety of adalimumab, Safety of etanercept and Safety of ustekinumab) suggested that there
was little difference in the short- and long-term rates of AEs between trial arms, with the potential exception
of etanercept, for which a higher rate of infections (not statistically significant) was observed than for
placebo. However, the trial data included a small number of observations for each treatment and a limited
follow-up period (from 52 weeks for adalimumab46,47 to 312 weeks for etanercept).49,52,80 Observational
studies in children and young people with psoriasis76,77 (see Chapter 3, Additional observational evidence) did
not report any increase in infections or SAEs associated with the use of biological therapies.
Given the paucity of robust evidence on the incidence of AEs in children and young people with moderate-
to-severe psoriasis, the costs of these were not included in the base-case analysis. However, scenario
analyses were conducted to explore the impact on the cost-effectiveness results of including the costs
associated with hospitalisations resulting from serious infections and malignancies (both NMSC and other).
The rates of AEs were sourced from TA350101 and supplemented with data from Dixon et al.174 for
methotrexate, whereas the unit costs were taken from NHS reference costs 2014–15.159 Table 69
summarises the adverse event rates applied in the model, alongside the corresponding unit costs.
The costs of AEs associated with biological therapies and methotrexate were applied in the model to
individuals while on treatment. Individuals treated with BSC were assumed not to develop AEs.
Analytical methods
Base-case analysis
The expected costs and QALYs of the interventions and comparators were determined for each population
and the relative cost-effectiveness was established using standard decision rules and reported using ICERs
as appropriate. The ICER examines the additional cost that one treatment option incurs over another and
TABLE 69 Adverse event rates applied in the model
AE
AE rate (per patient-year)
Unit cost (£)Adalimumab Etanercept Ustekinumab Methotrexate
NMSC 0.0097 0.0354 0.0065 – 2160.37a
Non-NMSC malignancies 0.006 0.00043 0.0016 – 4974.76b
Severe infections 0.0519 0.0513 0.01 0.0414 2679.66c
a Activity-weighted average of intermediate skin procedures (currency codes JC42B and JC43A for ages ≤ 12 years and
≥ 13 years) for non-elective admissions, excess bed-days.
b Activity-weighted average of intermediate skin procedures (currency codes JC42B and JC43A for ages ≤ 12 years and
≥ 13 years) and malignant lymphoma (currency codes SA31A–E) for non-elective admissions, excess bed-days.
c Activity-weighted average of pneumonia (currency codes DZ14F–J, DZ23H–N, DZ11K–V), skin disorders (JS07A–D),
infections of bones or joints (currency codes HD25D–H) and kidney or urinary tract infections (currency codes LA04H–S)
for non-elective admissions, excess bed-days.
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compares this with the additional health benefits to give the additional cost of the treatment for each
additional QALY gained. When more than two treatment options are being compared, the ICERs are
calculated using the following process:
1. The treatment options are ranked in terms of mean QALYs (from the least effective to the
most effective).
2. If a treatment option is more costly and less effective than any other option, then this treatment is said
to be dominated and is excluded from the calculation of the ICERs.
3. The ICERs are calculated for each successive alternative, from the least effective to the most effective.
If the ICER for a given treatment option is higher than that of any more effective option, then this
treatment option is ruled out on the basis of extended dominance.
4. Finally, the ICERs are recalculated, excluding any treatment options that are ruled out by principles of
dominance or extended dominance.
The resulting ICERs provide the basis for establishing which treatment appears optimal based on
cost-effectiveness considerations. Guidance from NICE150 suggests that an incremental cost per additional
QALY of around £20,000–30,000 is considered to represent an appropriate threshold for the health
opportunity costs to the NHS.
The ICER comparing all interventions and comparators relates to a situation in which the decision-maker can
choose only one of the treatment options. However, in psoriasis, as indicated previously, if an individual
patient does not respond to or tolerate one of the biological therapies, an alternative one is usually tried. This
means that treatments are usually trialled on an individual basis until an effective option is found. The ICERs
comparing each intervention with BSC (after systemic therapy) or methotrexate (before systemic therapy) are
also presented, to indicate the optimum ordering of treatments in terms of their cost-effectiveness. The most
cost-effective order in which to give the therapies based on total expected costs and QALYs associated with
each treatment option is dependent on the cost-effectiveness threshold.
Probabilistic sensitivity analysis was used to represent uncertainty in the cost-effectiveness results. The
effectiveness data were entered as simulated posterior distributions from the Markov chain Monte Carlo
analysis to reflect uncertainty in the mean estimates. Monte Carlo simulation was used to propagate the
uncertainty in the input parameters over 10,000 draws, from which mean costs and QALYs were then
obtained by averaging over the 10,000 simulations. The probability that a treatment is first in the sequence
was also estimated.
Differences in the marketing authorisations of the interventions by age and the positioning of adalimumab
before non-biological systemic therapy means that the comparative cost-effectiveness of the interventions
needs to be evaluated by age and before or after use of systemics. The relevant comparator also depends
on the position of the particular intervention in the pathway. Before systemic therapy, methotrexate is the
relevant comparator (as the current standard of care), whereas after systemic therapy BSC represents the
most relevant comparator. Three base-case populations are presented:
1. children and young people aged 4–17 years with adalimumab compared with methotrexate, that is,
as a second-line therapy in individuals who are inadequately controlled by, or who are intolerant to,
topical therapy and phototherapies
2. children and young people aged 6–11 years with adalimumab and etanercept compared with BSC and
with each other, that is, as third-line therapy in individuals who are inadequately controlled by, or who
are intolerant to, systemic therapies or phototherapies
3. children and young people aged 12–17 years with adalimumab, etanercept and ustekinumab compared
with BSC and with each other, that is, as third-line therapy in individuals who are inadequately
controlled by, or who are intolerant to, systemic therapies or phototherapies.
Table 70 summarises the input parameters used in the base-case analysis.
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TABLE 70 Summary of parameters used in the model
Parameter Mean SE Source
Baseline age (years) 4, 6 or 12 – According to the licence for each
comparator
Discount rate (per year) 3.5% – NICE methods guidance150
Time horizon (years) 14, 12 or 6 – Assumption: until individuals reach
18 years
Duration of treatment trial period (weeks)
Adalimumab 16 – Licence definition of timing for
treatment response assessment
Etanercept 12 –
Ustekinumab 16 –
Methotrexate 16 – Response assessment in the
adalimumab trial (M04-717)
Treatment response: adalimumab
Probability of PASI 50 91.5% Simulated posterior
distribution from
the Bayesian NMA
NMA (see Chapter 4, Adjusting for
differences in population and
placebo response rates)Probability of PASI 75 79.0%
Probability of PASI 90 54.6%
Treatment response: etanercept
Probability of PASI 50 75.2% Simulated posterior
distribution from
the Bayesian NMA
NMA (see Chapter 4, Adjusting for
differences in population and
placebo response rates)Probability of PASI 75 54.4%
Probability of PASI 90 27.9%
Treatment response: ustekinumab
Probability of PASI 50 93.4% Simulated posterior
distribution from
the Bayesian NMA
NMA (see Chapter 4, Adjusting for
differences in population and
placebo response rates)Probability of PASI 75 82.4%
Probability of PASI 90 59.4%
Treatment response: methotrexate
Probability of PASI 50 70.8% Simulated posterior
distribution from
the Bayesian NMA
NMA (see Chapter 4, Adjusting for
differences in population and
placebo response rates)Probability of PASI 75 49.2%
Probability of PASI 90 23.9%
Treatment response: BSC
Probability of PASI 50 26.5% Simulated posterior
distribution from
the Bayesian NMA
NMA (see Chapter 4, Adjusting for
differences in population and
placebo response rates)Probability of PASI 75 11.5%
Probability of PASI 90 2.9%
Withdrawal rate (annual) 0.20 Mean/4 Assumption based on previous TAs
in adults
Mortality rate Age dependent – Life table data for England and
Wales 2013–15151
Baseline utility (Confidential
information has
been removed)
– PedsQL data from the CADMUS
trial mapped onto EQ-5D utility
values using the algorithm from
Khan et al.153
Utility increment for PASI < 50 (Confidential
information has
been removed)
–
continued
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TABLE 70 Summary of parameters used in the model (continued )
Parameter Mean SE Source
Utility increment for PASI 50–74 (Confidential
information has
been removed)
–
Utility increment for PASI 75–89 (Confidential
information has
been removed)
–
Utility increment for PASI ≥ 90 (Confidential
information has
been removed)
–
Drug acquisition resource use and costs
Adalimumab administrations in the
‘trial period’
9 – According to licence
Etanercept administrations in the ‘trial
period’
12 –
Ustekinumab administrations in the
‘trial period’
2 –
Methotrexate administrations in the
‘trial period’
16 –
Adalimumab administrations per cycle
in ‘continued use’
2 –
Etanercept administrations per cycle in
‘continued use’
4 –
Ustekinumab administrations per cycle
in ‘continued use’
0.33 –
Methotrexate administrations per cycle
in ‘continued use’ and ‘BSC’
4 –
Ciclosporin administrations per cycle
in ‘BSC’
28 –
Proportion of patients on
methotrexate in ‘BSC’
61% – Assumption
Proportion of patients on ciclosporin
in ‘BSC’
29% –
Dosage of methotrexate (per kg) 0.4 mg – Same as in the adalimumab trial
(M04-717); de Jager et al.78
Dosage of ciclosporin (per kg) 5 mg – Clinical opinion of Dr Ruth Murphy;
Mahé et al.;170 Pereira et al.175
Adalimumab cost per dose £352.14 – MIMS160
Etanercept cost per dose
(< 10 years old)
£89.38 – MIMS160
Etanercept cost per dose
(≥ 10 years old)
£178.75 – MIMS160
Ustekinumab cost per dose £2147.00 – MIMS160
Methotrexate cost per mg £0.71 – BNF161
Ciclosporin cost per mg £0.02 – BNF161
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Scenario analysis
A number of alternative scenarios were considered in which the assumptions used as part of the base-case
analysis were varied. These analyses were undertaken to assess the robustness of the base-case results to
variation in the assumptions and sources of the data used to populate the model. Table 71 summarises the
alternative scenarios considered. For each element, the position in the base-case analysis is outlined,
alongside the alternative assumptions applied. The cost-effectiveness of the interventions was considered
under each of the scenarios for each of the licensed populations.
TABLE 70 Summary of parameters used in the model (continued )
Parameter Mean SE Source
Drug administration costs
Self-administration instruction (hours) 3 – Assumption
Cost of hospital nurse band 5
(per hour)
£43 – Curtis and Burns
Monitoring frequency
FBC, LFT, U&E and physician visits for
adalimumab, etanercept, ustekinumab
and methotrexate in the ‘trial period’
2 – Assumption based on adult data, as
described in Chapter 5, Resource
use and costs in the York model
and subsequent appraisals
FBC, LFT, U&E and physician visits for
adalimumab, etanercept, ustekinumab
and methotrexate per annum in
‘continued use’
4 –
FBC, LFT, U&E and physician visits for
ciclosporin and methotrexate per
annum in ‘BSC’
4 –
GFR for ciclosporin per annum in
‘BSC’
1 –
Monitoring test costs
FBC £3.05 – TA10397,140
LFT £0.77 –
U&E £1.41 –
GFR £195.07 – NHS reference costs 2014–15159
Physician monitoring visit £119.99 –
Palliative care resource use and costs in BSC
NBUVB sessions per cycle 3.84 – Assumption based on CG153173
(adults)
Day centre care visits 5 –
Outpatient visits 0.5 –
NBUVB cost per sessions £95.53 – NHS reference costs 2014–15159
Day centre care cost per visit £472.55 –
Outpatient cost per visit £119.99 –
FBC, full blood count; GFR, glomerular filtration rate; LFT, liver function tests; SE, standard error; U&E, urea and electrolytes.
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TABLE 71 Details of the key elements of the base-case analysis and the variations used in scenario analyses
Scenario Element Position in the base-case analysis Variation in scenario analysis
Intervention and comparators
1 Off-label use of biologics
outside age constraints
Adalimumab licensed for those aged
≥ 4 years
Adalimumab, etanercept and
ustekinumab for those aged
≥ 4 years
Etanercept licensed for those aged
≥ 6 years
Ustekinumab licensed those for aged
≥ 12 years
Model time horizon
2 Time horizon of the
model
14 years, 12 years and 6 years for
the adalimumab, etanercept and
ustekinumab populations respectively
(i.e. until individuals reach 18 years)
Common time horizon of 14 years
Treatment effectiveness estimates
3a Direct trial evidence for
treatment effects in
children and young
people
NMA using full network of evidence
in children, young people and adults
M04-717 trial44,46 used to inform
adalimumab vs. methotrexate
20030211 trial49 used to inform
etanercept vs. BSC
CADMUS trial72 used to inform
ustekinumab vs. BSC
3b Indirect treatment
comparison in children
and young people
Indirect treatment comparison used
to inform etanercept vs.
ustekinumab vs. BSC
3c Treatment effects from
the NMA using minimum
evidence from the adult
population
NMA using minimum evidence
from the adult population
(CHAMPION study106) to link the
trials in children and young people
3d PASI response assessment PASI 75 PASI 50
HRQoL utility values
4a EQ-5D utility estimates
from adults
PedsQL data mapped onto EQ-5D-Y
utility values
EQ-5D values from TA10397
TA14699
TA180100
4b Utility estimates for BSC Utility gains for BSC weighted by
PASI response associated with
placebo from the NMA
Utility in BSC equal to the baseline
value (i.e. no utility gain associated
with BSC)
BSC costs
5 Hospitalisations for BSC No inpatient stay included for
children and young people
6.49 days per annum based on
data in adults from Fonia et al.144
26.6 days per annum based on
data in adults from CG153173
AE costs
6 Costs associated with AEs Not included Costs of severe infections included
Costs of severe infections and
malignancies included
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Results
Results of the base-case cost-effectiveness analysis
Table 72 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy.
Adalimumab is more costly (additional cost of £27,084) but also more effective than methotrexate
(incremental gain in QALYs of 0.088). The resulting ICER is £308,329 per QALY gained. The small
incremental gain in QALYs for adalimumab compared with methotrexate is a result of the modest utility
increments in EQ-5D-Y for the different PASI response categories (< 50, 50–74, 75–89, ≥ 90). The average
proportion of individuals achieving a PASI 75 response is 79% for adalimumab compared with 49% for
methotrexate but the utility gains for individuals achieving a PASI 75–89 response and PASI ≥ 90 response
are very small at 0.0340 and 0.0810 respectively. Therefore, the difference in effectiveness translates into
a small utility gain while on treatment with adalimumab compared with methotrexate. The difference in
total costs for adalimumab compared with methotrexate is driven by the difference in treatment costs:
adalimumab has a cost of £704.28 per 4-week cycle in the model (i.e. £352.14 per dose every 2 weeks)
whereas methotrexate has a cost of approximately £60 per 4-week cycle. The difference in treatment costs is
partly offset by the greater efficacy associated with adalimumab, which results in lower costs associated with
BSC (i.e. less time spent in BSC) for non-responders compared with higher costs on BSC with methotrexate,
but this offset is not sufficient to outweigh the difference in treatment costs. The probability that
adalimumab is cost-effective at a threshold of £30,000 per additional QALY is zero.
Table 73 presents the cost-effectiveness results for the interventions after failed systemic therapy by age
group. The difference by age group reflects the fact that ustekinumab does not have marketing authorisation
for use in children and young people aged <12 years. For the younger age group of 6–11 years, adalimumab
is the most effective treatment (8.890 QALYs), followed by etanercept (8.813 QALYs) and BSC (8.710 QALYs).
In terms of costs, adalimumab is the most costly treatment (£57,251), followed by etanercept (£43,808) and
BSC (£36,406). Based on a fully incremental analysis, the ICER of etanercept compared with BSC is £71,903
per additional QALY, whereas the ICER of adalimumab compared with etanercept is £174,519 per additional
QALY. The individual pairwise ICERs for etanercept and adalimumab compared with BSC are £71,903 and
£115,825 per additional QALY respectively.
TABLE 71 Details of the key elements of the base-case analysis and the variations used in scenario analyses (continued )
Scenario Element Position in the base-case analysis Variation in scenario analysis
Treatment withdrawal rates
7 Withdrawal rates from
treatment
20% per annum 10% per annum
30% per annum
Biosimilars
8 Biosimilar for etanercept Unit cost of etanercept Unit cost of 50 mg of Benepali
(biosimilar)
TABLE 72 Base-case probabilistic results for adalimumab as an alternative to systemic therapy
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 34,914 9.939 – – – MTX
ADA 61,999 10.027 27,084 0.088 308,329
ADA, adalimumab; MTX, methotrexate.
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For children and young people aged 12–17 years, ustekinumab is the most effective treatment (4.960
QALYs), followed by adalimumab (4.950 QALYs), etanercept (4.887 QALYs) and BSC (4.804 QALYs). In
terms of costs, ustekinumab is the most costly treatment (£39,975), followed by adalimumab (£37,852),
etanercept (£33,199) and BSC (£21,749). Based on a fully incremental analysis, etanercept is extendedly
dominated by adalimumab (i.e. etanercept produces additional gains in effectiveness at incremental costs
higher than those of the next most effective strategy of adalimumab, observed by a higher ICER for
etanercept than for adalimumab), the ICER of adalimumab compared with BSC is £110,430 per additional
QALY and the ICER of ustekinumab compared with adalimumab is £201,507 per additional QALY. The
individual pairwise ICERs for etanercept, adalimumab and ustekinumab compared with BSC are £137,059,
£110,430 and £116,568 per additional QALY respectively.
There are two important differences to note between the two age populations. First, the reduction in total
costs and QALYs for the interventions in the older age group is an artefact of the difference in the model
time horizon used in each analysis (i.e. 12 years for age group 6–11 years and 6 years for age group
12–17 years). The time horizon of the model extends until individuals reach 18 years of age, at which
point it was assumed that separate NICE recommendations for the interventions in adults apply. A
separate scenario analysis is presented below that considers a common time horizon of 14 years for both
populations, which is sufficient to capture differences in costs and effects between the interventions.
Second, the total costs of etanercept are proportionally greater in the older age group than in the younger
age group. This is because of the higher drug acquisition costs of etanercept once individuals reach the
age of 10 years, that is, etanercept costs £715 per 4-week cycle in the model (i.e. £178.75 per 50-mg
dose each week) for those aged ≥ 10 years and £357.50 per 4-week cycle in the model (i.e. £89.38 per
25-mg dose each week) for those aged < 10 years.
For children and young people aged 6–11 years, adalimumab is the most effective treatment but the
incremental gain in QALYs compared with etanercept is relatively small because the utility gains in EQ-5D-Y
associated with higher PASI response rates are small. Therefore, the benefits of achieving a greater PASI
response do not translate into a large improvement in health outcomes. The benefit of more individuals
achieving a higher PASI response rate manifests itself in lower costs associated with less time spent in BSC.
The average proportion of individuals achieving a PASI 75 response is 79% for adalimumab and 54% for
etanercept. The higher efficacy associated with adalimumab compared with etanercept, which results in
fewer individuals accumulating the costs associated with BSC (approximately £284 per 4-week cycle), is
not sufficient to offset the additional treatment costs of adalimumab, which are £704.28 per 4-week cycle
TABLE 73 Base-case probabilistic results for interventions after failed systemic therapy
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 43,808 8.813 7402 0.103 71,903 71,903
ADA 57,251 8.890 13,444 0.077 174,519 115,825
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 33,199 4.887 11,450 0.084 ED ADA 137,059
ADA 37,852 4.950 16,103 0.146 110,430 110,430
UST 39,975 4.960 2123 0.011 201,507 116,568
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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(i.e. £352.14 per dose every 2 weeks), compared with £357.50 per 4-week cycle for etanercept in children
aged < 10 years and £715 per 4-week cycle for children aged ≥ 10 years (note that, although the costs for
etanercept increase at age 10 years, there are fewer individuals receiving treatment at this point because the
starting age in the model is 6 years and the treatment withdrawal rate is assumed to be 20% per annum).
For children and young people aged 12–17 years, ustekinumab is the most effective treatment but again the
incremental gain in QALYs compared with the alternative interventions is relatively small because of the small
magnitude of utility gains for the different PASI response categories in the population of children and young
people compared with adults (see Utility estimates by health state). The drug acquisition costs of etanercept in
young people aged ≥ 12 years are greater than those of adalimumab (£715 for etanercept vs. £704.28 for
adalimumab per 4-week cycle) whereas the efficacy for adalimumab is greater than that for etanercept, which
reduces the time spent on BSC for those treated with adalimumab. As a result, it might be expected that the
total costs of adalimumab would be lower than those for etanercept; however, the improved efficacy of
adalimumab also extends the time that individuals receive the intervention and therefore the overall costs of
adalimumab increase. Despite this, the incremental costs of etanercept relative to BSC are greater for each
additional gain in QALYs than the incremental costs of adalimumab relative to BSC for each QALY gain. As a
result, adalimumab extendedly dominates etanercept, which rules out etanercept as a potential cost-effective
treatment option.
Treatment with ustekinumab results in the highest average proportion of individuals achieving a PASI 75
response rate (82% vs. 79% for adalimumab and 54% for etanercept), but also has the highest total
costs. The higher total costs for ustekinumab compared with adalimumab are the result of the marginally
higher drug acquisition costs associated with ustekinumab [£715.67 per 4-week cycle (i.e. £2147.00 per
dose with each dose given at 12 weekly intervals) vs. £704.28 per 4-week cycle (i.e. £352.14 per dose
at fortnightly intervals) for adalimumab] and the greater cost of ustekinumab during the induction period
(i.e. a cost of £2147.00 per dose given at baseline, 4 weeks and 16 weeks) than of adalimumab in the
induction period (i.e. a cost of £352.14 per dose given at baseline, 1 week and then every 2 weeks up to
week 16). The higher efficacy associated with ustekinumab compared with adalimumab, with an average of
3% more individuals achieving a PASI 75 response, results in a reduction in costs associated with individuals
on ustekinumab remaining off BSC for longer, but this reduction is not sufficient to offset the additional
treatment costs associated with ustekinumab.
The pairwise ICERs for each of the interventions compared with BSC indicate the ICER at which the
particular therapy might enter a sequence. Under base-case assumptions, these ICERs are very high,
ranging from £110,430 (adalimumab) to £137,059 (etanercept) per additional QALY in children and young
people aged 12–17 years. The optimal treatment option is BSC up until the threshold reaches £111,000
per QALY gained, when adalimumab would then enter as the first treatment in the sequence. The fact
that BSC is the only form of management available until the threshold reaches £111,000 per QALY
suggests that, under base-case assumptions, none of the biological therapies are sufficiently cost-effective
to enter the sequence until this threshold is used. The probability that any of the biologics are cost-
effective at a threshold of £30,000 per additional QALY is zero.
Cost-effectiveness results for alternative scenarios
Intervention and comparators
Scenario 1: off-label use of biologics outside age constraints and position in the pathway
As discussed in Decision problem and patient population, the biological interventions differ in their
marketing authorisation by age and positioning of treatment in the pathway. Adalimumab is licensed for
the youngest age group from ≥ 4 years and is the only biological treatment positioned as a second-line
therapy in individuals who are inadequately controlled by, or who are intolerant to, topical therapy and
phototherapies, that is, as an alternative to systemic therapy. This makes the comparison of adalimumab
with etanercept and ustekinumab more problematic as the latter interventions are licensed as third-line
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therapies in individuals who are inadequately controlled by, or who are intolerant to, systemic therapies
or phototherapies and who are aged ≥ 6 years in the case of etanercept and ≥ 12 years in the case of
ustekinumab. In this scenario, the off-label use of the biologics outside their age constraints and positioning
in the management pathway is considered.
In the absence of clinical effectiveness evidence in a systemic therapy-naive population, the same efficacy
estimates as in the base-case analysis were used in this scenario. Therefore, the only difference between
this scenario and the base-case assumptions is the comparator, which is methotrexate in the analysis that
considers biologics as an alternative to systemic therapy, and the time horizon of the model, which extends
to 14 years because the starting age in the model is now 4 years.
Table 74 presents the cost-effectiveness results for the use of the interventions as an alternative to systemic
therapy for all ages (4–17 years). Ustekinumab is the most effective treatment, followed by adalimumab,
etanercept and methotrexate, as the efficacy of the treatments follow in this order. In terms of costs,
ustekinumab is the most costly treatment, followed by adalimumab, etanercept and methotrexate. The
reason for this ordering is the same as in the base-case results, with ustekinumab costing £715.67 per
4-week cycle compared with a cost per cycle of £704.28 for adalimumab, £357.50 and £715 for etanercept
for those aged < 10 years and ≥ 10 years, respectively, and approximately £60 for methotrexate, with the
reduction in costs associated with improved efficacy (i.e. less time spent on BSC) not sufficient to offset the
additional treatment costs. Based on a fully incremental analysis, the incremental costs of etanercept and
adalimumab relative to methotrexate are greater for each additional gain in QALY than the incremental
costs of ustekinumab relative to methotrexate for each QALY gain. Therefore, etanercept and adalimumab
are extendedly dominated by ustekinumab. The ICER of ustekinumab compared with methotrexate is very
high at £293,117 per QALY gained. As a result, the optimal treatment option in a systemic therapy-naive
population is methotrexate.
Table 75 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy for all ages (4–17 years). The only difference between this scenario and the base-case analysis is
the starting age of 4 years used in the model. The total absolute costs and QALYs are greater than in the
base case because of the longer model time horizon of 14 years. The ordering of the treatments in terms
of costs and QALYs follows that in the base case, with ustekinumab the most effective but most costly
treatment, followed by adalimumab, etanercept and BSC. Based on a fully incremental analysis, adalimumab
is extendedly dominated by ustekinumab. Compared with the base-case population aged 12–17 years,
etanercept is no longer extendedly dominated because more individuals receive a lower dose of etanercept,
at the cost of a 25-mg vial rather than a 50-mg vial. The ICERs are lower than in the base-case analysis but
the optimal treatment option remains BSC. BSC is the optimal option until the threshold reaches £60,000 per
QALY gained, when etanercept would then enter as the first treatment in the sequence.
TABLE 74 Scenario 1 results for interventions as an alternative to systemic therapy: off-label use of biologics
outside age constraints and position in the pathway
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. MTX
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 4–17 years
MTX 34,914 9.939 – – – – MTX
ETA 46,767 9.948 11,853 0.009 ED ADA 1,319,539
ADA 61,999 10.027 27,084 0.088 ED UST 308,329
UST 64,426 10.040 29,512 0.101 293,117 293,117
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; MTX, methotrexate; UST, ustekinumab.
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Model time horizon
Scenario 2: time horizon of the model
The time horizon of the model was chosen to reflect the fact that once individuals reach 18 years of age
separate NICE recommendations for the use of the interventions in adults apply. To incorporate these
recommendations, evidence on the efficacy of the treatments in biologic-experienced patients (i.e.
effectiveness estimates conditional on previous biological therapy) would be required. This would involve
modelling the sequential use of therapies, with every possible potential treatment sequence considered
based on current recommendations in adults. As well as being outside the scope of this appraisal, this
would represent a significant challenge for two reasons: first, there is very limited evidence on the efficacy
of biologics when used in sequence, that is, in biologic-experienced patients, and, second, current NICE
recommendations for the use of biologic therapies in moderate to severe psoriasis in adults have been
informed by a series of STAs98–102 rather than a MTA that establishes the optimal sequence of treatments
in adults.
Furthermore, the differences in the marketing authorisations of the interventions by age inevitably mean
that the time horizon of the model will differ according to age group. In this scenario, the impact of the
time horizon was assessed by considering a common time horizon of 14 years for all age groups, but with
the same starting age for each group as used in the base-case analysis. The time horizon of 14 years is
sufficient to capture differences in costs and effects between the interventions under comparison because
all individuals on each treatment in the model have moved to BSC by 14 years. This time horizon is also
greater than the 10 years used in previous TAs in adults.
The base case already considers a time horizon of 14 years for adalimumab as an alternative to systemic
therapy because the starting age is 4 years. Therefore, Table 76 presents the cost-effectiveness results for
treatment with the interventions after failed systemic therapy for a common time horizon of 14 years.
By extending the time horizon, the total costs and QALYs for the interventions are greater than in the
base case, but the relative cost-effectiveness of the interventions remains the same, that is, the ICERs
for each intervention relative to the next best treatment option or BSC are similar to those observed in
the base case. Therefore, the model time horizon used in the base-case analysis is sufficient to capture the
differences between the interventions in terms of costs and QALYs.
TABLE 75 Scenario 1 results for treatment with the interventions after failed systemic therapy: off-label use of
biologics outside age constraints
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 4–17 years
BSC 40,478 9.843 – – – – BSC
ETA 46,767 9.948 6289 0.105 59,924 59,924
ADA 61,999 10.027 15,231 0.079 ED UST 117,080
UST 64,426 10.040 17,659 0.092 193,573 121,779
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Treatment effectiveness estimates
Scenario 3a: direct trial evidence for treatment effects in children and young people
As discussed in Chapter 4, a NMA was used in the base-case analysis to connect the evidence from the
adalimumab trial (M04-717) in children and young people to the evidence from the etanercept (20030211)
and ustekinumab (CADMUS) trials by drawing strength from the wider network of evidence in adults. In
this scenario, the relative cost-effectiveness of adalimumab compared with methotrexate and of etanercept
and ustekinumab compared with BSC is considered using the direct efficacy estimates derived from their
corresponding trials. The limitation of this approach is that it does not allow the relative cost-effectiveness
of all three biologics to be assessed in the same analysis. However, it may give an indication of how much
influence the wider network of evidence has on the individual pairwise comparisons.
Table 77 presents the cost-effectiveness results for use of adalimumab as an alternative to systemic
therapy using the efficacy estimates from the M04-717 trial alone. The incremental cost (£20,256) and
QALYs (0.037) for adalimumab compared with methotrexate are lower than the base-case incremental
cost (£27,084) and QALYs (0.088). The PASI 75 response rate is 58% for adalimumab and 32% for
methotrexate in the M04-717 trial compared with 79% and 49%, respectively, in the NMA. The NMA
estimates higher absolute values for PASI 75 response but the incremental difference between adalimumab
TABLE 76 Scenario 2 results for treatment with the interventions after failed systemic therapy: common time
horizon of 14 years
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 41,413 9.842 – – – – BSC
ETA 49,109 9.948 7696 0.105 73,153 73,153
ADA 62,723 10.027 13,614 0.079 172,000 115,592
Children and young people aged 12–17 years
BSC 44,010 9.836 – – – – BSC
ETA 58,286 9.942 14,275 0.105 ED ADA 135,354
ADA 64,204 10.021 20,194 0.184 109,531 109,531
UST 66,503 10.033 2299 0.012 188,715 114,439
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
TABLE 77 Scenario 3a results for adalimumab as an alternative to systemic therapy: direct trial evidence for
treatment effects in children and young people
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 36,601 9.919 – – – MTX
ADA 56,857 9.956 20,256 0.037 549,899
ADA, adalimumab; MTX, methotrexate.
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and methotrexate is of a similar magnitude in the NMA (30% difference in PASI 75 response) and the
M04-717 trial (26% difference in PASI 75 response). This smaller difference in relative effectiveness
between adalimumab and methotrexate in the M04-717 trial means that the incremental cost for each
additional gain in QALYs is greater for adalimumab compared with methotrexate. The resulting ICER
increases from £308,329 per additional QALY in the base-case analysis to £549,899 per additional QALY
using the direct trial evidence.
Table 78 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy using the efficacy estimates from the etanercept trial (20030211) and the ustekinumab trial
(CADMUS). The total costs and QALYs for etanercept and ustekinumab compared with BSC are very
similar to those in the base case. This is because the PASI 75 response rates estimated from the NMA for
etanercept (54%), ustekinumab (82%) and placebo (11.5%) are very similar to the corresponding response
rates from the individual trials (CADMUS: 81% for ustekinumab vs. 11% for placebo; 20030211: 57%
for etanercept vs. 11.4% for placebo). As a result, the pairwise ICERs for etanercept and ustekinumab
compared with BSC are similar to those in the base-case analysis: the ICER for etanercept compared with
BSC increases from £71,903 per QALY in the base-case analysis to £75,350 per QALY using the direct trial
evidence and the ICER for ustekinumab compared with BSC increases marginally from £116,568 per QALY
in the base-case analysis to £116,982 per QALY using the direct trial evidence.
Scenario 3b: indirect treatment comparison estimates in children and young people
In this scenario, the relative cost-effectiveness of etanercept and ustekinumab compared with BSC is
considered using the indirect treatment comparison estimates from the 20030211 and CADMUS trials,
with placebo used as a common comparator. The limitation of this approach is that it does not allow the
relative cost-effectiveness of etanercept and ustekinumab compared with adalimumab to be determined
because of the absence of a placebo arm in the M04-717 trial.
Table 79 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy using efficacy estimates from an indirect treatment comparison of etanercept from the 20030211
trial and ustekinumab from the CADMUS trial. The total costs and QALYs for etanercept, ustekinumab and
BSC are similar to those in the base-case analysis. This is expected as the efficacy estimates from the
individual trials for these interventions are similar to those estimated in the NMA. Etanercept is extendedly
dominated by ustekinumab as the incremental costs of etanercept relative to BSC are greater for each
additional gain in QALYs than the incremental costs of ustekinumab relative to BSC for each QALY gain.
This occurs because ustekinumab has a better efficacy (78% PASI 75 response) than etanercept (57% PASI
75 response), which results in improved health outcomes for ustekinumab. Interestingly, the total cost for
TABLE 78 Scenario 3a results for treatment with the interventions after failed systemic therapy: direct trial
evidence for treatment effects in children and young people
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. BSC (£)
Incremental
QALYs vs. BSC
ICER vs. BSC
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 6–11 years
BSC 36,406 8.720 – – – BSC
ETA 44,108 8.822 7701 0.102 75,350
Children and young people aged 12–17 years
BSC 21,749 4.814 – – – BSC
UST 39,622 4.966 17,873 0.153 116,982
ADA, adalimumab; ETA, etanercept; UST, ustekinumab.
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ustekinumab is greater than that for etanercept despite the fact that the drug acquisition costs are similar
between the two treatments in children and young people aged 12–17 years. This arises because, although
the improved efficacy of ustekinumab reduces the time spent on BSC, it also means that a greater proportion
of time is spent on a cost-ineffective treatment option. The ICER of ustekinumab compared with BSC is
£119,092 per QALY gained. As a result, the optimal treatment option is BSC unless the cost-effectiveness
threshold reaches £120,000 per additional QALY.
Scenario 3c: treatment effects from the network meta-analysis using minimum evidence
from the adult population
In Chapter 4 the disconnected network of evidence in children and young people was connected in the
first instance by bringing together the minimum amount of evidence required from the adult population to
link the adalimumab trial with the other paediatric trials. The CHAMPION study in adults,106 which was a
three-arm trial comparing adalimumab, methotrexate and placebo, represented the best way of connecting
adalimumab to etanercept and ustekinumab using the least amount of evidence borrowed from the adult
population. In this scenario, the relative cost-effectiveness of the interventions was considered in the
base-case populations using the treatment effects estimated from the minimum network of evidence.
Table 80 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy using
the NMA with minimum links to the adult evidence. The incremental cost of £18,422 for adalimumab
compared with methotrexate is lower than the incremental cost of £27,084 in the base-case analysis.
This is because of a larger difference in PASI 75 response rates between adalimumab and methotrexate in
the minimum NMA (approximately 40% difference) than in the full network of evidence (approximately
30% difference). Although there is a higher efficacy difference between adalimumab and methotrexate
in this scenario, the health outcomes also depend on the utility associated with BSC, which is based on
the proportion of individuals in the different PASI response categories in the placebo arm in the NMA. The
PASI response rates for placebo are greater in the minimum NMA than in the full network. Therefore, the
gain in utility associated with better efficacy on adalimumab is offset by a higher gain in utility associated
with BSC. As a result, the incremental QALYs for adalimumab compared with methotrexate are very similar
to those in the base-case analysis. The corresponding ICER for adalimumab compared with methotrexate is
reduced from £308,329 per additional QALY in the base case to £211,259 per additional QALY.
Table 81 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy using the NMA with minimum links to the adult evidence. The incremental costs and QALYs for
etanercept and ustekinumab compared with BSC are similar to those in the base-case analysis, but the
incremental costs and QALYs for adalimumab are reduced in both age groups. This is because the
differences in PASI 75 response rate between the interventions and BSC in the minimum NMA and the full
NMA are similar for etanercept (44% vs. 43%) and ustekinumab (66% vs. 71%) but are much smaller for
TABLE 79 Scenario 3b results for treatment with the interventions after failed systemic therapy: indirect treatment
comparison estimates in children and young people
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 12–17 years
BSC 21,749 4.809 – – – – BSC
ETA 33,662 4.901 11,913 0.092 ED UST 128,903
UST 39,105 4.955 17,356 0.146 119,092 119,092
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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adalimumab (44% vs. 68%). As a result, adalimumab is less cost-effective in children and young people
aged 6–11 years (ICER vs. BSC increases from £115,825 per additional QALY in the base case to £137,329
per additional QALY) and is extendedly dominated by ustekinumab in the 12–17 years age group. The
ICER for etanercept is reduced by £3400 in children aged 6–11 years, but etanercept is also extendedly
dominated by ustekinumab in children aged 12–17 years. The ICER for ustekinumab compared with BSC
increases slightly from the base-case value of £116,568 per QALY gained to £118,515 per QALY gained
using the minimum NMA.
Scenario 3d: Psoriasis Area and Severity Index response assessment
In this scenario, PASI 50 is considered as the primary efficacy end point for response assessment at the end
of the trial period instead of PASI 75, as used in the base-case analysis.
Table 82 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy using
PASI 50 as the primary efficacy end point. The incremental costs and QALYs for adalimumab compared
with methotrexate increase compared with the base case because there is a smaller difference in PASI 50
response rates between the interventions (91.5% adalimumab vs. 71% methotrexate) than for PASI 75
response rates (79% adalimumab vs. 49% methotrexate). As a result, the ICER increases from £308,329
per QALY gained to £353,148 per QALY gained.
TABLE 80 Scenario 3c results for adalimumab as an alternative to systemic therapy: treatment effects from the
NMA using minimum evidence from the adult population
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 38,177 9.879 – – – MTX
ADA 56,599 9.966 18,422 0.087 211,259
ADA, adalimumab; MTX, methotrexate.
TABLE 81 Scenario 3c results for treatment with the interventions after failed systemic therapy: treatment effects
from the NMA using minimum evidence from the adult population
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.717 – – – – BSC
ETA 44,063 8.828 7657 0.112 68,485 68,485
ADA 52,067 8.831 8004 0.002 3,587,196 137,329
Children and young people aged 12–17 years
BSC 21,749 4.807 – – – – BSC
ETA 33,598 4.898 11,849 0.091 ED UST 130,389
ADA 33,977 4.899 380 0.001 ED UST 132,682
UST 39,264 4.955 17,515 0.148 118,515 118,515
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Table 83 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy using PASI 50 as the primary efficacy end point. The incremental cost per additional QALY gained
is greater for all interventions than in the base-case analysis. This is because the total costs have increased
(a greater proportion of individuals continue treatment as responders) but the total QALYs have decreased
across the interventions. The difference in PASI 50 response rate between the interventions and BSC is
similar to the difference observed in PASI 75 response rates. The decrease in QALYs results from the
proportionally smaller utility gain associated with the PASI 50–75 response category than with the PASI
75–90 and PASI ≥ 90 response categories. BSC remains the optimal treatment option and the probability
that any of the biologics are cost-effective at a threshold of £30,000 per additional QALY is zero.
Health-related quality-of-life utility values
Scenario 4a: EuroQol-5 Dimensions utility estimates from adults
The HRQoL utility values in children and young people are subject to considerable uncertainty. EQ-5D-Y values
mapped from PedsQL data from the CADMUS trial (ustekinumab) at baseline and 12 weeks’ follow-up were
used to estimate utility gains from baseline associated with different PASI response categories (< 50, 50–74,
75–89, ≥ 90). The utility values associated with treatment were then based on the proportion of individuals
in the different PASI response categories from the NMA and the associated utility gain for each PASI category.
As discussed in Utility estimates used in the model, the estimated EQ-5D-Y utility gains mapped from the
PedsQL data were of a much smaller magnitude than the EQ-5D values used in previous TAs in adults.97–102
TABLE 82 Scenario 3d results for adalimumab as an alternative to systemic therapy: PASI 50 response assessment
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 32,765 9.932 – – – MTX
ADA 65,008 10.023 32,243 0.091 353,148
ADA, adalimumab; MTX, methotrexate.
TABLE 83 Scenario 3d results for treatment with the interventions after failed systemic therapy: PASI 50
response assessment
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 46,396 8.807 9990 0.097 103,388 103,388
ADA 60,091 8.886 13,695 0.079 172,967 134,724
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 36,930 4.882 15,180 0.078 ED ADA 193,536
ADA 40,024 4.947 18,275 0.143 127,783 127,783
UST 41,833 4.957 1809 0.010 131,128 131,128
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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It was also noted that the gains in CDLQI score by PASI response category were of a smaller magnitude than
the DLQI values reported in adults. It is not clear whether these smaller utility increments observed in children
and young people are a reflection of a lower impact of severe psoriasis on quality of life in a paediatric
population or a result of the small sample sizes and the limited data in this population.
In this scenario, EQ-5D utility values from the adult population were used to inform the gains in utility
associated with PASI response in children and young people. Utility values from TA10397 (etanercept) were
used; however, the implications of using alternative adult utility values from TA14699 (adalimumab) and
TA180100 (ustekinumab) were also considered (see Table 62 for a comparison of utility values in children
and young people and adults).
Table 84 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy using
utility estimates from an adult population. The total QALYs for the interventions are lower than those in
the base-case analysis, but this is because of the use of a lower baseline utility value in this scenario to
prevent the utility values rising above 1.0. Note that changing the baseline utility value used in the model
does not significantly affect the cost-effectiveness results because the model is driven by the incremental
changes in utility from baseline. The incremental QALYs of 0.150 for adalimumab compared with
methotrexate are significantly higher than the incremental QALYs of 0.088 in the base case. As a
result, the ICER for adalimumab compared with methotrexate reduces from £308,329 to £180,773 per
additional QALY. The implications of using adult utility values from TA180100 and TA14699 are even more
pronounced, with an incremental gain in QALYs of 0.204 and 0.260, respectively, for adalimumab compared
with methotrexate, resulting in corresponding ICERs of £132,616 and £104,010 per additional QALY
(see Appendix 8 for results based on utility estimates from TA180100).
Table 85 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy using utility estimates from an adult population. The incremental QALYs for the interventions
compared with BSC are substantially greater than those in the base case. Ustekinumab is the most effective
intervention, followed by adalimumab, etanercept and BSC, and the incremental gain in QALYs from moving
from one intervention to the next is greater than in the base case. As a result, all of the ICERs are substantially
lower than in the base case, falling by 55–61%. Etanercept shows the largest reduction in the ICER and, at a
threshold of £30,000 per additional QALY, etanercept becomes the optimal treatment in the 6–11 years age
group. In the 12–17 years age group, etanercept is extendedly dominated by adalimumab because of the
higher drug acquisition costs associated with this age group requiring more than a 25-mg dose. In those aged
12–17 years, the optimal treatment option remains BSC up until a threshold of £51,000 per QALY gained,
when adalimumab would then enter as the first treatment in the sequence. At a threshold of £60,000 per
QALY, adalimumab represents the only cost-effective treatment option based on a fully incremental analysis,
whereas all of the biologics would be considered cost-effective based on a pairwise comparison with BSC.
TABLE 84 Scenario 4a results for adalimumab as an alternative to systemic therapy: EQ-5D utility estimates
from adults
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Utility estimates sourced from TA103:97 children and young people aged 4–17 years
MTX 34,931 9.116 – – – MTX
ADA 62,043 9.266 27,112 0.150 180,773
Utility estimates sourced from TA146:99 children and young people aged 4–17 years
MTX 34,919 9.229 – – – MTX
ADA 62,000 9.489 27,081 0.260 104,010
ADA, adalimumab; MTX, methotrexate.
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The implications of using adult utility values from TA180100 and TA14699 are even more pronounced than when
using utility gains from TA10397 because of the greater utility gains in the PASI 75–89 and ≥ 90 categories.
The ICERs for children and young people aged 6–11 years are £22,578 (TA14699) and £21,546 (TA180100) for
etanercept compared with BSC and £37,125 (TA14699) and £39,682 (TA180100) for adalimumab compared with
BSC. The lowest ICERs for children and young people aged 12–17 years are £33,517 for adalimumab compared
with BSC, £35,612 for ustekinumab compared with BSC and £39,247 for etanercept compared with BSC.
Scenario 4b: utility estimates for best supportive care
The base-case analysis assumes that the utility associated with BSC is based on the proportion of individuals
in the different PASI response categories in the placebo arm of the NMA. In this scenario, the utility for
BSC was set equal to the baseline value, that is, assuming that there is no utility gain associated with BSC.
Table 86 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy assuming
that there is no utility benefit associated with BSC. For the comparison of adalimumab and methotrexate, the
assumption of no utility benefit on BSC affects only the utility of non-responders. The total QALYs for both
interventions are reduced and the incremental QALYs for adalimumab compared with methotrexate increase
from 0.088 in the base case to 0.102 because of the higher efficacy of adalimumab, which reduces the time
spent in BSC.
TABLE 85 Scenario 4a results for treatment with the interventions after failed systemic therapy: EQ-5D utility
estimates from adults
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Utility estimates sourced from TA103:97 children and young people aged 6–11 years
BSC 36,406 7.844 – – – – ETA
ETA 43,798 8.102 7392 0.257 28,740 28,740
ADA 57,257 8.237 13,459 0.135 99,419 53,112
Utility estimates sourced from TA146:99 children and young people aged 6–11 years
BSC 36,406 7.890 – – – – ETA
ETA 43,829 8.219 7423 0.329 22,578 22,578
ADA 57,215 8.450 13,386 0.232 57,762 37,125
Utility estimates sourced from TA103:97 children and young people aged 12–17 years
BSC 21,749 4.326 – – – – BSC
ETA 33,181 4.535 11,432 0.209 ED ADA 54,717
ADA 37,844 4.644 16,095 0.318 50,578 50,578
UST 39,968 4.661 2124 0.016 131,702 54,491
Utility estimates sourced from TA146:99 children and young people aged 12–17 years
BSC 21,749 4.326 – – – – BSC
ETA 33,195 4.618 11,446 0.292 ED ADA 39,247
ADA 37,873 4.807 16,124 0.481 33,517 33,517
UST 39,928 4.837 2055 0.029 69,895 35,612
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Table 87 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy assuming that there is no utility benefit associated with BSC. This assumption reduces the total
QALYs for the comparator of BSC and the utility of non-responders. As a result, the incremental QALYs for
the interventions compared with BSC increase and the incremental gain in QALYs for the interventions
relative to the next best option (e.g. ustekinumab is the most effective treatment, followed by adalimumab
and etanercept) also increases as less time is spent on BSC. Consequently, the ICERs for the interventions
are reduced compared with the base-case values.
Costs associated with best supportive care
Scenario 5a: number of hospitalisations per annum for best supportive care
The resource use associated with BSC, in particular the number of hospitalisations per annum, was
identified as an area of high uncertainty and a key driver of cost-effectiveness in previous TAs in adults.97–102
Two main sources have been referred to in previous appraisals: (1) NICE CG153,173 in which an average of
26.6 inpatient days per year was estimated for individuals whose psoriasis has not responded to treatment,
and (2) Fonia et al.,144 who estimated an average of 6.49 days of hospitalisation per annum. During previous
NICE appraisals, the clinical experts considered that both sources are likely to overestimate the actual
number of hospital days and resource use associated with BSC. This is in part because of the populations
considered in CG153173 and the study by Fonia et al.,144 with CG153173 considering a high-need population
TABLE 86 Scenario 4b results for adalimumab as an alternative to systemic therapy: utility in BSC equal to the
baseline value
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 34,925 9.833 – – – MTX
ADA 62,010 9.935 27,085 0.102 266,161
ADA, adalimumab; MTX, methotrexate.
TABLE 87 Scenario 4b results for treatment with the interventions after failed systemic therapy: utility in BSC equal
to the baseline value
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.593 – – – – BSC
ETA 43,785 8.724 7378 0.131 56,430 56,430
ADA 57,208 8.812 13,423 0.089 151,299 94,780
Children and young people aged 12–17 years
BSC 21,749 4.739 – – – – BSC
ETA 33,193 4.846 11,444 0.106 ED ADA 107,462
ADA 37,844 4.917 16,095 0.178 90,292 90,292
UST 39,969 4.929 2124 0.012 180,232 95,871
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
DOI: 10.3310/hta21640 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 64
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
with very severe psoriasis and the study by Fonia et al.144 describing care in a tertiary care centre known for
treating the most severely affected individuals. The clinical experts in recent appraisals also noted that the
number of individuals hospitalised for severe psoriasis has fallen over time and is continuing to fall. They
also indicated that BSC is mostly given to individuals during their outpatient visits. As a result, the resource
use associated with BSC is an area of considerable uncertainty and both sources of data have a number of
shortcomings, even in the adult population.
In the base-case analysis in children and young people, it was assumed that there are no hospitalisations
for psoriasis in this population. This was informed by clinical opinion, with our clinical advisor suggesting
that hospitalisations in children and young people are very rare, partly because this population has not yet
developed the comorbidities that often complicate more severe cases of psoriasis in adults. In this scenario,
the implications of assuming no inpatient stays for children and young people were explored by using an
estimate of 6.49 hospitalisations per annum based on the study by Fonia et al.144 and 26.6 hospitalisations
per annum based on CG153173 in adults.
Table 88 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy,
assuming hospitalisations for BSC. For the comparison of adalimumab and methotrexate, the total costs for
both interventions are increased, but the incremental cost of adalimumab compared with methotrexate
decreases because of the higher efficacy associated with adalimumab, which reduces the time spent in
BSC. The resulting ICER decreases from £308,329 per additional QALY in the base case to £281,029 per
additional QALY for 6.49 inpatient days per annum and £202,571 per additional QALY for 26.6 inpatient
days per annum.
Table 89 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy, assuming hospitalisations for BSC. Under this assumption, the costs of BSC increase by £147.67
and £605.25 per 4-week cycle for 6.49 and 26.6 inpatient days per annum respectively. As a result, the
total costs associated with the comparator of BSC increase and the costs for non-responders increase. For
children and young people aged 6–11 years, the reduction in the incremental cost of etanercept compared
with BSC is sufficient to make etanercept the optimal treatment option at a threshold of £30,000 per
QALY for a stay of 6.49 inpatient days per annum. When the hospitalisation LOS per annum is increased
to 26.6 days in this age group, etanercept becomes the least costly treatment option and BSC becomes
dominated by etanercept (i.e. BSC costs more than etanercept but produces fewer QALYs). Adalimumab
enters as a cost-effective option only if the threshold increases to £70,000 per QALY gained.
TABLE 88 Scenario 5a results for adalimumab as an alternative to systemic therapy: number of hospitalisations per
annum for BSC
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
6.49 hospitalisation days per annum for BSC:144 children and young people aged 4–17 years
MTX 52,280 9.939 – – – MTX
ADA 77,153 10.027 24,873 0.089 281,029
26.6 hospitalisation days per annum for BSC:173 children and young people aged 4–17 years
MTX 106,053 9.939 – – – MTX
ADA 123,929 10.027 17,876 0.088 202,571
ADA, adalimumab; MTX, methotrexate.
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For children and young people aged 12–17 years, etanercept is dominated by adalimumab. The ICER for
adalimumab compared with BSC is £74,501 per QALY when 6.49 inpatient days per annum are assumed.
When 26.6 inpatient days per annum are assumed, adalimumab becomes the least costly treatment option
and the most cost-effective option at a threshold of £30,000 per QALY. The ICER for ustekinumab compared
with adalimumab is £118,665 per QALY for a stay of 26.6 inpatient days per annum.
TABLE 89 Scenario 5a results for treatment with the interventions after failed systemic therapy: number of
hospitalisations per annum for BSC
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
costs vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
6.49 hospitalisation days per annum for BSC144
Children and young people aged 6–11 years
BSC 55,597 8.710 – – – – ETA
ETA 58,500 8.813 2903 0.103 28,286 28,286
ADA 70,016 8.891 11,516 0.078 148,586 80,046
Children and young people aged 12–17 years
BSC 32,333 4.804 – – – – BSC
ETA 40,099 4.887 7766 0.083 ED ADA 93,102
ADA 43,188 4.950 10,855 0.146 74,501 74,501
UST 45,064 4.960 1875 0.010 186,634 81,735
26.6 hospitalisation days per annum for BSC173
Children and young people aged 6–11 years
BSC 115,063 8.710 5550 –0.180 Dominated – ETA
ETA 104,113 8.813 – – – Dominant
ADA 109,512 8.891 5399 0.077 69,797 Dominant
Children and young people aged 12–17 years
BSC 65,129 4.804 4119 –0.156 Dominated – ADA
ETA 61,537 4.887 1777 –0.062 Dominated Dominant
ADA 59,760 4.950 – – – Dominant
UST 61,010 4.960 1250 0.011 118,665 Dominant
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Costs associated with adverse events
Scenario 6: costs of severe infections and malignancies
In the absence of robust evidence on the incidence of AEs associated with treatment in children and young
people, the base-case analysis assumed that there were no AEs associated with treatment. In this scenario,
the costs associated with SAEs, including NMSC, malignancies other than NMSC and severe infections,
are included. These events are expected to be very rare.
Table 90 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy with
the costs of AEs included. The incremental cost of adalimumab increases by only £400. The resulting
impact on the ICER is minor, with an increase from £308,329 per QALY gained in the base case to
£311,067 per QALY gained.
Table 91 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy with the costs of AEs included. As expected, the incremental costs for the interventions relative to
BSC increase, but the resulting impact on the ICERs for all interventions is very minor.
TABLE 90 Scenario 6 results for adalimumab as an alternative to systemic therapy: costs of severe infections and
malignancies included
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
MTX 35,176 9.939 – – – MTX
ADA 62,694 10.027 27,518 0.088 311,067
ADA, adalimumab; MTX, methotrexate.
TABLE 91 Scenario 6 results for treatment with the interventions after failed systemic therapy: costs of severe
infections and malignancies included
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 44,310 8.813 7904 0.103 76,810 76,810
ADA 57,911 8.891 13,601 0.077 176,012 119,357
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 33,584 4.887 11,835 0.083 ED ADA 142,041
ADA 38,382 4.950 16,633 0.146 113,974 113,974
UST 40,063 4.960 1682 0.010 169,254 117,497
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Treatment withdrawal rates
Scenario 7: withdrawal rates from treatment
In the base-case analysis discontinuation from treatment is modelled as an all-cause withdrawal probability
of 20% per annum, which is applied to all interventions. This withdrawal rate has been used in all previous
TAs in adults97–102 and is consistent with long-term survival rates of biologics from the BADBIR audit.94 In the
absence of alternative data in children and young people, this scenario considered two separate withdrawal
rates of 10% and 30% per annum.
Table 92 presents the cost-effectiveness results for adalimumab as an alternative to systemic therapy for
treatment withdrawal rates of 10% and 30% per annum. The lower withdrawal rate implies that individuals
spend longer on treatment before moving to BSC, whereas the higher withdrawal rate means that individuals
spend less time on treatment and more time on BSC. The total costs for adalimumab increase for the 10%
rate and decrease for the 30% rate, whereas the total costs for methotrexate decrease for the 10% rate and
increase for the 30% rate. This opposite effect between the treatments arises because the drug acquisition
cost of adalimumab (£704.28 per 4-week cycle) is proportionally greater than the cost of BSC (approximately
£284 per 4-week cycle) compared with the drug acquisition cost of methotrexate (approximately £60 per
4-week cycle) relative to the cost of BSC. As a result, the withdrawal rate has less impact on the total cost
of methotrexate than on the total cost of adalimumab. The incremental costs of adalimumab compared
with methotrexate are £40,781 and £19,692 for the 10% and 30% annual withdrawal rates, respectively,
compared with the base-case incremental cost of £27,084. In terms of health outcomes, the more time spent
on treatment the higher the utility gains; therefore, the QALYs increase for the lower withdrawal rate and
decrease for the higher withdrawal rate. The resulting ICERs for adalimumab compared with methotrexate are
£298,846 and £318,188 per additional QALY for the 10% and 30% annual withdrawal rates, respectively,
compared with the base-case value of £308,329 per additional QALY.
Table 93 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy for treatment withdrawal rates of 10% and 30% per annum. The total costs for all of the
interventions increase for the 10% rate and decrease for the 30% rate because of the accumulation of
higher drug acquisition costs while on treatment for longer. This increase in costs is counterbalanced by an
increase in utility gains while on treatment. The resulting impact on the ICERs is minimal. BSC remains the
optimal treatment option at a threshold of £30,000 per QALY gained.
TABLE 92 Scenario 7 results for adalimumab as an alternative to systemic therapy: treatment withdrawal rates of
10% and 30% per annum
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
Withdrawal rate of 10% per annum
MTX 32,274 9.990 – – – MTX
ADA 73,055 10.126 40,781 0.136 298,846
Withdrawal rate of 30% per annum
MTX 36,364 9.912 – – – MTX
ADA 56,057 9.974 19,692 0.062 318,188
ADA, adalimumab; MTX, methotrexate.
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Biosimilars
Scenario 8: reduction in the cost of etanercept
The biosimilar of etanercept, Benepali (50 mg), does not have marketing authorisation for use in children
and young people. In this scenario, the drug acquisition cost of etanercept was reduced by approximately
10% to match the cost of Benepali in adults.
Table 94 presents the cost-effectiveness results for treatment with the interventions after failed systemic
therapy for a 10% reduction in the acquisition cost of etanercept. For children and young people aged
6–11 years, the incremental cost of etanercept relative to BSC is reduced by £580, which reduces the ICER
from £71,903 to £66,240 per additional QALY. For children and young people aged 12–17 years, the
incremental cost of etanercept relative to BSC is reduced by £1480, which is a greater reduction than that
observed in the younger age group because it is assumed that the 10% reduction in the drug acquisition
cost of etanercept applies only to children aged ≥ 10 years who require 50 mg of etanercept. The cost
reduction has a very minor impact on the cost-effectiveness results.
TABLE 93 Scenario 7 results for treatment with the interventions after failed systemic therapy: treatment
withdrawal rates of 10% and 30% per annum
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Withdrawal rate of 10% per annum
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 49,361 8.864 12,955 0.154 84,138 84,138
ADA 66,830 8.977 17,469 0.113 154,817 114,029
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 36,194 4.911 14,445 0.107 ED ADA 135,131
ADA 42,002 4.989 20,253 0.185 109,399 109,399
UST 44,400 5.002 2398 0.013 182,511 114,244
Withdrawal rate of 30% per annum
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 40,978 8.784 4572 0.074 61,924 61,924
ADA 51,745 8.841 10,766 0.056 190,888 117,774
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 30,952 4.870 9203 0.066 ED ADA 139,568
ADA 34,732 4.920 3780 0.050 75,289 111,784
UST 36,599 4.928 1867 0.008 230,608 119,527
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Discussion of the cost-effectiveness results and alternative scenarios
The results of the base-case analysis suggest that adalimumab is not a cost-effective treatment option
when positioned in the pathway as an alternative to systemic therapy, with an ICER of £308,329 per QALY
gained compared with methotrexate. When positioned after systemic therapy, the ICER for adalimumab
compared with BSC is £115,825 per QALY gained for ages 6–11 years and £110,430 per QALY gained for
ages 12–17 years. At a threshold of £30,000 per QALY gained, etanercept is not a cost-effective option
for the treatment of severe plaque psoriasis in individuals who are inadequately controlled by, or who
are intolerant to, systemic therapies or phototherapies. The ICER for etanercept compared with BSC is
£71,903 per QALY gained for ages 6–11 years and etanercept is extendedly dominated by adalimumab
for those aged 12–17 years. Ustekinumab is the most effective treatment in children and young people
aged 12–17 years but it is also the most costly treatment. Based on a fully incremental analysis, the ICER
for ustekinumab compared with adalimumab is £201,507 per QALY gained, whereas the ICER for
ustekinumab compared with BSC is £116,568 per QALY gained. The base-case results suggest that
BSC is the only cost-effective form of management for the treatment of severe plaque psoriasis unless
the threshold reaches ≥ £111,000 per additional QALY. The probability that any of the biologics are
cost-effective at a threshold of £30,000 per QALY is zero.
The lack of cost-effectiveness appears to result from the very modest QALY gains associated with treatment.
The small incremental difference in health benefits between the treatments is a result of the relatively small
EQ-5D-Y utility gains associated with higher PASI response rates. As a consequence, the benefits of achieving a
greater PASI response do not translate into large improvements in health outcomes. The acquisition costs of
the treatments are also not substantially different: ustekinumab costs £715.67 per 4-week cycle (i.e. £2147.00
per dose with each dose given at 12 weekly intervals) compared with £704.28 per 4-week cycle (i.e. £352.14
per dose given every 2 weeks) for adalimumab and £715.00/£357.50 per 4-week cycle (i.e. £178.75 per
50-mg/£89.38 per 25-mg dose given each week) for etanercept, depending on patient weight.
A number of scenarios were used to explore the impact of alternative assumptions on the cost-effectiveness
of the biological treatments. Tables 95 and 96 summarise the cost-effectiveness results for the scenario
analyses for adalimumab as an alternative to systemic therapy and the use of the interventions after failed
systemic therapy respectively.
TABLE 94 Scenario 8 results for treatment with the interventions after failed systemic therapy: reduction in the
cost of etanercept to match the unit cost of Benepali
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 8.710 – – – – BSC
ETA 43,225 8.813 6819 0.103 66,240 66,240
ADA 57,272 8.891 14,047 0.077 181,897 115,815
Children and young people aged 12–17 years
BSC 21,749 4.804 – – – – BSC
ETA 31,719 4.887 9970 0.083 ED ADA 119,501
ADA 37,826 4.949 16,077 0.146 110,437 110,437
UST 39,908 4.960 2082 0.010 205,422 116,619
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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TABLE 95 Summary of the cost-effectiveness results for adalimumab as an alternative to systemic therapy:
base-case results and alternative scenarios
Analysis
ICER: ADA vs. MTX
(£/QALY)
Children and young people aged 4–17 years
Base case 308,329
Scenario 1: off-label use of biologics outside age constraints –
Scenario 2: common time horizon of 14 years –
Scenario 3a: direct trial evidence estimates of effect 549,899
Scenario 3b: indirect treatment comparison estimates –
Scenario 3c: treatment effects from the NMA using minimum evidence from the adult population 211,259
Scenario 3d: PASI 50 response assessment 353,148
Scenario 4a
EQ-5D utility estimates from TA10397 in adults 180,773
EQ-5D utility estimates from TA14699 in adults 104,010
Scenario 4b: utility on BSC equal to baseline value 266,161
Scenario 5
Hospitalisations of 6.49 days per annum 281,029
Hospitalisations of 26.6 days per annum 202,571
Scenario 6: costs associated with AEs 311,067
Scenario 7
Treatment withdrawal rate of 10% per annum 298,846
Treatment withdrawal rate of 30% per annum 318,188
Scenario 8: unit cost of biosimilar for etanercept –
–, scenario not applicable; ADA, adalimumab; MTX, methotrexate.
TABLE 96 Summary of the pairwise cost-effectiveness results for treatment with the interventions after failed
systemic therapy: base-case results and alternative scenarios
Analysis
ICER (£/QALY)
ADA vs. BSC ETA vs. BSC UST vs. BSC
Base case 117,080 – –
Scenario 1: off-label use of biologics outside age constraints 117,080 59,924 121,779
Children and young people aged 6–11 years
Base case 115,825 71,903 –
Scenario 1: off-label use of biologics outside age constraints – – –
Scenario 2: common time horizon of 14 years 115,592 73,153 –
Scenario 3a: direct trial evidence estimates of effect – 75,350 –
Scenario 3b: indirect treatment comparison estimates – – –
Scenario 3c: treatment effects from the NMA using minimum
evidence from the adult population
137,329 68,485 –
INDEPENDENT ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
TABLE 96 Summary of the pairwise cost-effectiveness results for treatment with the interventions after failed
systemic therapy: base-case results and alternative scenarios (continued )
Analysis
ICER (£/QALY)
ADA vs. BSC ETA vs. BSC UST vs. BSC
Scenario 3d: PASI 50 response assessment 134,724 103,388 –
Scenario 4a
EQ-5D utility estimates from TA10397 in adults 53,112 28,740 –
EQ-5D utility estimates from TA14699 in adults 37,125 22,578 –
Scenario 4b: utility in BSC equal to baseline value 94,780 56,430 –
Scenario 5
Hospitalisations of 6.49 days per annum 80,046 28,286 –
Hospitalisations of 26.6 days per annum Dominant Dominant –
Scenario 6: costs associated with AEs 119,357 76,810 –
Scenario 7
Treatment withdrawal rate of 10% per annum 114,029 84,138 –
Treatment withdrawal rate of 30% per annum 117,774 61,924 –
Scenario 8: unit cost of biosimilar for etanercept 115,815 66,240 –
Children and young people aged 12–17 years
Base-case 110,430 137,059 116,568
Scenario 1: off-label use of biologics outside age constraints – – –
Scenario 2: common time horizon of 14 years 109,531 135,354 114,439
Scenario 3a: direct trial evidence estimates of effect – – 116,982
Scenario 3b: indirect treatment comparison estimates – 128,903 119,092
Scenario 3c: treatment effects from the NMA using minimum
evidence from the adult population
132,682 130,389 118,515
Scenario 3d: PASI 50 response assessment 127,783 193,536 131,128
Scenario 4a
EQ-5D utility estimates from TA10397 in adults 50,578 54,717 54,491
EQ-5D utility estimates from TA14699 in adults 33,517 39,247 35,612
Scenario 4b: utility in BSC equal to baseline value 90,292 107,462 95,871
Scenario 5
Hospitalisations of 6.49 days per annum 74,501 93,102 81,735
Hospitalisations of 26.6 days per annum Dominant Dominant Dominant
Scenario 6: costs associated with AEs 113,974 142,041 117,497
Scenario 7
Treatment withdrawal rate of 10% per annum 109,399 135,131 114,244
Treatment withdrawal rate of 30% per annum 111,784 139,568 119,527
Scenario 8: unit cost of biosimilar for etanercept 110,437 119,501 116,619
–, scenario not applicable; ADA, adalimumab; ETA, etanercept; MTX, methotrexate; UST, ustekinumab.
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The scenarios that have the most impact on the cost-effectiveness results are (1) use of utility estimates
from an adult population (scenario 4a), (2) assuming that no health benefits are associated with BSC
(scenario 4b) and (3) assuming that hospitalisations are associated with BSC (scenario 5).
The gains in utility in the adult population for the different PASI response categories are up to 6.6 times
greater than the utility gains estimated in children and young people. It is unclear whether this difference
reflects a lower impact of severe psoriasis on HRQoL in children and young people or the limited data
available in this population and the significant uncertainty surrounding quality-of-life estimates in paediatric
psoriasis populations. The use of utility values from an adult population brings the ICER for etanercept
compared with BSC under the threshold of £30,000 per QALY gained in children and young people aged
6–11 years. The ICERs for ustekinumab and adalimumab using adult utility data are reduced significantly
but remain above the £30,000 per QALY threshold, even using the most favourable estimates from
TA146.99 Under the assumption of no health benefits associated with BSC, the ICERs are reduced by up to
£30,000 from the base-case values but remain quite high, with the lowest ICER of £56,430 per QALY
gained for etanercept compared with BSC.
The number of hospitalisations associated with BSC is a key driver of the cost-effectiveness of the biological
interventions. This was also identified as a key consideration in previous TAs in adults.97–102 Based on clinical
opinion, in the base-case analysis it was assumed that hospitalisations for severe psoriasis are very rare in
children and young people. If the average hospitalisation LOS per annum is increased to 6.49 days based on
the study by Fonia et al.,144 the ICERs for the interventions reduce significantly; however, the only ICER that
falls below the threshold of £30,000 is for the use of etanercept compared with BSC in children and young
people aged 6–11 years. If the average number of hospitalisations per annum is increased significantly to
26.6 days per annum, based on the very high-need population described in CG153,173 the biological
treatments compared with BSC are all considered cost-effective in individuals who have failed systemic therapy.
However, recent appraisals in adults have considered the estimate of 26.6 days per annum to be too high.
The combined impact of the most optimistic utility estimates in adults (TA14699), 6.49 inpatient days per
annum and no health benefits for BSC are presented in Tables 97 and 98 for the use of the interventions
before and after systemic therapy. The combined impact of the utility gains from an adult population and
an assumption of 6.49 hospitalisations per annum is sufficient to reduce the pairwise ICERs for the
interventions compared with BSC to below a threshold of £30,000 per additional QALY, whereas the
additional assumption of no health benefits for BSC reduces the ICERs further to below a threshold of
£20,000 per additional QALY. Based on a fully incremental analysis, etanercept is the optimal treatment
for children and young people aged 6–11 years, whereas adalimumab is the optimal treatment for children
and young people aged 12–17 years.
TABLE 97 Combined impact of alternative assumptions on the cost-effectiveness of adalimumab as an alternative
to systemic therapy
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children and young people aged 4–17 years
Adult utility data (TA146) + 6.49 hospitalisations per annum
MTX 52,273 9.229 – – – MTX
ADA 77,106 9.489 24,834 0.260 95,527
Adult utility data (TA146) + 6.49 hospitalisations per annum+ no health benefits for BSC
MTX 52,291 8.351 – – – MTX
ADA 77,136 8.727 24,845 0.376 66,126
ADA, adalimumab; MTX, methotrexate.
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TABLE 98 Combined impact of alternative assumptions on the cost-effectiveness of the interventions after failed
systemic therapy
Intervention
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
Adult utility data (TA146) + 6.49 hospitalisations per annum
BSC 55,597 7.890 – – – – ETA
ETA 58,515 8.218 2917 0.328 8897 8897
ADA 69,982 8.451 11,467 0.233 49,274 25,657
Adult utility data (TA146) + 6.49 hospitalisations per annum+ no health benefits for BSC
BSC 55,597 6.918 – – – – ETA
ETA 58,506 7.474 2909 0.557 5227 5227
ADA 70,021 7.809 11,515 0.334 34,438 16,190
Children and young people aged 12–17 years
Adult utility data (TA146) + 6.49 hospitalisations per annum
BSC 32,333 4.351 – – – – ADA
ETA 40,102 4.618 7769 0.266 ED ADA 29,177
ADA 43,193 4.807 10,860 0.455 23,861 23,861
UST 45,087 4.837 1894 0.031 61,722 26,253
Adult utility data (TA146) + 6.49 hospitalisations per annum+ no health benefits for BSC
BSC 32,333 3.815 – – – – ADA
ETA 40,100 4.269 7767 0.454 ED ADA 17,108
ADA 43,194 4.537 10,861 0.722 15,040 15,040
UST 45,099 4.579 1905 0.042 45,818 16,716
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Chapter 7 Assessment of factors relevant to the
NHS and other parties
The potential extra cost to the NHS of providing adalimumab, etanercept or ustekinumab to childrenand young people with moderate to severe plaque psoriasis is largely uncertain, given the paucity of
evidence on the health-care resource use specific to this population and the uncertainties in the effectiveness
evidence base. The resource use associated with BSC in terms of the expected number of hospitalisations
per annum was identified as a key area of uncertainty, as in previous TAs of psoriasis in adults. Reducing
uncertainty at this level would allow a more accurate assessment of the potential impact on the consumption
of NHS resources of providing biological treatment to children and young people with moderate to severe
plaque psoriasis.
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Chapter 8 Discussion
Statement of principal findings
One multicentre RCT (M04-717) found that adalimumab at the licensed dose of 0.8 mg/kg (up to 40 mg)
led to a significantly greater response than methotrexate for the outcomes of PASI 50 and PASI 75, but not
PASI 90, at 16 weeks. PGA 0/1 response rates were non-significantly higher for 0.8 mg/kg of adalimumab
than for methotrexate. The benefits of half-dose adalimumab were not statistically greater than those for
methotrexate. Evidence on quality of life was inconsistent across different measures, possibly because of
baseline imbalances on the PedsQL. In children and young people, adalimumab did not appear to be
associated with an increase in adverse effects relative to methotrexate over 16 weeks, although the
possibility of rare AEs cannot be entirely excluded. The trial did not provide any comparative evidence for
children aged 4–6 years. (Confidential information has been removed.)
One multicentre RCT (20030211) found etanercept to be significantly more effective than placebo in
improving the severity of plaque psoriasis based on PASI 50, 75 and 90 and PGA 0/1 response rates at
12 weeks. Improvements in HRQoL were larger for etanercept than for placebo, but reached statistical
significance only when measured by the CDLQI. AE rates were mostly similar in the etanercept and placebo
groups at 12 weeks, with no serious AEs observed for either treatment. However, a higher observed rate of
infections among participants receiving etanercept was of borderline statistical significance. Relatively few
young children (9% aged < 8 years; 4.3% aged < 6 years) were included in the study. Up to 6 years of
open-label follow-up (20050111) found that the proportions of PASI and PGA responders were stable over
time, although only 36% of participants were available at the latest follow-up point. The proportion of
participants withdrawing because of lack of efficacy is unknown. Through 264 weeks of follow-up,
withdrawals because of AEs were infrequent and no deaths or malignancies were observed.
One multicentre trial (CADMUS) in children aged 12–17 years found that both the standard dosage and
the half-standard dosage of ustekinumab were significantly more effective than placebo in improving the
severity of plaque psoriasis based on PASI 50, 75 and 90 and PGA 0/1 responses at 12 weeks. Both
ustekinumab dosages also led to significantly greater improvements in HRQoL (measured using the CDLQI
and PedsQL). Among participants originally allocated to ustekinumab, PASI and PGA effects observed at
12 weeks appeared to be largely sustained at 52 weeks, with few withdrawals because of lack of efficacy.
There were no notable adverse effects associated with ustekinumab, although the number of observations
was small and the longest follow-up time was just 60 weeks. Few participants withdrew because of
adverse effects.
No statistically significant differences were identified in PASI response outcomes across different age
groups within the trials. Therefore, to establish the relative efficacy of the interventions the analyses
assumed that treatment effects were exchangeable across ages in the population of children and young
people. Based on an indirect treatment comparison of PASI response outcomes at 12 weeks from the
20030211 trial and the CADMUS trial, using the placebo arms of the trials as a common comparator,
ustekinumab is a more effective treatment option than etanercept. The lack of a common comparator arm
between the adalimumab trial (M04-717) and etanercept trial (20030211) and the CADMUS trial meant
that it was not possible to draw conclusions about the relative efficacy of adalimumab, etanercept and
ustekinumab based on the three trials in children and young people alone. To fill this evidence gap for the
economic analysis it was necessary to draw strength from a wider evidence base of trials examining the
efficacy of the interventions in adults. This wider network of evidence was used to facilitate an indirect
comparison of adalimumab with etanercept and ustekinumab by examining the relationships that exist
between the different interventions and study populations (i.e. children and young people and adults) and
drawing conclusions for each population based on the full network of evidence. Adjustments were also
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made for differences in placebo response rates across the trials. The NMA results – adjusted for differences in
population and placebo response rates – demonstrated that ustekinumab is the most effective intervention
in children and young people, followed by adalimumab, etanercept and methotrexate. These rankings also
matched those in the adult population. The absolute PASI response outcomes were estimated to be higher
in children and young people than in adults because of higher placebo response rates in the etanercept trial
(20030211) and the ustekinumab trial (CADMUS), but the relative effectiveness of the interventions was
similar across the two populations.
The cost-effectiveness of adalimumab, etanercept and ustekinumab was evaluated by comparing the
additional costs of the interventions relative to each other and to either methotrexate or BSC, depending on
the position of the interventions in the pathway, with the additional health benefits over a time horizon that
was sufficient to capture differences in costs and effects. Health outcomes were expressed in QALYs and all
costs were considered from the perspective of the NHS and PSS. Because of differences in the marketing
authorisations of the interventions by age and the positioning of adalimumab before non-biological
systemic therapy, cost-effectiveness estimates were presented for three base-case populations: (1) children
and young people aged 4–17 years, with adalimumab compared with methotrexate; (2) children and young
people aged 6–11 years, with adalimumab and etanercept compared with BSC; and (3) children and young
people aged 12–17 years, with adalimumab, etanercept and ustekinumab compared with BSC.
The paucity of clinical and economic evidence to inform the evaluation of cost-effectiveness in children and
young people resulted in there being a number of strong assumptions and uncertainties in the analysis.
These assumptions arose from the need to extrapolate data from the adult population to inform the
population of children and young people. A number of alternative scenarios were considered to examine
the impact of these assumptions on the cost-effectiveness results. The base-case cost-effectiveness results
indicated that adalimumab was not a cost-effective treatment option when positioned in the treatment
pathway as an alternative to systemic therapy. When positioned after systemic therapy, the ICER for
adalimumab compared with BSC was more favourable, but it still remained well above conventional NICE
thresholds of cost-effectiveness. Etanercept was also not considered a cost-effective option after systemic
therapy for ages 6–11 years and was extendedly dominated by adalimumab for ages 12–17 years.
Ustekinumab was the most effective treatment in children and young people aged 12–17 years but it was
also the most costly treatment. The ICERs for ustekinumab compared with adalimumab and BSC were
> £100,000 per QALY gained. Based on the base-case assumptions, the probability that any of the
biological treatments would be considered cost-effective at the higher end of the NICE threshold of
£30,000 per QALY was zero.
The lack of cost-effectiveness of the biologics compared with BSC was the result of the very modest QALY
gains associated with improvements in PASI response outcomes. The difference in total costs between the
interventions was driven by the time spent on BSC (non-responders). The acquisition costs of the biologics
were not significantly different. The key drivers of cost-effectiveness were the utility estimates, the health
benefits associated with BSC and the number of hospitalisations on BSC. Extrapolating utility estimates
from the adult population to the population of children and young people reduced the ICERs by > 50%
because the gains in utility associated with different PASI response outcomes were up to 6.6 times greater
than the estimated utility gains from mapping PedsQL data from the CADMUS trial onto EQ-5D-Y utility
values. The choice of EQ-5D utility values from other previous TAs in adults also had a significant impact.
The base-case analysis included the possibility that psoriasis can improve with BSC and used the response
rates for placebo from the NMA to inform this. When this assumption was altered to assume that there
were no health benefits from BSC, the ICERs were reduced by £20,000–30,000 per additional QALY.
The resource use associated with BSC in terms of the expected number of hospitalisations per annum also
had a major impact on the cost-effectiveness results, reducing the ICERs compared with BSC considerably
the more days of hospitalisation were assumed. This was also identified as a key area of uncertainty in
previous TAs of psoriasis in adults.
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Strengths and limitations of the assessment
Strengths
The reviews of clinical effectiveness and cost-effectiveness were based on comprehensive searches of the
literature, which were supplemented by data from multiple additional sources, including European
Medicines Agency and US Food and Drugs Agency documents and CSRs, allowing the inclusion of
unpublished studies and data.
The clinical effectiveness review focused directly on evidence relating to children and young people with
plaque psoriasis, resulting in the identification of only four relevant studies for the three biologics of
interest. Consequently, the total number of included participants and the average length of follow-up
(for adalimumab and ustekinumab) were limited. However, this provides the best evidence of the efficacy
and short- to medium-term safety of adalimumab, etanercept and ustekinumab directly relevant to the
decision problem.
A key strength of this evaluation was the fact that it went beyond the scope of the appraisal by bringing
together evidence from the adult population to support an economic evaluation in children and young
people. The review of cost-effectiveness evidence in this population, and the absence of economic models
from the companies, highlighted the challenges involved in evaluating the cost-effectiveness of biological
interventions in children and young people with plaque psoriasis. The fundamental challenge was the
limited clinical evidence base for short- and long-term outcomes. Therefore, any estimation was going to
be subject to a number of uncertainties. Clinical opinion suggests that the management and approach to
care of treatment appears to mirror that used in adults. Therefore, in the absence of evidence, it seemed
reasonable to extrapolate data from the adult population to inform the economic model in children and
young people. This approach was also supported by the companies.
A major strength of the NMA was the fact that it brought together clinical evidence from the adult
population to allow the evidence from the M04-717 trial to be connected with evidence from the other
paediatric trials, while making an adjustment for any differences in PASI outcomes by population. This
enabled the relative effectiveness of adalimumab, etanercept and ustekinumab to be estimated in children
and young people by using what is already known about the relative effectiveness of the interventions
in adults.
The economic model represents the first attempt to evaluate the cost-effectiveness of biological treatments
in children and young people. This model used the same approach as the most widely accepted York
model, which has been used in previous TAs in adults. This ensures consistency in the approaches
undertaken for both populations. The main changes have been the availability of new evidence, including
evidence in a paediatric population, HRQoL outcomes specific to a paediatric population and resource use
and cost estimates. The analysis also attempted to reflect differences between the interventions in terms of
their marketing authorisation by age and positioning of treatment before and after systemic therapy.
Limitations
The flow of participants through the etanercept studies was complex, with data spread across a number of
publications and regulatory data sources. No CSR data were available to investigate this in further detail.
Similarly, the lack of a CSR meant that some details about study conduct required for a complete risk-of-
bias assessment were unavailable. Whenever possible, we avoided making assumptions and presented the
most complete data as reported. The open-label design of the included follow-up studies may also have
introduced additional biases.
In the absence of sufficient clinical evidence and economic data in children and young people, a simplified
modelling approach was undertaken. This simplified approach involved modelling a single line of therapy
before receiving BSC. However, plaque psoriasis is a lifelong chronic condition and, if the condition no
longer responds to a biological treatment, individuals are usually offered another biological treatment,
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a pattern that is likely to be repeated over their lifetime. This means that treatments are usually trialled on
an individual basis until an effective option is found. If individuals do not respond to multiple biological
interventions, then the only remaining option is BSC. This approach to treatment is expected to be similar
for children and young people and adults. However, much more caution is usually exercised in the younger
population because of the limited availability of licensed treatment options. Therefore, the modelling
approach undertaken is likely to be a simplification of reality. This simplification was necessary because of
an absence of evidence on the sequential use of biological treatments in children and young people, in
which treatment response would need to be conditioned on the previous biological treatments received.
The modelling of sequential treatments also requires every potential treatment permutation to be
considered. This has already presented a significant issue in the most recent TAs in adults that did consider
more than one line of therapy (TA368102 for apremilast and the appraisal of ixekizumab,176 which is currently
out for consultation), in which the modelled sequences did not reflect current clinical practice. Any attempt
at treatment sequencing in the population of children and young people would be highly uncertain; this is
not only because of the lack of data but also because of the further complication of the differences
between the biological treatments in terms of marketing authorisation by age, severity and positioning in
the treatment pathway. Furthermore, if a cost-effectiveness analysis identifies the optimal treatment
sequence in children and young people, this is less likely to be helpful to clinical practice as that particular
sequence may not be suitable for all (or any) individuals. For example, treatment in this population is usually
tailored to the child or young person because of needle phobia or the presence of psoriatic arthritis.
Uncertainties
Evidence on the efficacy and safety of adalimumab, etanercept and ustekinumab in younger children is
mostly absent from the included RCTs. The ustekinumab trial (CADMUS) restricted inclusion to participants
aged > 12 years. Only one subject aged < 6 years received the licensed dose of adalimumab (0.8 mg/kg),
with the majority of participants in the adalimumab trial being aged 9–18 years. Similarly, only 19 children
(9%) included in the trial evaluating etanercept were aged < 8 years.
It has not been possible to define moderate or severe psoriasis in children and young people. The definition
varied across the three trials in this population, with ustekinumab licensed for moderate to severe psoriasis
and etanercept and adalimumab licensed for severe psoriasis. Previous TAs in adults defined severe psoriasis
as a PASI score of ≥ 10 and a DLQI score of > 10. The trial populations for etanercept and ustekinumab
included children or young people with a baseline PASI score of ≥ 12 (the mean score was around 18–21),
with ≥ 10% of BSA affected (for ≥ 6 months in the case of ustekinumab) and a PGA score of ≥ 3. The trial
population for adalimumab included a baseline PASI score of > 20, involvement of > 20% of BSA or very
thick lesions and involvement of > 10% of BSA, a sPGA score of ≥ 4 or a baseline PASI score of > 10 (the
mean score was 18.3 in the trial) and a number of other characteristics such as active psoriatic arthritis or a
CDLQI score of > 10. There does not appear to be a standard routine assessment because the PASI and
CDLQI tools have not been validated for the purpose of disease severity measurement in this population.
There were also differences in the inclusion criteria in the trials in children and young people with regard
to the previous use of topical therapies, with only one trial requiring a previous failure to respond to
topical therapies (adalimumab, M04-717 trial). Another area of uncertainty pertains to the lack of exact
correspondence between the populations in the trials of biological agents for psoriasis in children and young
people and the marketing authorisations for these drugs in terms of the requirement for previous failure on
non-biological systemic therapy. None of the three trials of biological therapies in children and young people
with psoriasis required previous failure on non-biological systemic therapy as an inclusion criterion. Therefore,
the model assumes that treatment effectiveness is independent of failure on non-biological systemic therapy
prior to starting biological therapy. It is unknown how the position in the care pathway is likely to affect
treatment effectiveness.
The complex flow of participants and the use of open-label designs limit inferences being made about the
longer-term efficacy and safety of adalimumab, etanercept and ustekinumab and their withdrawal rates.
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The paucity of clinical and economic evidence to inform the cost-effectiveness of biological treatments in a
population of children and young people has led to a number of uncertainties. The most significant of
these is the HRQoL gains associated with treatment. The incremental health benefits between the
biological treatments are very sensitive to the utility gains associated with PASI response outcomes. In the
base-case analysis these gains were estimated based on mapping PedsQL data from the ustekinumab trial
onto EQ-5D-Y utility values. The PedsQL data were based on a very small sample size. In the absence of
any other data, this represented the only method available to estimate EQ-5D values in this population.
However, the PedsQL or CDLQI instruments have not been validated for the assessment of disease severity
in a population of children and young people with psoriasis and the PedsQL instrument does not appear to
be used routinely in clinical practice. Furthermore, these instruments are not specific to psoriasis and
therefore may not capture all of the important impacts of the condition, such as on anxiety, depression,
schooling and social interactions with friends. The PedsQL data from the ustekinumab trial are also based
on a population aged 12–17 years; therefore, these data are unlikely to reflect the same quality-of-life
outcomes in younger children. For example, very young children may not have developed a certain level of
self-awareness, which means that any quality-of-life instrument in young children is unlikely to be accurate.
Quality-of-life outcomes in children and young people can be lower because of the fear of subcutaneous
injections rather than because of the severity of the condition itself. There are other potential benefits of
the treatment of psoriasis in children and young people for which no quantitative estimates are available
for the interventions in this MTA. These potential benefits include educational benefits from improved
school attendance and a reduction in the prevalence of comorbidities later in life for children and young
people with psoriasis, as well as reduced spillover disutility from the illness to carers. In the absence of
quantitative estimates of these potential benefits, we were unable to incorporate these into the economic
analysis. Any attempt to add arbitrary values to the utility estimates that are already highly uncertain will
introduce further uncertainty.
The cost-effectiveness results are also very sensitive to the benefits and resource use associated with BSC. The
number of hospitalisations per annum in children and young people is an area of considerable uncertainty.
Extrapolating the data on hospitalisations from adults to this population is also subject to uncertainty because
of a number of shortcomings that exist among all sources of data on resource use for BSC. Given these
uncertainties the results from the base-case cost-effectiveness analysis should be considered alongside the
results of the separate scenarios.
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Chapter 9 Conclusions
E tanercept and ustekinumab, within their licensed indications, lead to significantly greater improvementsin psoriasis symptoms than placebo at 12 weeks’ follow-up. Quality-of-life benefits were also observed.
Although these effects appear to persist beyond 12 weeks, their magnitude and persistence is less certain.
Adalimumab at the licensed dose of 0.8 mg/kg (up to 40 mg) leads to significantly greater improvements in
psoriasis symptoms than methotrexate for some, but not all, measures at 16 weeks. Observed quality-of-life
benefits were inconsistent across different measures.
There was a lack of comparative evidence for these biologics in very young children.
With the exception of a non-significantly higher observed rate of infections among participants receiving
etanercept, there was little evidence of short-term AEs. However, the relatively small number of
observations and the limited length of follow-up across trials cannot exclude the possibility of rare events
being undetected.
The absence of head-to-head comparisons of the three drugs meant that these treatments would have to
be compared indirectly. In addition, the lack of a common comparator meant that a wider network of
data from adults with psoriasis needed to be used to connect the network. This further increased the
uncertainty about the relative effects of these treatments and further diminished the relative contribution
of data from children to the analysis.
Based on the economic assessment, the majority of ICERs for the use of biologics in children and young
people were in excess of NICE’s usual cost-effectiveness threshold and were reduced significantly only
when combined assumptions that align with those in the management of psoriasis in adults were adopted.
Implications for service provision
Although two biologics are licensed for younger children with plaque psoriasis (adalimumab from age
4 years, etanercept from age 6 years), the existing randomised trials include very few young children.
Consequently, evidence on the effectiveness and safety of these treatments in younger children has been
generalised from observations in older children and young people.
Suggested research priorities
l With the introduction of biological treatments in the population of children and young people,
continued collection of data through biological therapy registries for children and young people
aged < 18 years is warranted to investigate safety, patterns of treatment switching and long-term
withdrawal rates. Although randomised clinical trials are the gold standard for evidence collection,
the small number of children and young people eligible for biological therapy in psoriasis hinders the
feasibility of carrying out large studies in this area. Registry data would constitute a potentially more
viable source of evidence to reduce the uncertainty around safety, patterns of treatment switching and
long-term withdrawal rates and inform clinical practice. The collection of observational data via these
registries may also contribute to quantifying the impact of biological therapy for psoriasis early in life on
the prevalence of comorbidities (e.g. hypertension, obesity and depression).
l Adequately powered RCTs could substantially reduce the uncertainty surrounding the effectiveness
of biological treatments in biologic-experienced populations of children and young people, that is,
treatment response rates conditional on previous treatment are required. In the absence of head-to-head
trials, placebo-controlled trials could facilitate NMAs.
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l In particular, further evidence is needed to inform the clinical effectiveness and safety of adalimumab
and etanercept in younger children.
l Further research is needed to establish the impact of biological therapies on improving the HRQoL of
children and young people. Future trials should consider collecting direct estimates of EQ-5D-Y utility
values. Research in this area also needs to consider whether or not the HRQoL measures capture the
potential impact of any educational benefits from improved school attendance and a reduction in the
prevalence of comorbidities later in life for children and young people with psoriasis (e.g. obesity,
cardiovascular disease, metabolic syndrome and mental health disorders), as well as reduced spillover
disutility from the illness to carers.
l There is a need for the PASI instrument and/or other tools to be validated for disease severity
assessment in a population of children and young people.
l Further research is needed into the resource use and costs associated with BSC.
CONCLUSIONS
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Appendix 1 Search strategies
The following searches were carried out to identify:
l RCTs of adalimumab, etanercept and ustekinumab for the treatment of children and young people
with plaque psoriasis
l cost-effectiveness studies of adalimumab, etanercept and ustekinumab for the treatment of children
and young people with plaque psoriasis
l quality-of-life values for children and young people with plaque psoriasis that could be incorporated in
the decision model.
Clinical and cost-effectiveness review
Database search strategies
MEDLINE [MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)]
Via Ovid (http://ovidsp.ovid.com/)
Date range searched: 1946 to present.
Date searched: 24 May 2016.
Records retrieved: 334.
The search was updated on 30 September 2016 and retrieved 347 records.
Search strategy
1. Psoriasis/ (29,080)
2. (psorias$ or psoriat$).ti,ab. (36,767)
3. parapsoriasis.ti,ab. (525)
4. pustul$ adj2 palm$).ti,ab. (785)
5. or 2 or 3 or 4 (42,607)
6. dalimumab/ (3349)
7. adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (5219)
8. adfrar or exemptia or MSB11022 or MSB 11022 or GP2017 or GP 2017 or GP2015 or GP 2015 or
M923 or “M 923” or ABP501 or ABP 501).af. (19)
9. Etanercept/ (4651)
10. (etanercept or enbrel or 185243-69-0).af. (6612)
11. (benepali or brenzys or SB4 or CHS-0214 or CHS0214).af. (107)
12. Ustekinumab/ (414)
13. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (796)
14. or/6-13 (10,289)
15. 5 and 14 (2651)
16. exp Child/ (1,665,584)
17. exp Infant/ (1,007,205)
18. Adolescent/ (1,731,066)
19. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab. (1,671,736)
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20. 16 or 17 or 18 or 19 (3,484,944)
21. 15 and 20 (334)
Key
/ = indexing term [medical subject heading (MeSH heading)].
exp = exploded indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = terms in any field.
adj = terms next to each other (order specified).
adj2 = terms within two words of each other (any order).
Cochrane Central Register of Controlled Trials (CENTRAL)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Date range searched: issue 4 of 12, April 2016.
Date searched: 24 May 2016.
Records retrieved: 32
The strategy below was used to search CENTRAL and CDSR. The search was updated on 30 September
2016 and retrieved 39 records from CENTRAL.
Search strategy
#1 MeSH descriptor: [Psoriasis] this term only (1891)
#2 (psorias* or psoriat*):ti,ab,kw (4321)
#3 parapsoriasis:ti,ab,kw (3)
#4 (pustul* near/2 palm*):ti,ab,kw (72)
#5 #1 or #2 or #3 or #4 (4353)
#6 MeSH descriptor: [Adalimumab] this term only (239)
#7 (adalimumab or humira or D2E7 or (D2 next E7) or “331731-18-1”) (1088)
#8 (adfrar or exemptia or MSB11022 or “MSB 11022” or GP2017 or “GP 2017” or GP2015 or “GP
2015” or M923 or “M 923” or ABP501 or “ABP 501”) (2)
#9 MeSH descriptor: [Etanercept] this term only (383)
#10 (etanercept or enbrel or “185243-69-0”) (1162)
#11 (benepali or brenzys or SB4 or CHS-0214 or CHS0214) (2)
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#12 MeSH descriptor: [Ustekinumab] this term only (49)
#13 (ustekinumab or stelara or “CNTO1275” or “CNTO-1275” or “815610-63-0”) (194)
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 (2054)
#15 #5 and #14 (614)
#16 MeSH descriptor: [Child] explode all trees (173)
#17 MeSH descriptor: [Infant] explode all trees (14,329)
#18 MeSH descriptor: [Adolescent] this term only (85,135)
#19 (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc* or
juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or teens or
teenage* or toddler* or youth or youths or “young people” or “young person” or “young persons”) (193,089)
#20 #16 or #17 or #18 or #19 (193,089)
#21 #15 and #20 (50)
Note that results at line #21 are the total results for all databases within The Cochrane Library.
Key
MeSH descriptor = indexing term (MeSH heading).
* = truncation.
ti,ab,kw = terms in either title or abstract or keyword fields.
near/2 = terms within two words of each other (any order).
next = terms are next to each other.
“ “ = phrase search.
Cochrane Database of Systematic Reviews (CDSR)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Date range searched: issue 5 of 12, May 2016.
Date searched: 24 May 2016.
Records retrieved: 10.
See above under CENTRAL for search strategy used. The search was updated on 30 September 2016 and
retrieved 10 records.
Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus
Via EBSCOhost (www.ebscohost.com/)
Date range searched: from inception to 23 May 2016.
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Date searched: 24 May 2016.
Records retrieved: 69.
The search was updated on 30 September 2016 and retrieved 77 records.
Search strategy
S19 S14 AND S18 (69)
S18 S15 OR S16 OR S17 (815,757)
S17 TX adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild*
or teens or teenage* or toddler* or youth or youths or “young people” or “young person” or “young
persons” (815,757)
S16 (MH “Adolescence+”) (355,038)
S15 (MH “Child+”) (459,154)
S14 S5 AND S13 (532)
S13 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 (2252)
S12 TX ustekinumab or stelara or CNTO1275 or “CNTO-1275” or “815610-63-0” (157)
S11 TX benepali or brenzys or SB4 or “CHS-0214” or CHS0214 (3)
S10 TX etanercept or enbrel or “185243-69-0” (1528)
S9 (MH “Etanercept”) (701)
S8 TX adfrar or exemptia or MSB11022 or “MSB 11022” or GP2017 or “GP 2017” or GP2015 or “GP
2015” or M923 or “M 923” or ABP501 or “ABP 501” (4)
S7 TX (adalimumab or humira or D2E7 or “D2-E7” or “D2 E7” or “331731-18-1”) (933)
S6 (MH “Adalimumab”) (124)
S5 S1 OR S2 OR S3 OR S4 (5573)
S4 TI (pustul* N2 palm*) OR AB (pustul* N2 palm*) (50)
S3 TI parapsoriasis OR AB parapsoriasis (11)
S2 TI ( psorias* or psoriat* ) OR AB ( psorias* or psoriat* ) (4364)
S1 (MH “Psoriasis”) (3589)
Key
MH = indexing term (CINAHL heading).
* = truncation.
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TI = terms in the title.
AB = terms in the abstract.
TX = all text – search of all of the database’s searchable fields.
“ “ = phrase search.
N2 = terms within two words of each other (any order).
Database of Abstracts of Reviews of Effects (DARE)
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 31 March 2015.
Date searched: 24 May 2016.
Records retrieved: 4
Search strategy
This search strategy was not updated as DARE closed at the end of March 2015.
1. MeSH DESCRIPTOR Psoriasis (202)
2. (psorias* or psoriat*) (311)
3. (parapsoriasis) (1)
4. (pustul* NEAR2 palm*) (2)
5. (palm* NEAR2 pustul*) (3)
6. #1 OR #2 OR #3 OR #4 OR #5 (311)
7. MeSH DESCRIPTOR Adalimumab (112)
8. (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”) (240)
9. MeSH DESCRIPTOR Etanercept (99)
10. (etanercept or enbrel or “185243-69-0”) (246)
11. MeSH DESCRIPTOR Ustekinumab (16)
12. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”) (32)
13. (adfrar or exemptia or MSB11022 or “MSB 11022” or GP2017 or “MSB-11022” or “GP 2017” or
“GP-2017” or GP2015 or “GP 2015” or “GP-2015” or M923 or “M 923” or “M-923” OR ABP501 or
“ABP 501” or “ABP-501”) (0)
14. (benepali or brenzys or SB4 or CHS-0214 or CHS0214) (0)
15. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 (355)
16. MeSH DESCRIPTOR child EXPLODE ALL TREES (4890)
17. MeSH DESCRIPTOR infant EXPLODE ALL TREES (2947)
18. MeSH DESCRIPTOR adolescent (4584)
19. (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc* or
juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or
teens or teenage* or toddler* or youth or youths or “young people” or “young person” or “young
persons”) (13,284)
20. #16 OR #17 OR #18 OR #19 (13,284)
21. #6 AND #15 AND #20 (11)
22. (#6 AND #15 AND #20) IN DARE (4)
23. (#6 AND #15 AND #20) IN HTA (7)
24. (#6 AND #15 AND #20) IN NHSEED (0)
DOI: 10.3310/hta21640 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 64
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
173
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
“ “ = phrase search.
NEAR2 = terms within two words of each other (order specified).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 20 May 2016.
Date searched: 23 May 2016.
Records retrieved: 771.
The search was updated on 30 September 2016 and retrieved 826 records.
Search strategy
1. exp psoriasis/ (57,775)
2. (psorias$ or psoriat$).ti,ab. (53,835)
3. parapsoriasis.ti,ab. (571)
4. (pustul$ adj2 palm$).ti,ab. (1042)
5. 1 or 2 or 3 or 4 (70,014)
6. adalimumab/ (20,228)
7. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (20,663)
8. (adfrar or exemptia or MSB11022 or MSB 11022 or GP2017 or GP 2017 or GP2015 or GP 2015 or
M923 or “M 923” or ABP501 or ABP 501).af. (49)
9. etanercept/ (22718)
10. (etanercept or enbrel or 185243-69-0).af. (23,579)
11. (benepali or brenzys or SB4 or CHS-0214 or CHS0214).af. (85)
12. ustekinumab/ (2696)
13. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (2813)
14. or/6-13 (34,307)
15. 5 and 14 (8172)
16. exp child/ (2,315,907)
17. exp adolescent/ (1,350,949)
18. juvenile/ (26,103)
19. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or
teens or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab.
(2,067,003)
20. 16 or 17 or 18 or 19 (3,558,532)
21. 15 and 20 (771)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
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ti,ab = terms in either title or abstract fields.
af = all fields.
adj2 = terms within two words of each other (any order).
Health Technology Assessment (HTA) database
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 24 May 2016.
Date searched: 24 May 2016.
Records retrieved: 7.
See above under DARE for search strategy used. The search was updated on 30 September 2016 and
retrieved seven records.
NHS Economic Evaluation Database (NHS EED)
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 24 May 2016.
Date searched: 24 May 2016.
Records retrieved: 0.
See above under DARE for search strategy used. This search strategy was not updated as NHS EED closed
at the end of March 2015.
PubMed
www.ncbi.nlm.nih.gov/pubmed/
Date searched: 24 May 2016.
Records retrieved: 333.
The search was updated on 30 September 2016 and retrieved 347 records.
Search strategy
(((((((((((((((((“Adalimumab”[Mesh:noexp]) OR ((adalimumab OR humira OR D2E7 OR “D2 E7” OR “D2-E7”
OR “331731-18-1”))) OR ((adfrar OR exemptia))) OR ((“MSB11022” OR “MSB 11022” OR “MSB 11022”)))
OR “Etanercept”[Mesh:noexp]) OR ((etanercept OR enbrel OR “185243-69-0”))) OR ((benepali OR
brenzys))) OR ((“SB4” OR “CHS-0214” OR “CHS0214”))) OR “Ustekinumab”[Mesh:noexp]) OR
((ustekinumab OR stelara OR CNTO1275 OR “CNTO-1275” OR “815610-63-0”))) OR (“M923”[All Fields]
OR “M 923”[All Fields] OR “M-923”[All Fields])) OR (((“ABP501”) OR “ABP 501”) OR “ABP-501”)) OR
(((“GP2017”) OR “GP-2017”) OR “GP 2017”)) OR ((“GP2015”[All Fields] OR “GP-2015”[All Fields] OR
“GP 2015”[All Fields])))) AND ((((“Psoriasis”[Mesh:noexp]) OR ((psorias*[Title/Abstract] OR psoriat*[Title/
Abstract]))) OR parapsoriasis[Title/Abstract]) OR ((pustul*[Title/Abstract] AND palm*[Title/Abstract]))))) AND
((((“Child”[Mesh]) OR “Infant”[Mesh]) OR “Adolescent”[Mesh]) OR ((adolescen*[Title/Abstract] OR baby
[Title/Abstract] OR babies[Title/Abstract] OR child[Title/Abstract] OR children[Title/Abstract] OR boy[Title/
Abstract] OR boys[Title/Abstract] OR girl[Title/Abstract] OR girls[Title/Abstract] OR infant*[Title/Abstract] OR
infanc*[Title/Abstract] OR juvenile*[Title/Abstract] OR paediatric[Title/Abstract] OR pediatric[Title/Abstract]
OR preschooler*[Title/Abstract] OR schoolboy*[Title/Abstract] OR schoolgirl*[Title/Abstract] OR schoolchild*
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[Title/Abstract] OR teens[Title/Abstract] OR teenage*[Title/Abstract] OR toddler*[Title/Abstract] OR youth
[Title/Abstract] OR youths[Title/Abstract] OR “young people”[Title/Abstract] OR “young person”[Title/
Abstract] OR "young persons”[Title/Abstract])))
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:noexp] = indexing term (MeSH heading) not exploded.
* = truncation.
“ “ = phrase search.
[Title/Abstract]) = terms in either title or abstract fields.
Science Citation Index
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1900 to 20 May 2016.
Searched on: 23 May 2016.
Records retrieved: 256.
The search was updated on 30 September 2016 and retrieved 272 records.
Search strategy
#13 256 #12 AND #11
Indexes=SCI-EXPANDED Timespan=All years
#12 1,516,336 TS = (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or
schoolchild* or teens or teenage* or toddler* or youth or youths or “young people” or “young
person” or “young persons”)
Indexes = SCI-EXPANDED Timespan = All years
#11 3490 #10 AND #4
Indexes = SCI-EXPANDED Timespan = All years
#10 13,549 #9 OR #8 OR #7 OR #6 OR #5
Indexes = SCI-EXPANDED Timespan = All years
#9 1006 TS = (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”)
Indexes = SCI-EXPANDED Timespan = All years
#8 145 TS = (benepali or brenzys or SB4 or CHS-0214 or CHS0214)
Indexes = SCI-EXPANDED Timespan = All years
#7 8405 TS = (etanercept or enbrel or “185243-69-0”)
Indexes = SCI-EXPANDED Timespan = All years
#6 12 TS = (adfrar or exemptia or MSB11022 or “MSB 11022” or GP2017 or “GP 2017” or GP2015 or
“GP 2015” or M923 or “M 923” or ABP501 or “ABP 501”)
Indexes = SCI-EXPANDED Timespan = All years
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#5 6376 TS= (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”)
Indexes = SCI-EXPANDED Timespan = All years
#4 46,577 #3 OR #2 OR #1
Indexes = SCI-EXPANDED Timespan = All years
#3 806 TS= (pustul* NEAR/2 palm*)
Indexes = SCI-EXPANDED Timespan = All years
#2 480 TS= parapsoriasis
Indexes = SCI-EXPANDED Timespan = All years
#1 45,734 TS= (psorias* or psoriat*)
Indexes = SCI-EXPANDED Timespan = All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
https://clinicaltrials.gov/
Date searched: 24 May 2016.
Records retrieved: 23.
Searches were carried out as per the search strings below. In total, 28 studies were found, which was
reduced to 23 studies after deduplication of the results.
The search was updated on 15 September 2016 (see Network meta-analysis searches, Search 2). Update
searches for the biosimilar drugs (lines 2, 3, 4 and 6) were carried out on 30 September 2016 but did not
identify any further studies.
1. Six studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (adalimumab OR humira OR D2E7 OR D2-E7 OR
331731-18-1)
2. No studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (adfrar OR exemptia)
3. No studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (MSB11022 OR “MSB 11022” OR MSB-11022 OR
GP2017 OR “GP 2017” OR GP-2017 OR GP2015 OR “GP 2015” OR GP-2015)
4. No studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (M923 OR “M 923” OR M-923 OR ABP501 OR
“ABP 501” OR ABP-501)
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5. Fifteen studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (etanercept OR enbrel OR 185243-69-0)
6. No studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child OR
children OR infant OR infancy OR infants) AND (benepali OR brenzys OR SB4 OR CHS-0214 OR CHS0214)
7. Seven studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (ustekinumab OR stelara OR CNTO1275 OR
CNTO-1275 OR 815610-63-0)
Conference Proceedings Citation Index – Science
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1990 to 20 May 2016.
Date searched: 23 May 2016.
Records retrieved: 21.
The search was updated on 30 September 2016 and retrieved 21 records.
Search strategy
#13 21 #12 AND #11
Indexes = CPCI-S Timespan = All years
#12 148,800 TS= (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc*
or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or
teens or teenage* or toddler* or youth or youths or “young people” or “young person” or “young
persons”)
Indexes = CPCI-S Timespan = All years
#11 633 #10 AND #4
Indexes = CPCI-S Timespan = All years
#10 2726 #9 OR #8 OR #7 OR #6 OR #5
Indexes = CPCI-S Timespan = All years
#9 179 TS= (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”)
Indexes = CPCI-S Timespan = All years
#8 30 TS= (benepali or brenzys or SB4 or CHS-0214 or CHS0214)
Indexes = CPCI-S Timespan = All years
#7 1341 TS= (etanercept or enbrel or “185243-69-0”)
Indexes = CPCI-S Timespan = All years
#6 6 TS= (adfrar or exemptia or MSB11022 or “MSB 11022” or GP2017 or “GP 2017” or GP2015 or
“GP 2015” or M923 or “M 923” or ABP501 or “ABP 501”)
Indexes = CPCI-S Timespan = All years
#5 1351 TS= (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”)
Indexes = CPCI-S Timespan = All years
#4 6375 #3 OR #2 OR #1
Indexes = CPCI-S Timespan = All years
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#3 68 TS= (pustul* NEAR/2 palm*)
Indexes = CPCI-S Timespan= All years
#2 18 TS= parapsoriasis
Indexes = CPCI-S Timespan= All years
#1 6317 TS= (psorias* or psoriat*)
Indexes = CPCI-S Timespan= All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
EU Clinical Trials Register
www.clinicaltrialsregister.eu/ctr-search/search
Date searched: 24 May 2016.
Records retrieved: 10.
The search was updated on 19 September 2016 (see Network meta-analysis searches, Search 2). Update
searches for the biosimilar drugs (lines 2, 3, 4 and 6) were carried out on 30 September 2016 but did not
identify any further studies.
1. Two result(s) found for (Psoriasis OR psoriatic) AND (adalimumab OR humira OR D2E7 OR D2-E7 OR
331731-18-1). Limited by age range to adolescent, children, infant and toddler, newborn, preterm,
under 18
2. No result(s) found for (Psoriasis OR psoriatic) AND (adfrar OR exemptia). Limited by age range to
adolescent, children, infant and toddler, newborn, preterm, under 18
3. One result(s) found for (Psoriasis OR psoriatic) AND (MSB11022 OR “MSB 11022” OR MSB-11022 OR
GP2017 OR “GP 2017” OR GP-2017 OR GP2015 OR “GP 2015” OR GP-2015) Limited by age range to
adolescent, children, infant and toddler, newborn, preterm, under 18
4. No result(s) found for (Psoriasis OR psoriatic) AND (M923 OR “M 923” OR M-923 OR ABP501 OR “ABP
501” OR ABP-501). Limited by age range to adolescent, children, infant and toddler, newborn,
preterm, under 18
5. Five result(s) found for (Psoriasis OR psoriatic) AND (etanercept OR enbrel OR 185243-69-0) Limited by
age range to adolescent, children, infant and toddler, newborn, preterm, under 18
6. No result(s) found for (Psoriasis OR psoriatic) AND (benepali OR brenzys OR SB4 OR CHS-0214 OR
CHS0214). Limited by age range to adolescent, children, infant and toddler, newborn, preterm,
under 18
7. Two result(s) found for (Psoriasis OR psoriatic) AND (ustekinumab OR stelara OR CNTO1275 OR CNTO-
1275 OR 815610-63-0) Limited by age range to adolescent, children, infant and toddler, newborn,
preterm, under 18
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PROSPERO
www.crd.york.ac.uk/PROSPERO/
Date searched: 24 May 2016.
Records retrieved: 32.
Search: psoriasis in all fields.
The search was updated on 30 September 2016 and retrieved 13 new records, added since the previous
search on 24 May 2016.
World Health Organization (WHO)’s International Clinical Trials Registry Platform
www.who.int/ictrp/search/en/
Date searched: 24 May 2016.
Records retrieved: 32.
The search was updated on 19 September 2016 (see Network meta-analysis searches, Search 2). Update
searches for the biosimilar drugs (lines 2, 3, 4 and 6) were carried out on 30 September 2016 but did not
identify any further studies.
1. Eight trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (adalimumab OR humira OR
D2E7 OR D2-E7 OR 331731-18-1) limited to clinical trials in children (birth to 18 years)
2. No trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (adfrar OR exemptia) limited to
clinical trials in children (birth to 18 years)
3. No trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (MSB11022 OR “MSB 11022”
OR MSB-11022 OR GP2017 OR “GP 2017” OR GP-2017 OR GP2015 OR “GP 2015” OR GP-2015)
limited to clinical trials in children (birth to 18 years)
4. No trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (M923 OR “M 923” OR M-923
OR ABP501 OR “ABP 501” OR ABP-501) limited to clinical trials in children (birth to 18 years)
5. Fifteen trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (etanercept OR enbrel OR
185243-69-0) limited to clinical trials in children (birth to 18 years)
6. Two trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (benepali OR brenzys OR SB4
OR CHS-0214 OR CHS0214) limited to clinical trials in children (birth to 18 years)
7. Seven trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (ustekinumab OR stelara OR
CNTO1275 OR CNTO-1275 OR 815610-63-0) limited to clinical trials in children (birth to 18 years)
Guideline searches
The following resources were searched for relevant guidelines on 25 May 2016. The same searches were
repeated on 30 September 2016, with one further guideline identified from NHS Evidence.
National Guideline Clearinghouse
www.guideline.gov/
Date searched: 25 May 2016 (update search on 30 September 2016).
Records retrieved: 4
Keyword: psorias* or psoriat*
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Age of target population: Infant, Newborn (to 1 month), Infant (1 to 23 months), Child (2 to 12 years),
Adolescent (13 to 18 years)
Ten results were browsed and four were identified as being potentially relevant.
National Institute for Health and Care Excellence Clinical Knowledge Summaries
http://cks.nice.org.uk/
Date searched: 25 May 2016 (update search on 30 September 2016).
Records retrieved: 1
The topics section was browsed and one Clinical Knowledge Summary for psoriasis was identified.
NHS Evidence
www.evidence.nhs.uk/
Date searched: 25 May 2016 (update search on 30 September 2016).
Records retrieved: 22
((intitle:psorias* OR intags: psorias* OR inurl:psorias*) AND (child* or infant* or adolescen*))
Results filtered by type of information = guidance. The results were scanned for relevance and 22
documents were identified.
National Institute for Health and Care Excellence Evidence summaries: new medicines
www.nice.org.uk/about/what-we-do/our-programmes/nice-advice/evidence-summaries-new-medicines
Date searched: 24 May 2016 (update search on 30 September 2016).
Records retrieved: 0
Browsed 63 titles of published evidence summaries – no relevant summaries found.
National Institute for Health and Care Excellence website
www.nice.org.uk/
Date searched: 25 May 2016 (update search on 30 September 2016).
Records retrieved: 4.
Browsed psoriasis topic page (www.nice.org.uk/guidance/conditions-and-diseases/skin-conditions/psoriasis) –
4 relevant documents identified.
Network meta-analysis searches
The following searches were carried out to identify:
1. RCTs of systemic non-biological (acitretin, methotrexate, ciclosporin) and biological (infliximab,
secukinumab) therapies in children and young people with plaque psoriasis
2. RCTs of adalimumab, etanercept, ustekinumab, acitretin, methotrexate, ciclosporin, infliximab or
secukinumab in adults with plaque psoriasis.
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Search 1
Randomised controlled trials of systemic non-biological (acitretin, methotrexate, ciclosporin) and biological
therapies (infliximab, secukinumab) in children and young people with plaque psoriasis.
Database search strategies
MEDLINE [MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)]
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to present.
Date searched: 31 May 2016.
Records retrieved: 760
The search was updated on 30 September 2016 and retrieved 784 records.
Search strategy
1. Psoriasis/ (29,106)
2. (psorias$ or psoriat$).ti,ab. (36,848)
3. parapsoriasis.ti,ab. (525)
4. (pustul$ adj2 palm$).ti,ab. (787)
5. or/1-4 (42,692)
6. Acitretin/ (922)
7. (acitretin$ or etretin or neotigason or soriatane or 55079-83-9).af. (2571)
8. Methotrexate/ (33,972)
9. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or 15475-56-6 or 59-05-2 or 7413-34-5).af. (48,192)
10. exp Cyclosporins/ (37,382)
11. (cyclosporin$ or ciclosporin$ or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or 59865-13-3 or 63798-73-2).af. (55,065)
12. Infliximab/ (7830)
13. (infliximab or remicade or 170277-31-3).af. (11,015)
14. (inflectra or remsima or CT-P13).af. (63)
15. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (193)
16. or/6-15 (111,288)
17. 5 and 16 (5655)
18. exp Child/ (1,666,387)
19. exp Infant/ (1,007,661)
20. Adolescent/ (1,732,216)
21. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab. (1,674,732)
22. or/18-21 (3,488,828)
23. 17 and 22 (761)
24. exp animals/ not humans/ (4,247,320)
25. 23 not 24 (760)
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Key
/ = indexing term (MeSH heading)
exp = exploded indexing term (MeSH heading)
$ = truncation
ti,ab = terms in either title or abstract fields
af = terms in any field
adj2 = terms within two words of each other (any order)
Cochrane Central Register of Controlled Trials (CENTRAL)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Date range searched: issue 5 of 12, May 2016.
Date searched: 31 May 2016.
Records retrieved: 70.
The strategy below was used to search CENTRAL and CDSR. The search was updated on 30 September 2016
and retrieved 79 records from CENTRAL.
Search strategy
#1 MeSH descriptor: [Psoriasis] this term only (1891)
#2 (psorias* or psoriat*):ti,ab,kw (4328)
#3 parapsoriasis:ti,ab,kw (3)
#4 (pustul* near/2 palm*):ti,ab,kw (73)
#5 #1 or #2 or #3 or #4 (4360)
#6 MeSH descriptor: [Acitretin] this term only (66)
#7 (acitretin* or etretin or neotigason or soriatane or “55079-83-9”) (162)
#8 MeSH descriptor: [Methotrexate] this term only (3050)
#9 (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”) (7671)
#10 MeSH descriptor: [Cyclosporins] explode all trees (2699)
#11 (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”) (6059)
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#12 MeSH descriptor: [Infliximab] this term only (433)
#13 (infliximab or remicade or “170277-31-3”) (1347)
#14 (inflectra or remsima or “CT-P13”) (17)
#15 (secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6”) (153)
#16 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (14,174)
#17 #5 and #16 (822)
#18 MeSH descriptor: [Child] explode all trees (178)
#19 MeSH descriptor: [Infant] explode all trees (14,343)
#20 MeSH descriptor: [Adolescent] this term only (85,203)
#21 (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc* or
juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or teens or
teenage* or toddler* or youth or youths or “young people” or “young person” or “young persons”) (193,591)
#22 #18 or #19 or #20 or #21 (193,591)
#23 #17 and #22 (89)
#24 #17 and #22 in Cochrane Reviews (Reviews and Protocols) (15)
#25 #17 and #22 in Trials (70)
Key
MeSH descriptor = indexing term (MeSH heading)
* = truncation
ti,ab,kw = terms in either title or abstract or keyword fields
near/2 = terms within two words of each other (any order)
“ “ = phrase search
Cochrane Database of Systematic Reviews (CDSR)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Date range searched: issue 5 of 12, May 2016.
Date searched: 31 May 2016.
Records retrieved: 15.
See above under CENTRAL for search strategy used. The search was updated on 30 September 2016 and
retrieved 15 records from CDSR.
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Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus
Via EBSCOhost (www.ebscohost.com/).
Date range searched: from inception to 30 May 2016.
Date searched: 31 May 2016.
Records retrieved: 68.
The search was updated on 30 September 2016 and retrieved 74 records.
Search strategy
S22 S17 AND S21 (68)
S21 S18 OR S19 OR S20 (816,943)
S20 TX adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild*
or teens or teenage* or toddler* or youth or youths or “young people” or “young person” or “young
persons” (816,943)
S19 (MH “Adolescence+”) (355,343)
S18 (MH “Child+”) (459,529)
S17 S5 AND S16 (718)
S16 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 (9936)
S15 TX (secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6”) (73)
S14 TX (inflectra or remsima or “CT-P13”) (34)
S13 TX (infliximab or remicade or “170277-31-3”) (2106)
S12 (MH “Infliximab”) (1001)
S11 TX (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”) (2710)
S10 (MH “Cyclosporins”) OR (MH “Cyclosporine”) (1875)
S9 TX methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”) (5106)
S8 (MH “Methotrexate”) (3692)
S7 TX acitretin* or etretin or neotigason or soriatane or “55079-83-9” (90)
S6 (MH “Retinoids”) (662)
S5 S1 OR S2 OR S3 OR S4 (5,585)
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S4 TI (pustul* N2 palm*) OR AB (pustul* N2 palm*) (50)
S3 TI parapsoriasis OR AB parapsoriasis (11)
S2 TI ( psorias* or psoriat* ) OR AB ( psorias* or psoriat* ) (4375)
S1 (MH “Psoriasis”) (3599)
Key
MH = indexing term (CINAHL heading).
* = truncation.
TI = terms in the title.
AB = terms in the abstract.
TX = all text – search of all of the database’s searchable fields.
“ “ = phrase search.
N2 = terms within two words of each other (any order).
Database of Abstracts of Reviews of Effects (DARE)
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 31 March 2015.
Date searched: 31 May 2016.
Records retrieved: 6.
This search strategy was not updated as DARE closed at the end of March 2015.
Search strategy
1. MeSH DESCRIPTOR Psoriasis (202)
2. (psorias* or psoriat*) (311)
3. (parapsoriasis) (1)
4. (pustul* NEAR2 palm*) (2)
5. (palm* NEAR2 pustul*) (3)
6. #1 OR #2 OR #3 OR #4 OR #5 (311)
7. MeSH DESCRIPTOR Acitretin (7)
8. (acitretin* or etretin or neotigason or soriatane or “55079-83-9”) (25)
9. MeSH DESCRIPTOR Methotrexate (176)
10. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”) (452)
11. MeSH DESCRIPTOR Cyclosporins EXPLODE ALL TREES (109)
12. (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or neciclopin
or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”) (279)
13. MeSH DESCRIPTOR Infliximab (163)
14. (infliximab or remicade or “170277-31-3”) (349)
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15. (inflectra or remsima or “CT-P13”) (5)
16. (secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6”) (11)
17. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 (921)
18. #6 AND #17 (118)
19. MeSH DESCRIPTOR child EXPLODE ALL TREES (4890)
20. MeSH DESCRIPTOR infant EXPLODE ALL TREES (2947)
21. MeSH DESCRIPTOR adolescent (4585)
22. (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc* or
juvenile* or paediatric or pediatric or preschooler*) (13,225)
23. (schoolboy* or schoolgirl* or schoolchild* or teens or teenage*) (148)
24. (toddler* or youth or youths or “young people” or “young person” or “young persons”) (614)
25. #19 OR #20 OR #21 OR #22 OR #23 OR #24 (13,340)
26. #18 AND #25 (7)
27. (#18 AND #25) IN DARE (6)
28. (#18 AND #25) IN HTA (1)
29. (#18 AND #25) IN NHSEED (0)
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
“ “ = phrase search.
NEAR2 = terms within two words of each other (order specified).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 27 May 2016.
Date searched: 31 May 2016.
Records retrieved: 1467.
The search was updated on 30 September 2016 and retrieved 1564 records.
Search strategy
1. exp psoriasis/ (57,814)
2. (psorias$ or psoriat$).ti,ab. (53,874)
3. parapsoriasis.ti,ab. (571)
4. (pustul$ adj2 palm$).ti,ab. (1043)
5. 1 or 2 or 3 or 4 (70,062)
6. etretin/ (4892)
7. (acitretin$ or etretin or neotigason or soriatane or 55079-83-9).af. (5033)
8. methotrexate/ (146,811)
9. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or 15475-56-6 or 59-05-2 or 7413-34-5).af. (152,425)
10. cyclosporin derivative/ (1950)
11. cyclosporin/ (70,557)
12. cyclosporin A/ (65,595)
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13. (cyclosporin$ or ciclosporin$ or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or 59865-13-3 or 63798-73-2).af.
(139,555)
14. infliximab/ (35,519)
15. (infliximab or remicade or 170277-31-3).af. (36,260)
16. (inflectra or remsima or CT-P13).af. (157)
17. secukinumab/ (768)
18. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (849)
19. or/6-18 (289,812)
20. 5 and 19 (15,485)
21. exp child/ (2,317,206)
22. exp adolescent/ (1,351,704)
23. juvenile/ (26,120)
24. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab. (2,068,480)
25. or/21-24 (3,560,620)
26. 20 and 25 (1468)
27. (animal/ or nonhuman/) not exp human/ (5,037,476)
28. 26 not 27 (1467)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = all fields.
adj2 = terms within two words of each other (any order).
Health Technology Assessment (HTA) database
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 31 May 2016.
Date searched: 31 May 2016.
Records retrieved: 1.
See above under DARE for search strategy used. The search was updated on 30 September 2016 and
retrieved one record.
PubMed
www.ncbi.nlm.nih.gov/pubmed/
Date searched: 31 May 2016.
Records retrieved: 698.
The search was updated on 30 September 2016 and retrieved 715 records.
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Search strategy
(((((((((((((“Acitretin”[Mesh:NoExp]) OR ((acitretin* OR etretin OR neotigason OR soriatane OR “55079-83-9”)))
OR “Methotrexate”[Mesh:NoExp]) OR ((methotrexate OR amethopterin OR MTX OR ebetrex OR maxtrex OR
metoject OR methofill OR namaxir OR zlatal OR trexall OR otrexup OR rasuvo OR “15475-56-6” OR “59-05-2”
OR “7413-34-5”))) OR “Cyclosporins”[Mesh]) OR ((cyclosporin$ OR ciclosporin$ OR capimune OR capsorin OR
deximune OR emulsoforal OR neoral OR neciclopin OR sandimmun OR syncloral OR vanquoral OR gengraf OR
“59865-13-3” OR “63798-73-2”))) OR “Infliximab”[Mesh:NoExp]) OR ((infliximab OR remicade OR “170277-
31-3”))) OR ((inflectra OR remsima OR CT-P13))) OR ((secukinumab OR Cosentyx OR AIN457 OR AIN-457 OR
“1229022-83-6”)))) AND ((((“Psoriasis”[Mesh:NoExp]) OR ((psorias*[Title/Abstract] OR psoriat*[Title/Abstract])))
OR parapsoriasis[Title/Abstract]) OR ((pustul*[Title/Abstract] AND palm*[Title/Abstract]))))) AND ((((“Child”[Mesh])
OR “Infant”[Mesh]) OR “Adolescent”[Mesh:NoExp]) OR ((adolescen*[Title/Abstract] OR baby[Title/Abstract] OR
babies[Title/Abstract] OR child[Title/Abstract] OR children[Title/Abstract] OR boy[Title/Abstract] OR boys[Title/
Abstract] OR girl[Title/Abstract] OR girls[Title/Abstract] OR infant*[Title/Abstract] OR infanc*[Title/Abstract] OR
juvenile*[Title/Abstract] OR paediatric[Title/Abstract] OR pediatric[Title/Abstract] OR preschooler*[Title/Abstract]
OR schoolboy*[Title/Abstract] OR schoolgirl*[Title/Abstract] OR schoolchild*[Title/Abstract] OR teens[Title/
Abstract] OR teenage*[Title/Abstract] OR toddler*[Title/Abstract] OR youth[Title/Abstract] OR youths[Title/
Abstract] OR “young people”[Title/Abstract] OR “young person”[Title/Abstract] OR “young
persons”[Title/Abstract])))
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:NoExp] = indexing term (MeSH heading) not exploded.
* = truncation.
“ “ = phrase search.
[Title/Abstract]) = terms in either title or abstract fields.
Science Citation Index
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1900 to 30 May 2016.
Date searched: 31 May 2016.
Records retrieved: 402.
The search was updated on 30 September 2016 and retrieved 420 records.
Search strategy
#14 402 #13 AND #12
Indexes = SCI-EXPANDED Timespan = All years
#13 1,529,440 TS= (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or
infanc* or juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or
schoolchild* or teens or teenage* or toddler* or youth or youths or “young people” or “young
person” or “young persons”)
Indexes = SCI-EXPANDED Timespan = All years
#12 6098 #11 AND #4
Indexes = SCI-EXPANDED Timespan = All years
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#11 122,506 #10 OR #9 OR #8 OR #7 OR #6 OR #5
Indexes = SCI-EXPANDED Timespan = All years
#10 329 TS = (secukinumab or Cosentyx or AIN457 or AIN-457 or “1229022-83-6”)
Indexes = SCI-EXPANDED Timespan = All years
#9 78 TS = (inflectra or remsima or CT-P13)
Indexes = SCI-EXPANDED Timespan = All years
#8 16,040 TS = (infliximab or remicade or “170277-31-3”)
Indexes = SCI-EXPANDED Timespan = All years
#7 67,052 TS = (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”)
Indexes = SCI-EXPANDED Timespan = All years
#6 44,388 TS = (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir
or zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”)
Indexes = SCI-EXPANDED Timespan = All years
#5 1259 TS = (acitretin* or etretin or neotigason or soriatane or “55079-83-9”)
Indexes = SCI-EXPANDED Timespan = All years
#4 46,956 #3 OR #2 OR #1
Indexes = SCI-EXPANDED Timespan = All years
#3 808 TS = (pustul* NEAR/2 palm*)
Indexes = SCI-EXPANDED Timespan = All years
#2 480 TS = parapsoriasis
Indexes = SCI-EXPANDED Timespan = All years
#1 46,113 TS = (psorias* or psoriat*)
Indexes = SCI-EXPANDED Timespan = All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
https://clinicaltrials.gov/
Date searched: 31 May 2016.
Records retrieved: 20.
Searches were carried out as per the search strings below. In total, 47 studies were found, which was
reduced to 20 studies after deduplication of the results.
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The search was updated on 15 September 2016 (see Network meta-analysis searches, Search 2).
1. Three studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (acitretin OR etretin OR neotigason OR
soriatane OR 55079-83-9)
2. Nine studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (methotrexate OR amethopterin OR MTX OR ebetrex
OR maxtrex OR metoject OR methofill OR namaxir OR zlatal)
3. Nine studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (trexall OR otrexup OR rasuvo OR 15475-56-6 OR
59-05-2 OR 7413-34-5)
4. Seven studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (cyclosporin OR ciclosporin OR capimune OR
capsorin OR deximune OR emulsoforal OR neoral OR neciclopin)
5. Seven studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (sandimmun OR syncloral OR vanquoral OR
gengraf OR 59865-13-3 OR 63798-73-2)
6. Nine studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (infliximab OR remicade OR 170277-31-3)
7. No studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR child
OR children OR infant OR infancy OR infants) AND (inflectra OR remsima OR CT-P13)
8. Three studies found for (Psoriasis OR psoriatic) AND (adolescent OR adolescence OR adolescents OR
child OR children OR infant OR infancy OR infants) AND (secukinumab OR Cosentyx OR AIN457 OR
AIN-457 OR 1229022-83-6)
Conference Proceedings Citation Index – Science
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1990 to 30 May 2016.
Date searched: 31 May 2016.
Records retrieved: 16.
The search was updated on 30 September 2016 and retrieved 16 records.
Search strategy
#14 16 #13 AND #12
Indexes = CPCI-S Timespan= All years
#13 149,897 TS= (adolescen* or baby or babies or child or children or boy or boys or girl or girls or infant* or infanc* or
juvenile* or paediatric or pediatric or preschooler* or schoolboy* or schoolgirl* or schoolchild* or teens or
teenage* or toddler* or youth or youths or “young people” or “young person” or “young persons”)
Indexes= CPCI-S Timespan=All years
#12 592 #11 AND #4
Indexes = CPCI-S Timespan= All years
#11 15,410 #10 OR #9 OR #8 OR #7 OR #6 OR #5
Indexes = CPCI-S Timespan= All years
#10 76 TS= (secukinumab or Cosentyx or AIN457 or AIN-457 or “1229022-83-6”)
Indexes = CPCI-S Timespan= All years
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#9 8 TS= (inflectra or remsima or CT-P13)
Indexes = CPCI-S Timespan = All years
#8 2781 TS= (infliximab or remicade or “170277-31-3”)
Indexes = CPCI-S Timespan = All years
#7 8929 TS= (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”)
Indexes = CPCI-S Timespan = All years
#6 4027 TS= (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”)
Indexes = CPCI-S Timespan = All years
#5 129 TS= (acitretin* or etretin or neotigason or soriatane or “55079-83-9”)
Indexes = CPCI-S Timespan = All years
#4 6417 #3 OR #2 OR #1
Indexes = CPCI-S Timespan = All years
#3 68 TS= (pustul* NEAR/2 palm*)
Indexes = CPCI-S Timespan = All years
#2 18 TS= parapsoriasis
Indexes = CPCI-S Timespan = All years
#1 6359 TS= (psorias* or psoriat*)
Indexes = CPCI-S Timespan = All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
EU Clinical Trials Register
www.clinicaltrialsregister.eu/ctr-search/search
Date searched: 31 May 2016.
Records retrieved: 7.
The search was updated on 19 September 2016 (see Network meta-analysis searches, Search 2).
1. No result(s) found for (Psoriasis OR psoriatic) AND (acitretin* OR etretin OR neotigason OR soriatane OR
55079-83-9). Limited by age range to adolescent, children, infant and toddler, newborn, preterm, under 18
2. Five result(s) found for (Psoriasis OR psoriatic) AND (methotrexate OR amethopterin OR MTX OR ebetrex
OR maxtrex OR metoject OR methofill OR namaxir OR zlatal OR trexall OR otrexup OR rasuvo OR
15475-56-6 OR 59-05-2 OR 7413-34-5) ). Limited by age range to adolescent, children, infant and
toddler, newborn, preterm, under 18
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3. No results found for (Psoriasis OR psoriatic) AND (cyclosporin* OR ciclosporin* OR capimune OR
capsorin OR deximune OR emulsoforal OR neoral OR neciclopin OR sandimmun OR syncloral OR
vanquoral OR gengraf OR 59865-13-3 OR 63798-73-2) Limited by age range to adolescent, children,
infant and toddler, newborn, preterm, under 18
4. One result(s) found for (Psoriasis OR psoriatic) AND (infliximab OR remicade OR 170277-31-3) Limited
by age range to adolescent, children, infant and toddler, newborn, preterm, under 18
5. No results(s) found for (Psoriasis OR psoriatic) AND (inflectra OR remsima OR CT-P13) Limited by age
range to adolescent, children, infant and toddler, newborn, preterm, under 18
6. One result(s) found for (Psoriasis OR psoriatic) AND (secukinumab OR Cosentyx OR AIN457 OR AIN-457
OR 1229022-83-6) Limited by age range to adolescent, children, infant and toddler, newborn, preterm,
under 18
Key
* = truncation.
World Health Organization (WHO)’s International Clinical Trials Registry Platform
www.who.int/ictrp/search/en/
Date searched: 30 May 2016.
Records retrieved: 25.
The search was updated on 19 September 2016 (see Network meta-analysis searches, Search 2).
1. One trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (acitretin* OR etretin OR
neotigason OR soriatane OR 55079-83-9) limited to clinical trials in children (birth to 18 years)
2. Five trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (methotrexate OR amethopterin
OR MTX OR ebetrex OR maxtrex OR metoject OR methofill OR namaxir OR zlatal OR trexall OR otrexup OR
rasuvo OR 15475-56-6 OR 59-05-2 OR 7413-34-5) limited to clinical trials in children (birth to 18 years)
3. Two trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (cyclosporin* OR ciclosporin*
OR capimune OR capsorin OR deximune OR emulsoforal OR neoral OR neciclopin OR sandimmun OR
syncloral OR vanquoral OR gengraf OR 59865-13-3 OR 63798-73-2) limited to clinical trials in children
(birth to 18 years)
4. Five trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (infliximab OR remicade OR
170277-31-3) limited to clinical trials in children (birth to 18 years)
5. One trial found for Condition: (psoriasis OR psoriatic) AND Intervention: (inflectra OR remsima OR
CT-P13) limited to clinical trials in children (birth to 18 years)
6. Twelve trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (secukinumab OR Cosentyx
OR AIN457 OR AIN-457 OR 1229022-83-6) limited to clinical trials in children (birth to 18 years)
Search 2
Randomised controlled trials of adalimumab, etanercept, ustekinumab, acitretin, methotrexate, ciclosporin,
infliximab or secukinumab in adults with plaque psoriasis.
Database search strategies
MEDLINE [MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)]
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to present.
Date searched: 14 September 2016.
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Records retrieved: 274.
The Cochrane Highly Sensitive Search Strategy (sensitivity-maximising version) for identifying randomised
trials in Ovid MEDLINE was used to limit retrieval to RCTs (lines 26–35).177
Search strategy
1. Psoriasis/ (29,604)
2. (psorias$ or psoriat$).ti,ab. (37,897)
3. parapsoriasis.ti,ab. (529)
4. (pustul$ adj2 palm$).ti,ab. (804)
5. 1 or 2 or 3 or 4 (43,797)
6. Adalimumab/ (3560)
7. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (5547)
8. Etanercept/ (4829)
9. (etanercept or enbrel or 185243-69-0).af. (6906)
10. Ustekinumab/ (449)
11. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (859)
12. or/6-11 (10,712)
13. Acitretin/ (944)
14. (acitretin$ or etretin or neotigason or soriatane or 55079-83-9).af. (2610)
15. Methotrexate/ (34,625)
16. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or 15475-56-6 or 59-05-2 or 7413-34-5).af. (49,306)
17. exp Cyclosporins/ (37,792)
18. (cyclosporin$ or ciclosporin$ or capimune or capsorin or deximune or emulsoforal or neoral or neciclopin
or sandimmun or syncloral or vanquoral or gengraf or 59865-13-3 or 63798-73-2).af. (55,843)
19. Infliximab/ (8112)
20. (infliximab or remicade or 170277-31-3).af. (11,419)
21. (inflectra or remsima or CT-P13).af. (78)
22. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (236)
23. or/13-22 (113,486)
24. 5 and 12 (2777)
25. 5 and 23 (5831)
26. randomized controlled trial.pt. (430,970)
27. controlled clinical trial.pt. (91,709)
28. randomized.ab. (370,512)
29. placebo.ab. (179,018)
30. clinical trials as topic.sh. (179,518)
31. randomly.ab. (263,747)
32. trial.ti. (162,078)
33. 26 or 27 or 28 or 29 or 30 or 31 or 32 (1,067,990)
34. exp animals/ not humans.sh. (4,316,367)
35. 33 not 34 (984,770)
36. 24 and 35 (611)
37. 25 and 35 (851)
38. 36 or 37 (1163)
39. (2014$ or 2015$ or 2016$).ed,dc. (3,860,024)
40. 38 and 39 (274)
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Key
/ = indexing term (MeSH heading).
exp = exploded indexing term (MeSH heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
adj2 = terms within two words of each other (any order).
af = terms in any field.
sh = subject heading.
ed = entry date field.
dc = date record created field.
pt = publication type.
Cochrane Central Register of Controlled Trials (CENTRAL)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Date range searched: issue 8 of 12, August 2016.
Date searched: 14 September 2016.
Records retrieved: 280.
Search strategy
The strategy below was used to search CENTRAL and CDSR.
#1 MeSH descriptor: [Psoriasis] this term only (1903)
#2 (psorias* or psoriat*):ti,ab,kw (4457)
#3 parapsoriasis:ti,ab,kw (3)
#4 (pustul* near/2 palm*):ti,ab,kw (75)
#5 #1 or #2 or #3 or #4 (4489)
#6 MeSH descriptor: [Adalimumab] this term only (253)
#7 (adalimumab or humira or D2E7 or (D2 next E7) or “331731-18-1”) (1167)
#8 MeSH descriptor: [Etanercept] this term only (391)
#9 (etanercept or enbrel or “185243-69-0”) (1216)
#10 MeSH descriptor: [Ustekinumab] this term only (50)
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#11 (ustekinumab or stelara or “CNTO1275” or “CNTO-1275” or “815610-63-0”) (207)
#12 #6 or #7 or #8 or #9 or #10 or #11 (2186)
#13 MeSH descriptor: [Acitretin] this term only (66)
#14 acitretin* or etretin or neotigason or soriatane or “55079-83-9” (167)
#15 MeSH descriptor: [Methotrexate] this term only (3087)
#16 methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5” (7891)
#17 MeSH descriptor: [Cyclosporins] explode all trees (2708)
#18 cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2” (6124)
#19 MeSH descriptor: [Infliximab] this term only (445)
#20 infliximab or remicade or “170277-31-3” (1404)
#21 inflectra or remsima or “CT-P13” (19)
#22 secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6” (187)
#23 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 (14,517)
#24 #5 and #12 (651)
#25 #5 and #23 (869)
#26 #24 or #25 (1271)
#27 #24 or #25 Publication Year from 2014 to 2016 (305)
Note that results at line #27 are the total results for this search including all databases within The
Cochrane Library.
Key
MeSH descriptor = indexing term (MeSH heading).
* = truncation.
ti,ab,kw = terms in either title or abstract or keyword fields.
near/2 = terms within two words of each other (any order).
“ “ = phrase search.
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Cochrane Database of Systematic Reviews (CDSR)
Via Wiley Online Library (http://onlinelibrary.wiley.com/).
Issue 9 of 12, September 2016.
Date searched: 14 September 2016.
Records retrieved: 10.
See above under CENTRAL for search strategy used.
Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus
Via EBSCOhost (www.ebscohost.com/).
Date range searched: from inception to 14 September 2016.
Date searched: 14 September 2016.
Records retrieved: 108.
Search strategy
S43 S40 OR S42 (108)
S42 S38 AND S41 (28)
S41 (ZD “in process”) (225,905)
S40 S38 AND S39 (80)
S39 EM 2014- (914,196)
S38 S25 AND S37 (378)
S37 S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 1,073,032
S36 TX allocat* random* (5244)
S35 (MH “Quantitative Studies”) (14,844)
S34 (MH “Placebos”) (9797)
S33 TX placebo* (39,440)
S32 TX random* allocat* (5244)
S31 (MH “Random Assignment”) (41,555)
S30 TX randomi* control* trial* (109,672)
S29 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX
( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) (850,155)
S28 TX clinic* n1 trial* (189,284)
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S27 PT Clinical trial (79,715)
S26 (MH “Clinical Trials+”) (202,495)
S25 S12 OR S24 (1104)
S24 S5 AND S23 (746)
S23 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 (10,196)
S22 TX (secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6”) (83)
S21 TX (inflectra or remsima or “CT-P13”) (37)
S20 TX (infliximab or remicade or “170277-31-3”) (2163)
S19 (MH “Infliximab”) (1013)
S18 TX (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”) (2766)
S17 (MH “Cyclosporins”) OR (MH “Cyclosporine”) (1909)
S16 TX methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir
or zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”) (5246)
S15 (MH “Methotrexate”) (3761)
S14 TX acitretin* or etretin or neotigason or soriatane or “55079-83-9” (95)
S13 (MH “Retinoids”) (672)
S12 S5 AND S11 (567)
S11 S6 OR S7 OR S8 OR S9 OR S10 (2369)
S10 TX ustekinumab or stelara or CNTO1275 or “CNTO-1275” or “815610-63-0” (176)
S9 TX etanercept or enbrel or “185243-69-0” (1590)
S8 (MH “Etanercept”) (708)
S7 TX ( adalimumab or humira or D2E7 or “D2-E7” or “D2 E7” or “331731-18-1” ) (1003)
S6 (MH “Adalimumab”) (135)
S5 S1 OR S2 OR S3 OR S4 (5815)
S4 TI (pustul* N2 palm*) OR AB (pustul* N2 palm*) (52)
S3 TI parapsoriasis OR AB parapsoriasis (11)
S2 TI ( psorias* or psoriat* ) OR AB ( psorias* or psoriat* ) (4590)
S1 (MH “Psoriasis”) (3656)
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Key
MH = indexing term (CINAHL heading).
* = truncation.
TI = terms in the title.
AB = terms in the abstract.
TX = all text – search of all of the database’s searchable fields.
“ “ = phrase search.
N2 = terms within two words of each other (any order).
Database of Abstracts of Reviews of Effects (DARE)
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 31 March 2015.
Date searched: 14 September 2016.
Records retrieved: 15.
Search strategy
1. MeSH DESCRIPTOR Psoriasis (203)
2. (psorias* or psoriat*) (312)
3. (parapsoriasis) (1)
4. (pustul* NEAR2 palm*) (2)
5. (palm* NEAR2 pustul*) (3)
6. #1 OR #2 OR #3 OR #4 OR #5 (312)
7. MeSH DESCRIPTOR Adalimumab (113)
8. (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”) (241)
9. MeSH DESCRIPTOR Etanercept (99)
10. (etanercept or enbrel or “185243-69-0”) (246)
11. MeSH DESCRIPTOR Ustekinumab (17)
12. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”) (33)
13. #7 OR #8 OR #9 OR #10 OR #11 OR #12 (357)
14. #6 AND #13 (111)
15. MeSH DESCRIPTOR Acitretin (7)
16. (acitretin* or etretin or neotigason or soriatane or “55079-83-9”) (25)
17. MeSH DESCRIPTOR Methotrexate (176)
18. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”) (453)
19. MeSH DESCRIPTOR Cyclosporins EXPLODE ALL TREES (109)
20. (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or neciclopin
or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”) (279)
21. MeSH DESCRIPTOR Infliximab (164)
22. (infliximab or remicade or “170277-31-3”) (350)
23. (inflectra or remsima or “CT-P13”) (5)
24. (secukinumab or Cosentyx or “AIN457” or “AIN-457” or “1229022-83-6”) (11)
25. #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 (923)
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26. #6 AND #25 (119)
27. #14 OR #26 (155)
28. (#14 OR #26) IN DARE, HTA FROM 2014 TO 2016 (26)
Key
MeSH DESCRIPTOR = indexing term (MeSH heading).
* = truncation.
“ “ = phrase search.
NEAR2 = terms within two words of each other (order specified).
EMBASE
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1974 to 13 September 2016.
Date searched: 14 September 2016.
Records retrieved: 832.
Search strategy
A search strategy developed by Lefebvre et al. to limit retrieval of studies to RCTs was used (see lines 29–45).178
1. exp psoriasis/ (59,685)
2. (psorias$ or psoriat$).ti,ab. (55,841)
3. parapsoriasis.ti,ab. (576)
4. (pustul$ adj2 palm$).ti,ab. (1072)
5. 1 or 2 or 3 or 4 (72,314)
6. adalimumab/ (21,367)
7. (adalimumab or humira or D2E7 or (D2 adj E7) or 331731-18-1).af. (21,859)
8. etanercept/ (23,491)
9. (etanercept or enbrel or 185243-69-0).af. (24,393)
10. ustekinumab/ (2986)
11. (ustekinumab or stelara or CNTO1275 or CNTO-1275 or 815610-63-0).af. (3119)
12. or/6-11 (35,874)
13. etretin/ (5060)
14. (acitretin$ or etretin or neotigason or soriatane or 55079-83-9).af. (5207)
15. methotrexate/ (149,388)
16. (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir or
zlatal or trexall or otrexup or rasuvo or 15475-56-6 or 59-05-2 or 7413-34-5).af. (155,196)
17. cyclosporin derivative/ (1951)
18. cyclosporin/ (71,661)
19. cyclosporin A/ (66,255)
20. (cyclosporin$ or ciclosporin$ or capimune or capsorin or deximune or emulsoforal or neoral or neciclopin
or sandimmun or syncloral or vanquoral or gengraf or 59865-13-3 or 63798-73-2).af. (141,395)
21. infliximab/ (36,969)
22. (infliximab or remicade or 170277-31-3).af. (37,773)
23. (inflectra or remsima or CT-P13).af. (227)
24. secukinumab/ (909)
25. (secukinumab or Cosentyx or AIN457 or AIN-457 or 1229022-83-6).af. (994)
26. or/13-25 (295,191)
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27. 5 and 12 (8698)
28. 5 and 26 (16,051)
29. random$.ti,ab. (1,123,629)
30. factorial$.ti,ab. (28,599)
31. crossover$.ti,ab. (59,028)
32. cross-over$.ti,ab. (26,272)
33. placebo$.ti,ab. (244,396)
34. (doubl$ adj blind$).ti,ab. (172,319)
35. (singl$ adj blind$).ti,ab. (18,249)
36. assign$.ti,ab. (296,256)
37. allocat$.ti,ab. (107,971)
38. volunteer$.ti,ab. (211,580)
39. Crossover Procedure/ (48,681)
40. double blind procedure/ (134,149)
41. Randomized Controlled Trial/ (420,204)
42. single blind procedure/ (23,202)
43. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 (1,760,154)
44. (animal/ or nonhuman/) not exp human/ (5,111,869)
45. 43 not 44 (1,564,985)
46. 27 and 45 (1443)
47. 28 and 45 (1756)
48. 46 or 47 (2351)
49. (2014$ or 2015$ or 2016$).em. (4,971,904)
50. 48 and 49 (832)
Key
/ = indexing term (Emtree heading).
exp = exploded indexing term (Emtree heading).
$ = truncation.
ti,ab = terms in either title or abstract fields.
af = all fields.
adj2 = terms within two words of each other (any order).
em = entry date.
Health Technology Assessment (HTA) database
Via www.crd.york.ac.uk/CRDWeb/
Date range searched: from inception to 14 September 2016.
Date searched: 14 September 2016.
Records retrieved: 11.
See above under DARE for search strategy used.
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PubMed
www.ncbi.nlm.nih.gov/pubmed/
Date searched: 14 September 2016.
Records retrieved: 225.
Search strategy
The Cochrane Highly Sensitive Search Strategy (sensitivity-maximising version) for identifying randomised
trials in PubMed was used to limit retrieval to clinical trials.177
((((((“Psoriasis”[Mesh:NoExp]) OR ((psorias*[Title/Abstract] OR psoriat*[Title/Abstract] OR parapsoriasis[Title/
Abstract]))) OR ((pustul*[Title/Abstract] AND palm*[Title/Abstract])))) AND ((((((((“Adalimumab”[Mesh:NoExp])
OR ((adalimumab OR humira OR D2E7 OR “D2 E7” OR “331731-18-1”))) OR “Etanercept”[Mesh:NoExp])
OR ((etanercept OR enbrel OR “185243-69-0”))) OR “Ustekinumab”[Mesh:NoExp]) OR ((ustekinumab OR
stelara OR CNTO1275 OR “CNTO-1275” OR “815610-63-0”)))) OR ((((((((((((acitretin* OR etretin OR
neotigason OR soriatane OR “55079-83-9”))) OR “Acitretin”[Mesh:NoExp]) OR “Methotrexate”[Mesh:
NoExp]) OR ((methotrexate OR amethopterin OR MTX OR ebetrex OR maxtrex OR metoject OR methofill OR
namaxir OR zlatal OR trexall OR otrexup OR rasuvo OR “15475-56-6” OR “59-05-2” OR “7413-34-5”)))
OR “Cyclosporins”[Mesh]) OR ((cyclosporin$ OR ciclosporin$ OR capimune OR capsorin OR deximune OR
emulsoforal OR neoral OR neciclopin OR sandimmun OR syncloral OR vanquoral OR gengraf OR “59865-13-3”
OR “63798-73-2”))) OR “Infliximab”[Mesh:NoExp]) OR ((infliximab OR remicade OR “170277-31-3”))) OR
((inflectra OR remsima OR CT-P13))) OR ((secukinumab OR Cosentyx OR AIN457 OR AIN-457 OR “1229022-
83-6”)))))) AND (((((((((randomized controlled trial [pt]) OR controlled clinical trial [pt]) OR randomized [tiab])
OR placebo [tiab]) OR clinical trials as topic [mesh: noexp]) OR randomly [tiab]) OR trial [ti])) NOT ((animals
[mh] NOT humans [mh]))) Filters: Publication date from 2014/01/01 to 2016/12/31
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:NoExp] = indexing term (MeSH heading) not exploded.
* = truncation.
“ “ = phrase search.
[Title/Abstract]) = terms in either title or abstract fields.
[tiab] = terms in either title or abstract fields.
[pt] = publication type.
[mh] = exploded indexing term (MeSH heading).
Science Citation Index
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1900 to 13 September 2016.
Date searched: 14 September 2016.
Records retrieved: 820.
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Search strategy
#28 820 #26 not #27
Indexes = SCI-EXPANDED Timespan = 2014-2016
#27 3,866,779 TS= (animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or sheep
or guinea*)
Indexes = SCI-EXPANDED Timespan = All years
#26 3,492 #24 AND #18
Indexes = SCI-EXPANDED Timespan = All years
#25 3492 #24 AND #18
Indexes = SCI-EXPANDED Timespan = All years
#24 5,910,291 #23 OR #22 OR #21 OR #20 OR #19
Indexes = SCI-EXPANDED Timespan = All years
#23 5,038,629 TS= (placebo* or random* or control* or prospectiv* or volunteer*)
Indexes = SCI-EXPANDED Timespan = All years
#22 518,826 TS= (clinic* SAME trial*)
Indexes = SCI-EXPANDED Timespan = All years
#21 15,215 TS= (singl* SAME mask*) or TS= (doubl* SAME mask*) or TS= (trebl* SAME mask*) or TS = (tripl*
SAME mask*)
Indexes = SCI-EXPANDED Timespan = All years
#20 218,910 TS= (singl* SAME blind*) or TS= (doubl* SAME blind*) or TS= (trebl* SAME blind*) or TS= (tripl*
SAME blind*)
Indexes = SCI-EXPANDED Timespan = All years
#19 1,076,694 TS= (stud* SAME design*)
Indexes = SCI-EXPANDED Timespan = All years
#18 8309 #17 OR #9
Indexes = SCI-EXPANDED Timespan = All years
#17 6234 #16 AND #4
Indexes = SCI-EXPANDED Timespan = All years
#16 123,797 #15 OR #14 OR #13 OR #12 OR #11 OR #10
Indexes = SCI-EXPANDED Timespan = All years
#15 374 TS= (secukinumab or Cosentyx or AIN457 or AIN-457 or “1229022-83-6”)
Indexes = SCI-EXPANDED Timespan = All years
#14 99 TS= (inflectra or remsima or CT-P13)
Indexes = SCI-EXPANDED Timespan = All years
#13 16,441 TS= (infliximab or remicade or “170277-31-3”)
Indexes = SCI-EXPANDED Timespan = All years
#12 67,409 TS= (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”)
Indexes = SCI-EXPANDED Timespan = All years
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#11 44,932 TS = (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir
or zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”)
Indexes = SCI-EXPANDED Timespan = All years
#10 1288 TS = (acitretin* or etretin or neotigason or soriatane or “55079-83-9”)
Indexes = SCI-EXPANDED Timespan = All years
#9 3641 #8 AND #4
Indexes = SCI-EXPANDED Timespan = All years
#8 13,940 #7 OR #6 OR #5
Indexes = SCI-EXPANDED Timespan = All years
#7 1098 TS = (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”)
Indexes = SCI-EXPANDED Timespan = All years
#6 8642 TS = (etanercept or enbrel or “185243-69-0”)
Indexes = SCI-EXPANDED Timespan = All years
#5 6703 TS = (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”)
Indexes = SCI-EXPANDED Timespan = All years
#4 47,963 #3 OR #2 OR #1
Indexes = SCI-EXPANDED Timespan = All years
#3 819 TS = (pustul* NEAR/2 palm*)
Indexes = SCI-EXPANDED Timespan = All years
#2 482 TS = parapsoriasis
Indexes = SCI-EXPANDED Timespan = All years
#1 47,116 TS = (psorias* or psoriat*)
Indexes = SCI-EXPANDED Timespan = All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
SAME = terms in the same record.
Ongoing, unpublished or grey literature search strategies
ClinicalTrials.gov
https://clinicaltrials.gov/
Date searched: 15 September 2016.
Records retrieved: 105.
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Searches were carried out as per the search strings below. In total, 171 studies were found, which was
reduced to 105 studies after deduplication of the results.
1. Twenty-six studies found for (Psoriasis OR psoriatic) AND (adalimumab OR humira OR D2E7 OR D2-E7
OR 331731-18-1) | Studies received from 1 January 2014 to 15 September 2016
2. Twenty-two studies found for (Psoriasis OR psoriatic) AND (etanercept OR enbrel OR 185243-69-0) |
Studies received from 1 January 2014 to 15 September 2016
3. Twenty-three studies found for (Psoriasis OR psoriatic) AND (ustekinumab OR stelara OR CNTO1275
OR CNTO-1275 OR 815610-63-0) | Studies received from 1 January 2014 to 15 September 2016
4. Five studies found for (Psoriasis OR psoriatic) AND (acitretin OR etretin OR neotigason OR soriatane OR
55079-83-9) | Studies received from 1 January 2014 to 15 September 2016
5. Twenty-four studies found for (Psoriasis OR psoriatic) AND (methotrexate OR amethopterin OR MTX
OR ebetrex OR maxtrex OR metoject OR methofill OR namaxir OR zlatal) | Studies received from 1
January 2014 to 15 September 2016
6. Twenty-four studies found for (Psoriasis OR psoriatic) AND (trexall OR otrexup OR rasuvo OR
15475-56-6 OR 59-05-2 OR 7413-34-5) | Studies received from 1 January 2014 to 15 September 2016
7. Four studies found for (Psoriasis OR psoriatic) AND (cyclosporin OR ciclosporin OR capimune OR
capsorin OR deximune OR emulsoforal OR neoral OR neciclopin) | Studies received from 1 January
2014 to 15 September 2016
8. Four studies found for (Psoriasis OR psoriatic) AND (sandimmun OR syncloral OR vanquoral OR gengraf
OR 59865-13-3 OR 63798-73-2) | Studies received from 1 January 2014 to 15 September 2016
9. Six studies found for (Psoriasis OR psoriatic) AND (infliximab OR remicade OR 170277-31-3) | Studies
received from 1 January 2014 to 15 September 2016
10. Three studies found for (Psoriasis OR psoriatic) AND (inflectra OR remsima OR CT-P13) | Studies
received from 1 January 2014 to 15 September 2016
11. Thirty studies found for (Psoriasis OR psoriatic) AND (secukinumab OR Cosentyx OR AIN457 OR
AIN-457 OR 1229022-83-6) | Studies received from 1 January 2014 to 15 September 2016
Conference Proceedings Citation Index – Science
Via Web of Science, Thomson Reuters (http://thomsonreuters.com/thomson-reuters-web-of-science/).
Date range searched: 1990 to 13 September 2016.
Daten searched: 14 September 2016.
Records retrieved: 33.
Search strategy
#28 33 #26 not #27
Indexes = CPCI-S Timespan = 2014-2016
#27 306,516 TS= (animal or animals or dog or dogs or hamster* or mice or mouse or rat or rats or bovine or sheep
or guinea*)
Indexes = CPCI-S Timespan = All years
#26 235 #24 AND #18
Indexes = CPCI-S Timespan = All years
#25 235 #24 AND #18
Indexes = CPCI-S Timespan = All years
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#24 1,276,541 #23 OR #22 OR #21 OR #20 OR #19
Indexes = CPCI-S Timespan = All years
#23 1,060,361 TS = (placebo* or random* or control* or prospectiv* or volunteer*)
Indexes = CPCI-S Timespan = All years
#22 41,861 TS = (clinic* SAME trial*)
Indexes = CPCI-S Timespan = All years
#21 5279 TS = (singl* SAME mask*) or TS= (doubl* SAME mask*) or TS= (trebl* SAME mask*) or TS =
(tripl* SAME mask*)
Indexes = CPCI-S Timespan = All years
#20 19,759 TS = (singl* SAME blind*) or TS= (doubl* SAME blind*) or TS= (trebl* SAME blind*) or TS= (tripl*
SAME blind*)
Indexes = CPCI-S Timespan = All years
#19 257,226 TS = (stud* SAME design*)
Indexes = CPCI-S Timespan = All years
#18 1159 #17 OR #9
Indexes = CPCI-S Timespan = All years
#17 599 #16 AND #4
Indexes = CPCI-S Timespan = All years
#16 15,543 #15 OR #14 OR #13 OR #12 OR #11 OR #10
Indexes = CPCI-S Timespan = All years
#15 83 TS = (secukinumab or Cosentyx or AIN457 or AIN-457 or “1229022-83-6”)
Indexes = CPCI-S Timespan = All years
#14 10 TS = (inflectra or remsima or CT-P13)
Indexes = CPCI-S Timespan = All years
#13 2799 TS = (infliximab or remicade or “170277-31-3”)
Indexes = CPCI-S Timespan = All years
#12 8983 TS = (cyclosporin* or ciclosporin* or capimune or capsorin or deximune or emulsoforal or neoral or
neciclopin or sandimmun or syncloral or vanquoral or gengraf or “59865-13-3” or “63798-73-2”)
Indexes = CPCI-S Timespan = All years
#11 4083 TS = (methotrexate or amethopterin or MTX or ebetrex or maxtrex or metoject or methofill or namaxir
or zlatal or trexall or otrexup or rasuvo or “15475-56-6” or “59-05-2” or “7413-34-5”)
Indexes = CPCI-S Timespan = All years
#10 133 TS = (acitretin* or etretin or neotigason or soriatane or “55079-83-9”)
Indexes = CPCI-S Timespan = All years
#9 645 #8 AND #4
Indexes = CPCI-S Timespan = All years
#8 2720 #7 OR #6 OR #5
Indexes = CPCI-S Timespan = All years
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
206
#7 185 TS= (ustekinumab or stelara or CNTO1275 or CNTO-1275 or “815610-63-0”)
Indexes = CPCI-S Timespan = All years
#6 1356 TS= (etanercept or enbrel or “185243-69-0”)
Indexes = CPCI-S Timespan = All years
#5 1361 TS= (adalimumab or humira or D2E7 or D2-E7 or “D2 E7” or “331731-18-1”)
Indexes = CPCI-S Timespan = All years
#4 6587 #3 OR #2 OR #1
Indexes = CPCI-S Timespan = All years
#3 69 TS= (pustul* NEAR/2 palm*)
Indexes = CPCI-S Timespan = All years
#2 18 TS= parapsoriasis
Indexes = CPCI-S Timespan = All years
#1 6529 TS= (psorias* or psoriat*)
Indexes = CPCI-S Timespan = All years
Key
TS = topic tag; searches terms in title, abstract, author keywords and keywords plus fields.
* = truncation.
“ “ = phrase search.
NEAR/2 = terms within two words of each other (any order).
SAME = terms in the same record.
EU Clinical Trials Register
www.clinicaltrialsregister.eu/ctr-search/search
Date searched: 19 September 2016.
Records retrieved: 85.
Date range searched: 1 January 2014 to 19 September 2016.
1. Seventeen result(s) found for (Psoriasis OR psoriatic) AND (adalimumab OR humira OR D2E7 OR D2-E7
OR 331731-18-1
2. Nine result(s) found for (Psoriasis OR psoriatic) AND (etanercept OR enbrel OR 185243-69-0)
3. Eleven result(s) found for (Psoriasis OR psoriatic) AND (ustekinumab OR stelara OR CNTO1275 OR
CNTO-1275 OR 815610-63-0)
4. One result(s) found for (Psoriasis OR psoriatic) AND (acitretin* OR etretin OR neotigason OR soriatane
OR 55079-83-9)
5. Twenty result(s) found for (Psoriasis OR psoriatic) AND (methotrexate OR amethopterin OR MTX OR
ebetrex OR maxtrex OR metoject OR methofill OR namaxir OR zlatal OR trexall OR otrexup OR rasuvo
OR 15475-56-6 OR 59-05-2 OR 7413-34-5)
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6. Five result(s) found for (Psoriasis OR psoriatic) AND (cyclosporin* OR ciclosporin* OR capimune OR
capsorin OR deximune OR emulsoforal OR neoral OR neciclopin OR sandimmun OR syncloral OR
vanquoral OR gengraf OR 59865-13-3 OR 63798-73-2)
7. Three result(s) found for (Psoriasis OR psoriatic) AND (infliximab OR remicade OR 170277-31-3)
8. One result(s) found for (Psoriasis OR psoriatic) AND (inflectra OR remsima OR CT-P13)
9. Eighteen result(s) found for (Psoriasis OR psoriatic) AND (secukinumab OR Cosentyx OR AIN457 OR
AIN-457 OR 1229022-83-6)
Key
* = truncation.
World Health Organization (WHO)’s International Clinical Trials Registry Platform
www.who.int/ictrp/search/en/
Date searched: 19 September 2016.
Records retrieved: 188.
Date range searched: 1 January 2014 to 19 September 2016.
1. Forty-one trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (adalimumab OR humira
OR D2E7 OR D2-E7 OR 331731-18-1)
2. Twenty-six trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (etanercept OR enbrel
OR 185243-69-0)
3. Twenty-five trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (ustekinumab OR
stelara OR CNTO1275 OR CNTO-1275 OR 815610-63-0)
4. Six trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (acitretin* OR etretin OR
neotigason OR soriatane OR 55079-83-9)
5. Thirty trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (methotrexate OR
amethopterin OR MTX OR ebetrex OR maxtrex OR metoject OR methofill OR namaxir OR zlatal OR
trexall OR otrexup OR rasuvo OR 15475-56-6 OR 59-05-2 OR 7413-34-5)
6. Four trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (cyclosporin* OR ciclosporin*
OR capimune OR capsorin OR deximune OR emulsoforal OR neoral OR neciclopin OR sandimmun OR
syncloral OR vanquoral OR gengraf OR 59865-13-3 OR 63798-73-2)
7. Seven trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (infliximab OR remicade OR
170277-31-3)
8. Two trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (inflectra OR remsima OR
CT-P13)
9. Forty-seven trials found for Condition: (psoriasis OR psoriatic) AND Intervention: (secukinumab OR
Cosentyx OR AIN457 OR AIN-457 OR 1229022-83-6)
Quality-of-life review
MEDLINE & MEDLINE In-Process & Other Non-Indexed Citations
Via Ovid (http://ovidsp.ovid.com/).
Date range searched: 1946 to present.
Date searched: 12 July 2016.
Records retrieved: 140.
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Search strategy
A search filter was used to limit retrieval to quality-of-life studies – see lines 1–28 below.
1. quality-adjusted life years/ (8623)
2. “Value of Life”/ (5514)
3. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kf. (7149)
4. (quality adjusted or adjusted life year$).ti,ab,kf. (11,017)
5. disability adjusted life.ti,ab,kf. (1947)
6. daly$1.ti,ab,kf. (1798)
7. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kf. (482)
8. (multiattribute$ or multi attribute$).ti,ab,kf. (639)
9. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kf. (24,175)
10. utility.ab. /freq=2 (12,201)
11. utilities.ti,ab,kf. (5156)
12. disutili$.ti,ab,kf. (305)
13. (HSUV or HSUVs).ti,ab,kf. (28)
14. health$1 year$1 equivalent$1.ti,ab,kf. (40)
15. (hye or hyes).ti,ab,kf. (58)
16. (hui or hui1 or hui2 or hui3).ti,ab,kf. (1129)
17. (illness state$1 or health state$1).ti,ab,kf. (4781)
18. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kf. (6257)
19. (eq-sdq or eqsdq).ti,ab,kf. (0)
20. (short form$ or shortform$).ti,ab,kf. (23,633)
21. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kf. (17,244)
22. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kf. (2480)
23. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kf. (3232)
24. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kf. (20)
25. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kf. (315)
26. (15D or 15-D or 15 dimension).ti,ab,kf. (4251)
27. (standard gamble$ or sg).ti,ab,kf. (7698)
28. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kf. (1478)
29. or/1-28 (104,742)
30. Child$ Dermatolog$ Life Quality Index$.ti,ab,kf. (121)
31. CDLQI.ti,ab,kf. (114)
32. Dermatolog$ Life Quality Index$.ti,ab,kf. (1067)
33. DLQI.ti,ab,kf. (779)
34. P?ediatric Quality of Life Inventor$.ti,ab,kf. (792)
35. PedsQL$.ti,ab,kf. (998)
36. Teen$ quality of life questionnaire$.ti,ab,kf. (0)
37. T-QoL.ti,ab,kf. (2)
38. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 (2459)
39. 29 or 38 (106,897)
40. Psoriasis/ (29,336)
41. (psorias$ or psoriat$).ti,ab. (37,350)
42. parapsoriasis.ti,ab. (527)
43. (pustul$ adj2 palm$).ti,ab. (797)
44. 40 or 41 or 42 or 43 (43,220)
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45. exp Child/ (1,694,336)
46. exp Infant/ (1,023,912)
47. Adolescent/ (1,758,843)
48. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab. (1,712,033)
49. 45 or 46 or 47 or 48 (3,547,384)
50. 39 and 44 (758)
51. 49 and 50 (140)
Key
/ = indexing term (MeSH heading).
exp = exploded indexing term (MeSH heading).
$ = truncation.
$1 = limited truncation – 1 or 0 characters after word.
? =wild card – 1 or 0 characters within a word.
ti,ab,kf = terms in either title or abstract or author keyword fields.
ab. /freq=2 = terms appear at least twice in the abstract.
adj3 = terms within three words of each other (any order).
Cost-effectiveness Analysis (CEA) Registry
https://research.tufts-nemc.org/cear4/
Date searched: 12 July 2016.
Records retrieved: 23.
1. psoriasis – 22 results
2. psoriatic – 0 results
3. parapsoriasis – 0 results
4. pustulosis – 0 results
5. pustular – 0 results
6. Child Dermatology Life Quality Index – 0 results
7. CDLQI – 0 results
8. Dermatology Life Quality Index – 4 results
9. DLQI – 3 results
10. Pediatric Quality of Life Inventory – 0 results
11. Paediatric Quality of Life Inventory – 0 results
12. PedsQL – 0 results
13. Teenagers quality of life questionnaire – 0 results
14. T-QoL – 0 results
EMBASE
Via Ovid http://ovidsp.ovid.com/
Date range searched: 1974 to 11 July 2016.
Date searched: 12 July 2016.
Records retrieved: 169.
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Search strategy
1. quality adjusted life year/ (16,494)
2. “quality of life index”/ (2102)
3. “quality of life assessment”/ (1928)
4. (qaly$ or qald$ or qale$ or qtime$).ti,ab,kw. (12,590)
5. (quality adjusted or adjusted life year$).ti,ab,kw. (15,220)
6. disability adjusted life.ti,ab,kw. (2301)
7. daly$1.ti,ab,kw. (2364)
8. ((index adj3 wellbeing) or (quality adj3 wellbeing) or qwb).ti,ab,kw. (725)
9. (multiattribute$ or multi attribute$).ti,ab,kw. (788)
10. (utility adj3 (score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or instrument$1 or weight
or weights or weighting or information or data or unit or units or health$ or life or estimat$ or elicit$
or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or analysis or
index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states or
status)).ti,ab,kw. (34,463)
11. utility.ab. /freq=2 (17,405)
12. utilities.ti,ab,kw. (7886)
13. disutili$.ti,ab,kw. (539)
14. (HSUV or HSUVs).ti,ab,kw. (41)
15. health$1 year$1 equivalent$1.ti,ab,kw. (43)
16. (hye or hyes).ti,ab,kw. (106)
17. (hui or hui1 or hui2 or hui3).ti,ab,kw. (1578)
18. (illness state$1 or health state$1).ti,ab,kw. (7514)
19. (euro qual or euro qual5d or euro qol5d or eq-5d or eq5-d or eq5d or euroqual or euroqol or
euroqual5d or euroqol5d).ti,ab,kw. (10,726)
20. (eq-sdq or eqsdq).ti,ab,kw. (0)
21. (short form$ or shortform$).ti,ab,kw. (29,716)
22. exp short form 36/ (18,971)
23. (sf36$ or sf 36$ or sf thirtysix or sf thirty six).ti,ab,kw. (26,999)
24. (sf6 or sf 6 or sf6d or sf 6d or sf six or sfsix or sf8 or sf 8 or sf eight or sfeight).ti,ab,kw. (3155)
25. (sf12 or sf 12 or sf twelve or sftwelve).ti,ab,kw. (5241)
26. (sf16 or sf 16 or sf sixteen or sfsixteen).ti,ab,kw. (35)
27. (sf20 or sf 20 or sf twenty or sftwenty).ti,ab,kw. (303)
28. (15D or 15-D or 15 dimension).ti,ab,kw. (5069)
29. (standard gamble$ or sg).ti,ab,kw. (10,415)
30. (time trade off$1 or time tradeoff$1 or tto or timetradeoff$1).ti,ab,kw. (1985)
31. or/1-30 (148,427)
32. Child$ Dermatolog$ Life Quality Index$.ti,ab,kw. (173)
33. CDLQI.ti,ab,kw. (172)
34. dermatology life quality index/ (1292)
35. Dermatolog$ Life Quality Index$.ti,ab,kw. (1864)
36. DLQI.ti,ab,kw. (1660)
37. P?ediatric Quality of Life Inventor$.ti,ab,kw. (1084)
38. PedsQL$.ti,ab,kw. (1779)
39. Teen$ quality of life questionnaire$.ti,ab,kw. (2)
40. T-QoL.ti,ab,kw. (8)
41. or/32-40 (4669)
42. 31 or 41 (152,183)
43. exp psoriasis/ (58,850)
44. (psorias$ or psoriat$).ti,ab. (54,945)
45. parapsoriasis.ti,ab. (573)
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46. (pustul$ adj2 palm$).ti,ab. (1062)
47. 43 or 44 or 45 or 46 (71,249)
48. 42 and 47 (2034)
49. exp child/ (2,336,115)
50. exp adolescent/ (1,362,547)
51. juvenile/ (26,527)
52. (adolescen$ or baby or babies or child or children or boy or boys or girl or girls or infant$ or infanc$ or
juvenile$ or paediatric or pediatric or preschooler$ or schoolboy$ or schoolgirl$ or schoolchild$ or teens
or teenage$ or toddler$ or youth or youths or young people or young person$).ti,ab. (2,090,417)
53. 49 or 50 or 51 or 52 (3,590,832)
54. 48 and 53 (169)
Key
/ = indexing term (MeSH heading).
exp = exploded indexing term (MeSH heading).
$ = truncation.
$1 = limited truncation – 1 or 0 characters after word.
? =wild card –1 or 0 characters within a word.
ti,ab,kf = terms in either title or abstract or author keyword fields.
ab. /freq=2 = terms appear at least twice in the abstract.
adj3 = terms within three words of each other (any order).
PubMed
www.ncbi.nlm.nih.gov/pubmed/
Date searched: 12 July 2016.
Records retrieved: 154.
Search strategy
((((((((((((((((((((((((((((((((“Quality-Adjusted Life Years”[Mesh:noexp]) OR “Value of Life”[Mesh:noexp]) OR
((qaly*[Text Word] OR qald*[Text Word] OR qale*[Text Word] OR qtime*[Text Word]))) OR ((“quality
adjusted”[Text Word] OR “adjusted life year”[Text Word] OR “adjusted life years”[Text Word]))) OR
“disability adjusted life”[Text Word]) OR daly*[Text Word]) OR ((((index[Text Word] AND wellbeing[Text
Word])) OR (quality[Text Word] AND wellbeing[Text Word])) OR qwb[Text Word])) OR ((multiattribute*[Text
Word] OR “multi attribute”[Text Word] OR “multi attributes”[Text Word]))) OR ((utility[Text Word]) AND
(score*[Text Word] OR scoring[Text Word] OR valu*[Text Word] OR measur*[Text Word] OR evaluat*[Text
Word] OR scale*[Text Word] OR instrument*[Text Word] OR weight[Text Word] OR weights[Text Word] OR
weighting[Text Word] OR information[Text Word] OR data[Text Word] OR unit[Text Word] OR units[Text
Word] OR health*[Text Word] OR life[Text Word] OR estimat*[Text Word] OR elicit*[Text Word] OR
disease*[Text Word] OR mean[Text Word] OR cost*[Text Word] OR expenditure*[Text Word] OR gain[Text
Word] OR gains[Text Word] OR loss[Text Word] OR losses[Text Word] OR lost[Text Word] OR analysis[Text
Word] OR index*[Text Word] OR indices[Text Word] OR overall[Text Word] OR reported[Text Word] OR
calculat*[Text Word] OR range*[Text Word] OR increment*[Text Word] OR state[Text Word] OR states[Text
Word] OR status[Text Word]))) OR utility[Title/Abstract]) OR utilities[Text Word]) OR disutili*[Text Word]) OR
((HSUV[Text Word] OR HSUVs[Text Word]))) OR ((((“healthy year equivalent”[Text Word] OR “healthy years
equivalent”[Text Word]) OR “healthy years equivalents”[Text Word]) OR “healthy year equivalents”[Text
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
212
Word]))) OR ((hye[Text Word] OR hyes[Text Word]))) OR ((hui[Text Word] OR hui1[Text Word] OR hui2[Text
Word] OR hui3[Text Word]))) OR ((“illness state”[Text Word] OR “illness states”[Text Word] OR “health
state”[Text Word] OR “health states”[Text Word]))) OR ((“euro qual”[Text Word] OR “euro qual5d”[Text
Word] OR “euro qol5d”[Text Word] OR eq-5d[Text Word] OR eq5-d[Text Word] OR eq5d[Text Word] OR
euroqual[Text Word] OR euroqol[Text Word] OR euroqual5d[Text Word] OR euroqol5d[Text Word]))) OR
((eq-sdq[Text Word] OR eqsdq[Text Word]))) OR ((“short form”[Text Word] OR “short forms”[Text Word]
OR shortform*[Text Word]))) OR ((sf36*[Text Word] OR sf-36*[Text Word] OR “sf thirtysix”[Text Word]
OR “sf thirty six”[Text Word]))) OR ((sf6[Text Word] OR “sf 6”[Text Word] OR sf6d[Text Word] OR “sf
6d”[Text Word] OR “sf six”[Text Word] OR sfsix[Text Word] OR sf8[Text Word] OR “sf 8”[Text Word]
OR “sf eight”[Text Word] OR sfeight[Text Word]))) OR ((sf12[Text Word] OR “sf 12”[Text Word] OR
“sf twelve”[Text Word] OR sftwelve[Text Word]))) OR ((sf16[Text Word] OR “sf 16”[Text Word] OR “sf
sixteen”[Text Word] OR sfsixteen[Text Word]))) OR ((sf20[Text Word] OR “sf 20”[Text Word] OR
“sf twenty”[Text Word] OR sftwenty[Text Word]))) OR ((15D[Text Word] OR 15-D[Text Word] OR “15
dimension”[Text Word]))) OR ((“standard gamble”[Text Word] OR “standard gambles”[Text Word] OR sg
[Text Word]))) OR ((“time trade off”[Text Word] OR “time trade offs”[Text Word] OR “time tradeoff”[Text
Word] OR “time tradeoffs”[Text Word] OR tto[Text Word] OR timetradeoff*[Text Word]))) OR ((Child* AND
Dermatolog* AND Life Quality Index*[Text Word]) OR (CDLQI[Text Word]) OR (Dermatolog* AND Life
Quality Index*[Text Word]) OR (DLQI[Text Word]) OR (Pediatric Quality of Life Inventor*[Text Word] OR
Paediatric Quality of Life Inventor*[Text Word]) OR (PedsQL*[Text Word]) OR (Teen* AND quality of life
questionnaire*[Text Word]) OR (T-QoL[Text Word])))) AND ((((“Psoriasis”[Mesh:noexp]) OR ((psorias*[Title/
Abstract] OR psoriat*[Title/Abstract]))) OR parapsoriasis[Title/Abstract]) OR ((pustul*[Title/Abstract] AND
palm*[Title/Abstract]))))) AND ((((“Child”[Mesh]) OR “Infant”[Mesh]) OR “Adolescent”[Mesh]) OR
((adolescen*[Title/Abstract] OR baby[Title/Abstract] OR babies[Title/Abstract] OR child[Title/Abstract] OR
children[Title/Abstract] OR boy[Title/Abstract] OR boys[Title/Abstract] OR girl[Title/Abstract] OR girls[Title/
Abstract] OR infant*[Title/Abstract] OR infanc*[Title/Abstract] OR juvenile*[Title/Abstract] OR paediatric
[Title/Abstract] OR pediatric[Title/Abstract] OR preschooler*[Title/Abstract] OR schoolboy*[Title/Abstract] OR
schoolgirl*[Title/Abstract] OR schoolchild*[Title/Abstract] OR teens[Title/Abstract] OR teenage*[Title/
Abstract] OR toddler*[Title/Abstract] OR youth[Title/Abstract] OR youths[Title/Abstract] OR “young
people”[Title/Abstract] OR “young person”[Title/Abstract] OR “young persons”[Title/Abstract])))
Key
[Mesh] = exploded indexing term (MeSH heading).
[Mesh:noexp] = indexing term (MeSH heading) not exploded.
* = truncation.
[Text Word] = searches in the title, abstract, MeSH headings and subheadings, other terms field, chemical
names of substances.
[Title/Abstract] = terms in either title or abstract fields.
“ “ = phrase search.
School of Health and Related Research Health Utilities Database (ScHARRHUD)
www.scharrhud.org/
Date searched: 12 July 2016.
Records retrieved: 20.
Search strategy
psorias* OR psoriat* OR parapsoriasis
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Pustulosis OR Pustular
Child* Dermatolog* Life Quality Index*
CDLQI
Dermatolog* Life Quality Index*
DLQI
Pediatric Quality of Life Inventor* OR Paediatric Quality of Life Inventor*
PedsQL*
Teen* quality of life questionnaire*
T-QoL
(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
Key
* = truncation.
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Appendix 2 Summary of included records
Study ID
(ClinicalTrials.gov ID) Design
First author
and year Title Record type
Adalimumab
M04-717
(NCT01251614)
RCT/open-label
extension
AbbVie 201045 A double blind study in pediatric
participants with chronic plaque
psoriasis, studying adalimumab
vs. methotrexate
Protocol
Papp 201340 Study design and baseline characteristics
from a Phase 3, randomized, double-
blind study of adalimumab versus
methotrexate treatment in pediatric
patients with chronic plaque psoriasis
Meeting
abstract
Papp 201439 Baseline characteristics in pediatric
patients with chronic plaque psoriasis
from a Phase 3, randomized, double-
blind study of adalimumab versus
methotrexate treatment
Meeting
abstract
Papp 201444 Study design and baseline
characteristics from a Phase 3,
randomised, double-blind study of
adalimumab versus methotrexate
treatment in paediatric patients with
chronic plaque psoriasis
Meeting
abstract
Papp 201542 Efficacy and safety of adalimumab
versus methotrexate treatment in
pediatric patients with severe chronic
plaque psoriasis: results from the
16-week randomized, double-blind
period of a Phase 3 study
Meeting
abstract
Phillip 201543 Efficacy, safety of adalimumab versus
methotrexate in pediatric patients
with severe chronic plaque psoriasis:
results from the treatment withdrawal
and double-blind retreatment periods
of a Phase 3 study
Meeting
abstract
European
Medicines
Agency 201546
Extension of indication variation
assessment report: Humira
(adalimumab). Procedure no. EMEA/
H/C/000481/II/0134
Regulatory
documentation
European
Medicines
Agency 201547
Assessment report for paediatric studies
submitted according to Article 46 of
the Regulation (EC) no. 1901/2006:
Humira (adalimumab)
Regulatory
documentation
Papp 201641 Adalimumab long-term safety/efficacy
results for pediatric patients with
chronic plaque psoriasis from a
Phase 3, randomized study
Meeting
abstract
Amgen 200479 Etanercept (Enbrel®) in Psoriasis –
Pediatrics
Siegfried 201080 Intermittent etanercept therapy in
pediatric patients with psoriasis
Thaci 201587 Safety and efficacy for pediatric
patients with chronic plaque psoriasis
who did not respond to 16 weeks of
double-blind methotrexate treatment
and switched to adalimumab
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Study ID
(ClinicalTrials.gov ID) Design
First author
and year Title Record type
Etanercept
20030211
(NCT00078819)
RCT/open label Amgen 200479 Etanercept (Enbrel®) in psoriasis –
pediatrics
Protocol
Levy 200554 Etanercept in children and
adolescents with psoriasis
Meeting
abstract
Siegfried 200655 Etanercept in children and
adolescents with psoriasis
Meeting
abstract
Paller 200756 A 12-week Phase 3 study of efficacy
and safety of etanercept therapy in
children and adolescents with
moderate to severe plaque psoriasis
Meeting
abstract
Paller 200849 Etanercept treatment for children and
adolescents with plaque psoriasis
Journal article
Paller 200857 Etanercept treatment in children and
adolescents with plaque psoriasis
Meeting
abstract
Langley 201148 Patient-reported outcomes in
pediatric patients with psoriasis
undergoing etanercept treatment:
12-week results from a Phase III
randomized controlled trial
Journal article
Siegfried 201080 Intermittent etanercept therapy in
pediatric patients with psoriasis
Journal article
Paller 201050 Subgroup analyses of etanercept in
pediatric patients with psoriasis
Research letter
Landells 201051 Efficacy and safety of etanercept in
children and adolescents aged ≥ 8
years with severe plaque psoriasis
Journal article
Paller 201058 Interim results of a long-term safety
and tolerability study of etanercept
treatment in children and adolescents
age 8 to 17 years with plaque
psoriasis
Meeting
abstract
US Food
and Drug
Administration
200861
Enbrel (etanercept) for the treatment
of pediatric plaque psoriasis
Regulatory
documentation
Amgen (via US
Food and Drug
Administration)
200862
Background information for the
Dermatologic and Ophthalmologic
Drugs Advisory Committee (DODAC)
meeting, 18 June 2008
Regulatory
documentation
European
Medicines
Agency 200863
Assessment report for Enbrel.
International nonproprietary name:
INN – etanercept. Procedure no.
EMEA/H/C/262/II/94
Regulatory
documentation
European
Medicines
Agency 201164
Assessment report for Enbrel.
International nonproprietary name:
etanercept. Procedure no. type II
variation EMEA/H/C/262/II/134
Regulatory
documentation
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Study ID
(ClinicalTrials.gov ID) Design
First author
and year Title Record type
20050111
(NCT00141921)
Observational
study (long-term
extension of study
20030211)
Amgen 200566 Pediatric open-label extension study Protocol
Amgen 201265 An open-label extension study to
evaluate the safety of etanercept in
pediatric participants with plaque
psoriasis
Protocol
Paller 201052 Long-term etanercept in pediatric
patients with plaque psoriasis
Journal article
Paller 201059 Safety and efficacy of etanercept
treatment in children and adolescents
with plaque psoriasis: 96-week results
of open-label extension study
Meeting
abstract
Paller 201553 Long-term safety and efficacy of
etanercept in children and
adolescents with plaque psoriasis
Journal article
Paller 201660 Five-year open-label extension study
of safety and efficacy of etanercept
in children and adolescents with
moderate to severe plaque psoriasis
Meeting
abstract
European
Medicines
Agency 201367
Enbrel: etanercept. Procedure no.
EMEA/H/C/000262/A46/134. CHMP
assessment report for paediatric
use studies submitted according to
Article 46 of the Regulation (EC)
no. 1901/2006
Regulatory
documentation
NCT01100034 Observational
study
Pfizer 201068 Study evaluating the safety and
effectiveness of etanercept for the
treatment of pediatric psoriasis
Protocol
NCT01432249 Observational
study
Pfizer 201169 Post marketing surveillance to observe
safety and efficacy of Enbrel In
pediatric patients with psoriasis
Protocol
CAIN457A2310
(NCT02471144)
RCT Novartis
Pharmaceuticals,
201570
Pediatric study in children and
adolescents with severe plaque
psoriasis
Protocol
Novartis
Pharmaceuticals
201571
A randomized, double-blind, placebo-
and active controlled multicenter trial to
demonstrate efficacy of subcutaneous
secukinumab compared to placebo and
etanercept (in a single blinded arm)
after twelve weeks of treatment, and
to assess the safety, tolerability, and
long-term efficacy in participants from
6 to less than 18 years of age with
severe chronic plaque psoriasis
Protocol
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Study ID
(ClinicalTrials.gov ID) Design
First author
and year Title Record type
Ustekinumab
CNTO1275PSO3006/
CADMUS
(NCT01090427)
RCT/open-label
extension
Janssen Research
& Development,
LLC 201074
A study of the safety and efficacy of
ustekinumab in adolescent patients
with psoriasis (CADMUS)
Protocol
Landells 201572 Ustekinumab in adolescent patients age
12 to 17 years with moderate-to-severe
plaque psoriasis: results of the
randomized Phase 3 CADMUS study
Journal article
Landells 201573 Safety and efficacy of ustekinumab in
adolescent patients with moderate to
severe plaque psoriasis: results through
1 year of the Phase 3 CADMUS trial
Meeting
abstract
European
Medicines
Agency 201575
Assessment report: Stelara.
International non-proprietary name:
ustekinumab. Procedure no. EMEA/H/
C/000958/II/0042
Regulatory
documentation
CR108129/
CNTO1275PSO3013/
CADMUS Jr
(NCT02698475)
Observational
study
Janssen Research
& Development,
LLC 201681
An efficacy, safety, and
pharmacokinetics study of
subcutaneously administered
ustekinumab in the treatment of
moderate to severe chronic plaque
psoriasis in pediatric participants greater
than 6 to less than 12 years of age
Protocol
Observational
study
Janssen-Cilag
International
201682
A Phase 3 open-label study to
assess the efficacy, safety, and
pharmacokinetics of subcutaneously
administered ustekinumab in the
treatment of moderate to severe
chronic plaque psoriasis in pediatric
participants greater than 6 to less
than 12 years of age
Protocol
Multiple biological/systemic treatments
Garber 2015 Observational
study
Garber 201576 Systemic treatment of recalcitrant
pediatric psoriasis: a case series and
literature review
Journal article
Klufas 2016 Observational
study
Klufas 201677 Treatment of moderate to severe
pediatric psoriasis: a retrospective
case series
Journal article
Systematic reviews
PROSPERO2015:
CRD42015025262
Systematic review Chingcuanco
201583
TNF-inhibitors: comparing the safety,
efficacy and physicochemical profiles
of biosimilars and innovators
Systematic
review protocol
PROSPERO2015:
CRD42015017538
Systematic review Smith 201584 In people with psoriasis (all types),
what are the clinical effectiveness/
efficacy, safety and tolerability of
systemic biologics (adalimumab,
etanercept, infliximab, secukinumab
or ustekinumab) compared with each
other, with methotrexate or with
placebo?
Systematic
review protocol
Sanclemente 2015 Systematic review Sanclemente
201585
Anti-TNF agents for paediatric
psoriasis
Systematic
review
de Jager 2010 Systematic review de Jager
201078,86
Efficacy and safety of treatments for
childhood psoriasis: a systematic
literature review
Systematic
review
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Appendix 3 List of excluded studies with reasons
for exclusion
Study Record title
Reason for
exclusiona
Vencovsky 2015179 A Phase III randomised, double-blind clinical study comparing SB4, an
etanercept biosimilar, with etanercept reference product (Enbrel) in patients
with moderate to severe rheumatoid arthritis despite methotrexate therapy
(24-week results)
1
Tarp 2015180 Comparative effectiveness associated with the use of biologics and small-
molecules for psoriasis: protocol for a systematic review and meta-analysis
1
Soliman 2015181 Combination therapy of methotrexate plus NBUVB phototherapy is more
effective than methotrexate monotherapy in the treatment of chronic plaque
psoriasis
2
Ruano 2015182 Short-term effectiveness and safety of new biologic agents targeting
IL-23/Th17 pathway for moderate to severe plaque psoriasis: a systematic
review and network meta-analysis
1
Puig 2015183 Long-term efficacy, safety and drug survival of ustekinumab in a Spanish
cohort of patients with moderate to severe plaque psoriasis
1
Lebwohl 2015184 Phase 3 studies comparing brodalumab with ustekinumab in psoriasis 1
Langley 2015185 Long-term efficacy and safety of ustekinumab, with and without dosing
adjustment, in patients with moderate-to-severe psoriasis: results from the
PHOENIX 2 study through 5 years of follow-up
1
Kimball 2015186 OBSERVE-5: observational postmarketing safety surveillance registry of
etanercept for the treatment of psoriasis final 5-year results
1
Bra˘nis¸teanu 2015187 Adverse reactions of biological therapy for psoriasis 2
Ali 2015188 A systematic review of the impact on quality of life of topical, systemic and
biologic therapies for psoriasis
1
NIHR Horizon Scanning
Centre 2014189
Adalimumab (Humira) for severe chronic plaque psoriasis in children and
adolescents – second line
4
Umezawa 2013190 Drug survival rates in patients with psoriasis after treatment with biologics 2
Strohal 2013191 Etanercept provides an effective, safe and flexible short- and long-term
treatment regimen for moderate-to-severe psoriasis: a systematic review of
current evidence
1
Park 2013192 A randomized, ‘head-to-head’ pilot study comparing the effects of
etanercept monotherapy vs. etanercept and narrowband ultraviolet B
(NB-UVB) phototherapy in obese psoriasis patients
1
NIHR Horizon Scanning
Centre 2013193
Ustekinumab (Stelara) for plaque psoriasis in adolescents 4
López-Ferrer 2013194 Adalimumab for the treatment of psoriasis in real life: a retrospective cohort
of 119 patients at a single Spanish centre
1
Lebwohl 2013195 A randomized study to evaluate the efficacy and safety of adding topical
therapy to etanercept in patients with moderate to severe plaque psoriasis
1
Janagond 2013196 Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients
with significant palmoplantar involvement: a prospective, randomized study
2
Gisondi 2013197 Metabolic abnormalities associated with initiation of systemic treatment for
psoriasis: evidence from the Italian Psocare Registry
1
da Silva 2013198 Methotrexate for psoriasis 5
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Study Record title
Reason for
exclusiona
Chen 2013199 Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or
psoralen-ultraviolet A photochemotherapy for psoriasis
3
Burmester 2013200 Adalimumab: long-term safety in 23 458 patients from global clinical trials in
rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis, psoriasis and Crohn’s disease
1
Balzola 2013201 Adalimumab: long-term safety in 23 458 patients from global clinical trials in
rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis, psoriasis and Crohn’s disease
1
All Wales Medicines
Strategy Group 2013202
AWMSG Secretariat Assessment Report. Etanercept (Enbrel®) 4
Strand 2012203 Comparison of health-related quality of life in rheumatoid arthritis, psoriatic
arthritis and psoriasis and effects of etanercept treatment
1
Lynde 2012204 A randomized study comparing the combination of nbUVB and etanercept to
etanercept monotherapy in patients with psoriasis who do not exhibit an
excellent response after 12 weeks of etanercept
1
Kim 2012205 Comparative efficacy of biologics in psoriasis: a review 1
Famenini 2012206 The safety of ustekinumab in psoriasis 1
Chiu 2012207 The effectiveness and safety of adalimumab in the treatment of
non-reimbursed patients with mild-to-moderate psoriasis
1
Burmester 2012208 Long-term safety of adalimumab in patients from global clinical trials in
rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis, psoriasis, and Crohn’s disease
1
Young 2011209 The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe
psoriasis patients
1
Ryan 2011210 Association between biologic therapies for chronic plaque psoriasis and
cardiovascular events: a meta-analysis of randomized controlled trials
1
Lara-Corrales 2011211 Childhood psoriasis treatment: evidence published over the last 5 years 5
Brunasso 2011212 Tolerability and safety of biological therapies for psoriasis in daily clinical
practice: a study of 103 Italian patients
1
Menter 2010213 Efficacy and safety of adalimumab across subgroups of patients with
moderate to severe psoriasis
1
Esposito 2010214 Continuous treatment of plaque-type psoriasis with etanercept: an
observational long-term experience
1
All Wales Medicines
Strategy Group 2010139
Final appraisal report etanercept (Enbrel) 5
National Horizon Scanning
Centre 2008215
Etanercept (Enbrel) for moderate-to-severe plaque psoriasis in children and
adolescents
4
Flytström 2008123 Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and
safety. A randomized controlled trial
1
Romero-Maté 2007216 Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated
review
1
Ranjan 2007217 Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to
treat moderate-to-severe chronic plaque psoriasis: a comparative study
1
Krueger 2006218 Patients with psoriasis respond to continuous open-label etanercept
treatment after initial incomplete response in a randomized, placebo-
controlled trial
1
Gordon 2006219 Efficacy of etanercept in an integrated multistudy database of patients with
psoriasis
1
Amornpinyokeit 2006220 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis 3
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Study Record title
Reason for
exclusiona
Bigby 2004221 A randomized controlled trial of methotrexate and cyclosporine in the
treatment of psoriasis
1
Heydendael 2002222 Cyclosporin trough levels: Is monitoring necessary during short-term
treatment in psoriasis? A systematic review and clinical data on trough levels
1
Faerber 2001223 Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients 1
Ho 1999224 Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive
to topical therapy: a 1-year multicentre, randomized study. The PISCES Study
Group
2
Zachariae 1998225 Conversion of psoriasis patients from the conventional formulation of
cyclosporin A to a new microemulsion formulation: a randomized, open,
multicentre assessment of safety and tolerability
1
Koo 1998226 A randomized, double-blind study comparing the efficacy, safety and optimal
dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients
with severe psoriasis. OLP302 Study Group
1
Laburte 1994227 Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term
treatment of chronic severe plaque psoriasis
1
Italian Multicenter Study
Group on Cyclosporin in
Psoriasis 1993228
Cyclosporin versus etretinate: Italian multicenter comparative trial in severe
plaque-form psoriasis
1
Christophers 1992229 Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque
psoriasis. The German Multicenter Study
1
Tanew 1991230 Photochemotherapy for severe psoriasis without or in combination with
acitretin: a randomized, double-blind comparison study
1
Ruzicka 1990231 Efficiency of acitretin in combination with UV-B in the treatment of severe
psoriasis
1
Kragballe 1989232 A double-blind comparison of acitretin and etretinate in the treatment of
severe psoriasis. Results of a Nordic multicentre study
1
Takashima 1988233 Comparison of therapeutic efficacy of topical PUVA, oral etretinate, and
combined PUVA and etretinate for the treatment of psoriasis and
development of PUVA lentigines and antinuclear antibodies
1
Geiger 1988234 Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies 1
Melis 1984235 [Treatment of plaque psoriasis with an aromatic retinoid (etretinate)] 2
Christiansen 1982236 Etretinate (Tigason) and betamethasone valerate (Celeston valerate) in the
treatment of psoriasis. A double-blind, randomized, multicenter trial
2
Janssen Biotech, Inc.237 Ustekinumab safety and surveillance program using the Ingenix NHI database 1
Wyeth 2008238 Study evaluating the safety of Enbrel (etanercept) 1
a 1= not children and/or young people who have moderate-to-severe plaque psoriasis; 2 =mixed adults and children –
unable to separate into subgroups; 3= does not include data on adalimumab, etanercept, ustekinumab, methotrexate,
ciclosporin or acitretin; 4 = does not measure a clinical outcome (e.g. only pharmacokinetics); 5= not a RCT, open-label
extension study or observational study (e.g. reject if a single case report).
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Appendix 4 Evidence synthesis modelling,
software and WinBUGS code
Bayesian NMA was conducted to pool trial results. NMA models were programmed in WinBUGS software(version 1.4.3) using a Bayesian statistical framework. WinBUGS is a Bayesian analysis software tool that,
through the use of Gibbs sampling (a Markov chain Monte Carlo method), evaluates posterior distributions
for the parameters of interest given likelihood functions derived from data and prior probabilities. Fixed- and
random-effects models were evaluated. Model selection was determined by model fit statistics (i.e. DIC and
total residual deviance) to identify the best model choice. Treatment effects were expressed in relation to
placebo. Uninformative priors were used throughout. The Bayesian NMA for PASI utilised a framework of
analysis that evaluated the probability of PASI responses in different categories of PASI thresholds (50, 75
and 90) within a single model. The analyses followed the principles outlined in the NICE Decision Support
Unit (DSU).95 The single synthesis multinomial model with a probit link is recommended by the NICE DSU
and assumes that there is an underlying continuous variable that has been categorised by specifying the
cut-off points. It assumes also that the treatment effect is the same regardless of the different cut-off points
in each trial. All PASI response models were run for 10,000 iterations after a burn-in of 20,000 on two
chains. Synthesis model results provide pooled probabilities of achieving PASI 50, 75 and 90 responses for
each treatment of interest, alongside a measure of uncertainty, that is, the 95% CrI. In brief, trials report rikj,
the number of patients in arm k of trial i belonging to different, mutually exclusive categories j = 1, 2, 3,
where these categories represent the different thresholds of PASI score (e.g. 50%, 75% or 90%
improvement). The responses for each arm k of trial i in category j follow a multinomial distribution:
r i,k, j = 1,: : :, J ∼Multinomial(pi,k, j = 1,: : :, J, ni,k) with∑
J
j = 1
pi,k, j = 1, (4)
which has been parameterised as a series of conditional binomial distributions, with parameters of interest
the probabilities, pikj, that a patient in arm k (k = 1, 2, 3) of trial i (i = 1,. . . . .,I) belongs to category j (j = 1,
2, 3). A probit link function was used, the inverse of the normal cumulative distribution function Φ, to
define pikj as a function of a set of threshold values, zj. The threshold values (estimated within the model)
are such that the probability that the standard normal (the probit score) will take a value less than or equal
to z1 will reflect the probability of obtaining a PASI response lower than 50%, that is, 1 – PASI50. The
probability that the standard normal will take a value less than or equal to z2 will reflect the probability of
obtaining a PASI response lower than 75%, that is, 1 – PASI75 and, analogously, evaluating Φ at z3 will
approximate 1 – PASI90. Placebo and treatments are assumed to shift the mean of the distribution. This
means that the pooled effect of taking the experimental treatment instead of the control is to change the
probit score (or z-score) of the control arm by di,1 standard deviations. Therefore, the model is written as:
pik j =Φ(µi + z j + δi, 1k Ifk≠1g). (5)
The terms zj are the differences on the standard normal scale between the response to category j and the
response to category j – 1 in all of the arms of trial i. The correlation structure induced by three-arm trials was
accounted for as a substantial proportion of the studies forming the evidence base had such characteristics.
We assumed that the baselines, µi, were trial specific (i.e. unconstrained – except for model 1b) and were
given a non-informative prior. A non-informative prior was assigned to the treatment effects parameter
(δt). A uniform prior was assigned to the parameter zj.
Alternative assumptions were tested in two analyses. The first assumed a meta-regression for placebo
effects (model 2a). In a second analysis we explored the impact on treatment effects of adjusting for age,
that is, explicitly modelling children and young people and adult subgroups (model 2b). The key
assumptions implemented for PASI responses in the models and detailed coding of the models are
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presented in Table 99. The preferred model was used to evaluate the estimated probability of achieving
PASI 50, 75 and 90 responses on treatment t, using:
T a jt = 1−Φ(A + δt + z j), (6)
for adults and:
T c jt = 1−Φ(A + δt + z j + B), (7)
for children and young people, where A is the pooled baseline effect. The baseline effect, A, was estimated as:
A =
∑µi1
NS
, (8)
where µi1 is the baseline effects, i is the studies and 1 = placebo, NS is the number of studies and B is the
common regression (slope) coefficient relating to the treatment*age interaction, which is assumed to be
identical for all treatments. This is a strong assumption but, because of only increasing the number of
parameters in the model by 1, is the least data demanding. Other interaction assumptions were tested
(i.e. independent and exchangeable)138 but the model was unable to appropriately estimate all parameters.
We adopted the WinBUGS code presented in DSU2239 for the analysis, although we identified that the
model was not specifying the z-score correctly in the linear predictor specification when the first category
of the response data (in this case PASI 50) was missing. A correction was made to incorporate the correct
specification for the z-score in the linear predictor specification.
TABLE 99 Description of models and underlying assumptions for PASI response
Model 2 Model 2a Model 2b
Likelihood
r ik j ∼Binomial(pik j ,nik j )
Model
qik j = 1−(pikC l, j=1 /pikC l, j )
θik j = µi + δt i, k − δt i,1 + z j
pikCi, j = 1−ADik j
ADik j = ϕ(θik, j=1)
δt ∼dnorm(dt ,σ
2)
Priors
σ∼dunif (0,2)
µi ∼dnorm(0,0:000001)
z j∼dunif (0,5)
Likelihood
r ik j ∼Binomial(pik jnik j)
Model
qik j = 1− (pikC i, j+1 /pikC i, j )
θik j = µi + δt i,k − δt i,1 + z j + β(µi − µ)
pikC i j = 1−ADik j
ADik j = ϕ(θik, j−1)
δt ∼dnorm(dt ,σ
2)
Priors
σ∼dunif (0,2)
µi ∼dnorm(0:0:0001)
β∼dnorm(0,0:0001)
z j ∼dunif (0,5)
Likelihood
r ik j ∼Binomial(pik jnik j )
Model
qik j = 1− (pikC i, j+1 /pikC i, j )
θik j = µi + δt i,k − δt i,1 + z j + β(µi − µ) + γ.x i
pikC i j = 1−ADik j
ADik j = ϕ(θik, j−1)
δi ∼dnorm(d i,σ
2)
Priors
σ∼dunif (0,2)
µi ∼dnorm(0,0:0001)
β∼dnorm(0,0:0001)
γ∼dnorm(0,0:0001)
z j ∼dunif (0,5)
Assumptions:
l unconstrained baselines
l independent treatment effects
l random effects
between studies
l fixed effect for each of the
j – 1 categories over all trials
Assumptions:
l unconstrained baselines
l independent treatment effects
l random effects between studies
l fixed effect for each of the j – 1
categories over all trials
l common interaction term between
studies (placebo effect
adjustment, β)
Assumptions:
l unconstrained baselines
l independent treatment effects
l random effects between studies
l fixed effect for each of the j – 1
categories over all trials
l common interaction term between
studies (placebo effect
adjustment, β)
l common interaction term between
studies (population adjustment, γ)
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WinBUGS code for the preferred model
model { 
     
    sw[1]<- 0 
    for(i in 1:N) { 
        p[i,1] <- 1  
        for (j in 1:nc[i]-1) {  
            r[i,j] ~ dbin(q[i,j],n[i,j])  
            q[i,j] <- 1-(p[i,C[i,j+1]]/p[i,C[i,j]]) 
            z.index[i,j]<- C[i,j+1]-1 
            theta[i,j] <- mu[s[i]] + delta[i]*(1-equals(t[i],b[i])) + z[z.index[i,j]] +  
                               betaplac*(mu[s[i]]-mu_m)*(1-equals(t[i],1)) +  
                (beta[t[i]]-beta[t[1]]) * (1-equals(t[i],1)) * pop[i] 
            rhat[i,j] <- q[i,j] * n[i,j]  
            dv[i,j] <- 2 * (r[i,j]*(log(r[i,j])-log(rhat[i,j])) + (n[i,j]-r[i,j])*(log(n[i,j]-r[i,j]) - log(n[i,j]-rhat[i,j]))) 
            } 
    dev[i] <- sum(dv[i,1:nc[i]-1]) 
 
    delta[i] ~ dnorm(md[i], prec) 
    md[i] <- d[t[i]] - d[b[i]] + equals(m[i],3) * sw[i]     
  
    for (j in 2:nc[i]) {  
        p[i,C[i,j]] <- 1 - phi.adj[i,j]  
        phi.adj[i,j] <- phi(theta[i,j-1]) 
        } 
    } 
  
    for(k in 2:N) {   
        sw[k]<- (delta[k-1] - d[t[k-1]] + d[b[k-1]]) / 2 
        } 
    totresdev <- sum(dev[])  
    z[1] <- 0  
    for (j in 2:Cmax-1) { 
        z.aux[j] ~ dunif(0,5)  
        z[j] <- z[j-1] + z.aux[j]  
        } 
 
    for(i in 1:ns){ mu[i] ~ dnorm(0,0.0001) } 
 
    d[1] <- 0 
    beta[1] <- 0  
    for (k in 2:nt){  
        d[k] ~ dnorm(0,0.00001) 
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        beta[k] <- B 
        }  
  
    betaplac ~ dnorm(0,0.00001) 
    tau~dunif(0,2) 
    tau.sq<-tau*tau 
    prec<-1/(tau.sq) 
 
#baseline mu - based on average of the 31 trials including it.  
    for (i in 1:31) { mu1[i]<-mu[i]*equals(b[i*2-1],1) } 
    for (i in 1:6) { mu1[31+i]<-mu[31+i]*equals(b[60+i*3],1) } 
  
    A<-sum(mu1[])/31 
    B ~ dnorm(0,0.0001)  
  
# calculate prob of achieving PASI50/75/90 on treat k for adults (Ta) and children (Tc) 
    for (k in 1:nt) {  
        for (j in 1: Cmax-1) { 
            Ta[j,k] <- 1 - phi(A + d[k] + z[j]) 
            Tc[j,k] <- 1 - phi(A + d[k] + z[j] + B) 
            } 
        } 
 
# calculate RR PASI50,75,90 on treat k 
    for (c in 1:(nt-1)) {  
        for (k in (c+1):nt) {  
            for (j in 1: Cmax-1) { 
 RRa[j,c,k] <- Ta[j,k]/Ta[j,c] 
 RRc[j,c,k] <- Tc[j,k]/Tc[j,c] 
 } 
            } 
        } 
 
} 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
226
Appendix 5 Studies excluded from the network
meta-analyses
No treatment arm of interest (12 studies)
Lebwohl 2003
Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator,
efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–13.
Gordon 2003
Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with
moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–80.
ACD2058g
ACD2058g. Phase III, randomised double blind placebo-controlled study evaluating 12 weeks of therapy
with XOMA1 efalizumab administered subcutaneously (SC), followed by either continued treatment for an
additional 12 weeks or re-treatment for 12 weeks following relapse. In Clinical and Cost-effectiveness of
Efalizumab (Raptiva) for Moderate to Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
ACD2600g
ACD2600g. Phase IIIb, randomised, double-blind, parallel group, placebocontrolled, multicentre study
evaluating 12 weeks therapy with subcutaneously administered Genentech efalizumab in adults with
moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and Cost-effectiveness of
Efalizumab (Raptiva) for Moderate to Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
IMP24011
IMP24011. Phase III, randomised, double blind, placebo-controlled, multicentre study evaluating 12 weeks
subcutaneous therapy with Genentech efalizumab in patients with moderate to severe psoriasis who are
candidates for systemic therapy. In Clinical and Cost-effectiveness of Efalizumab (Raptiva) for Moderate to
Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
Rich 2013
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and
maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-
controlled, Phase II regimen-finding study. Br J Dermatol 2013;168:402–11.
Papp 2013
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of
secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind,
placebo controlled Phase II dose-ranging study. Br J Dermatol 2013;168:412–21.
SCULPTURE 2013
Novartis. Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens
versus re-Treatment Upon start of Relapse (SCULPTURE). 2013.
Mroweitz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-
needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized,
double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015;73:27–36.e1.
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ERASURE 2014
Rich P, Karpov A, Papavassilis C, Marmur E, Klingo K, et al. Secukinumab efficacy stratified by body
weight: a subanalysis from the ERASURE study. J Am Acad Dermatol 2014;70:AB186.
Papp K, Karpov A, Papavassilis C, Melendez E, Nakagawa H, et al. Secukinumab efficacy in relationship
with response to previous biologic psoriasis therapy: a subanalysis from the ERASURE Study. J Am Acad
Dermatol 2014;70:AB186.
Lebwohl M, Vender R, Menter A, Karpov A, Papavassilis C. ERASURE: Secukinumab Shows Sustained
Efficacy in Subjects Regardless of Previous Biologic Exposure. European Association of Dermatology and
Venereology (EADV) Congress, Amsterdam, the Netherlands, October 2014.
Gottlieb A, Gnanasakthy A, Strober B, Zhang JJ, Tran MH. Secukinumab’s time to posriasis response on
patient-reported symptoms (ERASURE study). J Am Acad Dermatol 2014;70:AB189.
Novartis. Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE). 2013.
FEATURE 2014
Blauvelt A, Gottlieb A, Prinz J, Pathan R, Cooper S. Secukinumab efficacy and safety in subjects with
moderate to severe plaque psoriasis: results from the Judging the efficacy of secUkinumab in patients with
psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE). J Am Acad
Dermatol 2014;70:AB185.
Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab adminstration by
pre-filled syringe: efficacy, safety and usability results from a randomised controlled trial in psoriasis
(FEATURE). Br J Dermatol 2015;172:484–93.
Novartis. First study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis:
response at 12 weeks (FEATURE). 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01555125 (accessed
15 September 2017).
JUNCTURE 2015
Blauvelt A, Gottlieb A, Prinz J, Pathan R, Cooper S. Secukinumab efficacy and safety in subjects with
moderate to severe plaque psoriasis: results from the Judging the efficacy of secUkinumab in patients with
psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE). J Am Acad
Dermatol 2014;70(Suppl. 1):AB185.
Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of
secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
J Eur Acad Dermatol Venereol 2015;29:1082–90.
Novartis. Judging the Efficacy of SecUkinumab in Patients with Psoriasis using Autoinjector: a Clinical Trial
EvalUating Treatment Results (JUNCTURE). 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01636687
(accessed 15 September 2017).
Rivas E, Griffiths C, Rich P, Gong Y, Papavassilis C. FIXTURE: Secukinumab Shows Sustained Efficacy in
Subjects Regardless of Previous Biologic Exposure. European Association of Dermatology and Venereology
(EADV) Congress, Amsterdam, the Netherlands, October 2014.
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FIXTURE 2014
Novartis. FIXTURE (Full year Investigative eXamination of secukinumab vs. eTanercept Using 2 dosing
Regimens to determine Efficacy in psoriasis). 2013.
Reich K, et al., editors. Sustainability of response with secukinumab to 52 weeks in moderate-to-severe
plaque psoriasis: data from the full year investigative examination of secukinumab vs. etanercept using
2 dosing regimens to determine efficacy in psoriasis (FIXTURE) study. 2014.
Psoriasis Area and Severity Index outcomes reported at irrelevant time
points (two studies)
van Joost 1988
van Joost T, Bos JD, Heule F, Meinardi MM. Low-dose cyclosporin A in severe psoriasis. A double-blind
study. Br J Dermatol 1988;118:183–90.
Ellis 1991
Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type
psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277–84.
Treatment arm of interest but not the recommended dose (four studies)
Tyring 2007
Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in
patients with psoriasis. Arch Dermatol 2007;143:719–26.
Bagel 2012
Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp
involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol
2012;67:86–92.
Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, et al. Patient-reported outcomes in
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Appendix 6 Evidence synthesis: fixed-effect
model results
TABLE 100 Network meta-analysis results for PASI response for analysis 2 assuming a fixed-effects approach:
probability of achieving a PASI 50, 75 and 90 response
Treatment
Analysis 2: fixed-effects approach
PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI) r
Placebo 0.212 (0.20 to 0.23) 0.087 (0.08 to 0.10) 0.020 (0.02 to 0.02) 5
Etanercept 0.726 (0.68 to 0.77) 0.517 (0.47 to 0.57) 0.259 (0.22 to 0.30) 3
Ustekinumab 0.863 (0.84 to 0.89) 0.704 (0.67 to 0.74) 0.439 (0.40 to 0.48) 2
Adalimumab 0.868 (0.84 to 0.90) 0.711 (0.67 to 0.76) 0.447 (0.40 to 0.50) 1
Methotrexate 0.369 (0.28 to 0.47) 0.187 (0.13 to 0.26) 0.099 (0.03 to 0.09) 4
Residual deviance,
mean (95% CI)
938.5a (921.2 to 959.8)
DIC 1790.3
r, ranking of treatments according to point estimates.
a Compared with 209 data points.
TABLE 101 Network meta-analysis results for PASI response for analysis 2a (placebo adjusted) assuming a
fixed-effects approach: probability of achieving a PASI 50, 75 and 90 response
Treatment
Analysis 2a: fixed-effects approach
PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI) r
Placebo 0.147 (0.13 to 0.17) 0.051 (0.04 to 0.06) 0.010 (0.01 to 0.01) 5
Etanercept 0.595 (0.55 to 0.65) 0.367 (0.32 to 0.42) 0.148 (0.12 to 0.18) 3
Ustekinumab 0.862 (0.83 to 0.89) 0.695 (0.65 to 0.74) 0.422 (0.37 to 0.47) 1
Adalimumab 0.821 (0.79 to 0.85) 0.632 (0.59 to 0.68) 0.356 (0.31 to 0.40) 2
Methotrexate 0.552 (0.49 to 0.62) 0.326 (0.27 to 0.39) 0.124 (0.09 to 0.16) 4
Residual deviance,
mean (95% CI)
406.3a (385.7 to 431.4)
DIC 1259.5
r, ranking of treatments according to point estimates.
a Compared with 209 data points.
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Appendix 7 Consistency assessment
The validity of a NMA depends on an assumption of homogeneity/exchangeability between all of thetrials included in the network, that is, that there are no essential differences between the methods,
populations and interventions being studied and that any differences are due to chance (as in a standard
meta-analysis). The lack of homogeneity/exchangeability between studies involving one of the treatments
of interest and studies involving the other treatments of interest may generate inconsistency. The main
potential threat to consistency of the evidence network is the pooling of evidence across trials in children
and young people with evidence from adult populations.
The main network evidence loops that require close examination are placebo compared with methotrexate
compared with adalimumab, placebo compared with etanercept compared with apremilast and placebo
compared with 45 mg of ustekinumab compared with 90 mg of ustekinumab (see Figure 5), as these involve
the main agents of interest. As illustrated in Figure 5, these evidence loops contain one, one and four
three-arm trials respectively (discontinued line boxes). Within a three-arm trial no inconsistency exists, and no
inconsistency is brought to the evidence network from these multiarm trials, potentially only between-trial
heterogeneity.240 These three evidence loops of interest include a mixture of two- and three-arm trial
evidence. In these circumstances defining and assessing inconsistency creates inherent technical difficulties.
Solutions to this problem are labelled by the NICE DSU Technical Support Document 4240,241 document on
inconsistency of evidence as ‘not entirely satisfactory’ and are ‘predicated on the assumption that the
majority of trials are two-arm trials and there is unlikely to be any material impact on detection
of inconsistency’.
To overcome these potential inconsistency assessment issues, a scenario analysis was performed that
consisted of excluding from the analysis the evidence from trials in children and young people and
synthesising only the evidence from adult populations. Therefore, analysis 2a (i.e. a baseline risk-adjusted
random-effects model) was replicated using only the evidence from the 34 adult trials and the results of
this scenario analysis were compared with the results obtained using the full evidence base.
Table 102 presents the PASI response outcomes for the trials in adult populations only. Overall, the results
were similar to those observed in analysis 2a (see Table 101). This provides some reassurance that
consistency exists between the two subpopulations.
TABLE 102 Network meta-analysis results for PASI response for analysis 2a restricted to adult evidence: probability
of achieving a PASI 50, 75 and 90 response
Treatment
Consistency assessment: analysis 2a restricted to adult subpopulation
PASI 50, mean (95% CrI) PASI 75, mean (95% CrI) PASI 90, mean (95% CrI) r
Placebo 0.144 (0.12 to 0.17) 0.050 (0.04 to 0.06) 0.010 (0.01 to 0.01) 5
Etanercept 0.619 (0.55 to 0.69) 0.389 (0.32 to 0.46) 0.161 (0.12 to 0.21) 3
Ustekinumab 45mg 0.875 (0.83 to 0.91) 0.714 (0.65 to 0.78) 0.442 (0.37 to 0.52) 1
Adalimumab 0.84 (0.78 to 0.89) 0.654 (0.57 to 0.73) 0.377 (0.30 to 0.46) 2
Methotrexate 0.548 (0.44 to 0.65) 0.322 (0.23 to 0.42) 0.121 (0.07 to 0.18) 4
Residual deviance,
mean (95% CI)
360.3a (337.2 to 387.0)
DIC 45.02
r, ranking of treatments according to point estimates.
a Compared with 191 data points.
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Appendix 8 Additional cost-effectiveness results
TABLE 103 Scenario results for adalimumab as an alternative to systemic therapy: EQ-5D utility estimates from
adults (TA180100)
Treatment
Mean
cost (£)
Mean
QALYs
Incremental
cost vs. MTX (£)
Incremental
QALYs vs. MTX
ICER vs. MTX
(£/QALY)
Optimal treatment
(£30,000 threshold)
Children aged 4–17 years
MTX 34,910 9.156 – – – MTX
ADA 62,019 9.361 27,109 0.204 132,616
ADA, adalimumab; MTX, methotrexate.
TABLE 104 Scenario results for interventions after failed systemic therapy: EQ-5D utility estimates from
adults (TA180100)
Treatment
Mean
cost (£)
Mean
QALYs
Incremental
cost vs.
next best
option (£)
Incremental
QALYs vs.
next best
option
ICER vs. next
best option
(£/QALY)
ICER vs. BSC
(£/QALY)
Optimal
treatment
(£30,000
threshold)
Children and young people aged 6–11 years
BSC 36,406 7.808 – – – –
ETA 43,779 8.150 7373 0.342 21,546 21,546 ETA
ADA 57,230 8.333 13,451 0.183 73,670 39,682
Children and young people aged 12–17 years
BSC 21,749 4.306 – – – –
ETA 33,186 4.585 11,437 0.278 ED ADA 41,085 BSC
ADA 37,848 4.732 16,099 0.426 37,802 37,802
UST 39,924 4.753 2075 0.021 100,423 40,700
ADA, adalimumab; ED, extendedly dominated by; ETA, etanercept; UST, ustekinumab.
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Appendix 9 Adalimumab risk-of-bias assessment
for trial extension periods
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Item
Period
B C D
Judgement Justification Judgement Justification Judgement Justification
Is the population based on a
representative sample selected from a
relevant population?
Unclear Only responders in period
A (RCT) entered this stage
of the study
No Not representative of participants
receiving first biological treatment
or switching biologic treatments:
all participants had received
adalimumab or methotrexate and
experienced loss of disease control
before being retreated
Yes Participants from periods A, B
and C were included
Are the criteria for inclusion explicit? Yes Participants with a PASI
75 and PGA 0/1 response
at the end of period A
Yes Participants from period B who
had 16 weeks of adalimumab or
methotrexate and experienced
loss of disease control were
included
Yes Participants from periods A, B
and C who met entry criteria in
period A were included
Were groups similar at baseline in terms
of important confounding variables?
If not, was the analysis adjusted to
account for the imbalance?
NA Unclear Insufficient demographic
information. PASI 50 rates differ
(p = 0.06)
NA Non-comparative observational
period
Was knowledge of the allocated
intervention by outcome assessors
adequately prevented during the study?
Unclear No information provided Yes Blinded retreatment NA Non-comparative observational
period. Adalimumab dose was
blinded for some participants
and open label for others
Were losses to follow-up < 20%? Yes 53 of 54 participants
entering group B
completed follow-up
Yes 34 of 38 participants completed
follow-up
Yes 90 of 108 participants
completed follow-up
Were all patients accounted for at the
end of study follow-up?
Yes Yes Yes
Were reliable methods used to measure
outcomes?
Yes PGA worsening by at
least two grades
Yes Outcomes and methods were
reported
Yes Outcomes and methods were
reported
Was the study sufficiently powered to
detect a treatment effect?
Unclear No information was
provided
Unclear No information was provided Unclear No information was provided
Was the study follow-up duration
sufficient to detect a long-term
treatment effect?
Yes Participants were
followed up for 36 weeks
Yes As in period A, participants were
followed up for 16 weeks
Yes Participants were followed up
for 52 weeks in period D
NA, not applicable.
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Appendix 10 Etanercept risk-of-bias assessment
for trial extension periods
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Item
Open-label treatment (24 weeks) Withdrawal–retreatment period (12 weeks) Long-term follow-up (264 weeks)
Judgement Justification Judgement Justification Judgement Justification
Is the population based on a
representative sample selected
from a relevant population?
Yes All patients who entered the
randomisation stage were
included
No Only those who achieved a PASI
50 response at week 24 or a
PASI 75 response at week 36
entered the study
Yes 182 of the 211 participants from the
blinded period and completing the
withdrawal–retreatment period
entered this study
Are the criteria for inclusion
explicit?
Yes With the exception of three
withdrawals, all patients who
entered the randomisation
stage were included
Yes Those who achieved a PASI 50
response at week 24 or a PASI
75 response at week 36 entered
the study
Yes All participants who completed the
withdrawal–retreatment period were
included
Were groups similar at
baseline in terms of important
confounding variables? If not,
was the analysis adjusted to
account for the imbalance?
NA All patients received the same
treatment (etanercept), that is,
no comparative efficacy
analyses were planned
Yes Participants were similar in terms
of age, sex, weight, height, PASI
scores and % BSA affected
NA The follow-up study did not aim to
carry out comparative analyses
Was knowledge of the
allocated intervention by
outcome assessors adequately
prevented during the study?
Unclear Every patient was receiving
etanercept
Unclear Although the participants,
caregivers, investigators and
outcome assessors were blinded
during the blinding period, no
information was available for this
phase of the study
Unclear Although the participants, caregivers,
investigators and outcome assessors
were blinded during the blinding
period, no information was available
for this phase of the study
Were losses to follow-up
< 20%?
Yes 94.7% (197/208) of participants
entering this stage were present
at the end of the stage
Yes 137 out of 138 participants
completed the study
No 115 out of 182 participants
withdrew by the end of the study
(week 264)
Were all patients accounted
for at the end of study follow-
up?
Yes 11 participants withdrew and
197 participants were present
at the end of the study
Yes 137 participants completed the
study and one was lost to
follow-up
Yes Withdrawals and reasons (e.g. AEs,
lost to follow-up, withdrawal consent
and protocol deviations) reported
Were reliable methods used
to measure outcomes?
Yes PASI scores and AEs were
recorded
Yes PASI scores were reported Yes PASI scores and AEs reported
Was the study sufficiently
powered to detect a
treatment effect?
NA Power analysis was not carried
out or needed for the study
Unclear No power calculation was
carried out or reported for this
phase of the study
Unclear No power calculations were carried
out or evidenced in the study reports
Was the study follow-up
duration sufficient to detect a
long-term treatment effect?
Yes Participants were followed up
for 24 weeks
Unclear The follow-up period was 12
weeks
Yes The follow-up period was 5 years
NA, not applicable.
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Appendix 11 Ustekinumab risk-of-bias
assessment for trial extension periods
Item
Period
Placebo crossover and active
treatment (12–52 weeks) Follow-up (52–60 weeks)
Judgement Justification Judgement Justification
Is the population based on
a representative sample
selected from a relevant
population?
Yes All participants from the
initial blinded period were
eligible to enter the
crossover phase of the study
Yes All participants from
previous phases were
eligible for follow-up
Are the criteria for inclusion
explicit?
Yes All participants from the
initial blinded period were
eligible to enter the
crossover phase of the study
Yes All participants from
previous phases were
eligible for follow-up
Were groups similar at
baseline in terms of
important confounding
variables? If not, was the
analysis adjusted to account
for the imbalance?
NA This phase of the study did
not aim for comparative
analysis
NA This phase of the study did
not aim for comparative
analysis
Was knowledge of the
allocated intervention by
outcome assessors
adequately prevented
during the study?
Yes The sponsor, investigative
study sites and participants
remained blinded to
treatment assignment until
the last participant enrolled
had completed the study
Yes The sponsor, investigative
study sites and participants
remained blinded to
treatment assignment until
the last participant enrolled
had completed the week
60 evaluations and the
database was locked
Were losses to follow-up
< 20%?
Yes Only 7 out of 110
participants withdrew by the
end of this phase
Unclear The total loss to follow-up
or withdrawals at this
phase of the study were
not reported
Were all patients accounted
for at the end of study
follow-up?
Yes Withdrawals and reasons
(e.g. AEs, death and lack of
efficacy) were reported
Unclear The total loss to follow-up
for this phase of the study
was not reported
Were reliable methods used
to measure outcomes?
Yes PASI scores were reported NA The follow-up was aimed
only at safety reports
Was the study sufficiently
powered to detect a
treatment effect?
NA The follow-up period did not
aim for comparative analyses
NA The follow-up period did
not aim for comparative
analyses
Was the study follow-up
duration sufficient to detect
a long-term treatment
effect?
Yes Participants were followed
up for 40 weeks
No Participants were followed
up for only 8 weeks
NA, not applicable.
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Appendix 12 Risk-of-bias assessment for
observational multiple biological therapy studies
Item
Study
Garber 201576 Klufas 201677
Judgement Justification Judgement Justification
Is the population based
on a representative
sample selected from a
relevant population?
Yes All patients with the disease
code ICD-9-CM 696.1 were
considered in the study
Yes All patients with the disease
code ICD-9-CM 696.1 were
considered in the study
Are the criteria for
inclusion explicit?
Yes Patients with a S-MAPA score
of ≥ 15 or otherwise
documented moderate to
severe psoriasis were included
Yes Patients with moderate to
severe psoriasis were included
Were groups similar at
baseline in terms of
important confounding
variables? If not, was
the analysis adjusted to
account for the
imbalance?
NA Not a comparative study NA Not a comparative study
Was knowledge of the
allocated intervention
by outcome assessors
adequately prevented
during the study?
Unclear No information provided Unclear No information provided
Were losses to follow-up
< 20%?
NA Retrospective analysis of
health records
NA Retrospective analysis of health
records
Were all patients
accounted for at the
end of study follow-up?
NA Retrospective analysis of
health records
NA Retrospective analysis of health
records
Were reliable methods
used to measure
outcomes?
Unclear No information was provided Unclear No information was provided
Was the study
sufficiently powered to
detect a treatment
effect?
NA Not a comparative analysis NA Not a comparative analysis
Was the study follow-up
duration sufficient to
detect a long-term
treatment effect?
No Mean duration of treatment
was as short as 11 weeks in
the etanercept +methotrexate
group
No Mean duration of treatment
was as short as 3 weeks in the
adalimumab +methotrexate
group
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NA, not applicable.
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